


<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10578744.str



chain nodes :

7 8 9 10 11

ring nodes :

1 2 3 4 5 6

chain bonds :

2-10 5-7 7-8 8-9 8-11

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact bonds :

2-10 5-7 7-8 8-9 8-11

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:CLASS

L6 STRUCTURE UPLOADED

=> d 16

L6 HAS NO ANSWERS

L6 STR

/ Structure 1 in file .gra /

Structure attributes must be viewed using STN Express query preparation.

=> s 16 fam sam

SAMPLE SEARCH INITIATED 09:34:00 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 139 TO ITERATE

100.0% PROCESSED 139 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 2073 TO 3487

PROJECTED ANSWERS: 1 TO 80

```

L7          1 SEA FAM SAM L6

=> s 16 fam full
FULL SEARCH INITIATED 09:34:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      3328 TO ITERATE

100.0% PROCESSED      3328 ITERATIONS          16 ANSWERS
SEARCH TIME: 00.00.01

L8          16 SEA FAM FUL L6

=> s 16 sss sam
SAMPLE SEARCH INITIATED 09:34:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      597 TO ITERATE

100.0% PROCESSED      597 ITERATIONS          26 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   10475 TO    13405
PROJECTED ANSWERS:      215 TO     825

L9          26 SEA SSS SAM L6

=> s 16 sss full
FULL SEARCH INITIATED 09:35:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    12087 TO ITERATE

100.0% PROCESSED    12087 ITERATIONS          412 ANSWERS
SEARCH TIME: 00.00.01

L10         412 SEA SSS FUL L6

=> d scan

L14         26 SEA SSS SAM L12

=> s 112 sss full
FULL SEARCH INITIATED 09:42:14 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    12087 TO ITERATE

100.0% PROCESSED    12087 ITERATIONS          412 ANSWERS
SEARCH TIME: 00.00.01

L15         412 SEA SSS FUL L12

=> d scan

L15  412 ANSWERS  REGISTRY  COPYRIGHT 2009 ACS on STN
IN   D-Tyrosine,  $\beta$ -ethyl- $\alpha$ -[(4-fluorobenzoyl)oxy]-3-hydroxy-
MF   C18 H18 F N O

=> s 115/prep
      3034 L15
      4705416 PREP/RL
L16   617 L15/PREP
      (L15 (L) PREP/RL)

```

```
=> s 116 and (py<2003 or ay<2003 or pry<2003)
    22983068 PY<2003
    4502889 AY<2003
    3971612 PRY<2003
L17      263 L16 AND (PY<2003 OR AY<2003 OR PRY<2003)
```

```
=> s 117 and 'chiral catalyst'
    129174 'CHIRAL'
    19 'CHIRALS'
    129179 'CHIRAL'
        ('CHIRAL' OR 'CHIRALS')
    827404 'CATALYST'
    823540 'CATALYSTS'
    1060120 'CATALYST'
        ('CATALYST' OR 'CATALYSTS')
    2138 'CHIRAL CATALYST'
        ('CHIRAL'(W)'CATALYST')
L18      0 L17 AND 'CHIRAL CATALYST'
```

```
=> s 117 and asymmetric hydrogenation
    76804 ASYMMETRIC
    31 ASYMMETRICS
    76835 ASYMMETRIC
        (ASYMMETRIC OR ASYMMETRICS)
    147804 ASYM
    6 ASYMS
    147807 ASYM
        (ASYM OR ASYMS)
    171488 ASYMMETRIC
        (ASYMMETRIC OR ASYM)
    184214 HYDROGENATION
    2478 HYDROGENATIONS
    184475 HYDROGENATION
        (HYDROGENATION OR HYDROGENATIONS)
    4061 ASYMMETRIC HYDROGENATION
        (ASYMMETRIC(W)HYDROGENATION)
L19      0 L17 AND ASYMMETRIC HYDROGENATION
```

```
=> s 117 and catalyst
    827404 CATALYST
    823540 CATALYSTS
    1060120 CATALYST
        (CATALYST OR CATALYSTS)
L20      7 L17 AND CATALYST
```

```
=> d 120 ibib abs 1-7
```

```
L20  ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:      2003:22888  CAPLUS  Full-text
DOCUMENT NUMBER:      138:73085
TITLE:                Preparation of 3-aryl- $\alpha$ -oxy substituted
                        propanoic acids for treatment of type II diabetes and
                        related disorders
INVENTOR(S):          Potlapally, Rajender Kumar; Velagala, Venkata Rama
                        Murali Krishna Reddy; Mamillapalli, Ramabhadra Sarma;
                        Gaddam, Om Reddy
PATENT ASSIGNEE(S):   Reddy's Research Foundation, India
SOURCE:               PCT Int. Appl., 54 pp.
                        CODEN: PIXXD2
DOCUMENT TYPE:        Patent
```

LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002575	A1	20030109	WO 2001-IN124	20010628 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001277663	A1	20030303	AU 2001-277663	20010628 <--
JP 2004530728	T	20041007	JP 2003-508956	20010628 <--
US 20040248849	A1	20041209	US 2004-481735	20040728 <--
PRIORITY APPLN. INFO.:			WO 2001-IN124	W 20010628 <--
OTHER SOURCE(S):	CASREACT 138:73085; MARPAT 138:73085			
GI				

/ Structure 28 in file .gra /

AB 3-Aryl- $\alpha$ -oxy substituted propanoic acids [I; wherein R1 = tert-butyldimethylsilyl, trimethylsilyl, alkoxyalkyl; R2 = H, (substituted)(C1-C6)alkyl] were prepared For example, Me tert-butyldimethylsilyloxy-3-(4-hydroxyphenyl)propanoate (II) was prepared in three steps. The prepared compds. are useful for treating diabetes, obesity, glucose intolerance, insulin resistance and other related disorders such as hypertension, coronary heart disease, atherosclerosis, stroke, peripheral vascular diseases and related disorders (no data). The prepared compds. are also useful for reducing total cholesterol, body weight, blood plasma glucose, triglycerides, LDL, VLDL and free fatty acids (no data).

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2002:620035 CAPLUS Full-text

DOCUMENT NUMBER: 138:89669

TITLE: Efficient synthesis of antihyperglycemic  
(S)- $\alpha$ -aryloxy- $\beta$ -phenylpropionic acid  
derivative using a bifunctional asymmetric  
catalyst

AUTHOR(S): Takamura, Makoto; Yanagisawa, Hiroaki; Kanai, Motomu;  
Shibasaki, Masakatsu

CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Sankyo Co.,  
Ltd., Tokyo, 140-8710, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (2002),  
50(8), 1118-1121

CODEN: CPBTAL; ISSN: 0009-2363

PUBLISHER: Pharmaceutical Society of Japan

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:89669



GI

/ Structure 29 in file .gra /

AB The title acid (I) was prepared using catalytic asym. cyanosilylation as a key reaction to construct the  $\alpha$ -oxycarboxylic acid moiety.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:286131 CAPLUS Full-text

DOCUMENT NUMBER: 136:309765

TITLE: Preparation of optically active 2-hydroxy-3-phenylpropionitrile

INVENTOR(S): Yanagisawa, Hiroaki; Takamura, Minoru

PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 2002114749	A	20020416	JP 2000-303538	20001003 <--
PRIORITY APPLN. INFO.:			JP 2000-303538	20001003 <--
OTHER SOURCE(S):			CASREACT 136:309765; MARPAT 136:309765	

AB The compds. p-R1OC6H4CH2CH(OH)CN (R1 = H, OH-protecting group) are prepared by reaction of p-R1OC6H4CH2CHO (R1 = same as above) with cyanating agents in the presence of optically active catalysts. 4-Benzyloxyphenylacetaldehyde was reacted with trimethylsilyl cyanide in the presence of Et2AlCl, (S)-3,3'-bis(diphenylphosphinoyl)-1,1'-binaphthol, and Bu3P(O) in CH2Cl2 at -40° for 53.5 h to give 116 mg (R)-3-(4-benzyloxyphenyl)-2-hydroxypropionitrile. (R)-3-(4-hydroxyphenyl)lactic acid was prepared from the compound

L20 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:784755 CAPLUS Full-text

DOCUMENT NUMBER: 132:166053

TITLE: Total syntheses of all four stereoisomers of piscidic acid via catalytic asymmetric dihydroxylation of (Z)- and (E)-trisubstituted olefins

AUTHOR(S): Toshima, Hiroaki; Saito, Masatoshi; Yoshihara, Teruhiko

CORPORATE SOURCE: Department of Bioscience and Chemistry, Faculty of Agriculture, Hokkaido University, Sapporo, 060-8589, Japan

SOURCE: Bioscience, Biotechnology, and Biochemistry (1999), 63(11), 1934-1941

CODEN: BBBIEJ; ISSN: 0916-8451

PUBLISHER: Japan Society for Bioscience, Biotechnology, and Agrochemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 132:166053

AB Four stereoisomers of (2S,3R)-(+)-piscidic acid were synthesized with high optical purity via Sharpless catalytic asym. dihydroxylation of (Z)- and (E)-trisubstituted olefins in 6 steps from (4-hydroxyphenyl)pyruvic acid. That is Wittig reaction of Me (4-hydroxyphenyl)pyruvate with (carbomethoxymethylene)triphenylphosphorane give (Z)- and (E)-trisubstituted olefins in a 3:1 ratio, protecting the phenolic hydroxyl group with tert-butyldimethylsilyl, then the (Z)-olefin was subjected to asym. dihydroxylation by using the chiral ligand, dihydroquinidine 1,4-anthraquinonediyl diether, gave the product with 89% e.e. Desilylation and subsequent alkaline hydrolysis gave (2S,3R)-(+)-piscidic acid with > 99% e.e. after recrystn. Use of ligand, dihydroquinine 1,4-anthraquinonediyl diether, gave (2R,3S)-(-)-piscidic acid. Asym. dihydroxylation of the (E)-olefin with phthalazine ligands (dihydroquinidine and dihydroquinine 1,4-phthalazinediyl diethers) also gave high e.e. values product, followed by the same procedure mentioned above, gave (2S,3S)-(+)-3-epi-piscidic acid and (2R,3R)-(-)-2-epi-piscidic acid resp.

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:262036 CAPLUS Full-text

DOCUMENT NUMBER: 124:289000

ORIGINAL REFERENCE NO.: 124:53583a,53586a

TITLE: Hydrogenation process and catalysts for the production of phenyllactic acids from phenylpyruvic acids

INVENTOR(S): Morita, Hikari; Mori, Hiroyuki

PATENT ASSIGNEE(S): Nitto Chemical Industry Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 8 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 696566	A1	19960214	EP 1995-112540	19950809 <--
EP 696566	B1	19980610		
R: CH, DE, LI				
JP 08053394	A	19960227	JP 1994-206102	19940809 <--
JP 3394606	B2	20030407		
US 5684186	A	19971104	US 1995-511152	19950804 <--
CN 1122325	A	19960515	CN 1995-109050	19950809 <--
CN 1083422	C	20020424		

PRIORITY APPLN. INFO.: JP 1994-206102 A 19940809 <--

OTHER SOURCE(S): CASREACT 124:289000; MARPAT 124:289000

GI

/ Structure 30 in file .gra /

AB Phenyllactic acids [I; R1, R2 = H, OH, (un)branched alkyl, (un)branched alkoxy; R3 = H, (un)branched alkyl; R1R2 = methylenedioxy], useful as intermediates in the preparation of agrochems. (no data) and pharmaceuticals (no data), are prepared in high yield by the hydrogenation of phenylpyruvic acids (II) in the presence of a catalyst containing  $\geq 1$  Group VIII metal (e.g., Pd, Pt, Ni, etc.). Thus, 3-(4-hydroxyphenyl)pyruvic acid was hydrogenated in

MeOH using a Pd/C catalyst at 25°/5 kg/cm<sup>2</sup>, producing 3-(4-hydroxyphenyl)lactic acid.

L20 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:603784 CAPLUS Full-text

DOCUMENT NUMBER: 119:203784

ORIGINAL REFERENCE NO.: 119:36369a,36372a

TITLE: Selectivity and specificity in substrate binding to proteases: novel hydrolytic reactions catalyzed by  $\alpha$ -chymotrypsin suspended in organic solvents with low water content and mediated by ammonium hydrogen carbonate

AUTHOR(S): Ricca, Jean Marc; Crout, David H. G.

CORPORATE SOURCE: Dep. Chem., University of Warwick, Coventry, CV4 7AL, UK

SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1993), (11), 1225-33  
CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 119:203784

AB  $\alpha$ -Chymotrypsin suspended in organic solvents with low water content catalyzed hydrolytic reactions in the presence of ammonium hydrogen carbonate. Mol. modeling studies were carried out and structure-reactivity relationships were estimated by studying the hydrolysis of amino acid derivs. and analogs. The enzyme was stereoselective with respect to the hydrolysis of L-amino acid derivs., but no stereoselectivity was observed when  $\alpha$ -hydroxy esters were used as substrates. A general procedure for the resolution of aromatic amino acid esters is given. The results are interpreted in terms of mol. modeling based on x-ray crystallog. data and literature data.

L20 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1955:84086 CAPLUS Full-text

DOCUMENT NUMBER: 49:84086

ORIGINAL REFERENCE NO.: 49:15798a-i,15799a-c

TITLE: Constituents of Cortex piscidia erythrinae. II. Synthesis of O-methylpiscidic acid

AUTHOR(S): Buckle, A. L. J.; McGookin, Alexander; Robertson, Alexander

CORPORATE SOURCE: Univ. Liverpool, UK

SOURCE: Journal of the Chemical Society (1954) 3981-6

CODEN: JCSEA9; ISSN: 0368-1769

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB cf. C.A. 42, 4981f. Piscidic acid was shown previously to be (+)-p-HOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>C(OH)(CO<sub>2</sub>H)CH(OH)CO<sub>2</sub>H (loc. cit.) and now has been confirmed by the synthesis of p-methoxybenzyltartaric acid, identical with natural O-Me piscidic acid. Several routes for the synthesis of tartaric acids of this type were examined Et  $\alpha$ -phenylacetoacetate, b<sub>0.8</sub> 110° (2,4-dinitrophenylhydrazone, m. 94-5°), prepared by the method of Attwood, et al. (C.A. 17, 3183), with Pb(OAc)<sub>4</sub> in HOAc, gave Et  $\alpha$ -acetoxy- $\alpha$ -phenylacetoacetate, b<sub>0.2</sub> 128-30°. Similarly, from Et  $\gamma$ -phenylacetoacetate there resulted Et  $\alpha$ -acetoxy- $\gamma$ -phenylacetoacetate (I), b<sub>0.5</sub> 143-5°. I was obtained also from phenylacetyl bromide, Et diazoacetate, and HOAc. A mixture of I, HCN, and NaOH after 12 h. was diluted with EtOH, saturated with HCl,

refluxed 4 h. and filtered to remove  $\text{NH}_4\text{Cl}$ . The residue after evaporation of the filtrate gave Et benzyltartrate as a mixture which was separated manually into equal amts. of racemate A, m.  $174-5^\circ$  (diamide,  $204-6^\circ$ ), and racemate B, m.  $194-5^\circ$  (diamide, m.  $185-6^\circ$ ). Reduction of Et phenyloxaloacetate with moist Al amalgam gave Et  $\beta$ -phenylmalate, b0.04  $131^\circ$ , which after hydrolysis with KOH and purification from EtOAc gave  $\beta$ -phenylmalic acid, m.  $150-60^\circ$ . Fractional crystallization from EtOAc gave the racemic isomeride A, m.  $172^\circ$ , and from EtOAc-light petroleum (b.p.  $60-80^\circ$ ) the racemic isomeride B, m.  $162^\circ$ . Dehydration with  $\text{Ac}_2\text{O}$  of a mixture of the isomerides gave phenylmaleic anhydride, m.  $120^\circ$ , which on treatment with alkali gave phenylmaleic acid (II), m.  $90-2^\circ$ . II with pyridine and  $\text{OsO}_4$  in  $\text{Et}_2\text{O}$  gave phenyltartaric acid, m.  $173-4^\circ$ . Oxidation of citraconic acid with  $\text{NaClO}_3$  and  $\text{OsO}_4$  gave C-methyltartaric acid, m.  $144-5^\circ$  (m.  $146^\circ$ , given by Schmidt and Perkow, C.A. 45, 2412h); Me ester, m.  $99-100^\circ$ ; diamide, m.  $152-3^\circ$ . The condensation of  $\text{NaOEt}$  and Et oxalate with Et  $\beta$ -p-methoxyphenylpropionate, gave Et  $\alpha$ -ethoxalyl- $\beta$ -p-methoxyphenylpropionate. After reduction with moist amalgam, there was isolated Et  $\beta$ -hydroxy- $\alpha$ -p-methoxybenzylsuccinate, b0.1.  $75-7^\circ$ . Hydrolysis with KOH gave a mixture of acids, m. about  $130^\circ$ . Fractional crystallization from EtOAc-light petroleum (b.p.  $60-80^\circ$ ) gave racemate A, m.  $136-7^\circ$ , and racemate B, m.  $125-6^\circ$ . A mixture of these racemates with  $\text{Ac}_2\text{O}$  gave p-methoxybenzylidenesuccinic anhydride (III), m.  $160^\circ$ , which on boiling with  $\text{H}_2\text{O}$  gave p-methoxybenzylidenesuccinic acid (IV), m. and mixed m.p.  $194-5^\circ$  (decomposition). IV was obtained also from the condensation of anisaldehyde, Et succinate, and  $\text{NaOEt}$ . IV with  $\text{Ac}_2\text{O}$  gave III, which by the boiling  $\text{MeOH-H}_2\text{SO}_4$  method gave Me p-methoxybenzylidenesuccinate (V), b0.5  $165^\circ$ . Hydrogenation with  $\text{PdCl}_2$  catalyst of IV gave p-methoxybenzylsuccinic acid (VI) m.  $98-101^\circ$ , and of V gave Me p-methoxybenzylsuccinate, b1  $156^\circ$ , m.  $35-7^\circ$ . Distillation of VI at  $180^\circ/0.5$  mm. gave the anhydride, m.  $91-2^\circ$ . From p-methoxybenzyl alc. with  $\text{PCl}_3$  in  $\text{Et}_2\text{O}$  there was obtained p-methoxybenzyl chloride as an unstable oil, b25  $125-7^\circ$ , which on condensation with Et sodiomalonate gave Et p-methoxybenzylmalonate (VII), b0.5  $145^\circ$ . There was isolated from  $\text{BrCH}_2\text{CO}_2\text{Et}$  and VII Et  $\alpha$ -ethoxycarbonyl- $\alpha$ -p-methoxybenzylsuccinate, b0.2  $166-9^\circ$  which on heating with  $\text{EtOH-KOH}$  gave  $\alpha$ -carboxy- $\alpha$ -p-methoxybenzylsuccinic acid, m.  $157-9^\circ$  (decomposition). When this was heated at  $160^\circ/25$  mm. for 15 min., there was obtained VI. A stirred mixture of N-bromosuccinimide, p-methoxybenzylsuccinic anhydride, benzoyl peroxide, and  $\text{CCl}_4$  or  $\text{CS}_2$  as solvent, after refluxing for 12 h., evaporating the filtered mixture and extracting with EtOAc gave III. III was heated until molten, then rapidly poured on to a cold surface, the solid pulverized and refluxed with  $\text{CS}_2$ , collected and washed with more solvent and the process repeated 22 times. Evaporation of the combined  $\text{CS}_2$  exts. left an orange semisolid which was extracted with  $\text{Et}_2\text{O}$ . The residue left on evaporation of  $\text{Et}_2\text{O}$  was extracted with light petroleum (b.p.  $40-60^\circ$ ) and on cooling, deposited p-methoxybenzylmaleic anhydride (VIII), m.  $64-5^\circ$ , which on recrystn. from  $\text{CHCl}_3$ -light petroleum (b.p.  $60-80^\circ$ ), m.  $65-6^\circ$ . VIII reverted to III on melting. Hydrolysis of VIII with  $\text{H}_2\text{O}$  gave p-methoxybenzylmaleic acid (IX), m.  $120^\circ$  (sintered at  $117^\circ$ ). Addition of pyridine and  $\text{OsO}_4$  to IX in  $\text{Et}_2\text{O}$  and the mixture kept in a closed vessel for 3 days resulted in a brown precipitate, which after collection was treated with aqueous KOH, the solution extracted with  $\text{Et}_2\text{O}$ , acidified, evaporated, the residue extracted with  $\text{Et}_2\text{O}$  in a Soxhlet apparatus 9 h. and the extract evaporated to obtain p-methoxybenzyltartaric acid (X), m.  $205-7^\circ$  (decomposition); brucine salt,  $[\alpha]_{23.5\text{D}} -14.39^\circ \pm 0.6^\circ$  (c 2.96, 50%  $\text{EtOH}$ ). Resolution of X with brucine gave p-O-methylpiscidic acid,  $[\alpha]_{23\text{D}} 44.01^\circ \pm 5.0^\circ$  (c 1.262,  $\text{H}_2\text{O}$ ), m.  $169-70^\circ$  (mixed m.p. with X,  $173-6^\circ$ ); cinchonine salt,  $[\alpha]_{17\text{D}} 139.6^\circ$  (c 6.1,  $\text{EtOH}$ ); brucine salt,  $[\alpha]_{24\text{D}} -13.03^\circ$  (c 2.131, 50%  $\text{EtOH}$ ); Me ester,  $[\alpha]_{18\text{D}} 78.16^\circ$  (c 1.54,  $\text{EtOH}$ ). The following derivs. of piscidic acid were cited: Me ester,  $[\alpha]_{23\text{D}} 41.52^\circ$  (c 1.325,  $\text{H}_2\text{O}$ ); Et ester,  $[\alpha]_{17.5\text{D}} 59.70^\circ$  (c 1.551,  $\text{EtOH}$ ); di-Me ester,  $[\alpha]_{19\text{D}} 23.71^\circ$  (c


6.367, EtOH); Me p-O-benzylpiscidate,  $[\alpha]_{19D}$  48.73° (c 1.786, EtOH); cinchonine salt,  $[\alpha]_{21D}$  146.2° (c 0.424, EtOH); (+)-N-methylphenylisopropylamine salt, m. 179°,  $[\alpha]_{24D}$  12.73° (c 2.09, H<sub>2</sub>O). Reduction of p-methoxyphenylpyruvic acid in aqueous NaOH with 2% Na-Hg gave p-methoxyphenyllactic acid, m. 88°; Me ester (XI), b<sub>0.1</sub> 135°. Methylation of XI with Ag<sub>2</sub>O in MeI gave the Me ether of Me p-methoxyphenyllactate, b<sub>0.5</sub> 120°.

<http://www.cas.org/legal/infopolicy.html>

=> activate all10578744/1

```
L21 (      0)SEA FILE=CAPLUS SPE=ON  ABB=ON  PLU=ON  "MATS T. LINDERBERG"
L22 (      0)SEA FILE=CAPLUS SPE=ON  ABB=ON  PLU=ON  'MATS T? LINDERBERG'
L23 (      0)SEA FILE=CAPLUS SPE=ON  ABB=ON  PLU=ON  'YOKOZAWA, TOHRU'
L24 (      0)SEA FILE=CAPLUS SPE=ON  ABB=ON  PLU=ON  "TOHRU YOKOZAWA"
L25 (      5)SEA FILE=CAPLUS SPE=ON  ABB=ON  PLU=ON  YOKOZAWA
L26          STR
L27 (      1)SEA FILE=REGISTRY FAM SAM L26
L28 (     16)SEA FILE=REGISTRY FAM FUL L26
L29 (     26)SEA FILE=REGISTRY SSS SAM L26
L30 (    412)SEA FILE=REGISTRY SSS FUL L26
L31          STR
L32          STR
L33 (      1)SEA FILE=REGISTRY FAM SAM L32
L34 (     26)SEA FILE=REGISTRY SSS SAM L32
L35 (    412)SEA FILE=REGISTRY SSS FUL L32
L36 (    617)SEA FILE=CAPLUS SPE=ON  ABB=ON  PLU=ON  L35/PREP
L37 (    263)SEA FILE=CAPLUS SPE=ON  ABB=ON  PLU=ON  L36 AND (PY<2003 OR AY<
L38 (      0)SEA FILE=CAPLUS SPE=ON  ABB=ON  PLU=ON  L37 AND 'CHIRAL CATALYS
L39 (      0)SEA FILE=CAPLUS SPE=ON  ABB=ON  PLU=ON  L37 AND ASYMMETRIC HYDR
L40 (      7)SEA FILE=CAPLUS SPE=ON  ABB=ON  PLU=ON  L37 AND CATALYST
```

Uploading C:\Program Files\Stnexp\Queries\10578744.str



```
chain nodes :
7 8 9 10 11
ring nodes :
1 2 3 4 5 6
chain bonds :
2-10 5-7 7-8 8-9 8-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact bonds :
2-10 5-7 7-8 8-9 8-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
```

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:CLASS

L42 STRUCTURE UPLOADED

=> s l42 sss full  
FULL SEARCH INITIATED 10:16:47 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 12087 TO ITERATE

100.0% PROCESSED 12087 ITERATIONS 412 ANSWERS  
SEARCH TIME: 00.00.01

L43 412 SEA SSS FUL L42

=> d scan

L43 412 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzenepropanoic acid, 4-hydroxy- $\alpha$ -methoxy-, ( $\alpha$ R)-(2S)-compd.  
with 2-amino-1-butanol (1:1)  
MF C10 H12 O4 . C4 H11 N O  
  
CM 1

Absolute stereochemistry.

/ Structure 34 in file .gra /

=> s l43/prep  
3034 L43  
4705416 PREP/RL  
L44 617 L43/PREP  
(L43 (L) PREP/RL)

=> s l44 and 'chiral catalyst'  
129174 'CHIRAL'  
19 'CHIRALS'  
129179 'CHIRAL'  
( 'CHIRAL' OR 'CHIRALS' )  
827404 'CATALYST'  
823540 'CATALYSTS'  
1060120 'CATALYST'  
( 'CATALYST' OR 'CATALYSTS' )  
2138 'CHIRAL CATALYST'  
( 'CHIRAL' (W) 'CATALYST' )  
L45 0 L44 AND 'CHIRAL CATALYST'

=> s l44 and "asymmetric hydrogenation"  
MISMATCHED QUOTE 'AND "ASYMMETRIC'  
Quotation marks (or apostrophes) must be used in pairs,  
one before and one after the expression you are setting  
off or masking.

=> s l44 and 'asymmetric hydrogenation'  
76804 'ASYMMETRIC'  
31 'ASYMMETRICS'

```

76835 'ASYMMETRIC'
      ('ASYMMETRIC' OR 'ASYMMETRICS')
147804 'ASYM'
      6 'ASYMS'
147807 'ASYM'
      ('ASYM' OR 'ASYMS')
171488 'ASYMMETRIC'
      ('ASYMMETRIC' OR 'ASYM')
184214 'HYDROGENATION'
      2478 'HYDROGENATIONS'
184475 'HYDROGENATION'
      ('HYDROGENATION' OR 'HYDROGENATIONS')
4061 'ASYMMETRIC HYDROGENATION'
      ('ASYMMETRIC'(W)'HYDROGENATION')
L46      2 L44 AND 'ASYMMETRIC HYDROGENATION'

```

=> d l46 abs ibib 1-2

L46 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

AB Chiral 2-alkoxy-3-arylpropanoic acids R<sub>2</sub>nC<sub>6</sub>H<sub>5</sub>-nCH<sub>2</sub>CH(OR<sub>1</sub>)CO<sub>2</sub>H or their alkali metal salts [1; R<sub>1</sub> = (un)substituted C<sub>1</sub>-18 alkyl, C<sub>4</sub>-24 aryl, C<sub>5</sub>-18 arylalkyl; R<sub>2</sub> = OH, halo, (alkyl)amino, C<sub>1</sub>-18 alkyl(oxy), C<sub>4</sub>-24 aryl, C<sub>5</sub>-18 arylalkyl, C<sub>1</sub>-18 alkylsulfonyl(amino), acyl(amino), acyloxy, preferably R<sub>2</sub> = OH; n = 1-5, preferably n = 1], useful as peroxisome proliferator activated receptors (PPAR) agonists, were prepared by an improved process comprising transition metal-catalyzed asym. hydrogenation of the corresponding cinnamic acids R<sub>2</sub>nC<sub>6</sub>H<sub>5</sub>-nCH:C(OR<sub>1</sub>)CO<sub>2</sub>H (2; same R, n) in the presence of at least one protic solvent. Compds. 2 were preferably prepared by Perkin condensation of benzaldehydes R<sub>2</sub>nC<sub>6</sub>H<sub>5</sub>-nCHO (3; same R<sub>2</sub>, n) with 2-alkoxyacetates R<sub>1</sub>OCH<sub>2</sub>CO<sub>2</sub>R<sub>3</sub> (4; same R<sub>1</sub>; R<sub>3</sub> = H, C<sub>1</sub>-18 alkyl, preferably C<sub>1</sub>-6 alkyl). In an example, sodium 4-hydroxy- $\alpha$ -methoxybenzenepropanoate ( $\alpha$ S)-4-HOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CH(OMe)CO<sub>2</sub>Na was prepared in 53% yield and 92% ee by asym. hydrogenation of 200.0 mmol of (2Z)-4-HOC<sub>6</sub>H<sub>4</sub>CH:C(OMe)CO<sub>2</sub>H catalyzed by 0.5 mmol of [Ir(COD)Cl]<sub>2</sub> and 1.0 mmol of (S,S)-2,4-bis(diphenylphosphino)pentane in 240 mL of iso-Pr acetate and 60 mL of MeOH for 24 h at 65° and 3 atm of H<sub>2</sub>.

ACCESSION NUMBER: 2007:696717 CAPLUS Full-text  
DOCUMENT NUMBER: 147:95305  
TITLE: Process for the preparation of enantiomer-enriched  
2-alkoxy-3-arylpropionic acids by asymmetric  
hydrogenation of substituted 2-alkoxycinnamic  
acids  
INVENTOR(S): Woltering, Michael; Bunlaksananusorn, Tanasri;  
Gerlach, Arne  
PATENT ASSIGNEE(S): Saltigo G.m.b.H., Germany  
SOURCE: Eur. Pat. Appl., 16pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 1801093	A1	20070627	EP 2006-25546	20061211
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
DE 102005061472	A1	20070705	DE 2005-102005061472	20051222
US 20070149804	A1	20070628	US 2006-635302	20061207
US 7429676	B2	20080930		

CN 1986516 A 20070627 CN 2006-10168677 20061222  
 PRIORITY APPLN. INFO.: DE 2005-102005061472A 20051222  
 OTHER SOURCE(S): CASREACT 147:95305; MARPAT 147:95305  
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN  
 GI

/ Structure 37 in file .gra /

AB Title compds. (I; R2 = alkyl; R5-R8 = H, substituent) and salts thereof were prepared by reaction of benzaldehydes (II; R1 = protective group; R5-R8 as defined above) with R2OCH2CO2R3 (R3 = hydrocarbyl; R2 as defined above), hydrolysis of the resulting cinnamate esters to give cinnamic acids, *asym.* hydrogenation, and O-deprotection. Thus, a mixture of 4-benzyloxybenzaldehyde, Me methoxyacetate, and NaOMe was refluxed 5 h in MeOH to give 80% Me 3-(4-benzyloxyphenyl)-2-methoxyacrylate. This was refluxed 2 h with 1N NaOH in MeOH to give 85% 3-(4-benzyloxyphenyl)-2-methoxyacrylic acid Na salt. The latter was hydrogenated in MeOH over [Ru(p-cymene)][(S)-dm-segphos]]Cl in MeOH at 5 MPa and 60° for 16 h to give Na 3-(4-hydroxyphenyl)-2-methoxypropionate in 20% yield and 92.9% enantiomeric excess.

ACCESSION NUMBER: 2005:490344 CAPLUS Full-text

DOCUMENT NUMBER: 143:43684

TITLE: Process for preparation of optically active 3-(4-hydroxyphenyl)propionic acids by reaction of protected 4-hydroxybenzaldehydes and glycolic acid derivatives to give cinnamates and *asymmetric* hydrogenation of the latter.

INVENTOR(S): Yokozawa, Tohru; Shimizu, Hideo; Fujiwara, Takahiro; Ino, Yasunori

PATENT ASSIGNEE(S): Takasago International Corporation, Japan

SOURCE: PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051882	A1	20050609	WO 2004-JP17998	20041126
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1687250	A1	20060809	EP 2004-819490	20041126
R: CH, DE, ES, FR, GB, LI, IE				
JP 2007512222	T	20070517	JP 2006-520429	20041126
US 20070142472	A1	20070621	US 2006-578744	20060510
PRIORITY APPLN. INFO.:			JP 2003-398201	A 20031127



OTHER SOURCE(S): CASREACT 143:43684; MARPAT 143:43684  
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s 144 and 'chiral? cataly?'
      129174 'CHIRAL'
      19 'CHIRALS'
      129179 'CHIRAL'
          ('CHIRAL' OR 'CHIRALS')
      2 'CATALY'
      0 'CHIRAL? CATALY?'
          ('CHIRAL'(W)'CATALY')
L47      0 L44 AND 'CHIRAL? CATALY?'
```

=> 147 and chiral catalyst  
 L47 IS NOT A RECOGNIZED COMMAND  
 The previous command name entered was not recognized by the system.  
 For a list of commands available to you in the current file, enter  
 "HELP COMMANDS" at an arrow prompt (=>).

```
=> s 144 and chiral catalyst
      129174 CHIRAL
      19 CHIRALS
      129179 CHIRAL
          (CHIRAL OR CHIRALS)
      827404 CATALYST
      823540 CATALYSTS
      1060120 CATALYST
          (CATALYST OR CATALYSTS)
      2138 CHIRAL CATALYST
          (CHIRAL(W)CATALYST)
L48      0 L44 AND CHIRAL CATALYST
```

```
=> s 144 and chiral
      129174 CHIRAL
      19 CHIRALS
      129179 CHIRAL
          (CHIRAL OR CHIRALS)
L49      24 L44 AND CHIRAL
```

```
=> s 124 and catalyst
      12 "TOHRU"
      5 "YOKOZAWA"
      0 "TOHRU YOKOZAWA"
          ("TOHRU"(W)"YOKOZAWA")
      827404 CATALYST
      823540 CATALYSTS
      1060120 CATALYST
          (CATALYST OR CATALYSTS)
L50      0 L24 AND CATALYST
```

```
=> s 144 and chiral ligand
      129174 CHIRAL
      19 CHIRALS
      129179 CHIRAL
          (CHIRAL OR CHIRALS)
      357859 LIGAND
```

243937 LIGANDS  
486682 LIGAND  
(LIGAND OR LIGANDS)  
4290 CHIRAL LIGAND  
(CHIRAL(W)LIGAND)  
L56 2 L44 AND CHIRAL LIGAND

=> d l44 ibib abs 1-2

L44 ANSWER 1 OF 617 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2008:1522131 CAPLUS Full-text  
TITLE: Inhibitory activity of *Melissa officinalis* L. extract  
on Herpes simplex virus type 2 replication  
AUTHOR(S): Mazzanti, G.; Battinelli, L.; Pompeo, C.; Serrilli, A.  
M.; Rossi, R.; Sauzullo, I.; Mengoni, F.; Vullo, V.  
CORPORATE SOURCE: Department of Human Physiology and Pharmacology,  
"Sapienza" University, Rome, Italy  
SOURCE: Natural Product Research, Part B: Bioactive Natural  
Products (2008), 22(16), 1433-1440  
CODEN: NPRPEA  
PUBLISHER: Taylor & Francis Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB *Melissa officinalis* (Lamiaceae) (lemon balm) is used in folk medicine for nervous complaints, lower abdominal disorders and, more recently, for treating Herpes simplex lesions. In this work the antiviral activity of a hydroalcoholic extract of lemon balm leaves against the Herpes simplex virus type 2 (HSV-2) was assessed by the cytopathic effect inhibition assay on Vero cells (ATCC CCL-81), in comparison with acyclovir. The cytotoxicity of the extract on Vero cells was previously tested by evaluating the cellular death and was confirmed by the Trypan blue test. Lemon balm showed to reduce the cytopathic effect of HSV-2 on Vero cells, in the range of non-toxic concns. of 0.025-1 mg mL<sup>-1</sup> (with reference to the starting crude herbal material). The maximum inhibiting effect (60%) was obtained with 0.5 mg mL<sup>-1</sup>. The viral binding assay showed that the extract does not prevent the entry of HSV-2 in the cells, thus suggesting a mechanism of action subsequent to the penetration of the virus in the cell. The extract was also chemical characterized by NMR and HPLC anal.; it showed to contain cinnamic acid-like compds., mainly rosmarinic acid (4.1% weight/weight). Our expts. support the use of lemon balm for treating Herpes simplex lesions and encourage clin. trials on this medicinal plant.

L44 ANSWER 2 OF 617 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2008:1433048 CAPLUS Full-text  
DOCUMENT NUMBER: 150:41243  
TITLE: Method for preparing salvianolic acid A of *Salvia miltiorrhiza* with salvianolic acid B  
INVENTOR(S): Li, Zhigang; Gu, Qun; Qu, Shoufeng; Mi, Changjiang;  
Lin, Zhirong  
PATENT ASSIGNEE(S): Beijing Bencao Tianyuan Pharmaceutical Research  
Institute, Peop. Rep. China  
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 20pp.  
CODEN: CNXXEV  
DOCUMENT TYPE: Patent  
LANGUAGE: Chinese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	-----	-----	-----	-----
CN 101311160	A	20081126	CN 2007-10099618	20070525
PRIORITY APPLN. INFO.:			CN 2007-10099618	20070525

AB The invention relates to a method for preparing salvianolic acid A of Salvia miltiorrhiza with salvianolic acid B. The method comprises (1) dissolving salvianolic acid B in water, adjusting pH to 3.5-6, heating at 110-130°C for 1-6h, filtering, concentrating, and drying to obtain salvianolic acid A extract; or dissolving salvianolic acid B in water, adjusting pH to 3.5-6, extracting under irradiation of microwave at 915-2450 MHZ and 1000-15000 W for 0.5-2 h, filtering, concentrating, and drying to obtain salvianolic acid A extract; (2) purifying by nonpolar or weak-polar macroporous resin column chromatog., silica gel chromatog., dextran gel LH-20 chromatog., polyamide chromatog. and/or extraction

L60 STRUCTURE UPLOADED

=> s 160  
SAMPLE SEARCH INITIATED 10:37:49 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 597 TO ITERATE

100.0% PROCESSED 597 ITERATIONS 26 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 10475 TO 13405  
PROJECTED ANSWERS: 215 TO 825

L61 26 SEA SSS SAM L60

=> d scan

> s 161/prep  
122 L61  
4705416 PREP/RL  
L62 50 L61/PREP  
(L61 (L) PREP/RL)

=>

=> s 165/prep  
3709 L65  
4705416 PREP/RL  
L66 1056 L65/PREP  
(L65 (L) PREP/RL)

=> s 166 and (py<2003 or ay<2003 or pry<2003)  
22983068 PY<2003  
4502889 AY<2003  
3971612 PRY<2003  
L67 600 L66 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> s 167 and (optical? activ?)

1145195 OPTICAL?

4457524 ACTIV?

51440 OPTICAL? ACTIV?

(OPTICAL?(W)ACTIV?)

L68 28 L67 AND (OPTICAL? ACTIV?)

=> s 167 and cataly?

1500302 CATALY?

L69 52 L67 AND CATALY?

=> d 169 ibib abs 1-5

L69 ANSWER 1 OF 52 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:491168 CAPLUS Full-text

DOCUMENT NUMBER: 139:69049

TITLE: Preparation of substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (PPAR)  
INVENTOR(S): Lindstedt Alstermark, Eva-Lotte; Olsson, Anna Christina; Li, Lanna

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2003051821	A1	20030626	WO 2002-GB5738	20021218 <--
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
CA 2470491	A1	20030626	CA 2002-2470491	20021218 <--
AU 2002366315	A1	20030630	AU 2002-366315	20021218 <--
EP 1458673	A1	20040922	EP 2002-804964	20021218 <--
EP 1458673	B1	20060906		
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK	
BR 2002014988	A	20041214	BR 2002-14988	20021218 <--
HU 2004002133	A2	20050228	HU 2004-2133	20021218 <--
CN 1620422	A	20050525	CN 2002-828123	20021218 <--
CN 1293044	C	20070103		
CN 1620423	A	20050525	CN 2002-828155	20021218 <--
JP 2005526011	T	20050902	JP 2003-552709	20021218 <--
JP 3784804	B2	20060614		
TW 253444	B	20060421	TW 2002-91136518	20021218 <--
NZ 533276	A	20060428	NZ 2002-533276	20021218 <--
TW 255807	B	20060601	TW 2002-91136519	20021218 <--
AT 338743	T	20060915	AT 2002-804964	20021218 <--
CN 1896045	A	20070117	CN 2006-10007173	20021218 <--

ES 2271381	T3	20070416	ES 2002-804964	20021218 <--
AT 363466	T	20070615	AT 2002-788145	20021218 <--
RU 2303031	C2	20070720	RU 2004-116917	20021218 <--
ES 2286310	T3	20071201	ES 2002-788145	20021218 <--
IN 2004DN01549	A	20070817	IN 2004-DN1549	20040604 <--
ZA 2004004657	A	20050829	ZA 2004-4657	20040611 <--
ZA 2004004658	A	20060222	ZA 2004-4658	20040611 <--
MX 2004PA06004	A	20040927	MX 2004-PA6004	20040618 <--
NO 2004003023	A	20040715	NO 2004-3023	20040715 <--
US 20050282822	A1	20051222	US 2004-26806	20041230 <--
HK 1068604	A1	20070302	HK 2005-100831	20050201 <--
US 20050171204	A1	20050804	US 2005-499261	20050304 <--
JP 2005336209	A	20051208	JP 2005-235794	20050816 <--
JP 2006298924	A	20061102	JP 2006-123399	20060427 <--
PRIORITY APPLN. INFO.:			SE 2001-4334	A 20011219 <--
			CN 2002-828123	A3 20021218 <--
			JP 2003-552709	A3 20021218 <--
			JP 2003-552710	A3 20021218 <--
			WO 2002-GB5738	W 20021218 <--
			WO 2002-GB5744	A 20021218 <--
			GB 2002-29931	A 20021221 <--
			GB 2003-14079	A 20030618
			WO 2003-GB5602	A 20031219
			WO 2004-EP6597	A 20040617
			US 2005-499261	A2 20050304

OTHER SOURCE(S):            MARPAT 139:69049  
GI

/ Structure 43 in file .gra /

AB    The S enantiomer of I, n = 1 or 2, (C<sub>6</sub>H<sub>13</sub> = hexyl) as well as their pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs are synthesized using various solvents and in presence of charcoal-supported palladium catalyst. The utility of these compds. in clin. conditions such as lipid disorders (dyslipidemias) whether or not associated with insulin resistance and therapeutic and other pharmaceutical activities is also investigated. For example, (2S)-3-(4{2-[benzyl(hexyl)amino]-2-oxoethoxy}phenyl)2-ethoxypropionic acid was prepared in 58% yield via reaction of (2S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate and benzyl bromoacetate.

REFERENCE COUNT:            8            THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L69 ANSWER 2 OF 52 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:            2003:22888 CAPLUS Full-text

DOCUMENT NUMBER:            138:73085

TITLE:                        Preparation of 3-aryl- $\alpha$ -oxy substituted propanoic acids for treatment of type II diabetes and related disorders

INVENTOR(S):                Potlapally, Rajender Kumar; Velagala, Venkata Rama Murali Krishna Reddy; Mamillapalli, Ramabhadra Sarma; Gaddam, Om Reddy

PATENT ASSIGNEE(S):        Reddy's Research Foundation, India

SOURCE:                     PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DOCUMENT TYPE:             Patent

LANGUAGE:                   English

FAMILY ACC. NUM. COUNT:    1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002575	A1	20030109	WO 2001-IN124	20010628 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001277663	A1	20030303	AU 2001-277663	20010628 <--
JP 2004530728	T	20041007	JP 2003-508956	20010628 <--
US 20040248849	A1	20041209	US 2004-481735	20040728 <--
PRIORITY APPLN. INFO.:			WO 2001-IN124	W 20010628 <--
OTHER SOURCE(S):			CASREACT 138:73085; MARPAT 138:73085	
GI				

/ Structure 44 in file .gra /

AB 3-Aryl- $\alpha$ -oxy substituted propanoic acids [I; wherein R1 = tert-butyl dimethylsilyl, trimethylsilyl, alkoxyalkyl; R2 = H, (substituted) (C1-C6)alkyl] were prepared For example, Me tert-butyl dimethylsilyloxy-3-(4-hydroxyphenyl)propanoate (II) was prepared in three steps. The prepared compds. are useful for treating diabetes, obesity, glucose intolerance, insulin resistance and other related disorders such as hypertension, coronary heart disease, atherosclerosis, stroke, peripheral vascular diseases and related disorders (no data). The prepared compds. are also useful for reducing total cholesterol, body weight, blood plasma glucose, triglycerides, LDL, VLDL and free fatty acids (no data).

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L69 ANSWER 3 OF 52 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:927394 CAPLUS Full-text

DOCUMENT NUMBER: 138:4416

TITLE: Process for the preparation 3-aryl-2-hydroxypropionic acid derivatives

INVENTOR(S): Ehrl, Robert; Ioannidis, Panagiotis; Mackintosh, William

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.

SOURCE: PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096865	A1	20021205	WO 2002-SE1040	20020530 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2448658	A1	20021205	CA 2002-2448658	20020530 <--
AU 2002309400	A1	20021209	AU 2002-309400	20020530 <--
NZ 529815	A	20031219	NZ 2002-529815	20020530 <--
EP 1404651	A1	20040407	EP 2002-736372	20020530 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2002010125	A	20040608	BR 2002-10125	20020530 <--
JP 2004528388	T	20040916	JP 2003-500045	20020530 <--
CN 1535262	A	20041006	CN 2002-814965	20020530 <--
CN 1247537	C	20060329		
ZA 2003009216	A	20040916	ZA 2003-9216	20031126 <--
MX 2003PA11011	A	20040227	MX 2003-PA11011	20031128 <--
US 20050014955	A1	20050120	US 2004-479159	20040823 <--

PRIORITY APPLN. INFO.: SE 2001-1979 A 20010601 <--  
 SE 2002-1004 A 20020402 <--  
 WO 2002-SE1040 W 20020530 <--

OTHER SOURCE(S): CASREACT 138:4416; MARPAT 138:4416

AB 2-Ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid (I) or its alkyl esters were prepared by etherification of 2-ethoxy-3-(4-hydroxyphenyl)propanoic acid (II) or alkyl ester with 4-MeSO<sub>3</sub>C<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CH<sub>2</sub>-X (X is a suitable leaving group) in the presence of a base and a phase transfer catalyst at 50-150°C. Thus, 4-MeSO<sub>3</sub>C<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CH<sub>2</sub>O<sub>3</sub>SMe (1.01 mol), (S)-II Et ester (406 mmol) and PEG-400 (81 mmol) were melted together at 110 °C, Na<sub>2</sub>CO<sub>3</sub> (536 mmol) added under vigorous stirring, and the reaction continued at this temperature for 5.5 h. Saponification of the ester afforded (S)-I, a compound for therapeutic use in the Insulin Resistance Syndrome (IRS).

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L69 ANSWER 4 OF 52 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:793403 CAPLUS Full-text

DOCUMENT NUMBER: 137:310931

TITLE: Preparation of phenylalkanoic acid derivatives as preventive or remedial agents for digestive tract diseases

INVENTOR(S): Horizoe, Tatsuo; Shinoda, Masanobu; Emori, Eita; Matsuura, Fumiyoshi; Kaneko, Toshihiko; Ohi, Norihito; Kasai, Shunji; Yoshitomi, Hideki; Yamazaki, Kazuto; Miyashita, Sadakazu; Hihara, Taro; Seiki, Takashi; Clark, Richard; Harada, Hitoshi

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: PCT Int. Appl., 344 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002080899	A1	20021017	WO 2002-JP3006	20020327 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,			

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 AU 2002242989 A1 20021021 AU 2002-242989 20020327 <--  
 PRIORITY APPLN. INFO.: JP 2001-101465 A 20010330 <--  
 JP 2001-105131 A 20010403 <--  
 WO 2002-JP3006 W 20020327 <--  
 OTHER SOURCE(S): MARPAT 137:310931  
 GI

/ Structure 45 in file .gra /

AB Disclosed is a preventive/remedy for digestive tract or inflammatory diseases, which contains as the active ingredient a novel carboxylic acid derivative represented by the following formula [I; R1 = H, OH, each (un)substituted C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 hydroxyalkyl, C1-6 hydroxyalkoxy, C1-6 hydroxyalkylthio, C1-6 aminoalkyl, C1-6 aminoalkoxy, C1-6 aminoalkylthio, C2-12 alkoxyalkyl, C3-7 cycloalkyl, C3-7 cycloalkyloxy, C3-7 cycloalkylthio, C2-6 alkenyl, C2-6 alkenyloxy, or C2-6 alkenylthio, etc.; L = a single or double bond, each (un)substituted C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene; M = a single bond, each (un)substituted C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene; T = a single bond, each (un)substituted C1-3 alkylene, C2-3 alkenylene, or C2-3 alkynylene; W = 2,4-dioxothiazolidin-5-yl, 2,4-dioxothiazolidin-5-ylidene, carboxy, (un)substituted CONH2; X = O, (un)substituted C2-6 alkenylene, hydroxymethylene, CO, CS, N-(un)substituted CQN, NHCQ, SO2NH, NHSO2, or NHCQN (Q = O, S); Y = (un)substituted C5-12 aromatic hydrocarbyl or C3-7 aliphatic hydrocarbyl optionally containing  $\geq 1$  heteroatoms; ring Z = C5-6 aromatic hydrocarbyl; Y = (un)substituted aromatic hydrocarbon group optionally containing  $\geq 1$  heteroatoms; some provisos given], a salt of the derivative, or a hydrate of either. The above digestive tract diseases include (1) inflammatory digestive tract diseases such as ulcerous colitis, Crohn's disease, pancreatitis, and gastritis, (2) digestive tract proliferative diseases such as digestive tract benign tumors, digestive tract polyp, hereditary (genetic) polyposis syndromes, colon cancer, rectum cancer, and stomach cancer, and (3) digestive tract ulcerous diseases such as duodenal ulcer, stomach ulcer, esophagus ulcer, regurgitant esophagitis, stress ulcer or erosion, erosion caused by drugs, and Zollinger-Ellison syndromes. The above inflammatory diseases include arthritic rheumatism, multiple sclerosis, immunodeficiency, cachexia, osteoarthritis, osteoporosis, asthma, and allergy. The compds. I are triple agonists for PPAR (peroxisome proliferator-activated receptor)  $\alpha$ ,  $\beta$ , and  $\gamma$  subtype. Thus, 2-isopropoxy-3-[4-methoxy-3-[[[4-(trifluoromethyl)benzyl]amino]carbonyl]phenyl]propanoic acid in vitro showed the transcription activity for PPAR $\alpha$ ,  $\beta$ , and  $\gamma$  with EC50 of 0.08, 2.513, and 0.382  $\mu$ M, resp., in CV-1 cell. (2S)-3-[3-[[[(2,4-dichlorobenzoyl)amino]methyl]-4-methoxyphenyl]-2-isopropoxypropanoic acid at 1 mg/kg/day p.o. for 3 days showed a disease activity index based on diarrhea, bloody excrement, and weight loss (DAI) of  $2.0 \pm 0.3$  in mice suffering from colitis induced by dextran sulfate sodium salt vs.  $2.8 \pm 0.2$  for the control group and  $2.1 \pm 0.3$  for the mice treated with rosiglitazone at 30 mg/kg/day. Many compds. prepared do not possess the thiazolidine skeleton and thereby may completely avoid toxicity such as liver disorder which was noted in the past as a problem for compds. having PPAR $\gamma$  agonist activity.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



ACCESSION NUMBER: 2002:620035 CAPLUS Full-text  
DOCUMENT NUMBER: 138:89669  
TITLE: Efficient synthesis of antihyperglycemic  
(S)- $\alpha$ -aryloxy- $\beta$ -phenylpropionic acid  
derivative using a bifunctional asymmetric  
catalyst  
AUTHOR(S): Takamura, Makoto; Yanagisawa, Hiroaki; Kanai, Motomu;  
Shibasaki, Masakatsu  
CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Sankyo Co.,  
Ltd., Tokyo, 140-8710, Japan  
SOURCE: Chemical & Pharmaceutical Bulletin (2002),  
50(8), 1118-1121  
CODEN: CPBTAL; ISSN: 0009-2363  
PUBLISHER: Pharmaceutical Society of Japan  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 138:89669  
GI

L70 STRUCTURE UPLOADED

=> s sss full l70  
FULL SEARCH INITIATED 11:17:13 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 12087 TO ITERATE

100.0% PROCESSED 12087 ITERATIONS 7767 ANSWERS  
SEARCH TIME: 00.00.01

L71 7767 SEA SSS FUL L70

=> s l71/prep  
3709 L71  
4705416 PREP/RL  
L72 1056 L71/PREP  
(L71 (L) PREP/RL)

=> s l72 and (py<2003 or ay<2003 or pry<2003)  
22983068 PY<2003  
4502889 AY<2003  
3971612 PRY<2003  
L73 600 L72 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> s l73 and chiral? and cataly?  
139278 CHIRAL?  
1500302 CATALY?  
L74 4 L73 AND CHIRAL? AND CATALY?

=> s l73 and ('asymmetric hydrogenation' or ' ?select? hydrogenation')  
76804 'ASYMMETRIC'  
31 'ASYMMETRICS'  
76835 'ASYMMETRIC'  
( 'ASYMMETRIC' OR 'ASYMMETRICS')  
147804 'ASYM'  
6 'ASYMS'  
147807 'ASYM'  
( 'ASYM' OR 'ASYMS')  
171488 'ASYMMETRIC'  
( 'ASYMMETRIC' OR 'ASYM')  
184214 'HYDROGENATION'

```

2478 'HYDROGENATIONS'
184475 'HYDROGENATION'
      ('HYDROGENATION' OR 'HYDROGENATIONS')
4061 'ASYMMETRIC HYDROGENATION'
      ('ASYMMETRIC'(W)'HYDROGENATION')
42578 'SELECT'
7625 'SELECTS'
49664 'SELECT'
      ('SELECT' OR 'SELECTS')
184214 'HYDROGENATION'
2478 'HYDROGENATIONS'
184475 'HYDROGENATION'
      ('HYDROGENATION' OR 'HYDROGENATIONS')
0 ' ?SELECT? HYDROGENATION'
      ('SELECT'(W)'HYDROGENATION')
L75 0 L73 AND ('ASYMMETRIC HYDROGENATION' OR ' ?SELECT? HYDROGENATION'
      )

```

=> d 174 ibib abs 1-4

```

L74 ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:    2001:836609  CAPLUS  Full-text
DOCUMENT NUMBER:     136:118291
TITLE:               Total synthesis of biologically active compounds
                      related to plant disease and the physiological
                      function
AUTHOR(S):           Toshima, Hiroaki
CORPORATE SOURCE:     Department of Bioresource Science, College of
                      Agriculture, Ibaraki University, Ibaraki, 300-0393,
                      Japan
SOURCE:              Yuki Gosei Kagaku Kyokaishi (2001), 59(11),
                      1121-1129
                      CODEN: YGKKAE; ISSN: 0037-9980
PUBLISHER:           Yuki Gosei Kagaku Kyokai
DOCUMENT TYPE:        Journal; General Review
LANGUAGE:             English
AB  A review, total synthesis of biol. active compds. related to plant disease and
    the physiol. function has been accomplished. Coronatine, its related compds.,
    β-resorcylic acid derivs., decumbic acid, aliphatic δ-lactones, cepaciamides,
    and piscidic acids, were selected as the synthetic targets. In these
    syntheses, the chiral pool method and catalytic asym. synthesis were also
    applied to introduce the requisite stereogenic centers. Combination of the
    two methods made it possible to synthesize a sufficient amount of the required
    enantiomers and diastereomers for biol. studies.
REFERENCE COUNT:     43  THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS
                      RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```

```

L74 ANSWER 2 OF 4  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:    1999:784755  CAPLUS  Full-text
DOCUMENT NUMBER:     132:166053
TITLE:               Total syntheses of all four stereoisomers of piscidic
                      acid via catalytic asymmetric
                      dihydroxylation of (Z)- and (E)-trisubstituted olefins
AUTHOR(S):           Toshima, Hiroaki; Saito, Masatoshi; Yoshihara,
                      Teruhiko
CORPORATE SOURCE:     Department of Bioscience and Chemistry, Faculty of
                      Agriculture, Hokkaido University, Sapporo, 060-8589,
                      Japan
SOURCE:              Bioscience, Biotechnology, and Biochemistry (
                      1999), 63(11), 1934-1941

```

CODEN: BBBIEJ; ISSN: 0916-8451  
PUBLISHER: Japan Society for Bioscience, Biotechnology, and Agrochemistry  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 132:166053  
AB Four stereoisomers of (2S,3R)-(+)-piscidic acid were synthesized with high optical purity via Sharpless catalytic asym. dihydroxylation of (Z)- and (E)-trisubstituted olefins in 6 steps from (4-hydroxyphenyl)pyruvic acid. That is Wittig reaction of Me (4-hydroxyphenyl)pyruvate with (carbomethoxymethylene)triphenylphosphorane give (Z)- and (E)-trisubstituted olefins in a 3:1 ratio, protecting the phenolic hydroxyl group with tert-butyldimethylsilyl, then the (Z)-olefin was subjected to asym. dihydroxylation by using the chiral ligand, dihydroquinidine 1,4-anthraquinonediyl diether, gave the product with 89% e.e. Desilylation and subsequent alkaline hydrolysis gave (2S,3R)-(+)-piscidic acid with > 99% e.e. after recrystn. Use of ligand, dihydroquinine 1,4-anthraquinonediyl diether, gave (2R,3S)-(-)-piscidic acid. Asym. dihydroxylation of the (E)-olefin with phthalazine ligands (dihydroquinidine and dihydroquinine 1,4-phthalazinediyl diethers) also gave high e.e. values product, followed by the same procedure mentioned above, gave (2S,3S)-(+)-3-epi-piscidic acid and (2R,3R)-(-)-2-epi-piscidic acid resp.  
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L74 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1999:363435 CAPLUS Full-text  
DOCUMENT NUMBER: 131:184794  
TITLE: Total synthesis of (+)-(2S,3R)-Piscidic acid via catalytic asymmetric dihydroxylation of a trisubstituted olefin  
AUTHOR(S): Toshima, Hiroaki; Saito, Masatoshi; Yoshihara, Teruhiko  
CORPORATE SOURCE: Department of Bioscience and Chemistry, Faculty of Agriculture, Hokkaido University, Sapporo, 060-8589, Japan  
SOURCE: Bioscience, Biotechnology, and Biochemistry (1999), 63(5), 964-967  
CODEN: BBBIEJ; ISSN: 0916-8451  
PUBLISHER: Japan Society for Bioscience, Biotechnology, and Agrochemistry  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 131:184794  
AB (+)-(2S,3R)-Piscidic acid was efficiently synthesized with high optical purity (90% e.e.) via Sharpless catalytic asym. dihydroxylation of a trisubstituted olefin in only 6 steps from com. available 4-hydroxyphenyl-pyruvic acid as the starting material. The reaction proceeded with high optical purity by using the chiral ligands, dihydroquinidine 2,5-diphenyl-4,6-pyrimidinediyl diether or dihydroquinidine 1,4-anthraquinonediyl diether.  
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L74 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1992:426523 CAPLUS Full-text  
DOCUMENT NUMBER: 117:26523  
ORIGINAL REFERENCE NO.: 117:4791a,4794a  
TITLE: Enantioselective synthesis of calcium channel blockers of the diltiazem group  
AUTHOR(S): Schwartz, Alan; Madan, Pradeep B.; Mohacsi, Erno;

CORPORATE SOURCE: O'Brien, Jay P.; Todaro, Louis J.; Coffen, David L.  
Roche Res. Cent., Hoffmann-La Roche Inc., Nutley, NJ,  
07110, USA  
SOURCE: Journal of Organic Chemistry (1992), 57(3),  
851-6  
CODEN: JOCEAH; ISSN: 0022-3263  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 117:26523  
GI

/ Structure 47 in file .gra /

AB A lipase-catalyzed kinetic resolution of racemic trans-2-phenylcyclohexanol readily provides the (-)-(1R,2S) enantiomer. This alc. is employed as its chloroacetate in a chiral auxiliary-induced asym. Darzens glycidic ester condensation with p-anisaldehyde. Crystallization of the Darzens product affords enantiomerically pure phenylcyclohexyl (methoxyphenyl)glycidate I, the structure of which was established by x-ray crystallog. The use of this glycidic ester in syntheses of diltiazem II (R = R1 = H) and maltiazem II [RR1 = (CH:CH)2], members of the diltiazem group of calcium channel blockers, provides these drug substances directly in enantiomerically pure form.

=> d 173 ibib abs 1-5

L73 ANSWER 1 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2008:994060 CAPLUS Full-text  
DOCUMENT NUMBER: 149:306485  
TITLE: Di-m-Chlorobis[Bis-(cyclooctene)rhodium]  
AUTHOR(S): Judd, Andrew S.  
CORPORATE SOURCE: USA  
SOURCE: e-EROS Encyclopedia of Reagents for Organic Synthesis  
(2001), No pp. given. John Wiley & Sons,  
Ltd.: Chichester, UK.  
CODEN: 69KUHI  
URL: <http://www3.interscience.wiley.com/cgi-bin/mrwhome/104554785/HOME>  
DOCUMENT TYPE: Conference; General Review; (online computer file)  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 149:306485  
AB A review of the article Di-m-Chlorobis[Bis-(cyclooctene)rhodium].

L73 ANSWER 2 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2008:302246 CAPLUS Full-text  
DOCUMENT NUMBER: 148:262617  
TITLE: Preparation of pyrimidine- and triazine-derivative  
endothelin receptor antagonists  
INVENTOR(S): Riechers, Hartmut; Klinge, Dagmar; Amberg, Wilhelm;  
Kling, Andreas; Mueller, Stefan; Baumann, Ernst;  
Rheinheimer, Joachim; Vogelbacher, Uwe Josef; Wernet,  
Wolfgang; Unger, Liliane; Raschack, Manfred  
PATENT ASSIGNEE(S): Abbott Gmbh & Co. KG, Germany  
SOURCE: U.S., 18pp., Cont. of U.S. Ser. No. 748,184.  
CODEN: USXXAM

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7109205	B2	20060919	US 2003-602275	20030624 <--
US 20040092742	A1	20040513		
DE 19533023	A1	19960418	DE 1995-19533023	19950907 <--
DE 19533023	B4	20070516		
WO 9611914	A1	19960425	WO 1995-EP3963	19951007 <--
W: AU, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, MX, NO, NZ, PL, RU, SG, SI, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1110952	A1	20010627	EP 2001-103889	19951007 <--
EP 1110952	B1	20040929		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
US 5932730	A	19990803	US 1997-809699	19970327 <--
US 5969134	A	19991019	US 1998-184152	19981102 <--
US 6197958	B1	20010306	US 1999-309770	19990511 <--
US 20020052495	A1	20020502	US 2000-748184	20001227 <--
US 6600043	B2	20030729		
US 20060160808	A1	20060720	US 2006-377879	20060316 <--
US 7119097	B2	20061010		
US 20060276645	A1	20061207	US 2006-502257	20060810 <--
US 20060276474	A1	20061207	US 2006-502293	20060810 <--
US 20070203338	A1	20070830	US 2007-789630	20070425 <--
PRIORITY APPLN. INFO.:				
			DE 1994-4436851	A 19941014 <--
			DE 1995-19533023	A 19950907 <--
			WO 1995-EP3963	W 19951007 <--
			US 1997-809699	A3 19970327 <--
			US 1998-184152	A3 19981102 <--
			US 1999-309770	A3 19990511 <--
			US 2000-748184	A1 20001227 <--
			EP 1995-935916	A3 19951007 <--
			US 2003-602275	A1 20030624
			US 2006-502257	B1 20060810
OTHER SOURCE(S): MARPAT 148:262617				
GI				

/ Structure 48 in file .gra /

AB The title compds. I [R = CHO, tetrazolyl, CN, CO<sub>2</sub>H, groups cleavable to CO<sub>2</sub>H; R<sub>2</sub> = (un)substituted NH<sub>2</sub>, halogen, (un)substituted alkyl, etc.; R<sub>3</sub> = H, OH, (un)substituted NH<sub>2</sub>, halogen, (un)substituted alkyl, etc.; R<sub>4</sub>, R<sub>5</sub> = (un)substituted Ph or naphthyl; R<sub>6</sub> = H, alkyl, alkenyl, alkynyl, alkylcarbonyl, (un)substituted Ph, etc.; X = N, (un)substituted CH; Y = direct bond, S, O; Z = S, O, SO, SO<sub>2</sub>, direct bond], and their pharmaceutically acceptable salts, are prepared and disclosed as endothelin receptor antagonists. In receptor binding assays, pyrimidine derivative II (R<sub>2</sub> and R<sub>3</sub> = MeO), m.p. 167°, demonstrated a K<sub>i</sub> ETA of 6 nM. In particular, the racemate and individual enantiomers of II (R<sub>2</sub> and R<sub>3</sub> = Me) are claimed.

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2007:899716 CAPLUS Full-text  
DOCUMENT NUMBER: 148:495971  
TITLE: Process for the preparation of antidiabetic compound  
PATENT ASSIGNEE(S): Dr. Reddy's Laboratories Ltd., India  
SOURCE: Indian Pat. Appl., 30pp.  
CODEN: INXXBQ  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
IN 2002MA00399	A	20070803	IN 2002-MA399	20020523 <--
PRIORITY APPLN. INFO.:			IN 2002-MA399	20020523 <--
OTHER SOURCE(S):	CASREACT 148:495971; MARPAT 148:495971			
GI				

/ Structure 49 in file .gra /

AB A invention relates to a process for the preparation of tromethamine salt of (-)-3-[4-(2-(5-ethyl-1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-6-yl)ethoxy)phenyl]-2-alkoxypropionic acid of the formula I, where R is C1-6 alkyl, c. Example compound I (R = Et) was prepared by etherification of iso-Pr 3-(4-hydroxyphenyl)-2(S)-hydroxypropionate with 5-ethyl-6-(2-chloroethyl)-1-methyl-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-7-one; the resulting (-)-[[(pyrazolo[4,3-d]pyrimidin-7-yl)ethoxy]phenyl]-2-hydroxypropanoate derivative underwent O-alkylation followed by hydrolysis to give the corresponding 2-alkoxypropanoic acid, which was reacted with tromethamine to give compound I.

L73 ANSWER 4 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:544712 CAPLUS Full-text  
DOCUMENT NUMBER: 148:449648  
TITLE: An improved process for the preparation of phenoxazine antidiabetic compounds  
INVENTOR(S): Rao, Siripragada Mahender; Reddy, Chepyala Naveen Kumar; Reddy, Challa Maheedhara; Sarma, Mamillapalli Ramabhandra; Reddy, Gaddam Om  
PATENT ASSIGNEE(S): Reddy's Laboratories Ltd., India  
SOURCE: Indian Pat. Appl., 18pp.  
CODEN: INXXBQ  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
IN 2002MA00508	A	20070511	IN 2002-MA508	20020708 <--
PRIORITY APPLN. INFO.:			IN 2002-MA508	20020708 <--
OTHER SOURCE(S):	CASREACT 148:449648; MARPAT 148:449648			
GI				

/ Structure 50 in file .gra /

AB The invention relates to an improved process for the preparation of antidiabetic phenoxazinylethoxyphenylalkoxypropanoate arginine salts I [R1 = Me, Et, Pr, i-Pr]. The process uses inexpensive chems. and an easy resolution via chiral amine salts. Thus, condensation of 4-[2-(phenoxazin-10-yl)ethoxy]benzaldehyde with Et chloroacetate using EtONa in EtOH gave the corresponding glycidic ester, which was hydrogenated over Pd/C, O-ethylated with di-Et sulfate in xylene, and saponified with aqueous NaOH in MeOH to give acid (±)-II. Resolution of this racemate using (-)-ephedrine and salification with L-arginine in i-PrOH gave I (R1 = Et).

L73 ANSWER 5 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:544708 CAPLUS Full-text

DOCUMENT NUMBER: 148:449647

TITLE: Process for the preparation of antidiabetic (S)-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid L-arginine salt

INVENTOR(S): Reddy, Gaddam Om

PATENT ASSIGNEE(S): Reddy's Laboratories Ltd., India

SOURCE: Indian Pat. Appl., 9pp.

CODEN: INXXBQ

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
IN 2002MA00017	A	20070511	IN 2002-MA17	20020107 <--
PRIORITY APPLN. INFO.:			IN 2002-MA17	20020107 <--
OTHER SOURCE(S):		CASREACT 148:449647; MARPAT 148:449647		

GI

/ Structure 51 in file .gra /

AB Claimed is a process for the preparation of compound I [R1 = alkyl] comprising (a) reacting a [(phenoxazinyl)ethoxy]phenylpropanoic acid derivative with 1-phenylethylamine in the presence of a solvent at 20°C to 50°C, (b) reacting the resulting salt with L-arginine in the presence of a solvent in the range of 20°C to reflux temperature for 4 to 24 h; (c) isolating the resulting product. I is an antidiabetic agent (no data). Thus, (S)-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid (II) in Et acetate was reacted with 1-phenylethylamine to give a salt ; a solution of said salt in methanol was treated with L-arginine to give II L-arginine salt.

L73 ANSWER 6 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:183455 CAPLUS Full-text

DOCUMENT NUMBER: 146:462276

TITLE: Preparation of pyrimidinone derivatives for use in medicine and pharmaceutical compositions containing them

INVENTOR(S): Madhavan, Gurram Ranga; Venkateswarlu, Akella; Rajagopalan, Ramanujam; Chakrabarti, Ranjan; Misra, Parimal; Lohray, Braj Bhushan; Lohray, Vidya Bhushan;

PATENT ASSIGNEE(S): Rao, Paraselli Bheema  
SOURCE: Dr. Reddy's Research Foundation, India  
Indian Pat. Appl., 112pp.  
CODEN: INXXBQ  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2001MA00568	A	20050304	IN 2001-MA568	20010710 <--
PRIORITY APPLN. INFO.:			IN 2001-MA568	20010710 <--
OTHER SOURCE(S):		CASREACT 146:462276; MARPAT 146:462276		
GI				

/ Structure 53 in file .gra /

AB Title compds. I [X = O or S; R1-3 independently when attached to C = H, halo, OH, CN, etc.; when R3 is attached to N, R3 = H, OH, CHO, etc.; R4 = H, halo, alkyl, etc.; R5 = H, halo, alkoxy, etc.; or R4 and R5 join to form a bond; R6 = H, (un)substituted alkyl, acyl, aryl, etc.; R7 = H, (un)substituted alkyl, cycloalkyl, aryl, etc.; Y = O or NR8, where R8 = H, alkyl, aryl, etc.; or R7 and R8 may join to form cyclic or heterocyclic ring; n = 1-4; Ar = (un)substituted aryl or heterocyclic group], and their pharmaceutically acceptable salts, are prepared and disclosed as antiobesity and anticholesteremic agents. Thus, e.g., II was prepared by substitution of Et 2-ethoxy-3-[4-(2-haloethoxy)phenyl]propanoate with 2-ethyl-4-phenyl-1,6-dihydropyrimidin-6-one followed by hydrolysis to provide the carboxylic acid. I were evaluated for hPPAR $\gamma$  activity, e.g., II was determined to have a PPAR $\gamma$  value of 23.9 at 1  $\mu$ M. The present invention relates to novel antiobesity and hypocholesterolemic compds., their derivs., their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable composition containing them.

L73 ANSWER 7 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:181507 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 148:355830

TITLE: Preparation of thiodiphenylamines and related compounds as hypolipemic agents

INVENTOR(S): Lohray, Braj Bhushan; Lohray, Vidya Bhushan; Bajji, Ashok Channa Veerappa; Kalchar, Shivaramayya; Rao, Paraselli Bheema; Madhavan, Gurram Ranga; Rajacopalan, Ramanujam; Chakrabarti, Ranjan

PATENT ASSIGNEE(S): Dr. Reddy's Research Foundation, India

SOURCE: Indian Pat. Appl., 75pp.

CODEN: INXXBQ

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 1999MA00483	A	20050304	IN 1999-MA483	19990428 <--
PRIORITY APPLN. INFO.:			IN 1999-MA483	19990428 <--



OTHER SOURCE(S):            MARPAT 148:355830  
GI

/ Structure 54 in file .gra /

AB     Title compds. I [Z = (CH<sub>2</sub>)<sub>m</sub>; m = 1-4; n = 0-1; R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> = H, halo, OH, etc.; A = 5 or 6-membered cyclic structure with provisos; X = O, S, NR<sub>9</sub>; R<sub>9</sub> = H, alkyl, aryl, etc.; Ar = fused aromatic, heterocyclic, etc.; R<sub>5</sub> = H, OH, halo, etc.; R<sub>6</sub> = H, OH, halo, etc.; R<sub>7</sub> = H, alkyl, cycloalkyl, etc.; R<sub>8</sub> = H, alkyl, cycloalkyl, etc.; Y = O, NR<sub>10</sub>; R<sub>10</sub> = H, alkyl, aryl, etc.] and their pharmaceutically acceptable salts were prepared For example, condensation of aldehyde II and triethyl-2-ethoxyphosphonoacetate afforded thiodiphenylamine III. In plasma triglyceride assays, 3-examples of compds. I exhibited 6-58% lowering of triglyceride concentration at 1 mg/kg dosage.

L73 ANSWER 8 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:            2005:1335635 CAPLUS Full-text

DOCUMENT NUMBER:            144:69628

TITLE:                        Preparation of phenoxyacetamide derivatives as modulators of peroxisome proliferator-activated receptors (PPAR)

INVENTOR(S):                Lindstedt Alstermark, Eva-Lotte; Olsson, Anna Christina; Li, Lanna

PATENT ASSIGNEE(S):        Swed.

SOURCE:                     U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S. Ser. No. 499,261.

CODEN: USXXCO

DOCUMENT TYPE:             Patent

LANGUAGE:                   English

FAMILY ACC. NUM. COUNT:    5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 20050282822	A1	20051222	US 2004-26806	20041230 <--
WO 2003051821	A1	20030626	WO 2002-GB5738	20021218 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003051822	A1	20030626	WO 2002-GB5744	20021218 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,			

	FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
CN 1896045	A	20070117 CN 2006-10007173 20021218 <--
WO 2004056748	A1	20040708 WO 2003-GB5602 20031219 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
WO 2004113270	A2	20041229 WO 2004-EP6597 20040617
WO 2004113270	A3	20050331
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
EP 1676833	A1	20060705 EP 2006-5766 20040617
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR	
CN 101239928	A	20080813 CN 2008-10009615 20040617
US 20050171204	A1	20050804 US 2005-499261 20050304 <--
JP 2005336209	A	20051208 JP 2005-235794 20050816 <--
JP 2006045240	A	20060216 JP 2005-253346 20050901 <--
JP 2006298924	A	20061102 JP 2006-123399 20060427 <--
JP 2006298925	A	20061102 JP 2006-139673 20060519
PRIORITY APPLN. INFO.:		SE 2001-4334 A 20011219 <--
		WO 2002-GB5738 W 20021218 <--
		WO 2002-GB5744 A 20021218 <--
		GB 2002-29931 A 20021221 <--
		GB 2003-14079 A 20030618
		WO 2003-GB5602 A 20031219
		WO 2004-EP6597 A 20040617
		US 2005-499261 A2 20050304
		CN 2002-828123 A3 20021218 <--
		JP 2003-552709 A3 20021218 <--
		JP 2003-552710 A3 20021218 <--
		JP 2004-561668 A3 20031219
		CN 2004-80023304 A3 20040617
		EP 2004-740044 A3 20040617
		JP 2006-515989 A3 20040617
OTHER SOURCE(S):	CASREACT 144:69628; MARPAT 144:69628	
GI		

AB The phenyl-, phenoxy-, or phenylthioalkanamidetitle compds., (in particular phenoxyacetamide derivs.) (I) [A is situated in the ortho, meta or para position and represents CR3R4CR1R2COR, CR3:CR1COR (wherein R = H, alkyl, (un)substituted HO or NH2; R1 = alkyl, aryl, alkenyl, alkynyl, or when A is CR3R4CR1R2COR, R1 can also be cyano, (un)substituted HO, SH, OCONH2, SO2NH2, CO2H, etc.; R2 = H, halogen, alkyl, aryl, alkylaryl; R3, R4 = H, alkyl, aryl, alkylaryl); Y = O, S, a single bond; n = an integer of 1-4; X = alkyl; R5, R6 = H, each (un)substituted C1-13 alkyl, C2-10 alkenyl, or C2-10 alkynyl; or R5, R6 = each (un)substituted C3-8 cycloalkyl, C3-C8 cycloalkenyl, aryl, heterocyclyl, or heteroaryl; or R5 and R6 together with the nitrogen atom to which they are attached form a single or a fused heterocyclic system] are prepared These compds. are useful in treating clin. conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, and other manifestations of the metabolic syndrome. Thus, a solution of 0.598 g N-butyl-N-[2-fluoro-4-(trifluoromethyl)benzyl]amine and 0.593 g [4-((2S)-2,3-diethoxy-3-oxopropyl)phenoxy]acetic acid in 20 mL CH2Cl2 was treated with 0.80 mL N,N-diisopropylethylamine and 0.674 g O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate and the reaction mixture was stirred at room temperature overnight to give, after workup and silica gel chromatog., 74% Et (2S)-3-[4-[2-[butyl[2-fluoro-4-(trifluoromethyl)benzyl]amino]-2-oxoethoxy]phenyl]-2-ethoxypropanoate (II). A solution of 0.748 g II in 70 mL MeCN was treated with 35 mL 0.10 M LiOH and the reaction mixture was stirred at room temperature overnight, neutralized with 5% HCl, concentrated, acidified with 5% HCl, and extracted with EtOAc to give 97% (2S)-3-[4-[2-[butyl[2-fluoro-4-(trifluoromethyl)benzyl]amino]-2-oxoethoxy]phenyl]-2-ethoxypropanoic acid (III). III showed EC50 of 0.001  $\mu$ mol/L for human PPAR $\alpha$ .

L73 ANSWER 9 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:519176 CAPLUS Full-text

DOCUMENT NUMBER: 143:71779

TITLE: Red-rooted Salvia root anti-peptic ulcer effective component and preparing process thereof

INVENTOR(S): Li, Hequan; Wang, Yulin; Li, Xi

PATENT ASSIGNEE(S): China Medical Univ., Peop. Rep. China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, No pp. given  
CODEN: CNXXEV

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1508133	A	20040630	CN 2002-144771	20021213 <--
CN 1208330	C	20050629		

PRIORITY APPLN. INFO.: CN 2002-144771 20021213 <--

AB The present invention relates to effective region of salvia root for resisting peptic ulcer and its preparation process. The chemical composition of said effective region contains danshenphenolic acid component using danshenphenolic acid B as main substance and small quantity of fatty acid component. Its preparation process includes the following steps: decocting Chinese medicinal material salvia root by adding water, making filtrate pass through polyamide column, washing with distilled water to remove impurity, eluting with Et alc., reduced pressure recovering Et alc. solution, heating with water and dissolving the obtained red tan solid, precipitation, filtering to obtain yellow supernatant fluid, precipitating, washing with water, reduced pressure removing water content to obtain the product (DSE-F), brown color, its yield

is about 0.6%. Said product can be made into tablet, powder, capsule and decoction preparation

L73 ANSWER 10 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2005:483308 CAPLUS Full-text  
DOCUMENT NUMBER: 143:225593  
TITLE: Method for preparing salvianolic acid B of Salvia  
miltiorrhiza  
INVENTOR(S): Zhang, Fengxia; Wang, Jiaping; Tan, Xuebing  
PATENT ASSIGNEE(S): Nanjing Hongqiao Institute of Medical Technology,  
Peop. Rep. China  
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 13 pp.  
CODEN: CNXXEV  
DOCUMENT TYPE: Patent  
LANGUAGE: Chinese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
CN 1425659	A	20030625	CN 2002-160771	20021231 <--
CN 1164582	C	20040901		

PRIORITY APPLN. INFO.: CN 2002-160771 20021231 <--

AB The method comprises extracting with water, acidifying to pH 1-6, purifying on macroporous resin column (ion exchange resin, Mcigel-Chp-20P, Sephadex LH-20, C18 bonded stationary phase, or C8 bonded stationary phase), and drying. The extraction and acidification processes may be simultaneously carried out by extraction with acidic solution (pH 1-6). The solvent extraction may be substituted by percolation, ultrasonic wave-aided extraction, or microwave-aided extraction methods.

=> d 173 ibib abs 11-15

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L73 ANSWER 11 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2005:483216 CAPLUS Full-text  
DOCUMENT NUMBER: 143:13395  
TITLE: Medical composition of active constituent of  
traditional Chinese medicine for treating  
cardiovascular and cerebrovascular diseases and its  
preparation  
INVENTOR(S): Zhang, Weidong; Su, Juan; Zhang, Chuan  
PATENT ASSIGNEE(S): Shanghai Botai Medical Science and Technology Co.,  
Ltd., Peop. Rep. China  
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 10 pp.  
CODEN: CNXXEV  
DOCUMENT TYPE: Patent  
LANGUAGE: Chinese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

CN 1425430 A 20030625 CN 2002-155004 20021219 <--  
 CN 100346798 C 20071107  
 PRIORITY APPLN. INFO.: CN 2002-155004 20021219 <--  
 AB The metal composition is composed of 1 part total salvianolic acid (its salvianolic acid B Mg salt content >50%) and 0.1-1 part total saponin (its astragalins A content >20%) of Astragalus membranaceus. The total salvianolic acid is isolated from Salvia multiorrhiza by percolating in acetone and purifying on macroporous adsorbent resin column. The total saponin is isolated from A. membranaceus by extracting with water and then purifying on macroporous adsorbent resin column. The metal composition may be used to prepare injection, large-capacity injection, powder injection, tablet, capsule, powder, etc.

L73 ANSWER 12 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2004:1154649 CAPLUS Full-text  
 DOCUMENT NUMBER: 142:93514  
 TITLE: Preparation of phenylpropanoic acid derivatives as PPAR $\alpha$  agonists  
 INVENTOR(S): Li, Lanna; Lindstedt-Alstermark, Eva-Lotte; Olsson, Christina  
 PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.  
 SOURCE: PCT Int. Appl., 100 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 5  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113270	A2	20041229	WO 2004-EP6597	20040617
WO 2004113270	A3	20050331		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004249409	A1	20041229	AU 2004-249409	20040617
AU 2004249409	B2	20080529		
CA 2528234	A1	20041229	CA 2004-2528234	20040617
EP 1675820	A2	20060705	EP 2004-740044	20040617
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
EP 1676833	A1	20060705	EP 2006-5766	20040617
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
BR 2004011484	A	20060725	BR 2004-11484	20040617
CN 1835913	A	20060920	CN 2004-80023304	20040617
JP 2006527730	T	20061207	JP 2006-515989	20040617
CN 101239928	A	20080813	CN 2008-10009615	20040617
US 20050282822	A1	20051222	US 2004-26806	20041230 <--
US 20050148656	A1	20050707	US 2005-518777	20050303
NO 2005005892	A	20060106	NO 2005-5892	20051212

MX 2005PA13712	A	20060308	MX 2005-PA13712	20051215
JP 2006298925	A	20061102	JP 2006-139673	20060519
US 20060258866	A1	20061116	US 2006-477168	20060628
US 20070244198	A1	20071018	US 2007-772474	20070702
IN 2008DN04240	A	20080815	IN 2008-DN4240	20080519
PRIORITY APPLN. INFO.:			GB 2003-14079	A 20030618
			SE 2001-4334	A 20011219 <--
			WO 2002-GB5738	W 20021218 <--
			WO 2002-GB5744	A 20021218 <--
			GB 2002-29931	A 20021221 <--
			WO 2003-GB5602	A 20031219
			CN 2004-80023304	A3 20040617
			EP 2004-740044	A3 20040617
			JP 2006-515989	A3 20040617
			WO 2004-EP6597	W 20040617
			IN 2005-DN5470	A3 20041128
			US 2005-518777	A3 20050303
			US 2005-499261	A2 20050304
			US 2006-477168	A1 20060628
OTHER SOURCE(S):			MARPAT 142:93514	
GI				

/ Structure 56 in file .gra /

AB Title compds. represented by the formula I [wherein A = CR<sub>3</sub>(R<sub>4</sub>)CR<sub>1</sub>(R<sub>2</sub>)COR or C(R<sub>3</sub>):C(R<sub>1</sub>)COR; R = H, alkoxy, (alkyl)aryloxy, amino, etc.; R<sub>1</sub> = alkyl, aryl, alkenyl, alkynyl, etc.; R<sub>2</sub> = H, halo, alkyl, (alkyl)aryl; R<sub>3</sub>, R<sub>4</sub> = independently H, alkyl, (alkyl)aryl; T = O, S or a single bond; n = 1-4; R<sub>5</sub>, R<sub>6</sub> = independently selected substituent comprising C, H, N, O, S, Se, P or halo; with provisos; optical isomers and racemates thereof as well as pharmaceutically acceptable salts, prodrugs, solvates and crystalline forms thereof] were prepared as PPAR $\alpha$  agonists. For example, II was given in a multi-step synthesis starting from the reaction of 2,4-difluorobenzylamine with octanoic acid. I had EC<sub>50</sub> values of less than 0.1  $\mu$ M/L for PPAR $\alpha$  and showed the ration of the EC<sub>50</sub>(PPAR $\gamma$ ) with EC<sub>50</sub>(PPAR $\alpha$ ) is greater than 150:1. Thus, I and their pharmaceutical compns. are useful for the treatment of clin. conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance (no data).

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 13 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:918600 CAPLUS Full-text

DOCUMENT NUMBER: 142:113816

TITLE: Rosmarinic acid derivatives as an immunosuppressant and an inhibitor of SH2

INVENTOR(S): Kang, Mi Ae; Kim, Hong Tae; Ko, Jae Gyun; Lee, Geon Hyeong; Lee, Jong Seong; Oh, Jae Taek; Oh, Jong Eun; Park, Si Hyeong; Won, Jong Hwa; Yoon, Yeong Dae

PATENT ASSIGNEE(S): Mogam Biotechnology Institute, S. Korea

SOURCE: Repub. Korean Kongkae Taeho Kongbo, No pp. given  
CODEN: KRXXA7

DOCUMENT TYPE: Patent

LANGUAGE: Korean

FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
KR 2002006643	A	20020124	KR 2000-39730	20000711 <--
PRIORITY APPLN. INFO.:			KR 2000-39730	20000711 <--
AB	A rosemarine derivative useful as an immunosuppressant and an inhibitor of SH2(src homol. region 2) in T lymphocyte cell kinase is provided, thereby diagnosing and preventing transplant rejection, inflammatory diseases, and autoimmune related diseases. The rosemarine derivative useful as an immunosuppressant and an inhibitor of SH2(src homol. region 2) in T lymphocyte cell kinase is represented by formula(1), in which R1, R2, R3, R4 and R5 are independent, wherein at least one of them is hydroxy, and others are selected from hydrogen, halogen, C1 to C3 alkoxy, aldehyde, carboxyl, amino, trifluormethyl and nitro; R6, R7, R8, R9 and R10 are independent, wherein at least one of them is hydroxy, and others are selected from hydrogen, halogen, C1 to C3 alkoxy, aldehyde, carboxyl, amino, trifluormethyl and nitro; X1 is O, S, NH, N-CH3, N-CH2CH3 or NHNH; X2 is CH2; X3 is (CH2)m; Y1 is selected from hydrogen, CH2, hydrogen, linear or branched alkyl or aryl-substituted amine; Y2 is none or -NZ11Z12, -O-Z2 or -S-Z2, wherein Z11 or Z12 is individually hydrogen, amine optionally substituted by t-butoxycarbonyl; C1 to C12 linear or branched alkyl, aryl, cycloalkyl or heteroalkyl; Z2 is hydrogen, C1 to C12 linear or branched alkyl, aryl, cycloalkyl or heteroalkyl; and B is hydrogen or alkyl.			

L73 ANSWER 14 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2004:867863 CAPLUS Full-text  
DOCUMENT NUMBER: 142:71652  
TITLE: Process for separating rosmarinic acid from Agastache rugosa  
INVENTOR(S): Cho, Gang Jin; Hwang, Yeong Su; Kim, Jeong Bong; Kim, Jong Beom; Park, No Dong  
PATENT ASSIGNEE(S): Republic of Korea Management : Rural Development Administration, S. Korea  
SOURCE: Repub. Korean Kongkae Taeho Kongbo, No pp. given  
CODEN: KRXXA7  
DOCUMENT TYPE: Patent  
LANGUAGE: Korean  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
KR 2001016848	A	20010305	KR 1999-32025	19990804 <--
PRIORITY APPLN. INFO.:			KR 1999-32025	19990804 <--
AB	Provided is a process for separating rosmarinic acid from Agastache rugosa in high purity, wherein the rosmarinic acid is used for producing antioxidizing material and used as additives in food or medical supplies. The process comprises the steps of: drying the Agastache rugosa to have a water content of less than 6 weight and then pulverizing; adding 2-6 times water, based on the weight of the pulverized Agastache rugosa, to obtain the extracted solution of the Agastache rugosa; filtering the extracted solution, performing an adsorption chromatog. and then collecting and condensing activated fractions to obtain the concentrated solution of the rosmarinic acid; performing a gel chromatog. of the concentrated solution and drying fractions containing the rosmarinic acid.			

L73 ANSWER 15 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:821008 CAPLUS Full-text  
 DOCUMENT NUMBER: 141:274556  
 TITLE: Method for separation and purification of high purity  
 rosmarinic acid from plant  
 INVENTOR(S): Kim, Geun Su; Kim, Sam Gon; Kim, Yeong Hoe; Kim, Yong  
 Ha; Lee, Dong Uk; Lee, Jong Cheol  
 PATENT ASSIGNEE(S): Korea Ginseng & Tobacco Research Experiment Station,  
 S. Korea  
 SOURCE: Repub. Korean Kongkae Taeho Kongbo, No pp. given  
 CODEN: KRXXA7  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Korean  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2001002275	A	20010115	KR 1999-22009	19990614 <--
PRIORITY APPLN. INFO.:			KR 1999-22009	19990614 <--
AB A method for separating and purifying rosmarinic acid as an antioxidant from a plant, in particular from the leaves of Perilla frutescens var. japonica Hara, using water or a polar solvent is provided; the title method gives highly pure rosmarinic acid at low cost.				

=> d 173 ibib abs 60-20

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:n

=> d 173 ibib abs 16-20

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L73 ANSWER 16 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:799722 CAPLUS Full-text  
 DOCUMENT NUMBER: 141:260400  
 TITLE: An improved process for the preparation of  
 (+)-(2S,3S)-3-(2-amino-phenylthio)-2-hydroxy-3-(4'-  
 mehoxyphenyl)propionic acid by using  
 (+)- $\alpha$ -methylbenzylamine as a resolving agent  
 INVENTOR(S): Sadanandam, Vennu Sangiah; Shetty, Meera Manjaya;  
 Sari, Imtiaz Ahmad; Yadav, Jhillu Singh; Rao,  
 Allavenkata Rama  
 PATENT ASSIGNEE(S): Council of Scientific & Industrial Research, India  
 SOURCE: Indian, 14 pp.  
 CODEN: INXXAP  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 182359	A1	19990327	IN 1993-DE1464	19931228 <--
PRIORITY APPLN. INFO.:			IN 1993-DE1464	19931228 <--
GI				



/ Structure 57 in file .gra /

AB The invention is directed to an improved process for the preparation of (+)-(2S,3S)-3-(2-amino-phenylthio)-2-hydroxy-3-(4'methoxyphenyl)propionic acid [(+)-(2S,3S)-I], key intermediate in the synthesis of Diltiazem, by using (+)- $\alpha$ -methylbenzylamine (II) as a resolving agent in the presence of a polar solvent and a base. The advantages include high yields of (+)-enantiomer, use of cheap materials and simple methodol. Thus, heating a mixture of ( $\pm$ )-(2RS,3RS)-I and (+)- $\alpha$ -methylbenzylamine in H<sub>2</sub>O in the presence of LiOH, separating the amine salt [(+)-(2S,3S)-I]•II, and neutralizing it with HCl solution gave acid [(+)-(2S,3S)-I] (m.p. = 136-138°) in 98.77% purity.

L73 ANSWER 17 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:668102 CAPLUS Full-text

DOCUMENT NUMBER: 142:313339

TITLE: Isodon lophanthoides extractant as natural medicine for treating hepatitis B

INVENTOR(S): Lai, Xiaoping; Hu, Yingjie; Chen, Jiannan; Zhu, Yutong; Liu, Zhongqiu

PATENT ASSIGNEE(S): Guangzhou University of Traditional Chinese Medicine, Peop. Rep. China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 18 pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
CN 1405177	A	20030326	CN 2002-135069	20021101 <--
PRIORITY APPLN. INFO.:			CN 2002-135069	20021101 <--

AB The extractant of Isodon lophanthoides is prepared by extracting with methanol or ethanol under refluxing, then concentrating and adding suitable amount of water, further extracting with petroleum ether, and freeze drying the petroleum ether-insol. phase. The extractant can be prepared by supercrit. CO<sub>2</sub> fluid extraction with 2.5-10% ethanol as entrainer at room temperature - 50°. The extractant containing 2-hydroxyursolic acid, 2,19-dihydroxyursolic acid, and rosmarinic acid, can be used for medical formulation (such as tablet, capsule, oral solution, injection, etc.) for treating hepatitis B. Thus, dried Isodon lophanthoides crude powder 4 kg, refluxing in methanol for three times with each time 2 h, after filtration, concentration the solution with reduced pressure, adding water to the residue, then extracted with petroleum ether (60-90°), reducing pressure concentration the petroleum ether insol. part, after freezing dry, crashed the residue and through 80 mesh screen, gave the final Isodon lophanthoides extractant.

L73 ANSWER 18 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:546469 CAPLUS Full-text

DOCUMENT NUMBER: 141:106266

TITLE: Preparation of phenylpropanoic acids derivatives as selective PPAR $\alpha$  modulators

INVENTOR(S): Lindstedt Alstermark, Eva-Lotte; Olsson, Anna  
Christina; Li, Lanna; Aurell, Carl-Johan; Minidis,

Anna; Yousefi-Salakdeh, Esmail; Dahlstrom, Mikael Ulf  
 Johan  
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SOURCE: PCT Int. Appl., 43 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 5  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056748	A1	20040708	WO 2003-GB5602	20031219 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2508851	A1	20040708	CA 2003-2508851	20031219 <--
AU 2003290309	A1	20040714	AU 2003-290309	20031219 <--
AU 2003290309	B2	20070118		
EP 1572626	A1	20050914	EP 2003-782668	20031219 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017458	A	20051116	BR 2003-17458	20031219 <--
CN 1753862	A	20060329	CN 2003-80109895	20031219 <--
CN 1308291	C	20070404		
JP 2006511572	T	20060406	JP 2004-561668	20031219 <--
JP 3786945	B2	20060621		
US 20050131068	A1	20050616	US 2004-499893	20040623 <--
US 7462644	B2	20081209		
US 20050282822	A1	20051222	US 2004-26806	20041230 <--
IN 2005DN02515	A	20070413	IN 2005-DN2515	20050610 <--
NO 2005002914	A	20050719	NO 2005-2914	20050615 <--
MX 2005PA06812	A	20050908	MX 2005-PA6812	20050621 <--
ZA 2005004730	A	20060927	ZA 2005-4730	20050622 <--
JP 2006045240	A	20060216	JP 2005-253346	20050901 <--
PRIORITY APPLN. INFO.:			GB 2002-29931	A 20021221 <--
			SE 2001-4334	A 20011219 <--
			WO 2002-GB5738	W 20021218 <--
			WO 2002-GB5744	A 20021218 <--
			GB 2003-14079	A 20030618
			JP 2004-561668	A3 20031219
			WO 2003-GB5602	W 20031219
			WO 2004-EP6597	A 20040617
			US 2005-499261	A2 20050304
OTHER SOURCE(S):			CASREACT 141:106266; MARPAT 141:106266	
GI				

AB Title compds. I [R1 = Cl, CF3, CF3O; R2 = H, F; R3 = alkyl] and their pharmaceutically acceptable salts, prodrugs were prepared For example, amidation of N-butyl-N-[2-fluoro-4-(trifluoromethyl)benzyl]amine, e.g., prepared from Et (2S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate in 3 steps, and {4-[(2S)-2,3-diethoxy-3-oxopropyl]phenoxy}acetic acid, followed by hydrolysis afforded compound (S)-I [R1 = CF3; R2 = F; R3 = butyl] in 72% yield. Compds. I have EC50 values <0.1 µmol/L for PPARα, e.g., the EC50 value of compound (S)-I [R1 = CF3; R2 = F; R3 = butyl] was 0.001 µmol/L. Of notes, compds. I exhibit improved metabolic stability (in vitro), promising toxicol. profile (no data provided) and particular compds. have the ratio of the EC50(PPARγ):EC50(PPARγ) <150:1. Compds. I are claimed useful for the treatment of hypertension, diabetes, etc.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 19 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:546467 CAPLUS Full-text

DOCUMENT NUMBER: 141:106263

TITLE: Preparation of dimeric dicarboxylic acid derivatives as PPAR agonists

INVENTOR(S): Sauerberg, Per; Jeppesen, Lone; Polivka, Zdenek; Sindelar, Karel

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.

SOURCE: PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056740	A1	20040708	WO 2003-DK895	20031218 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040259950	A1	20041223	US 2003-734368	20031212 <--
AU 2003287912	A1	20040714	AU 2003-287912	20031218 <--
EP 1578716	A1	20050928	EP 2003-779752	20031218 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006510687	T	20060330	JP 2004-561080	20031218 <--
PRIORITY APPLN. INFO.:			DK 2002-1966	A 20021220 <--
			US 2003-439410P	P 20030110
			WO 2003-DK895	W 20031218

OTHER SOURCE(S): MARPAT 141:106263

GI

/ Structure 59 in file .gra /

AB The title compds. DOC(O)AXLTZUMYBC(O)OE [I; A, B = (un)substituted alkylene, O(alkylene), S(alkylene); D, E = H, alkyl, cycloalkyl; L, M = O, S; T, U = (un)substituted divalent saturated carbon chain, NR1(alkylene) (wherein R1 = H, alkyl); X, Y = (un)substituted arylene, heteroarylene; Z = (un)substituted arylene, heteroarylene, divalent polycyclic ring system] which may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR) (no specific biol. data given), were prepared and formulated. E.g., a multi-step synthesis of II, is given. The compds. I are claimed as selective PPAR $\delta$  agonists useful in treating diabetes, syndrome X, cardiovascular diseases, dyslipidemia, and hypercholesteremia.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 20 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:453192 CAPLUS Full-text

DOCUMENT NUMBER: 141:6919

TITLE: Preparation of substituted aralkyl derivatives as antidiabetic, hypolipidemic and hypocholesterolemic agents

INVENTOR(S): Lohray, Braj Bhushan; Lohray, Vidya Bhushan; Jain, Mukul R.; Basu, Sujay; Pingali, Harikishore; Raval, Saurin K.; Raval, Preeti S.

PATENT ASSIGNEE(S): Cadila Healthcare Limited, India

SOURCE: PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004046119	A1	20040603	WO 2003-IN358	20031114 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2002MU00992	A	20060901	IN 2002-MU992	20021115 <--
IN 2003MU00792	A	20050401	IN 2003-MU792	20030812
CA 2506112	A1	20040603	CA 2003-2506112	20031114 <--
AU 2003302111	A1	20040615	AU 2003-302111	20031114 <--
EP 1569916	A1	20050907	EP 2003-808341	20031114 <--
EP 1569916	B1	20090107		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015713	A	20050913	BR 2003-15713	20031114 <--
CN 1738807	A	20060222	CN 2003-80108836	20031114 <--
JP 2006514976	T	20060518	JP 2004-570329	20031114 <--
NZ 540474	A	20080430	NZ 2003-540474	20031114 <--
MX 2005PA05063	A	20050816	MX 2005-PA5063	20050511 <--
NO 2005002413	A	20050726	NO 2005-2413	20050513
US 20060142277	A1	20060629	US 2005-534726	20051118 <--
PRIORITY APPLN. INFO.:			IN 2002-MU992	A 20021115 <--
			IN 2003-MU792	A 20030812

OTHER SOURCE(S): MARPAT 141:6919  
GI

/ Structure 60 in file .gra /

AB The present invention relates to novel substituted aralkyl derivs. of formula  $A(CH_2)_nX-Ar-CH_2CH(R)CHR_1R_2$  [A = (substituted) aryl, heteroaryl, heterocyclyl; n = 1-3; X = O, S; Ar = aromatic, heteroarom. or heterocyclic group; R, R<sub>1</sub> = (substituted) amino, (substituted) OH, N<sub>3</sub>, CN, COOH, tetrazolyl, etc.; R<sub>2</sub> = H, alkyl, cycloalkyl], their derivs., their analogs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, pharmaceutical compns. containing them, use of these compds. in medicine and the intermediates involved in their preparation The compds. are useful as antidiabetic, hypolipidemic and hypocholesterolemic agents. Thus, I was prepared, and lowered serum triglyceride in Swiss albino mice by 78%.

=> d 173 ibib abs 21-25

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L73 ANSWER 21 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:412810 CAPLUS Full-text

DOCUMENT NUMBER: 140:423665

TITLE: Preparation of substituted 4-alkoxyoxazole derivatives as PPAR agonists

INVENTOR(S): Binggeli, Alfred; Grether, Uwe; Hilpert, Hans; Hirth, Georges; Maerki, Hans-Peter; Meyer, Markus; Mohr, Peter

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041275	A1	20040521	WO 2003-EP12189	20031031 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2503117	A1	20040521	CA 2003-2503117	20031031 <--
AU 2003276234	A1	20040607	AU 2003-276234	20031031 <--
AU 2003276234	B2	20070419		

EP 1572203 A1 20050914 EP 2003-810427 20031031 <--  
 EP 1572203 B1 20071107  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 BR 2003016091 A 20050927 BR 2003-16091 20031031 <--  
 CN 1711084 A 20051221 CN 2003-80102841 20031031 <--  
 JP 2006508097 T 20060309 JP 2004-548844 20031031 <--  
 AT 377419 T 20071115 AT 2003-810427 20031031 <--  
 RU 2312106 C2 20071210 RU 2005-117964 20031031 <--  
 ES 2295692 T3 20080416 ES 2003-810427 20031031 <--  
 US 20040157898 A1 20040812 US 2003-700417 20031104 <--  
 US 7109225 B2 20060919  
 MX 2005PA04743 A 20050803 MX 2005-PA4743 20050503 <--  
 IN 2005CN00841 A 20070810 IN 2005-CN841 20050505 <--  
 PRIORITY APPLN. INFO.: EP 2002-25001 A 20021108 <--  
 WO 2003-EP12189 W 20031031  
 OTHER SOURCE(S): CASREACT 140:423665; MARPAT 140:423665  
 GI

/ Structure 61 in file .gra /

AB Alkoxyoxazole derivs. of formula I [R1 = alkyl, fluoroalkyl, cycloalkyl, bicyclo-alkyl, tricyclo-alkyl; R2 = H, alkyl, fluoroalkyl; R3-R6 = H, OH, halo, alkyl, etc.; R3R4 = CH=CH-S, alkylene, etc.; R7 = alkyl, fluoroalkyl, aryl, etc.; R8 = H, alkyl] are prepared The compds. are useful for the treatment of diseases such as diabetes. Pharmaceutical compns. containing I are described. Thus, II was prepared in several steps, and had IC50 of 53 nmol/l against PPAR $\alpha$ .

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 22 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:308424 CAPLUS Full-text

DOCUMENT NUMBER: 140:321346

TITLE: Preparation of chiral oxazole-arylpropionic acid derivatives and their use as PPAR $\alpha$  and PPAR $\gamma$  agonists for disorders like type II diabetes

INVENTOR(S): Binggeli, Alfred; Boehringer, Markus; Grether, Uwe; Hilpert, Hans; Hirth, Georges; Maerki, Hans-Peter; Meyer, Markus; Mohr, Peter; Ricklin, Fabienne

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 108 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031162	A1	20040415	WO 2003-EP11030	20031006 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,			

TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2499721 A1 20040415 CA 2003-2499721 20031006 <--  
 AU 2003273949 A1 20040423 AU 2003-273949 20031006 <--  
 AU 2003273949 B2 20070405  
 US 20040116487 A1 20040617 US 2003-679604 20031006 <--  
 US 6969725 B2 20051129  
 EP 1551814 A1 20050713 EP 2003-757914 20031006 <--  
 EP 1551814 B1 20080723  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 BR 2003015114 A 20050816 BR 2003-15114 20031006 <--  
 JP 2006504709 T 20060209 JP 2004-540787 20031006 <--  
 RU 2303593 C2 20070727 RU 2005-114373 20031006 <--  
 NZ 538465 A 20070831 NZ 2003-538465 20031006 <--  
 AT 402153 T 20080815 AT 2003-757914 20031006 <--  
 NO 2005001011 A 20050502 NO 2005-1011 20050224 <--  
 MX 2005PA03392 A 20050622 MX 2005-PA3392 20050330 <--  
 ZA 2005002664 A 20060222 ZA 2005-2664 20050401 <--  
 IN 2005CN00553 A 20070615 IN 2005-CN553 20050405 <--  
 US 20050267180 A1 20051201 US 2005-183360 20050718 <--  
 US 7348349 B2 20080325  
 HK 1083339 A1 20081114 HK 2006-104701 20060419 <--  
 PRIORITY APPLN. INFO.: EP 2002-22286 A 20021007 <--  
 US 2003-679604 A3 20031006  
 WO 2003-EP11030 W 20031006  
 OTHER SOURCE(S): MARPAT 140:321346  
 GI

/ Structure 62 in file .gra /

AB The present invention relates to chiral oxazole-arylpropionic acid derivs.  
 (shown as I; variables defined below; e.g. II) and pharmaceutically acceptable  
 salts and esters thereof. The compds. are useful for the treatment and/or  
 prevention of diseases, which are modulated by PPAR $\alpha$  and/or PPAR $\gamma$  agonists as  
 e.g. type II diabetes. For I: R1 is aryl or heteroaryl; R2 is H, lower-alkyl,  
 or fluoro-lower-alkyl; R3 and R4 = H, hydroxy, halogen, lower-alkyl, fluoro-  
 lower-alkyl, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl, lower-alkoxy,  
 fluoro-lower-alkoxy, hydroxy-lower-alkoxy, lower-alkoxy-lower-alkoxy, or  
 lower-alkenyl, wherein at least one of R3 and R4 is not H; R5 is lower-alkoxy,  
 fluoro-lower-alkoxy, lower-alkenyloxy, fluoro-lower-alkenyloxy, aryloxy, aryl-  
 lower-alkoxy, or arylfluoro-lower-alkoxy; R6 is H or lower-alkyl; n is 1.  
 EC50 and IC50 values for 10 examples of I towards PPAR $\alpha$  and PPAR $\gamma$  are  
 tabulated, e.g. IC50 = 30 and 58 nmol/L for PPAR $\alpha$  and PPAR $\gamma$ , resp. for II. A  
 method of preparation involving removing a protective ester radical (R6 =  
 protective group) is claimed. Approx. 50 examples prepns. of I are included.  
 For example, II was prepared in 4 steps starting with cyclization of diacetyl  
 monooxime with 4-isopropoxybenzaldehyde to give 2-(4-isopropoxyphenyl)-4,5-  
 dimethyloxazole 3-oxide hydrochloride, which was converted with POCl3 to 4-  
 chloromethyl-2-(4-isopropoxyphenyl)-5-methyloxazole, which was coupled to  
 (2S)-2-ethoxy-3-(4-hydroxy-2-methylphenyl)propionic acid Me ester to give (S)-  
 2-ethoxy-3-[4-[2-(4-isopropoxyphenyl)-5-methyloxazol-4-ylmethoxy]-2-

methylphenylpropionic acid Me ester, which was hydrolyzed by LiOH to the acid.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 23 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:271229 CAPLUS Full-text

DOCUMENT NUMBER: 140:269926

TITLE: Rosmarinic acid-rich Perilla extract, its manufacture and use as seasoning, and seasoned foods and beverages  
INVENTOR(S): Harasawa, Mitsuo; Matsumoto, Katsuyuki; Okutsuka, Mariko

PATENT ASSIGNEE(S): Ogawa and Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 2004097108	A	20040402	JP 2002-264219	20020910 <--
JP 4088127	B2	20080521		

PRIORITY APPLN. INFO.: JP 2002-264219 20020910 <--

AB Title extract is manufactured by extraction of shredded Perilla with alc. solvent at -19 to 5°, then concentration Thus, shredded Perilla frutescens crispa leaves were extracted with aqueous 40% EtOH at -15° for 96 h to give an extract, which had good flavor and contained 0.6% rosmarinic acid.

L73 ANSWER 24 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:220326 CAPLUS Full-text

DOCUMENT NUMBER: 140:270727

TITLE: Preparation of furan derivatives for treatment of abnormal lipid metabolism, arteriosclerosis, and diabetes

INVENTOR(S): Hamamura, Kazumasa; Sasaki, Shigekazu; Amano, Yuichiro; Sakamoto, Junichi; Fukatsu, Kohji

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 325 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2004022551	A1	20040318	WO 2003-JP11308	20030904 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG



CA 2497901	A1	20040318	CA 2003-2497901	20030904 <--
AU 2003261935	A1	20040329	AU 2003-261935	20030904 <--
EP 1535915	A1	20050601	EP 2003-794233	20030904 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005035966	A	20050210	JP 2003-314293	20030905 <--
US 20060100261	A1	20060511	US 2005-526507	20050929 <--
PRIORITY APPLN. INFO.:			JP 2002-261873	A 20020906 <--
			JP 2003-185241	A 20030627
			WO 2003-JP11308	W 20030904
OTHER SOURCE(S): MARPAT 140:270727				
GI				

/ Structure 63 in file .gra /

AB The title compds. I [wherein R = (un)substituted hydrocarbyl or heterocyclyl; p = 0-2; R1 = H or (un)substituted hydrocarbyl; R2 = (un)substituted aryl; ring A = (un)substituted aromatic ring; X1 = O or S; X2 = a bond, O, S, SO, or SO2; Y = a bond, O, S, SO, SO2, CO, (un)substituted CONH, or NHCO; M1-M3 = independently a bond or (un)substituted aliphatic hydrocarbyl; M4 = (un)substituted aliphatic hydrocarbyl; with exclusions], or prodrugs, or pharmaceutically acceptable salts thereof are prepared For example, the compound II was prepared in a multi-step synthesis. II exhibited EC50 of 0.10 µM towards human G protein-coupled receptors (GPR40). I are useful for the treatment of abnormal lipid metabolism, arteriosclerotic diseases, secondary diseases, diabetes, etc. (no data). Formulations containing I as an active ingredient were also described.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 25 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:203818 CAPLUS Full-text

DOCUMENT NUMBER: 140:253565

TITLE: Preparation of novel 2-arylthiazole compounds as peroxisome proliferator activated receptors (PPARα and PPARγ) agonists

INVENTOR(S): Binggeli, Alfred; Grether, Uwe; Hilpert, Hans; Hirth, Georges; Maerki, Hans-Peter; Meyer, Markus; Mohr, Peter

PATENT ASSIGNEE(S): F.Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 169 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2004020420	A1	20040311	WO 2003-EP9281	20030821 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2495942	A1	20040311	CA 2003-2495942	20030821 <--
AU 2003273801	A1	20040319	AU 2003-273801	20030821 <--
EP 1537091	A1	20050608	EP 2003-757762	20030821 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013946	A	20050712	BR 2003-13946	20030821 <--
CN 1678596	A	20051005	CN 2003-820543	20030821 <--
JP 2006502151	T	20060119	JP 2004-532104	20030821 <--
RU 2296754	C2	20070410	RU 2005-109163	20030821 <--
NZ 537897	A	20070831	NZ 2003-537897	20030821 <--
US 20040110807	A1	20040610	US 2003-650434	20030828 <--
US 6809110	B2	20041026		
NO 2005000620	A	20050303	NO 2005-620	20050203 <--
MX 2005PA02115	A	20050523	MX 2005-PA2115	20050223 <--
IN 2005CN00276	A	20070907	IN 2005-CN276	20050225 <--
PRIORITY APPLN. INFO.:			EP 2002-19146	A 20020830 <--
			WO 2003-EP9281	W 20030821
OTHER SOURCE(S):		MARPAT 140:253565		
GI				

/ Structure 64 in file .gra /

AB The present invention relates to compds. of formula (I) [R1 = aryl, heteroaryl; R2 = H, lower-alkyl, fluoro-lower-alkyl; R3, R4, R5 = H, HO, lower-alkenyl, halogen, lower-alkyl, fluoro-lower-alkyl, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl, lower-alkoxy, fluoro-lower-alkoxy, hydroxy-lower-alkoxy, lower-alkoxy-lower-alkoxy; wherein at least one of R3, R4, R5 and R6 is not hydrogen, or R3 and R4 are bonded to each other to form a ring together with the carbon atoms to which they are attached, and R3 and R4 together are -CH:CH-S-, -S-CH:CH-, -CH:CH-O-, -O-CH:CH-, -CH:CHCH:CH-, -(CH2)3-5, -O-(CH2)2-3- or -(CH2)2-3-O-, and R5 and R6 are as defined above; R7 = lower-alkyl, lower-alkoxy, lower-alkenyloxy, aryloxy, aryl-lower-alkoxy; R8 = H, lower-alkyl; R9, R10 = H, lower-alkyl, lower-alkenyl, cycloalkyl, Ph, -[1,3]dioxan-2-ethyl; n = 1-3] and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compds. I exceed the compds. known in the art, in as much as they bind to and activate both, PPAR $\alpha$  and PPAR $\gamma$ , simultaneously and very efficiently. Therefore, these compds. I combine the anti-glycemic effect of PPAR $\gamma$  activation with the anti-dyslipidemic effect of PPAR $\alpha$  activation. Consequently, plasma glucose and insulin are reduced (i.e. insulin sensitization), triglycerides lowered and HDL cholesterol increased (i.e. improved lipid profile) and in addition, such compds. may also lower LDL cholesterol, decrease blood pressure, and counteract inflammatory atherosclerosis. Thereby, the compds. I are useful for the treatment of diseases such as diabetes, noninsulin dependent diabetes mellitus, elevated blood pressure, increased lipid and cholesterol levels, atherosclerotic diseases, metabolic syndrome, endothelial dysfunction, procoagulant state, dyslipidemia, polycystic ovary syndrome, inflammatory diseases, or proliferative diseases. For example, rac-3-[4-[3-[2-(4-tert-butylphenyl)-5-methylthiazol-4-yl]propoxy]-2-methylphenyl]-2-ethoxypropionic acid showed IC50 of 15 and 20 nM against PPAR $\alpha$  and PPAR $\gamma$ , resp., in luciferase transcriptional reporter gene assays using baby hamster kidney cells transfected with either pFA-PPAR $\gamma$ -LBD or pFA-PPAR $\alpha$ -LBD expression plasmids and a reporter plasmid.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 173 ibib abs 30-40

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L73 ANSWER 30 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:826813 CAPLUS Full-text

DOCUMENT NUMBER: 139:311997

TITLE: Rosmarinic acid compositions containing fragrances or cationic surfactants

INVENTOR(S): Someya, Keita; Mizushima, Yukako; Matsukawa, Hiroshi

PATENT ASSIGNEE(S): Lion Corp., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 140 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 2003300811	A	20031021	JP 2002-104240	20020405 <--
JP 3821222	B2	20060913		
JP 2006249092	A	20060921	JP 2006-90601	20060329 <--
PRIORITY APPLN. INFO.:			JP 2002-104240	A3 20020405 <--

AB The compns., useful for flavoring materials, perfumes, and hair or fiber treatment agents, contain rosmarinic acid (I) and fragrances or cationic surfactants. I improves fragrance stability and hand feel of hair and fiber products. A fragrance composition comprising fragrant preparation 0.01, I 0.1, 1,3-butanediol 30, and H2O to 100 weight% showed good fragrance after storage in a cup at room temperature for 1 day.

L73 ANSWER 31 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:796655 CAPLUS Full-text

DOCUMENT NUMBER: 139:292053

TITLE: Etherification process for the preparation of 2-ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid derivatives

INVENTOR(S): Larsson, Maria

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 9 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2003082812	A2	20031009	WO 2003-GB1395	20030328 <--
WO 2003082812	A3	20040108		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,  
 PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,  
 TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2478650 A1 20031009 CA 2003-2478650 20030328 <--  
 AU 2003226523 A1 20031013 AU 2003-226523 20030328 <--  
 BR 2003008297 A 20041228 BR 2003-8297 20030328 <--  
 EP 1492764 A2 20050105 EP 2003-745340 20030328 <--  
 EP 1492764 B1 20060628  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 JP 2005521725 T 20050721 JP 2003-580280 20030328 <--  
 CN 1646487 A 20050727 CN 2003-807685 20030328 <--  
 CN 1285571 C 20061122  
 NZ 534989 A 20060428 NZ 2003-534989 20030328 <--  
 AT 331704 T 20060715 AT 2003-745340 20030328 <--  
 ES 2266842 T3 20070301 ES 2003-745340 20030328 <--  
 ZA 2004006589 A 20050921 ZA 2004-6589 20040818 <--  
 NO 2004004045 A 20041018 NO 2004-4045 20040924 <--  
 MX 2004PA09686 A 20050111 MX 2004-PA9686 20041001 <--  
 US 20050215808 A1 20050929 US 2005-509654 20050505 <--  
 HK 1071353 A1 20061208 HK 2005-104064 20050513 <--  
 PRIORITY APPLN. INFO.: SE 2002-1005 A 20020402 <--  
 WO 2003-GB1395 W 20030328  
 OTHER SOURCE(S): CASREACT 139:292053; MARPAT 139:292053  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB An efficient industrial-scale process for the preparation of 2-ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid derivs. [I; R = H, acid-protecting group; 1-(S)-2-ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid] is described which comprises the etherification of 2-ethoxy-3-(4-hydroxyphenyl)propanoate derivs. [II; e.g., Et (S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate] with 2-(4-methanesulfonyloxyphenyl)ethyl derivs. [III; X = leaving group; e.g., 2-(4-methanesulfonyloxyphenyl)ethyl methanesulfonate] in the presence of a base (e.g., sodium carbonate) and using water as a diluent.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 32 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:696734 CAPLUS Full-text

DOCUMENT NUMBER: 139:230768

TITLE: Preparation of (arylalkyl)thiazoles and oxazoles as peroxisome proliferator activated receptor modulators for treating diabetes mellitus, syndrome X, and cardiovascular disease

INVENTOR(S): Conner, Scott Eugene; Knobelsdorf, James Allen; Mantlo, Nathan Bryan; Schkeryantz, Jeffrey Michael; Shen, Quanrong; Warshawsky, Alan M.; Zhu, Guoxin

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 223 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072100	A1	20030904	WO 2003-US2679	20030213 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003217274	A1	20030909	AU 2003-217274	20030213 <--
EP 1480640	A1	20041201	EP 2003-713316	20030213 <--
EP 1480640	B1	20070815		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005529077	T	20050929	JP 2003-570846	20030213 <--
AT 369855	T	20070915	AT 2003-713316	20030213 <--
ES 2290439	T3	20080216	ES 2003-713316	20030213 <--
US 20050107449	A1	20050519	US 2004-505089	20040817 <--
US 7153878	B2	20061226		
PRIORITY APPLN. INFO.:			US 2002-359808P	P 20020225 <--
			WO 2003-US2679	W 20030213
OTHER SOURCE(S):			MARPAT 139:230768	
GI				

/ Structure 65 in file .gra /

AB Title compds. I [wherein R3, R4, R30, and R40= independently H, alkyl, halo, or alkoxy; R5 = (un)substituted alkyl, alkenyl, aryl(oxy)alkyl, or arylthioalkyl; or when R5 = alkyl, R5 may be combined with W to form a heterocycloalkyl fused to the oxazole or thiazole ring; R6 = trihalomethyl, trihalomethoxy, (hydroxy)alkyl, alkylcarbamoyl, tetramethyldioxaborolanyl, halo, alkanoyl, carboxyalkoxy, (cyclo)alkoxy, tetrahydropyranyloxy, morpholinyl, or (un)substituted aryloxy, arylthio, heterocyclyloxy, pyridinyl, pyrimidinyl, pyrazinyl, or arylalkyl; R7 and R8 = independently H, CF3, or alkyl; R9 = (un)substituted (aryl)alkyl or alkenyl; R10 = H or alkyl; Q = a bond, O, or CH2; T1 = C or N; W = CH2, O, OCH2, S, SO2, or (un)substituted CONH, NH, or NHCH2; X = C, CH2C, or CCH2; Y and Z = independently O, N, or S wherein at least 1 of Y and Z = O or S; A = CO2H, alkyl nitrile, CONH2, or (CH2)nCO2R19; n = 0-3; R19 = H or alkyl; and pharmaceutically acceptable salts thereof] were prepared as peroxisome proliferator activated receptor  $\delta$  (PPAR $\delta$ ) modulators (no data). For example, (4-mercapto-2-methylphenoxy)acetic acid Et ester was condensed with 1-[4-[2-(2-chloro-6-fluorophenyl)ethyl]-2-(4-trifluoromethylphenyl)thiazol-5-yl]ethanol in the presence of PBu3 and 1,1'-(azodicarbonyl)bipiperidine in toluene. Deesterification with LiOH in THF produced II. I and their pharmaceutical compns. are useful for the prevention and or treatment of diabetes mellitus, syndrome X, and cardiovascular disease (no data).

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 33 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2003:678776 CAPLUS Full-text  
DOCUMENT NUMBER: 139:214119  
TITLE: Preparation of 3-phenylpropionic acid derivatives for treatment of diabetes and hyperlipemia  
INVENTOR(S): Kawanishi, Masashi; Umeno, Hiroshi  
PATENT ASSIGNEE(S): Asahi Kasei Kabushiki Kaisha, Japan  
SOURCE: PCT Int. Appl., 546 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070692	A1	20030828	WO 2003-JP1695	20030218 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2477205	A1	20030828	CA 2003-2477205	20030218 <--
AU 2003211383	A1	20030909	AU 2003-211383	20030218 <--
EP 1484316	A1	20041208	EP 2003-705266	20030218 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1649834	A	20050803	CN 2003-806586	20030218 <--
CN 1296349	C	20070124		
US 20040072690	A1	20040415	US 2003-367857	20030219 <--
US 7015345	B2	20060321		
MX 2004PA08191	A	20041126	MX 2004-PA8191	20040820 <--
HK 1077806	A1	20070601	HK 2005-109938	20051108 <--
PRIORITY APPLN. INFO.:			JP 2002-45287	A 20020221 <--
			US 2002-358328P	P 20020222 <--
			WO 2003-JP1695	W 20030218
OTHER SOURCE(S):			MARPAT 139:214119	
GI				

/ Structure 66 in file .gra /

AB The title compds. I [wherein R1 = (un)substituted alkyl or Ph; R2 = (un)substituted alkyl with exclusions; R3 = halo, alkyl, or alkoxy; m = 0-4; R4 = alkyl; R5 = H or alkyl; n = 2-4; X = NH or O] and salts thereof are prepared I are highly effective in lowering blood sugar, lipid, and total cholesterol, and are useful for the treatment of diabetes and hyperlipemia. For example, compound II was prepared in a multi-step synthesis. II lowered

42% of blood sugar and 51% of lipids in rat in the amount of 1 mg/kg in 15 days.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 34 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:633683 CAPLUS Full-text

DOCUMENT NUMBER: 139:185673

TITLE: Preparation and compositions of polymorphic forms of bicyclic antidiabetic agents

INVENTOR(S): Srisilla, Raju; Potlapally, Rajender Kumar; Mamillapalli, Ramabhadra Sarma; Gaddam, Om Reddy

PATENT ASSIGNEE(S): Reddy's Laboratories Limited, India

SOURCE: PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2003066612	A1	20030814	WO 2003-IB408	20030207 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
IN 2002MA00095	A	20050304	IN 2002-MA95	20020207 <--
AU 2003244514	A1	20030902	AU 2003-244514	20030207 <--
PRIORITY APPLN. INFO.:			IN 2002-MA95	A 20020207 <--
			WO 2003-IB408	W 20030207

AB This invention relates to novel polymorphic/pseudopolymorphic forms and compns. of arginine salt of 3-[4-[2-(3,4-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, preferably, L-arginine salt of (2S)-3-[4-[2-(3,4-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoic acid. The polymorphic forms of the present invention are more active, as antidiabetic and hypolipidemic agent, than the 3-[4-[2-(2,3-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoic acid.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 35 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:570941 CAPLUS Full-text

DOCUMENT NUMBER: 139:133829

TITLE: Processes for the preparation of glutamic acid compounds and intermediates thereof and novel intermediates used in the processes

INVENTOR(S): Kawahara, Shigeru; Amino, Yusuke; Mori, Kenichi; Funakoshi, Nao; Takemoto, Tadashi

PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan

SOURCE: PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2003059865	A1	20030724	WO 2002-JP12473	20021129 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2471847	A1	20030724	CA 2002-2471847	20021129 <--
AU 2002349606	A1	20030730	AU 2002-349606	20021129 <--
EP 1466890	A1	20041013	EP 2002-783682	20021129 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
CN 1610658	A	20050427	CN 2002-826402	20021129 <--
RU 2305677	C2	20070910	RU 2004-122910	20021129 <--
JP 4196832	B2	20081217	JP 2003-559970	20021129 <--
US 20050004394	A1	20050106	US 2004-872573	20040622 <--
US 7064219	B2	20060620		
US 20060074249	A1	20060406	US 2005-283943	20051122 <--
US 7390909	B2	20080624		
US 20080091032	A1	20080417	US 2007-951395	20071206 <--

PRIORITY APPLN. INFO.:

JP 2001-396300	A	20011227 <--
JP 2002-149069	A	20020523 <--
JP 2002-149078	A	20020523 <--
JP 2002-182032	A	20020621 <--
WO 2002-JP12473	W	20021129 <--
US 2004-872573	A3	20040622
US 2005-283943	A3	20051122

OTHER SOURCE(S): CASREACT 139:133829; MARPAT 139:133829

AB This document discloses the following : a process for preparing industrially and efficiently glutamic acid compds. (such as monatin) useful as sweeteners or intermediates for the production of drugs or the like; a process for preparation of intermediates used therein; novel intermediates included among them; a process for preparation of optically active monatin; a process for preparation of intermediates used therein; and novel intermediates included among them. Specifically, this document discloses a process for the preparation of glutamic acid compds. (or salts thereof) including monatin, which comprises preparing a ketoglutaric acid compound serving as a precursor of the target glutamic acid compound by condensing a specific pyruvic acid compound with oxalacetic acid or pyruvic acid through cross-aldol reaction and, if necessary, subjecting the obtained condensate to decarboxylation, and replacing the carbonyl group of the ketoglutaric acid compound by an amino group.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 36 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:511336 CAPLUS Full-text

DOCUMENT NUMBER: 139:85372

TITLE: Preparation of pyrazolopyrimidines and related compounds as hPPAR $\alpha$  and hPPAR $\gamma$  ligands

INVENTOR(S): Das, Saibal Kumar; Bhuniya, Debnath; Madhavan, Gurram



PATENT ASSIGNEE(S): Ranga; Iqbal, Javed; Chakrabarti, Ranjan  
 SOURCE: Reddy's Laboratories Ltd., India  
 PCT Int. Appl., 139 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003053974	A1	20030703	WO 2002-IB5442	20021217 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2001MA01029	A	20050304	IN 2001-MA1029	20011221 <--
AU 2002348829	A1	20030709	AU 2002-348829	20021217 <--
US 20050096331	A1	20050505	US 2004-499852	20040621 <--
PRIORITY APPLN. INFO.:			IN 2001-MA1029	A 20011221 <--
			WO 2002-IB5442	W 20021217 <--
OTHER SOURCE(S):			CASREACT 139:85372; MARPAT 139:85372	
GI				

/ Structure 67 in file .gra /

AB Title compds. I [R1 = H, halo, OH, etc.; R2 = H, OH, halo, etc.; R3 = H, (un)substituted alkyl, cycloalkyl, etc.; Z = O, NR4; R4 = H, (un)substituted alkyl, aryl, etc.; Y = O, S, NR6, etc.; R6 = H, (un)substituted alkyl, aryl, etc.; Ar = (un)substituted aromatic, heteroarom., heterocyclic; G = O, S; X = O, NHR5, (CH2)pO, etc.; R5 = H, (un)substituted alkyl, aryl, etc.; n = 1-4; p = 0-4; A = (un)substituted pyrazolopyrimidine, imidazolopyrimidine] and their pharmaceutically acceptable salts and formulations were prepared For example, O-alkylation of 5-ethyl-1,4-dihydro-1-methyl-3-propyl-7H-pyrazolo[4,3-d]pyrimidin-7-one by chloroacetyl II, e.g., prepared from 4-aminothiophenol in 3-steps, followed by ester hydrolysis, afforded claimed pyrazolopyrimidine III in 5% yield. In hPPAR $\alpha$  and hPPAR $\gamma$  Luciferase ligand binding assays, 2-examples of compds. I, e.g., pyrazolopyrimidine III, exhibited activity at 50 and 1  $\mu$ M, resp. The test compds. also inhibited HMG CoA reductase (no data provided). Compds. I are claimed useful as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic agents.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 37 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2003:504661 CAPLUS Full-text  
 DOCUMENT NUMBER: 139:68323  
 TITLE: Manufacture of extracts containing phenols from salted red Perilla frutescens leaves  
 INVENTOR(S): Natsume, Midori; Osakabe, Naoko; Kashiwazaki, Hideaki

PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan; Toyotama Perfumery Co., Ltd.  
 SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003180286	A	20030702	JP 2001-388962	20011221 <--
JP 3775584	B2	20060517		

PRIORITY APPLN. INFO.: JP 2001-388962 20011221 <--

AB The exts. containing phenols are manufactured by extraction of components from salted red leaves of *Perilla frutescens* with hydrophilic solvents under acidic and heating conditions, chromatog. of the exts. with adsorptive resins, and concentration and pulverization of the exts. The exts. containing antiallergy phenols (e.g., rosmarinic acid) are useful for foods and beverages for treatment of pollinosis, atopic dermatitis, etc.

L73 ANSWER 38 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:491169 CAPLUS Full-text

DOCUMENT NUMBER: 139:69054

TITLE: Preparation of substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (PPAR)

INVENTOR(S): Lindstedt Alstermark, Eva-Lotte; Olsson, Anna Christina; Li, Lanna

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051822	A1	20030626	WO 2002-GB5744	20021218 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2469302	A1	20030626	CA 2002-2469302	20021218 <--
AU 2002352427	A1	20030630	AU 2002-352427	20021218 <--
EP 1458672	A1	20040922	EP 2002-788145	20021218 <--
EP 1458672	B1	20070530		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002014986	A	20041214	BR 2002-14986	20021218 <--
HU 2004002022	A2	20050128	HU 2004-2022	20021218 <--
CN 1620422	A	20050525	CN 2002-828123	20021218 <--

CN 1293044	C	20070103		
CN 1620423	A	20050525	CN 2002-828155	20021218 <--
JP 2005526704	T	20050908	JP 2003-552710	20021218 <--
JP 3820249	B2	20060913		
NZ 533274	A	20051223	NZ 2002-533274	20021218 <--
TW 253444	B	20060421	TW 2002-91136518	20021218 <--
TW 255807	B	20060601	TW 2002-91136519	20021218 <--
AT 338743	T	20060915	AT 2002-804964	20021218 <--
CN 1896045	A	20070117	CN 2006-10007173	20021218 <--
ES 2271381	T3	20070416	ES 2002-804964	20021218 <--
RU 2300517	C2	20070610	RU 2004-116918	20021218 <--
AT 363466	T	20070615	AT 2002-788145	20021218 <--
ES 2286310	T3	20071201	ES 2002-788145	20021218 <--
IN 2004DN01550	A	20070302	IN 2004-DN1550	20040604 <--
ZA 2004004657	A	20050829	ZA 2004-4657	20040611 <--
ZA 2004004658	A	20060222	ZA 2004-4658	20040611 <--
MX 2004PA06003	A	20040927	MX 2004-PA6003	20040618 <--
NO 2004003164	A	20040716	NO 2004-3164	20040716 <--
US 20050113362	A1	20050526	US 2004-499378	20040907 <--
US 7256307	B2	20070814		
US 20050282822	A1	20051222	US 2004-26806	20041230 <--
HK 1068870	A1	20071026	HK 2005-101304	20050216 <--
JP 2005336209	A	20051208	JP 2005-235794	20050816 <--
JP 2006298924	A	20061102	JP 2006-123399	20060427 <--

PRIORITY APPLN. INFO.:

SE 2001-4334	A	20011219 <--
CN 2002-828123	A3	20021218 <--
JP 2003-552709	A3	20021218 <--
JP 2003-552710	A3	20021218 <--
WO 2002-GB5738	W	20021218 <--
WO 2002-GB5744	W	20021218 <--
GB 2002-29931	A	20021221 <--
GB 2003-14079	A	20030618
WO 2003-GB5602	A	20031219
WO 2004-EP6597	A	20040617
US 2005-499261	A2	20050304

OTHER SOURCE(S):            MARPAT 139:69054  
GI

/ Structure 68 in file .gra /

AB    The present invention provides the S enantiomer of a compound of formula (I) (wherein R1 represents 2,4-difluorophenyl or cyclohexyl) as well as pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs thereof, processes for preparing such compds., their the utility in treating clin. conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, methods for their therapeutic use, and pharmaceutical compns. containing them. Thus, to a solution of [4-((2S)-2,3-diethoxy-3-oxopropyl)phenoxy]acetic acid (0.108 g) 3.6 mL CH<sub>2</sub>Cl<sub>2</sub> were added N-(cyclohexylmethyl)-N-heptylamine hydrochloride (0.090 g) and DMAP (0.098 g) followed by 1-ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride (0.070 g) and the reaction mixture was stirred at room temperature overnight to give, after workup and silica gel chromatog., Et (2S)-3-[4-[2-[(cyclohexylmethyl)(heptyl)amino]-2- oxoethoxy]phenyl]-2-ethoxypropanoate which (0.031 g) was saponified with LiOH in aqueous THF at room temperature overnight and acidified with aqueous 2 M HCl to give (2S)-3-[4-[2-[(cyclohexylmethyl)(heptyl)amino]-2-oxoethoxy]phenyl]-2- ethoxypropanoic acid. The compds. I had EC<sub>50</sub> of less than 0.5 µmol/L for PPAR $\alpha$  and preferred compds.

have EC50 of less than 0.05  $\mu\text{mol/L}$  for PPAR $\alpha$ . They were more potent with respect to PPAR $\alpha$  than with respect to PPAR $\gamma$ .

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 39 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:491168 CAPLUS Full-text

DOCUMENT NUMBER: 139:69049

TITLE: Preparation of substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (PPAR)

INVENTOR(S): Lindstedt Alstermark, Eva-Lotte; Olsson, Anna Christina; Li, Lanna

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051821	A1	20030626	WO 2002-GB5738	20021218 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2470491	A1	20030626	CA 2002-2470491	20021218 <--
AU 2002366315	A1	20030630	AU 2002-366315	20021218 <--
EP 1458673	A1	20040922	EP 2002-804964	20021218 <--
EP 1458673	B1	20060906		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002014988	A	20041214	BR 2002-14988	20021218 <--
HU 2004002133	A2	20050228	HU 2004-2133	20021218 <--
CN 1620422	A	20050525	CN 2002-828123	20021218 <--
CN 1293044	C	20070103		
CN 1620423	A	20050525	CN 2002-828155	20021218 <--
JP 2005526011	T	20050902	JP 2003-552709	20021218 <--
JP 3784804	B2	20060614		
TW 253444	B	20060421	TW 2002-91136518	20021218 <--
NZ 533276	A	20060428	NZ 2002-533276	20021218 <--
TW 255807	B	20060601	TW 2002-91136519	20021218 <--
AT 338743	T	20060915	AT 2002-804964	20021218 <--
CN 1896045	A	20070117	CN 2006-10007173	20021218 <--
ES 2271381	T3	20070416	ES 2002-804964	20021218 <--
AT 363466	T	20070615	AT 2002-788145	20021218 <--
RU 2303031	C2	20070720	RU 2004-116917	20021218 <--
ES 2286310	T3	20071201	ES 2002-788145	20021218 <--
IN 2004DN01549	A	20070817	IN 2004-DN1549	20040604 <--
ZA 2004004657	A	20050829	ZA 2004-4657	20040611 <--
ZA 2004004658	A	20060222	ZA 2004-4658	20040611 <--
MX 2004PA06004	A	20040927	MX 2004-PA6004	20040618 <--

NO 2004003023	A	20040715	NO 2004-3023	20040715 <--
US 20050282822	A1	20051222	US 2004-26806	20041230 <--
HK 1068604	A1	20070302	HK 2005-100831	20050201 <--
US 20050171204	A1	20050804	US 2005-499261	20050304 <--
JP 2005336209	A	20051208	JP 2005-235794	20050816 <--
JP 2006298924	A	20061102	JP 2006-123399	20060427 <--
PRIORITY APPLN. INFO.:			SE 2001-4334	A 20011219 <--
			CN 2002-828123	A3 20021218 <--
			JP 2003-552709	A3 20021218 <--
			JP 2003-552710	A3 20021218 <--
			WO 2002-GB5738	W 20021218 <--
			WO 2002-GB5744	A 20021218 <--
			GB 2002-29931	A 20021221 <--
			GB 2003-14079	A 20030618
			WO 2003-GB5602	A 20031219
			WO 2004-EP6597	A 20040617
			US 2005-499261	A2 20050304

OTHER SOURCE(S):            MARPAT 139:69049  
GI

/ Structure 69 in file .gra /

AB    The S enantiomer of I, n = 1 or 2, (C<sub>6</sub>H<sub>13</sub> = hexyl) as well as their pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs are synthesized using various solvents and in presence of charcoal-supported palladium catalyst. The utility of these compds. in clin. conditions such as lipid disorders (dyslipidemias) whether or not associated with insulin resistance and therapeutic and other pharmaceutical activities is also investigated. For example, (2S)-3-(4{2-[benzyl(hexyl)amino]-2-oxoethoxy}phenyl)2-ethoxypropionic acid was prepared in 58% yield via reaction of (2S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate and benzyl bromoacetate.

REFERENCE COUNT:            8            THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L73 ANSWER 40 OF 600 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:            2003:454296 CAPLUS Full-text

DOCUMENT NUMBER:            139:36527

TITLE:                        Preparation of imidazolidinone derivatives as peroxisome proliferator activated receptor agonists

INVENTOR(S):                Gibson, Tracey Ann; Johnston, Richard Duane; Mantlo, Nathan Bryan; Thompson, Richard Craig; Wang, Xiaodong; Winneroski, Leonard Larry, Jr.; Xu, Yanping

PATENT ASSIGNEE(S):        Eli Lilly and Company, USA

SOURCE:                     PCT Int. Appl., 408 pp.

CODEN: PIXXD2

DOCUMENT TYPE:             Patent

LANGUAGE:                  English

FAMILY ACC. NUM. COUNT:    1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048130	A2	20030612	WO 2002-US36128	20021126 <--
WO 2003048130	A3	20031120		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,

PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,  
 TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2468846	A1	20030612	CA 2002-2468846	20021126	<--
AU 2002356927	A1	20030617	AU 2002-356927	20021126	<--
EP 1453811	A2	20040908	EP 2002-804416	20021126	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
BR 2002014437	A	20041013	BR 2002-14437	20021126	<--
CN 1582279	A	20050216	CN 2002-823800	20021126	<--
HU 2004002486	A2	20050329	HU 2004-2486	20021126	<--
HU 2004002486	A3	20070502			
JP 2005517643	T	20050616	JP 2003-549322	20021126	<--
NZ 532909	A	20060831	NZ 2002-532909	20021126	<--
US 20050020652	A1	20050127	US 2004-496770	20040525	<--
ZA 2004004173	A	20050823	ZA 2004-4173	20040527	<--
IN 2004KN00716	A	20061110	IN 2004-KN716	20040527	<--
MX 2004PA05123	A	20050217	MX 2004-PA5123	20040528	<--
NO 2004002737	A	20040817	NO 2004-2737	20040629	<--
PRIORITY APPLN. INFO.:			US 2001-334453P	P	20011130 <--
			WO 2002-US36128	W	20021126 <--
OTHER SOURCE(S): MARPAT 139:36527					
GI					

/ Structure 70 in file .gra /

AB The present invention is directed to compds. represented by the following structural Formula (I) [wherein R1 = H, each (un)substituted C1-C8 alkyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, C3-6 cycloalkylaryl-C0-2-alkyl, or CH2-C(O)-R17-R18 (wherein R17 = O, NH; R18 = optionally substituted benzyl); R2 = C1-6 alkyl, C1-6 alkenyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, C1-4 alkylsulfonamide, C1-4 alkylamide, OH, C1-4 alkoxy, C3-6 cycloalkyl; W = O, S; X = an optionally substituted C1-5 alkylene linker wherein one carbon atom of the linker may optionally be replaced with O, NH, S, and optionally two carbons together may form a double bond; Y = C, O, S, NH, a single bond; E = C(R3)(R4)A, A, (CH2)nCO2R19; wherein A = CO2H, C1-3 alkyl nitrile, carboxamide, each (un)substituted sulfonamide, acylsulfonamide, tetrazole, or isoxazole; R3 = H, C1-5 alkyl, C1-5 alkoxy; R4 = H, halo, each (un)substituted C1-5 alkyl, C1-5 alkoxy, C3-6 cycloalkyl, aryl-C0-4-alkyl, aryl-C0-2 alkoxy, or Ph; or R3 and R4 are combined to form a C3-8 cycloalkyl; R19 = H, each (un)substituted arylmethyl or C1-4 alkyl; n = 0-3; R21 = H, oxo, each (un)substituted C1-6 alkyl, aryl, C1-4 alkylaryl, or heteroaryl; R22 = H, each (un)substituted C1-6 alkyl, aryl, C1-4 alkyl-aryl, or heteroaryl]. These compds. are useful for preventing or treating diabetes mellitus or treating syndrome X or cardiovascular disease (no data). Thus, To a solution of 2-methyl-2-[2-methyl-4-[2-(3-methyl-2-oxoimidazolidin-4-yl)ethoxy]phenoxy]propionic acid Et ester (0.040 g) in DMF (2.0 mL), was added NaH (60% in mineral oil, 0.0066 g) in one portion and the mixture was stirred for 15 min at room temperature, treated with 4-tert-butylbenzyl bromide (0.030 mL), and stirred for 4 h at room temperature to give, after workup, an Et ester intermediate, which was treated with a mixture of MeOH (2 mL)/5.0 N NaOH (1 mL) at room temperature overnight, concentrated, diluted with water (2 mL), cooled down to 0°, and acidified to pH 2 by adding concentrated HCl dropwise to give, after purification on a Chem elut 1005 tube, 2-[4-[2-[1-(4-tert-Butylbenzyl)-3-

methyl-2-oxoimidazolidin-4-yl]ethoxy]-2- methylphenoxy]-2-methylpropionic acid  
as an colorless oil (0.022 g, 42%).  
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s l1 sss sam  
SAMPLE SEARCH INITIATED 12:49:53 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 2561 TO ITERATE

78.1% PROCESSED 2000 ITERATIONS 50 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 48185 TO 54255  
PROJECTED ANSWERS: 3861 TO 5717

L2 50 SEA SSS SAM L1

=> d scan

L2 50 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzenepropanoic acid,  $\alpha$ ,2-diethoxy-4-[2-(5-methyl-2-phenyl-4-  
thiazolyl)ethoxy]-, ethyl ester  
MF C27 H33 N O5 S

/ Structure 84 in file .gra /

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 50 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(4-ethoxy-9H-carbazol-9-  
yl)ethoxy]-, ethyl ester  
MF C29 H33 N O5

=> s l1 sss full  
FULL SEARCH INITIATED 12:51:33 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 50873 TO ITERATE

100.0% PROCESSED 50873 ITERATIONS 4362 ANSWERS  
SEARCH TIME: 00.00.01

L3 4362 SEA SSS FUL L1

=> s l3/prep  
1060 L3  
4706241 PREP/RL  
L4 821 L3/PREP  
(L3 (L) PREP/RL)

=> s 14 and (py<2003 or ay<2003 or pry<2003)  
 22983071 PY<2003  
 4502933 AY<2003  
 3971676 PRY<2003  
 L5 587 L4 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> S L5 AND HYDROGENA?  
 301729 HYDROGENA?  
 L6 49 L5 AND HYDROGENA?

=> S L6 AND CHIRAL?  
 139312 CHIRAL?  
 L7 6 L6 AND CHIRAL?

=> S L6 AND (CHIRAL? OR OPTICAL?)  
 139312 CHIRAL?  
 1145559 OPTICAL?  
 L8 8 L6 AND (CHIRAL? OR OPTICAL?)

=> D L8 1-8 IBIB ABS TI HIT

L8 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2007:544712 CAPLUS Full-text  
 DOCUMENT NUMBER: 148:449648  
 TITLE: An improved process for the preparation of phenoxazine  
 antidiabetic compounds  
 INVENTOR(S): Rao, Siripragada Mahender; Reddy, Chepyala Naveen  
 Kumar; Reddy, Challa Maheedhara; Sarma, Mamillapalli  
 Ramabhandra; Reddy, Gaddam Om  
 PATENT ASSIGNEE(S): Reddy's Laboratories Ltd., India  
 SOURCE: Indian Pat. Appl., 18pp.  
 CODEN: INXXBQ  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
IN 2002MA00508	A	20070511	IN 2002-MA508	20020708 <--
PRIORITY APPLN. INFO.:			IN 2002-MA508	20020708 <--
OTHER SOURCE(S):	CASREACT 148:449648; MARPAT 148:449648			
GI				

/ Structure 99 in file .gra /

AB The invention relates to an improved process for the preparation of  
 antidiabetic phenoxazinylethoxyphenylalkoxypropanoate arginine salts I [R1 =  
 Me, Et, Pr, i-Pr]. The process uses inexpensive chems. and an easy resolution  
 via chiral amine salts. Thus, condensation of 4-[2-(phenoxazin-10-  
 yl)ethoxy]benzaldehyde with Et chloroacetate using EtONa in EtOH gave the  
 corresponding glycidic ester, which was hydrogenated over Pd/C, O-ethylated  
 with di-Et sulfate in xylene, and saponified with aqueous NaOH in MeOH to give  
 acid (±)-II. Resolution of this racemate using (-)-ephedrine and salification  
 with L-arginine in i-PrOH gave I (R1 = Et).  
 TI An improved process for the preparation of phenoxazine antidiabetic



	compounds PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	IN 2002MA00508	A	20070511	IN 2002-MA508	20020708 <--
PRAI	IN 2002-MA508		20020708	<--	
AB	The invention relates to an improved process for the preparation of antidiabetic phenoxazinylethoxyphenylalkoxypropanoate arginine salts I [R1 = Me, Et, Pr, i-Pr]. The process uses inexpensive chems. and an easy resolution via chiral amine salts. Thus, condensation of 4-[2-(phenoxazin-10-yl)ethoxy]benzaldehyde with Et chloroacetate using EtONa in EtOH gave the corresponding glycidic ester, which was hydrogenated over Pd/C, O-ethylated with di-Et sulfate in xylene, and saponified with aqueous NaOH in MeOH to give acid (±)-II. Resolution of this racemate using (-)-ephedrine and salification with L-arginine in i-PrOH gave I (R1 = Et).				
IT	222834-12-0P 222834-14-2P 222834-21-1P 222834-30-2P 267228-45-5P 493014-69-0P 493014-71-4P 493014-73-6P 493014-77-0P 493014-78-1P 493014-79-2P 493014-82-7P 493014-83-8P 493014-84-9P 493014-96-3P 493014-97-4P 493014-98-5P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (improved preparation of phenoxazine antidiabetic compds.)				

L8 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2003:76765 CAPLUS Full-text  
 DOCUMENT NUMBER: 138:137318  
 TITLE: An improved process for the preparation of antidiabetic phenoxazine compounds, e.g., ragaglitazar L-arginine salt  
 INVENTOR(S): Siripragada, Mahender Rao; Chepyala, Naveen Kumar Reddy; Challa, Maheedharareddy; Mamillapalli, Ramabhadra Sarma; Gaddam, Om Reddy  
 PATENT ASSIGNEE(S): Reddy's Laboratories Ltd., India  
 SOURCE: PCT Int. Appl., 31 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	WO 2003008397	A1	20030130	WO 2002-IB2776	20020716 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	IN 191728	A1	20031220	IN 2001-MA585	20010718 <--
	IN 2001MA00585	A	20081128		
	AU 2002313569	A1	20030303	AU 2002-313569	20020716 <--
PRIORITY APPLN. INFO.:				IN 2001-MA585	A 20010718 <--
				WO 2002-IB2776	W 20020716 <--
OTHER SOURCE(S):	CASREACT 138:137318; MARPAT 138:137318				
GI					

/ Structure 100 in file .gra /

AB The invention relates to an improved, multi-step process for the preparation of antidiabetic compds. I [where R1 represents an alkyl group such as Me, Et, Pr, iso-Pr, Bu, tert-Bu, and the like]. I are known antidiabetic, hypolipidemic, and antihypercholesterolemic agents. Older methods of preparing I are industrially unsuitable for a variety of reasons, including exotic and moisture-sensitive reactions, tedious purifns., low yields, and long cycle times. The new method is simple, robust, scalable, and provides I with high chemical and chiral purity. The use of highly reactive, difficult-to-handle, and expensive chems. is avoided, and simple, inexpensive chems. such as di-Et sulfate and K2CO3 are used instead. Two variants of the process are claimed and illustrated, in which the resolution step occurs at different points. For instance, Darzen's condensation of 4-[2-(phenoxazin-10-yl)ethoxy]benzaldehyde with Et chloroacetate using EtONa in EtOH gave the corresponding glycidic ester, which was hydrogenated over Pd/C and saponified with aqueous NaOH in MeOH to give acid ( $\pm$ )-II. Two-step resolution of this racemate using (S)-phenylglycinol and then (-)- $\alpha$ -methylbenzylamine gave (S)-II of 99.2% purity. Combined etherification/esterification of the latter with NaH and EtI, saponification of the ester with aqueous NaOH in MeOH, and salification with L-arginine in iso-PrOH gave I (R1 = Et), i.e., the arginine salt of ragaglitazar.. The alternative sequence involves Darzen's condensation, hydrogenation, etherification/esterification, ester saponification, resolution, and salification.

II An improved process for the preparation of antidiabetic phenoxazine compounds, e.g., ragaglitazar L-arginine salt

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
PI WO 2003008397	A1	20030130	WO 2002-IB2776	20020716 <--
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 191728	A1	20031220	IN 2001-MA585	20010718 <--
IN 2001MA00585	A	20081128		
AU 2002313569	A1	20030303	AU 2002-313569	20020716 <--
PRAI IN 2001-MA585	A	20010718	<--	
WO 2002-IB2776	W	20020716	<--	

AB The invention relates to an improved, multi-step process for the preparation of antidiabetic compds. I [where R1 represents an alkyl group such as Me, Et, Pr, iso-Pr, Bu, tert-Bu, and the like]. I are known antidiabetic, hypolipidemic, and antihypercholesterolemic agents. Older methods of preparing I are industrially unsuitable for a variety of reasons, including exotic and moisture-sensitive reactions, tedious purifns., low yields, and long cycle times. The new method is simple, robust, scalable, and provides I with high chemical and chiral purity. The use of highly reactive, difficult-to-handle, and expensive chems. is avoided, and simple, inexpensive chems. such as di-Et sulfate and K2CO3 are used instead. Two variants of the process

are claimed and illustrated, in which the resolution step occurs at different points. For instance, Darzen's condensation of 4-[2-(phenoxazin-10-yl)ethoxy]benzaldehyde with Et chloroacetate using EtONa in EtOH gave the corresponding glycidic ester, which was hydrogenated over Pd/C and saponified with aqueous NaOH in MeOH to give acid ( $\pm$ )-II. Two-step resolution of this racemate using (S)-phenylglycinol and then (-)- $\alpha$ -methylbenzylamine gave (S)-II of 99.2% purity. Combined etherification/esterification of the latter with NaH and EtI, saponification of the ester with aqueous NaOH in MeOH, and salification with L-arginine in iso-PrOH gave I (R1 = Et), i.e., the arginine salt of ragaglitazar.. The alternative sequence involves Darzen's condensation, hydrogenation, etherification/esterification, ester saponification, resolution, and salification.

- IT 222834-12-0P, Ethyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoate 222834-14-2P, Ethyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-hydroxypropanoate 222834-21-1P, 3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid 222834-23-3P, 3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-hydroxypropanoic acid 222834-30-2P, (S)-3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid 493014-69-0P, Ethyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2,3-epoxypropanoate 493031-09-7P 493031-10-0P  
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; improved preparation of antidiabetic phenoxazine derivs., e.g., ragaglitazar arginine salt)
- IT 222834-24-4P, 3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-butoxypropanoic acid 267228-44-4P, Methyl (S)-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-methoxypropanoate 267228-45-5P, (S)-3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-methoxypropanoic acid 493014-71-4P, (S)-3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-propoxypropanoic acid 493014-73-6P, (S)-3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-isopropoxypropanoic acid 493014-75-8P, (S)-3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-tert-butoxypropanoic acid 493014-77-0P, Methyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2,3-epoxypropanoate 493014-78-1P, Propyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2,3-epoxypropanoate 493014-79-2P, Isopropyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2,3-epoxypropanoate 493014-80-5P, Butyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2,3-epoxypropanoate 493014-81-6P, tert-Butyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2,3-epoxypropanoate 493014-82-7P, Methyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-hydroxypropanoate 493014-83-8P, Propyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-hydroxypropanoate 493014-84-9P, Isopropyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-hydroxypropanoate 493014-85-0P, Butyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-hydroxypropanoate 493014-86-1P, tert-Butyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-hydroxypropanoate 493014-87-2P, Propyl (S)-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-propoxypropanoate 493014-88-3P, Isopropyl (S)-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-isopropoxypropanoate 493014-89-4P, Butyl (S)-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-butoxypropanoate 493014-90-7P, tert-Butyl (S)-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-tert-butoxypropanoate 493014-91-8P, Methyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-methoxypropanoate 493014-92-9P, Propyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-propoxypropanoate 493014-93-0P, Isopropyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-isopropoxypropanoate 493014-94-1P, Butyl

3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-butoxypropanoate  
493014-95-2P, tert-Butyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-  
2-tert-butoxypropanoate 493014-96-3P,  
3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-methoxypropanoic acid  
493014-97-4P, 3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-propoxypropanoic  
acid 493014-98-5P, 3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-  
isopropoxypropanoic acid 493014-99-6P,  
3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-tert-butoxypropanoic acid  
493031-11-1P, (S)-3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-  
butoxypropanoic acid  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP  
(Preparation); RACT (Reactant or reagent)  
(intermediate; improved preparation of antidiabetic phenoxazine derivs.,  
e.g., ragaglitazar arginine salt)

L8 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:229636 CAPLUS Full-text

DOCUMENT NUMBER: 123:111772

ORIGINAL REFERENCE NO.: 123:19965a

TITLE: 2,3-Diaza-1,3-dienes (Azines) as Substrates for the  
Staudinger Reaction. Synthesis and Reactivity of  
N-Imino- $\beta$ -lactams

AUTHOR(S): Alcaide, Benito; Miranda, Miguel; Perez-Castells,  
Javier; Polanco, Concepcion; Sierra, Miguel A.

CORPORATE SOURCE: Facultad de Quimica, Universidad Complutense, Madrid,  
28040, Spain

SOURCE: Journal of Organic Chemistry (1994), 59(26),  
8003-10

CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 123:111772

GI

/ Structure 101 in file .gra /

AB The reaction of aromatic and aliphatic azines with different ketene  
precursors, such as the acid chloride/Et<sub>3</sub>N system, alkoxychromium(0) carbenes,  
and free di-Ph ketene, gives N-imino- $\beta$ -lactams, e.g., I (R<sub>1</sub> = PhO, MeO,  
PhCH<sub>2</sub>O, phthalimidyl, MeCO<sub>2</sub>, Me<sub>3</sub>CO, R<sub>2</sub> = 4-MeOC<sub>6</sub>H<sub>4</sub>, Ph, 2-furyl, etc., R<sub>3</sub> = H,  
Me), in good to excellent yields, with good levels of cis,trans-selectivity.  
A wide variety of sym.-substituted azines derived from aldehydes and ketones  
are compatible with the Staudinger reaction. Chiral N-imino- $\beta$ -lactams derived  
from sym. or unsym. (mixed) chiral azines are also obtained in good yields as  
essentially single enantiomers (de > 95%). Different reaction intermediates,  
including hemiaminals, oxadiazols, and hydrazides have been isolated. Free di-  
Ph ketene forms Diels-Alder adducts and N-acylazadienes in addition to the  
previously reported N-imino- $\beta$ -lactams. The usual reactivity of the  $\beta$ -lactam  
ring is modified in N-imino- $\beta$ -lactams by the presence of the imino group.  
Thus,  $\beta$ -hydrazono esters, N-alkylamino- $\beta$ -lactams, and NH- $\beta$ -lactams can be  
efficiently obtained by base-catalyzed 2-azetidinone ring opening, catalytic  
hydrogenation, and ozonolysis, resp.

TI 2,3-Diaza-1,3-dienes (Azines) as Substrates for the Staudinger Reaction.  
Synthesis and Reactivity of N-Imino- $\beta$ -lactams

SO Journal of Organic Chemistry (1994), 59(26), 8003-10

CODEN: JOCEAH; ISSN: 0022-3263

AB The reaction of aromatic and aliphatic azines with different ketene precursors, such as the acid chloride/Et<sub>3</sub>N system, alkoxychromium(0) carbenes, and free di-Ph ketene, gives N-imino- $\beta$ -lactams, e.g., I (R<sub>1</sub> = PhO, MeO, PhCH<sub>2</sub>O, phthalimidyl, MeCO<sub>2</sub>, Me<sub>3</sub>CO, R<sub>2</sub> = 4-MeOC<sub>6</sub>H<sub>4</sub>, Ph, 2-furyl, etc., R<sub>3</sub> = H, Me), in good to excellent yields, with good levels of cis,trans-selectivity. A wide variety of sym.-substituted azines derived from aldehydes and ketones are compatible with the Staudinger reaction. Chiral N-imino- $\beta$ -lactams derived from sym. or unsym. (mixed) chiral azines are also obtained in good yields as essentially single enantiomers (de > 95%). Different reaction intermediates, including hemiaminals, oxadiazols, and hydrazides have been isolated. Free di-Ph ketene forms Diels-Alder adducts and N-acylazadienes in addition to the previously reported N-imino- $\beta$ -lactams. The usual reactivity of the  $\beta$ -lactam ring is modified in N-imino- $\beta$ -lactams by the presence of the imino group. Thus,  $\beta$ -hydrazono esters, N-alkylamino- $\beta$ -lactams, and NH- $\beta$ -lactams can be efficiently obtained by base-catalyzed 2-azetidinone ring opening, catalytic hydrogenation, and ozonolysis, resp.

IT 145654-57-5P 165374-81-2P 165374-82-3P 165374-83-4P  
165374-90-3P 165374-91-4P 165374-92-5P  
165374-93-6P 165374-94-7P 165374-95-8P 165374-96-9P  
165374-97-0P 165374-98-1P 165374-99-2P 165375-00-8P 165375-01-9P  
165375-02-0P 165375-03-1P 165375-04-2P 165375-05-3P 165375-06-4P  
165375-07-5P 165375-08-6P 165874-18-0P 865855-67-0P 865856-13-9P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(Staudinger reaction of azines and preparation and reactions of  
N-imino- $\beta$ -lactams)

L8 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:539588 CAPLUS Full-text

DOCUMENT NUMBER: 119:139588

ORIGINAL REFERENCE NO.: 119:25059a,25062a

TITLE: New ligands for asymmetric dihydroxylation: multiple  
cinchona alkaloid units attached to a central  
heterocyclic core

INVENTOR(S): Hartung, Jens; Sharpless, K. Barry

PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA

SOURCE: PCT Int. Appl., 121 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9307142	A1	19930415	WO 1992-US8544	19921006 <--
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
US 5260461	A	19931109	US 1991-775683	19911010 <--
EP 608307	A1	19940803	EP 1992-921493	19921006 <--
EP 608307	B1	20040204		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
JP 07500323	T	19950112	JP 1993-507170	19921006 <--
JP 3982829	B2	20070926		
CA 2120919	C	20030701	CA 1992-2120919	19921006 <--
AT 258932	T	20040215	AT 1992-921493	19921006 <--
ES 2215989	T3	20041016	ES 1992-921493	19921006 <--
PRIORITY APPLN. INFO.:			US 1991-775683	A 19911010 <--
			US 1988-142692	B2 19880111 <--

US 1988-159064	A2 19880223 <--
US 1988-250378	A2 19880928 <--
US 1990-512934	A2 19900423 <--
WO 1991-US2778	W 19910423 <--
US 1991-699183	A2 19910513 <--
WO 1992-US8544	W 19921006 <--

GI

/ Structure 102 in file .gra /

AB Osmium-catalyzed methods of addition to an olefin are studied. In the method of asym. dihydroxylation of the present invention, an olefin, a chiral ligand, an organic solvent, an aqueous solution, a base, a ferricyanide salt and an osmium-containing compound are combined. The chiral ligand is an alkaloid or alkaloid derivative linked to an organic substituent of at least 300 daltons mol. weight through a planar aromatic spacer group. The organic substituent can be another alkaloid or alkaloid derivative With the described chiral ligands, asym. dihydroxylation of olefins with high yields and enantiomeric excesses are achieved. Thus, dihydroquinidine was treated with 1,4-dichlorophthalazine in DMF containing NaH to give 1,4-bis(9'-O-dihydroquinidyl)phthalazine (I). To a well stirred solution of I, a solution of potassium ferricyanide, K<sub>2</sub>CO<sub>3</sub>, OsO<sub>4</sub> in toluene was added a Me<sub>3</sub>COH-H<sub>2</sub>O solution of 1-decene, the solution was stirred for 24 h at 0° followed by addition of sodium sulfite to give 83% 1,2-decanediol with 84% ee.

TI New ligands for asymmetric dihydroxylation: multiple cinchona alkaloid units attached to a central heterocyclic core

PI WO 9307142 A1 19930415

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9307142	A1	19930415	WO 1992-US8544	19921006 <--
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
	US 5260461	A	19931109	US 1991-775683	19911010 <--
	EP 608307	A1	19940803	EP 1992-921493	19921006 <--
	EP 608307	B1	20040204		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
	JP 07500323	T	19950112	JP 1993-507170	19921006 <--
	JP 3982829	B2	20070926		
	CA 2120919	C	20030701	CA 1992-2120919	19921006 <--
	AT 258932	T	20040215	AT 1992-921493	19921006 <--
	ES 2215989	T3	20041016	ES 1992-921493	19921006 <--
PRAI	US 1991-775683	A	19911010	<--	
	US 1988-142692	B2	19880111	<--	
	US 1988-159064	A2	19880223	<--	
	US 1988-250378	A2	19880928	<--	
	US 1990-512934	A2	19900423	<--	
	WO 1991-US2778	W	19910423	<--	
	US 1991-699183	A2	19910513	<--	
	WO 1992-US8544	W	19921006	<--	

AB Osmium-catalyzed methods of addition to an olefin are studied. In the method of asym. dihydroxylation of the present invention, an olefin, a chiral ligand, an organic solvent, an aqueous solution, a base, a ferricyanide salt and an osmium-containing compound are combined. The chiral ligand is an alkaloid or alkaloid derivative linked to an organic substituent of at least 300 daltons mol. weight through a planar aromatic spacer group. The organic substituent can be another alkaloid or alkaloid derivative With the described chiral

ligands, asym. dihydroxylation of olefins with high yields and enantiomeric excesses are achieved. Thus, dihydroquinidine was treated with 1,4-dichlorophthalazine in DMF containing NaH to give 1,4-bis(9'-O-dihydroquinidyl)phthalazine (I). To a well stirred solution of I, a solution of potassium ferricyanide, K<sub>2</sub>CO<sub>3</sub>, OsO<sub>4</sub> in toluene was added a Me<sub>3</sub>COH-H<sub>2</sub>O solution of 1-decene, the solution was stirred for 24 h at 0° followed by addition of sodium sulfite to give 83% 1,2-decanediol with 84% ee.

IT 100-13-0, p-Nitrostyrene 110-57-6 300-57-2, Allylbenzene 447-53-0  
558-37-2 611-15-4, o-Methylstyrene 623-70-1 637-69-4,  
p-Methoxystyrene 674-76-0 692-70-6 695-12-5 762-63-0 768-49-0  
932-66-1, 1-Acetylcyclohexene 935-00-2 1193-18-6 1746-13-0, Allyl  
phenyl ether 1754-62-7 2039-89-6 2039-90-9 2157-18-8 2738-19-4  
3054-95-3 4192-77-2 5820-22-4 7367-82-0 7642-04-8 13389-42-9  
14663-11-7 18448-47-0, Methyl 1-cyclohexene carboxylate 20710-38-7  
21040-45-9 21087-29-6 22946-43-6 27829-72-7 31552-04-2  
34352-92-6 50555-04-9 63511-93-3 63511-95-5 66323-99-7  
67364-02-7 71338-71-1 72551-28-1 78277-23-3 81703-93-7  
105018-99-3 125187-81-7 125187-82-8 125187-83-9 125206-15-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(asym. dihydroxylation of, chiral dihydroquinidine derivative for osmium catalyzed)

IT 98-83-9, reactions 100-42-5, reactions 103-30-0, trans-Stilbene  
766-90-5 771-98-2, 1-Phenylcyclohexene 827-54-3, 2-Vinylnaphthalene  
872-05-9, 1-Decene 873-66-5 1463-04-3 3901-07-3, trans-Methyl  
4-methoxycinnamate 6714-96-1 7433-56-9, trans-5-Decene 13269-52-8,  
trans-3-Hexene 13633-26-6 17343-88-3 61142-41-4, Vinylcyclooctane

RL: RCT (Reactant); RACT (Reactant or reagent)

(asym. dihydroxylation of, chiral dihydroquinidine ligand for osmium catalyzed)

IT 56-54-2, Quinidine

RL: RCT (Reactant); RACT (Reactant or reagent)

(hydrogenation of)

IT 2325-10-2P 16355-00-3P 25779-13-9P 31612-63-2P 32345-64-5P  
34281-90-8P 35638-92-7P 40421-51-0P 40560-98-3P 49801-14-1P  
52340-78-0P 53448-10-5P 57495-92-8P 77977-74-3P 78805-31-9P  
79299-22-2P 83603-02-5P 84276-14-2P 84518-30-9P 87827-60-9P  
87858-06-8P 88196-06-9P 89063-88-7P 98464-24-5P 99881-77-3P  
108666-29-1P 108741-12-4P 110549-79-6P 113162-03-1P 113162-04-2P  
113162-11-1P 115889-27-5P 121564-12-3P ~~122517-80-0P~~  
124649-67-8P 125132-75-4P 130876-03-8P 130932-13-7P 130932-14-8P  
132486-47-6P 135042-86-3P 135042-87-4P 135096-77-4P 136031-93-1P  
138890-41-2P 139093-40-6P 139093-41-7P 139093-42-8P 139093-44-0P  
139093-45-1P 139093-46-2P 139093-47-3P 139165-53-0P 139165-54-1P  
139165-55-2P 139165-56-3P 139165-57-4P 139165-58-5P 139165-59-6P  
139165-60-9P 139165-61-0P 139165-62-1P 139165-63-2P 139165-64-3P  
139165-65-4P 139165-66-5P 139165-67-6P 139165-68-7P 139165-69-8P  
139165-70-1P 143536-11-2P 149519-66-4P 149519-67-5P 149519-68-6P  
149519-69-7P 149562-10-7P 149562-11-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

L8 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1992:486257 CAPLUS Full-text

DOCUMENT NUMBER: 117:86257

ORIGINAL REFERENCE NO.: 117:14967a,14970a

TITLE: A lipid-lipase aggregate with ether linkage as a new type of immobilized enzyme for enantioselective hydrolysis in organic solvents

AUTHOR(S): Akita, Hiroyuki; Umezawa, Isao; Matsukura, Hiroko; Oishi, Takeshi

CORPORATE SOURCE: Sch. Pharm. Sci., Toho Univ., Funabashi, 274, Japan  
SOURCE: Chemical & Pharmaceutical Bulletin (1992),  
40(2), 318-24  
CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal  
LANGUAGE: English

AB For the purpose of carrying out smoothly enzymic reaction of water-insol. substrates in organic solvents, a new type of immobilized enzyme, a lipid-lipase aggregate, was developed. To prepare various kinds of lipid-lipase aggregates, 27 kinds of dialkyl ether-type phospholipid analogs were newly synthesized and used for the preparation of aggregates with lipase. Thus obtained lipid-lipase aggregates catalyzed the enantioselective hydrolysis of the (+)- $\alpha$ -acyloxy ester 2 much more efficiently than lipase immobilized with synthetic prepolymer (ENTP-4000) in water-saturated iso-Pr ether. The reaction time became much shorter (2 to 3 days for completion as compared with 21 days) and the chemical and optical yields of the reaction products were high.

TI A lipid-lipase aggregate with ether linkage as a new type of immobilized enzyme for enantioselective hydrolysis in organic solvents

SO Chemical & Pharmaceutical Bulletin (1992), 40(2), 318-24  
CODEN: CPBTAL; ISSN: 0009-2363

AB For the purpose of carrying out smoothly enzymic reaction of water-insol. substrates in organic solvents, a new type of immobilized enzyme, a lipid-lipase aggregate, was developed. To prepare various kinds of lipid-lipase aggregates, 27 kinds of dialkyl ether-type phospholipid analogs were newly synthesized and used for the preparation of aggregates with lipase. Thus obtained lipid-lipase aggregates catalyzed the enantioselective hydrolysis of the (+)- $\alpha$ -acyloxy ester 2 much more efficiently than lipase immobilized with synthetic prepolymer (ENTP-4000) in water-saturated iso-Pr ether. The reaction time became much shorter (2 to 3 days for completion as compared with 21 days) and the chemical and optical yields of the reaction products were high.

IT 64599-78-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and hydrogenation of)

IT 125354-94-1P 125354-96-3P  
RL: PREP (Preparation)  
(preparation of, by lipid-lipase aggregate hydrolysis in solvents)

L8 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1990:406196 CAPLUS Full-text

DOCUMENT NUMBER: 113:6196

ORIGINAL REFERENCE NO.: 113:1203a,1206a

TITLE: Synthesis of threo-3-aryl-2,3-dihydroxypropanoic acid derivatives with high optical purity

AUTHOR(S): Matthews, Barry R.; Gountzos, Helen; Jackson, W. Roy; Watson, Keith G.

CORPORATE SOURCE: Dep. Chem., Monash Univ., Clayton, 3168, Australia  
SOURCE: Tetrahedron Letters (1989), 30(38), 5157-8

CODEN: TELEAY; ISSN: 0040-4039

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 113:6196

GI

/ Structure 103 in file .gra /



AB Cyanohydrins of aromatic aldehydes can be obtained in high optical purity using the Inoue dipeptide catalyst system and converted into enantiomerically and diastereochem. pure threo-3-aryl-2,3-dihydroxypropanoic acid derivs. via a route which involves a base-catalyzed equilibration of the acetonides of the cyano diols. Thus, (R)-(+)-4-MeOC6H4CH(OH)CN was hydrogenated over Ni and treated sequentially with NaHSO<sub>3</sub>, NaCN, and (MeO)<sub>2</sub>CMe<sub>2</sub> and acid to give cis- and trans-dioxolanes I. Hydrolysis and epimerization of I with KOH in EtOH and then treatment with aqueous acid followed by HCl-MeOH gave the enantiomerically pure threo-4-MeOC6H4CH(OH)CH(OH)CO<sub>2</sub>Me (II). II was successfully converted into diltiazem.

TI Synthesis of threo-3-aryl-2,3-dihydroxypropanoic acid derivatives with high optical purity

TI Synthesis of threo-3-aryl-2,3-dihydroxypropanoic acid derivatives with high optical purity

SO Tetrahedron Letters (1989), 30(38), 5157-8  
CODEN: TELEAY; ISSN: 0040-4039

AB Cyanohydrins of aromatic aldehydes can be obtained in high optical purity using the Inoue dipeptide catalyst system and converted into enantiomerically and diastereochem. pure threo-3-aryl-2,3-dihydroxypropanoic acid derivs. via a route which involves a base-catalyzed equilibration of the acetonides of the cyano diols. Thus, (R)-(+)-4-MeOC6H4CH(OH)CN was hydrogenated over Ni and treated sequentially with NaHSO<sub>3</sub>, NaCN, and (MeO)<sub>2</sub>CMe<sub>2</sub> and acid to give cis- and trans-dioxolanes I. Hydrolysis and epimerization of I with KOH in EtOH and then treatment with aqueous acid followed by HCl-MeOH gave the enantiomerically pure threo-4-MeOC6H4CH(OH)CH(OH)CO<sub>2</sub>Me (II). II was successfully converted into diltiazem.

IT 97070-73-0  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(hydrogenation and cyanation of)

IT 122517-80-0P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and conversion of, to diltiazem)

L8 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1990:75971 CAPLUS Full-text

DOCUMENT NUMBER: 112:75971

ORIGINAL REFERENCE NO.: 112:12975a,12978a

TITLE: Ligand-accelerated catalytic asymmetric dihydroxylation

INVENTOR(S): Marko, Istvan E.; Sharpless, K. Barry

PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA

SOURCE: PCT Int. Appl., 66 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 8906225	A1	19890713	WO 1989-US86	19890110 <--
W: JP				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
US 4871855	A	19891003	US 1988-159068	19880223 <--
US 4965364	A	19901023	US 1988-250378	19880928 <--
EP 395729	A1	19901107	EP 1989-901900	19890110 <--
EP 395729	B1	19950927		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 03503885	T	19910829	JP 1989-501814	19890110 <--
JP 3153540	B2	20010409		

EP 658532	A1	19950621	EP 1995-200458	19890110 <--
EP 658532	B1	19990407		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 128449	T	19951015	AT 1989-901900	19890110 <--
AT 178578	T	19990415	AT 1995-200458	19890110 <--
JP 2001192383	A	20010717	JP 2000-335775	19890110 <--
CA 1338314	C	19960507	CA 1989-587964	19890111 <--
PRIORITY APPLN. INFO.:			US 1988-142692	A 19880111 <--
			US 1988-159068	A 19880223 <--
			US 1988-250378	A 19880928 <--
			EP 1989-901900	A3 19890110 <--
			JP 1989-501814	A3 19890110 <--
			WO 1989-US86	W 19890110 <--
AB	Vicinal diols are prepared by asym. dihydroxylation of olefins in the presence of a chiral ligand, an Os-containing catalyst, an amine oxide, an organic solvent, and H2O. OsO4 was injected into a solution of trans-stilbene, hydroquinidine p-chlorobenzoate, and N-methylmorpholine N-oxide in Me2CO and H2O at 0-4° with shaking, Na2S2O5 added, and the mixture worked up to give 55% (R,R)-PhCH(OH)CH(OH)Ph of 99% enantiomeric excess. Preparation of dihydroquinidine derivs. and their recovery were also given. Asym. dihydroxylations of trans-3-hexene, 1-phenylcyclohexene, β-methylstyrene, and Me (E)-4-methoxycinnamate were also given.			
TI	Ligand-accelerated catalytic asymmetric dihydroxylation			
PI	WO 8906225 A1 19890713			
	PATENT NO.	KIND	DATE	APPLICATION NO. DATE
	-----	----	-----	-----
PI	WO 8906225	A1	19890713	WO 1989-US86 19890110 <--
	W: JP			
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE			
	US 4871855	A	19891003	US 1988-159068 19880223 <--
	US 4965364	A	19901023	US 1988-250378 19880928 <--
	EP 395729	A1	19901107	EP 1989-901900 19890110 <--
	EP 395729	B1	19950927	
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE			
	JP 03503885	T	19910829	JP 1989-501814 19890110 <--
	JP 3153540	B2	20010409	
	EP 658532	A1	19950621	EP 1995-200458 19890110 <--
	EP 658532	B1	19990407	
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE			
	AT 128449	T	19951015	AT 1989-901900 19890110 <--
	AT 178578	T	19990415	AT 1995-200458 19890110 <--
	JP 2001192383	A	20010717	JP 2000-335775 19890110 <--
	CA 1338314	C	19960507	CA 1989-587964 19890111 <--
PRAI	US 1988-142692	A	19880111	<--
	US 1988-159068	A	19880223	<--
	US 1988-250378	A	19880928	<--
	EP 1989-901900	A3	19890110	<--
	JP 1989-501814	A3	19890110	<--
	WO 1989-US86	W	19890110	<--
AB	Vicinal diols are prepared by asym. dihydroxylation of olefins in the presence of a chiral ligand, an Os-containing catalyst, an amine oxide, an organic solvent, and H2O. OsO4 was injected into a solution of trans-stilbene, hydroquinidine p-chlorobenzoate, and N-methylmorpholine N-oxide in Me2CO and H2O at 0-4° with shaking, Na2S2O5 added, and the mixture worked up to give 55% (R,R)-PhCH(OH)CH(OH)Ph of 99% enantiomeric excess. Preparation of dihydroquinidine derivs. and their recovery were also given. Asym. dihydroxylations of trans-3-hexene, 1-phenylcyclohexene, β-methylstyrene, and Me (E)-4-methoxycinnamate were also given.			
ST	asym dihydroxylation olefin chiral ligand			
IT	Hydroxylation			

(osmylation, stereoselective, of olefins, chiral ligands as accelerators for)

IT 56-54-2

RL: RCT (Reactant); RACT (Reactant or reagent)  
(hydrogenation of)

IT 40421-51-0P 52340-78-0P 53448-10-5P 125073-64-5P  
125132-75-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

L8 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1987:534332 CAPLUS Full-text

DOCUMENT NUMBER: 107:134332

ORIGINAL REFERENCE NO.: 107:21708h,21709a

TITLE: Preparation of 1,5-benzothiazepin-4-one derivatives as blood platelet aggregation inhibitors

INVENTOR(S): Inoue, Hirozumi; Otsuka, Hisao

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 62096482	A	19870502	JP 1986-141592	19860617 <--
JP 05081597	B	19931115		
PRIORITY APPLN. INFO.:			JP 1985-136569	A1 19850621 <--

GI

/ Structure 104 in file .gra /

AB The title compds. [I, II and III; R1 = alkyl, alkoxy; R2 = H, alkanoyl; R3 = alkyl; R4 = H; R5 or R6 is H and the other is Cl; R7 or R8 is alkyl, alkoxy, alkylthio, F, PhCO2O or OH and the other is H, or R7 = R8 = alkoxy], useful as blood platelet aggregation inhibitors, were prepared by treatment of I, II and III (R4 = alkyl) with acid halides of haloformic acids, e.g., COCl2, or their esters, e.g., CCl3O2CCl, and deacylation of the resulting I, II and III (R4 = COR9; R9 = halo or ester residue). COCl2 (31.91 g) in toluene was added to a solution of 20.21 g II (R1 = OMe, R2 = Ac, R3 = R4 = Me, R5 = Cl, R6 = H) in toluene and the mixture was stirred for 16 h at 30° to give II (R1 = OMe, R2 = Ac, R3 = Me, R4 = COCl, R5 = Cl, R6 = H), which was treated with 10% aqueous HCl and MeCN under reflux to give II (R1 = OMe, R2 = R4 = R6 = H, R3 = Me, R5 = Cl) (as the fumarate). In vitro, this inhibited collagen-induced blood platelet aggregation.

TI Preparation of 1,5-benzothiazepin-4-one derivatives as blood platelet aggregation inhibitors

PI JP 62096482 A 19870502 Showa

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
PI JP 62096482	A	19870502	JP 1986-141592	19860617 <--
JP 05081597	B	19931115		
PRAI JP 1985-136569	A1	19850621	<--	

IT 103921-06-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and cyclization of, dihydrobenzothiazepine derivative from)

IT 103921-05-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and hydrogenation of)

IT 100902-58-7P, (±)-cis-2-(4-Methoxyphenyl)-3-hydroxy-9-chloro-2,3-dihydro-1,5-benzothiazepine-4(5H)-one  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and resolution of, via chiral (naphthylsulfonyl)pyrrolidinecarboxylate ester)

=> S L6 AND (Ru? or Rh? or Pd? or Os?)

1446878 RU?

783851 RH?

329541 PD?

581552 OS?

L9 18 L6 AND (RU? OR RH? OR PD? OR OS?)

=> d 19 1-5 ibib abs ti hit

L9 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:544712 CAPLUS Full-text

DOCUMENT NUMBER: 148:449648

TITLE: An improved process for the preparation of phenoxazine antidiabetic compounds

INVENTOR(S): Rao, Siripragada Mahender; Reddy, Chepyala Naveen Kumar; Reddy, Challa Maheedhara; Sarma, Mamillapalli Ramabhandra; Reddy, Gaddam Om

PATENT ASSIGNEE(S): Reddy's Laboratories Ltd., India

SOURCE: Indian Pat. Appl., 18pp.

CODEN: INXXBQ

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
IN 2002MA00508	A	20070511	IN 2002-MA508	20020708 <--
PRIORITY APPLN. INFO.:			IN 2002-MA508	20020708 <--
OTHER SOURCE(S):		CASREACT 148:449648; MARPAT 148:449648		

GI

/ Structure 105 in file .gra /

AB The invention relates to an improved process for the preparation of antidiabetic phenoxazinylethoxyphenylalkoxypropanoate arginine salts I [R1 = Me, Et, Pr, i-Pr]. The process uses inexpensive chems. and an easy resolution via chiral amine salts. Thus, condensation of 4-[2-(phenoxazin-10-yl)ethoxy]benzaldehyde with Et chloroacetate using EtONa in EtOH gave the corresponding glycidic ester, which was hydrogenated over Pd/C, O-ethylated with di-Et sulfate in xylene, and saponified with aqueous NaOH in MeOH to give

acid ( $\pm$ )-II. Resolution of this racemate using (-)-ephedrine and salification with L-arginine in i-PrOH gave I (R1 = Et).

II An improved process for the preparation of phenoxazine antidiabetic compounds

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI IN 2002MA00508	A	20070511	IN 2002-MA508	20020708 <--
PRAI IN 2002-MA508		20020708	<--	

AB The invention relates to an improved process for the preparation of antidiabetic phenoxazinylethoxyphenylalkoxypropanoate arginine salts I [R1 = Me, Et, Pr, i-Pr]. The process uses inexpensive chems. and an easy resolution via chiral amine salts. Thus, condensation of 4-[2-(phenoxazin-10-yl)ethoxy]benzaldehyde with Et chloroacetate using EtONa in EtOH gave the corresponding glycidic ester, which was hydrogenated over Pd/C, O-ethylated with di-Et sulfate in xylene, and saponified with aqueous NaOH in MeOH to give acid ( $\pm$ )-II. Resolution of this racemate using (-)-ephedrine and salification with L-arginine in i-PrOH gave I (R1 = Et).

IT 222834-12-0P 222834-14-2P 222834-21-1P 222834-30-2P  
267228-45-5P 493014-69-0P 493014-71-4P 493014-73-6P 493014-77-0P  
493014-78-1P 493014-79-2P 493014-82-7P 493014-83-8P  
493014-84-9P 493014-96-3P 493014-97-4P 493014-98-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP  
(Preparation); RACT (Reactant or reagent)

(improved preparation of phenoxazine antidiabetic compds.)

L9 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:242286 CAPLUS Full-text

DOCUMENT NUMBER: 138:271396

TITLE: Preparation of 3-aryl-2-alkoxypropanoates from  
3-aryl-2-oxopropanoates via ketalization and reduction  
INVENTOR(S): Siripragada, Mahender Rao; Vanadanapu, Loka Appala  
Purushotham; Mamillapalli, Ramabhadra Sarma; Gaddam,  
Om Reddy

PATENT ASSIGNEE(S): Reddy's Laboratories Ltd., India

SOURCE: PCT Int. Appl., 12 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024915	A1	20030327	WO 2002-IB3874	20020919 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
IN 193612	A1	20040724	IN 2001-MA779	20010920 <--
AU 2002339216	A1	20030401	AU 2002-339216	20020919 <--
PRIORITY APPLN. INFO.:			IN 2001-MA779	A 20010920 <--
			WO 2002-IB3874	W 20020919 <--

OTHER SOURCE(S): CASREACT 138:271396; MARPAT 138:271396

AB 4-HOC6H4CH2CH(OR1)CO2R2 (R1 = H, alkyl; R2 = alkyl), were prepared by converting 4-HOC6H4CH2COCO2H to 4-HOC6H4CH2C(OR1)2CO2R2 (variables as above) in the presence of acid followed by reduction in HOAc at 40-80 psi for 6-12 h. Thus, 4-hydroxyphenylpyruvic acid was stirred in EtOH at 10-15° for 3 h, at room temperature for 6 h, and at 50-60° for 4 h to give 4-HOC6H4CH2C(OEt)2CO2Et. The latter was hydrogenated in EtOH/HOAc over Rh/Al2O3 at 60 psi for 12 h to give 4-HOC6H4CH2CH(OEt)CO2Et.

TI Preparation of 3-aryl-2-alkoxypropanoates from 3-aryl-2-oxopropanoates via ketalization and reduction

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024915	A1	20030327	WO 2002-IB3874	20020919 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 193612	A1	20040724	IN 2001-MA779	20010920 <--
AU 2002339216	A1	20030401	AU 2002-339216	20020919 <--
PRAI IN 2001-MA779	A	20010920	<--	
WO 2002-IB3874	W	20020919	<--	

AB 4-HOC6H4CH2CH(OR1)CO2R2 (R1 = H, alkyl; R2 = alkyl), were prepared by converting 4-HOC6H4CH2COCO2H to 4-HOC6H4CH2C(OR1)2CO2R2 (variables as above) in the presence of acid followed by reduction in HOAc at 40-80 psi for 6-12 h. Thus, 4-hydroxyphenylpyruvic acid was stirred in EtOH at 10-15° for 3 h, at room temperature for 6 h, and at 50-60° for 4 h to give 4-HOC6H4CH2C(OEt)2CO2Et. The latter was hydrogenated in EtOH/HOAc over Rh/Al2O3 at 60 psi for 12 h to give 4-HOC6H4CH2CH(OEt)CO2Et.

IT 1314-15-4, Platinum dioxide 7440-02-0, Nickel, uses 7440-16-6, Rhodium, uses  
 RL: CAT (Catalyst use); USES (Uses)  
 (preparation of 3-aryl-2-alkoxypropanoates from 3-aryl-2-oxopropanoates via ketalization and reduction)

IT 4375-92-2P  
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of 3-aryl-2-alkoxypropanoates from 3-aryl-2-oxopropanoates via ketalization and reduction)

IT 197299-16-4P  
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of 3-aryl-2-alkoxypropanoates from 3-aryl-2-oxopropanoates via ketalization and reduction)

L9 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:76765 CAPLUS Full-text

DOCUMENT NUMBER: 138:137318

TITLE: An improved process for the preparation of antidiabetic phenoxazine compounds, e.g., ragaglitazar L-arginine salt

INVENTOR(S): Siripragada, Mahender Rao; Chepyala, Naveen Kumar Reddy; Challa, Maheedharareddy; Mamillapalli, Ramabhadra Sarma; Gaddam, Om Reddy

PATENT ASSIGNEE(S): Reddy's Laboratories Ltd., India  
 SOURCE: PCT Int. Appl., 31 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2003008397	A1	20030130	WO 2002-IB2776	20020716 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 191728	A1	20031220	IN 2001-MA585	20010718 <--
IN 2001MA00585	A	20081128		
AU 2002313569	A1	20030303	AU 2002-313569	20020716 <--
PRIORITY APPLN. INFO.:			IN 2001-MA585	A 20010718 <--
			WO 2002-IB2776	W 20020716 <--
OTHER SOURCE(S):			CASREACT 138:137318; MARPAT 138:137318	
GI				

/ Structure 106 in file .gra /

AB The invention relates to an improved, multi-step process for the preparation of antidiabetic compds. I [where R1 represents an alkyl group such as Me, Et, Pr, iso-Pr, Bu, tert-Bu, and the like]. I are known antidiabetic, hypolipidemic, and antihypercholesterolemic agents. Older methods of preparing I are industrially unsuitable for a variety of reasons, including exotic and moisture-sensitive reactions, tedious purifns., low yields, and long cycle times. The new method is simple, robust, scalable, and provides I with high chemical and chiral purity. The use of highly reactive, difficult-to-handle, and expensive chems. is avoided, and simple, inexpensive chems. such as di-Et sulfate and K2CO3 are used instead. Two variants of the process are claimed and illustrated, in which the resolution step occurs at different points. For instance, Darzen's condensation of 4-[2-(phenoxazin-10-yl)ethoxy]benzaldehyde with Et chloroacetate using EtONa in EtOH gave the corresponding glycidic ester, which was hydrogenated over Pd/C and saponified with aqueous NaOH in MeOH to give acid ( $\pm$ )-II. Two-step resolution of this racemate using (S)-phenylglycinol and then (-)- $\alpha$ -methylbenzylamine gave (S)-II of 99.2% purity. Combined etherification/esterification of the latter with NaH and EtI, saponification of the ester with aqueous NaOH in MeOH, and salification with L-arginine in iso-PrOH gave I (R1 = Et), i.e., the arginine salt of ragaglitazar.. The alternative sequence involves Darzen's condensation, hydrogenation, etherification/esterification, ester saponification, resolution, and salification.

II An improved process for the preparation of antidiabetic phenoxazine compounds, e.g., ragaglitazar L-arginine salt

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

## RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003008397	A1	20030130	WO 2002-IB2776	20020716 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 191728	A1	20031220	IN 2001-MA585	20010718 <--
IN 2001MA00585	A	20081128		
AU 2002313569	A1	20030303	AU 2002-313569	20020716 <--
PRAI IN 2001-MA585	A	20010718	<--	
WO 2002-IB2776	W	20020716	<--	

AB The invention relates to an improved, multi-step process for the preparation of antidiabetic compds. I [where R1 represents an alkyl group such as Me, Et, Pr, iso-Pr, Bu, tert-Bu, and the like]. I are known antidiabetic, hypolipidemic, and antihypercholesterolemic agents. Older methods of preparing I are industrially unsuitable for a variety of reasons, including exotic and moisture-sensitive reactions, tedious purifns., low yields, and long cycle times. The new method is simple, robust, scalable, and provides I with high chemical and chiral purity. The use of highly reactive, difficult-to-handle, and expensive chems. is avoided, and simple, inexpensive chems. such as di-Et sulfate and K2CO3 are used instead. Two variants of the process are claimed and illustrated, in which the resolution step occurs at different points. For instance, Darzen's condensation of 4-[2-(phenoxazin-10-yl)ethoxy]benzaldehyde with Et chloroacetate using EtONa in EtOH gave the corresponding glycidic ester, which was hydrogenated over Pd/C and saponified with aqueous NaOH in MeOH to give acid ( $\pm$ )-II. Two-step resolution of this racemate using (S)-phenylglycinol and then (-)- $\alpha$ -methylbenzylamine gave (S)-II of 99.2% purity. Combined etherification/esterification of the latter with NaH and EtI, saponification of the ester with aqueous NaOH in MeOH, and salification with L-arginine in iso-PrOH gave I (R1 = Et), i.e., the arginine salt of ragaglitazar.. The alternative sequence involves Darzen's condensation, hydrogenation, etherification/esterification, ester saponification, resolution, and salification.

IT 222834-12-0P, Ethyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoate 222834-14-2P, Ethyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-hydroxypropanoate 222834-21-1P, 3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid 222834-23-3P, 3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-hydroxypropanoic acid 222834-30-2P, (S)-3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid 493014-69-0P, Ethyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2,3-epoxypropanoate 493031-09-7P 493031-10-0P  
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; improved preparation of antidiabetic phenoxazine derivs., e.g., ragaglitazar arginine salt)

IT 222834-24-4P, 3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-butoxypropanoic acid 267228-44-4P, Methyl (S)-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-methoxypropanoate 267228-45-5P, (S)-3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-methoxypropanoic acid 493014-71-4P, (S)-3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-propoxypropanoic acid



493014-73-6P, (S)-3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-isopropoxypropanoic acid 493014-75-8P, (S)-3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-tert-butoxypropanoic acid 493014-77-0P, Methyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2,3-epoxypropanoate 493014-78-1P, Propyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2,3-epoxypropanoate 493014-79-2P, Isopropyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2,3-epoxypropanoate 493014-80-5P, Butyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2,3-epoxypropanoate 493014-81-6P, tert-Butyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2,3-epoxypropanoate 493014-82-7P, Methyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-hydroxypropanoate 493014-83-8P, Propyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-hydroxypropanoate 493014-84-9P, Isopropyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-hydroxypropanoate 493014-85-0P, Butyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-hydroxypropanoate 493014-86-1P, tert-Butyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-hydroxypropanoate 493014-87-2P, Propyl (S)-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-propoxypropanoate 493014-88-3P, Isopropyl (S)-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-isopropoxypropanoate 493014-89-4P, Butyl (S)-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-butoxypropanoate 493014-90-7P, tert-Butyl (S)-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-tert-butoxypropanoate 493014-91-8P, Methyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-methoxypropanoate 493014-92-9P, Propyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-propoxypropanoate 493014-93-0P, Isopropyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-isopropoxypropanoate 493014-94-1P, Butyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-butoxypropanoate 493014-95-2P, tert-Butyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-tert-butoxypropanoate 493014-96-3P, 3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-methoxypropanoic acid 493014-97-4P, 3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-propoxypropanoic acid 493014-98-5P, 3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-isopropoxypropanoic acid 493014-99-6P, 3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-tert-butoxypropanoic acid 493031-11-1P, (S)-3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-butoxypropanoic acid

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; improved preparation of antidiabetic phenoxazine derivs., e.g., ragaglitazar arginine salt)

L9 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:262036 CAPLUS Full-text

DOCUMENT NUMBER: 124:289000

ORIGINAL REFERENCE NO.: 124:53583a,53586a

TITLE: Hydrogenation process and catalysts for the production of phenyllactic acids from phenylpyruvic acids

INVENTOR(S): Morita, Hikari; Mori, Hiroyuki

PATENT ASSIGNEE(S): Nitto Chemical Industry Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 8 pp.  
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 696566	A1	19960214	EP 1995-112540	19950809 <--
EP 696566	B1	19980610		
R: CH, DE, LI				
JP 08053394	A	19960227	JP 1994-206102	19940809 <--
JP 3394606	B2	20030407		
US 5684186	A	19971104	US 1995-511152	19950804 <--
CN 1122325	A	19960515	CN 1995-109050	19950809 <--
CN 1083422	C	20020424		
PRIORITY APPLN. INFO.:			JP 1994-206102	A 19940809 <--
OTHER SOURCE(S):			CASREACT 124:289000; MARPAT 124:289000	
GI				

/ Structure 107 in file .gra /

AB Phenyllactic acids [I; R1, R2 = H, OH, (un)branched alkyl, (un)branched alkoxy; R3 = H, (un)branched alkyl; R1R2 = methylenedioxy], useful as intermediates in the preparation of agrochemicals. (no data) and pharmaceuticals (no data), are prepared in high yield by the hydrogenation of phenylpyruvic acids (II) in the presence of a catalyst containing  $\geq 1$  Group VIII metal (e.g., Pd, Pt, Ni, etc.). Thus, 3-(4-hydroxyphenyl)pyruvic acid was hydrogenated in MeOH using a Pd/C catalyst at 25°/5 kg/cm<sup>2</sup>, producing 3-(4-hydroxyphenyl)lactic acid.

TI Hydrogenation process and catalysts for the production of phenyllactic acids from phenylpyruvic acids

TI Hydrogenation process and catalysts for the production of phenyllactic acids from phenylpyruvic acids

PI EP 696566 A1 19960214

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 696566	A1	19960214	EP 1995-112540	19950809 <--
EP 696566	B1	19980610		
R: CH, DE, LI				
JP 08053394	A	19960227	JP 1994-206102	19940809 <--
JP 3394606	B2	20030407		
US 5684186	A	19971104	US 1995-511152	19950804 <--
CN 1122325	A	19960515	CN 1995-109050	19950809 <--
CN 1083422	C	20020424		

PRAI JP 1994-206102 A 19940809 <--

AB Phenyllactic acids [I; R1, R2 = H, OH, (un)branched alkyl, (un)branched alkoxy; R3 = H, (un)branched alkyl; R1R2 = methylenedioxy], useful as intermediates in the preparation of agrochemicals. (no data) and pharmaceuticals (no data), are prepared in high yield by the hydrogenation of phenylpyruvic acids (II) in the presence of a catalyst containing  $\geq 1$  Group VIII metal (e.g., Pd, Pt, Ni, etc.). Thus, 3-(4-hydroxyphenyl)pyruvic acid was hydrogenated in MeOH using a Pd/C catalyst at 25°/5 kg/cm<sup>2</sup>, producing 3-(4-hydroxyphenyl)lactic acid.

ST phenyllactic acid prepn; hydroxyphenyllactic acid prepn; phenylpyruvic hydrogenation prepn phenyllactic acid

IT Hydrogenation catalysts  
(Group VIII metals for the conversion of phenylpyruvic acids into phenyllactic acids)

IT Group VIII elements  
RL: CAT (Catalyst use); USES (Uses)  
(hydrogenation catalysts for the production of phenyllactic acids from phenylpyruvic acids)

IT Hydrogenation

(of phenylpyruvic acids in the production of phenyllactic acids)

IT 7440-02-0, Nickel, uses 7440-05-3, Palladium, uses 7440-06-4, Platinum, uses 7440-16-6, Rhodium, uses 7440-48-4, Cobalt, uses

RL: CAT (Catalyst use); USES (Uses)

(hydrogenation process and catalysts for the production of phenyllactic acids from phenylpyruvic acids)

IT 123-08-0, 4-Hydroxybenzaldehyde 156-06-9 543-24-8, N-Acetyl glycine 884-18-4 1201-77-0 4228-66-4 4607-41-4 28030-16-2 38335-22-7 39829-17-9 69882-69-5 70028-57-8 100612-75-7 115863-73-5 175897-64-0 175897-71-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(hydrogenation process and catalysts for the production of phenyllactic acids from phenylpyruvic acids)

IT 156-39-8P, 3-(4-Hydroxyphenyl)pyruvic acid 38243-39-9P 52507-17-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(hydrogenation process and catalysts for the production of phenyllactic acids from phenylpyruvic acids)

IT 306-23-0P, 3-(4-Hydroxyphenyl)lactic acid 828-01-3P 949-14-4P 3247-74-3P 6803-09-4P 23028-17-3P 28030-15-1P 52262-43-8P 55301-58-1P 175897-65-1P 175897-66-2P 175897-67-3P 175897-68-4P 175897-69-5P 175897-70-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

(hydrogenation process and catalysts for the production of phenyllactic acids from phenylpyruvic acids)

L9 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:539588 CAPLUS Full-text

DOCUMENT NUMBER: 119:139588

ORIGINAL REFERENCE NO.: 119:25059a,25062a

TITLE: New ligands for asymmetric dihydroxylation: multiple cinchona alkaloid units attached to a central heterocyclic core

INVENTOR(S): Hartung, Jens; Sharpless, K. Barry

PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA

SOURCE: PCT Int. Appl., 121 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9307142	A1	19930415	WO 1992-US8544	19921006 <--
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
US 5260461	A	19931109	US 1991-775683	19911010 <--
EP 608307	A1	19940803	EP 1992-921493	19921006 <--
EP 608307	B1	20040204		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
JP 07500323	T	19950112	JP 1993-507170	19921006 <--
JP 3982829	B2	20070926		
CA 2120919	C	20030701	CA 1992-2120919	19921006 <--
AT 258932	T	20040215	AT 1992-921493	19921006 <--
ES 2215989	T3	20041016	ES 1992-921493	19921006 <--
PRIORITY APPLN. INFO.:			US 1991-775683	A 19911010 <--
			US 1988-142692	B2 19880111 <--
			US 1988-159064	A2 19880223 <--

US 1988-250378	A2 19880928 <--
US 1990-512934	A2 19900423 <--
WO 1991-US2778	W 19910423 <--
US 1991-699183	A2 19910513 <--
WO 1992-US8544	W 19921006 <--

GI

/ Structure 108 in file .gra /

AB Osmium-catalyzed methods of addition to an olefin are studied. In the method of asym. dihydroxylation of the present invention, an olefin, a chiral ligand, an organic solvent, an aqueous solution, a base, a ferricyanide salt and an osmium-containing compound are combined. The chiral ligand is an alkaloid or alkaloid derivative linked to an organic substituent of at least 300 daltons mol. weight through a planar aromatic spacer group. The organic substituent can be another alkaloid or alkaloid derivative. With the described chiral ligands, asym. dihydroxylation of olefins with high yields and enantiomeric excesses are achieved. Thus, dihydroquinidine was treated with 1,4-dichlorophthalazine in DMF containing NaH to give 1,4-bis(9'-O-dihydroquinidyl)phthalazine (I). To a well stirred solution of I, a solution of potassium ferricyanide, K<sub>2</sub>CO<sub>3</sub>, OsO<sub>4</sub> in toluene was added a Me<sub>3</sub>COH-H<sub>2</sub>O solution of 1-decene, the solution was stirred for 24 h at 0° followed by addition of sodium sulfite to give 83% 1,2-decanediol with 84% ee.

TI New ligands for asymmetric dihydroxylation: multiple cinchona alkaloid units attached to a central heterocyclic core

PI WO 9307142 A1 19930415

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9307142	A1	19930415	WO 1992-US8544	19921006 <--
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
	US 5260461	A	19931109	US 1991-775683	19911010 <--
	EP 608307	A1	19940803	EP 1992-921493	19921006 <--
	EP 608307	B1	20040204		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
	JP 07500323	T	19950112	JP 1993-507170	19921006 <--
	JP 3982829	B2	20070926		
	CA 2120919	C	20030701	CA 1992-2120919	19921006 <--
	AT 258932	T	20040215	AT 1992-921493	19921006 <--
	ES 2215989	T3	20041016	ES 1992-921493	19921006 <--
PRAI	US 1991-775683	A	19911010	<--	
	US 1988-142692	B2	19880111	<--	
	US 1988-159064	A2	19880223	<--	
	US 1988-250378	A2	19880928	<--	
	US 1990-512934	A2	19900423	<--	
	WO 1991-US2778	W	19910423	<--	
	US 1991-699183	A2	19910513	<--	
	WO 1992-US8544	W	19921006	<--	

AB Osmium-catalyzed methods of addition to an olefin are studied. In the method of asym. dihydroxylation of the present invention, an olefin, a chiral ligand, an organic solvent, an aqueous solution, a base, a ferricyanide salt and an osmium-containing compound are combined. The chiral ligand is an alkaloid or alkaloid derivative linked to an organic substituent of at least 300 daltons mol. weight through a planar aromatic spacer group. The organic substituent can be another alkaloid or alkaloid derivative. With the described chiral ligands, asym. dihydroxylation of olefins with high yields and enantiomeric

excesses are achieved. Thus, dihydroquinidine was treated with 1,4-dichlorophthalazine in DMF containing NaH to give 1,4-bis(9'-O-dihydroquinidyl)phthalazine (I). To a well stirred solution of I, a solution of potassium ferricyanide, K<sub>2</sub>CO<sub>3</sub>, OsO<sub>4</sub> in toluene was added a Me<sub>3</sub>COH-H<sub>2</sub>O solution of 1-decene, the solution was stirred for 24 h at 0° followed by addition of sodium sulfite to give 83% 1,2-decanediol with 84% ee.

ST asym dihydroxylation catalyst dihydroquinidine ligand; alkene dihydroxylation catalyst; cinchona alkaloid osmylation catalyst

IT Asymmetric synthesis and induction  
(osmium catalyzed dihydroxylation, cinchona alkaloid derivs. as accelerator for)

IT Hydroxylation catalysts  
(osmylation, stereoselective, ligand accelerated, dihydroquinidine derivs. for)

IT 100-13-0, p-Nitrostyrene 110-57-6 300-57-2, Allylbenzene 447-53-0  
558-37-2 611-15-4, o-Methylstyrene 623-70-1 637-69-4,  
p-Methoxystyrene 674-76-0 692-70-6 695-12-5 762-63-0 768-49-0  
932-66-1, 1-Acetylcyclohexene 935-00-2 1193-18-6 1746-13-0, Allyl  
phenyl ether 1754-62-7 2039-89-6 2039-90-9 2157-18-8 2738-19-4  
3054-95-3 4192-77-2 5820-22-4 7367-82-0 7642-04-8 13389-42-9  
14663-11-7 18448-47-0, Methyl 1-cyclohexene carboxylate 20710-38-7  
21040-45-9 21087-29-6 22946-43-6 27829-72-7 31552-04-2  
34352-92-6 50555-04-9 63511-93-3 63511-95-5 66323-99-7  
67364-02-7 71338-71-1 72551-28-1 78277-23-3 81703-93-7  
105018-99-3 125187-81-7 125187-82-8 125187-83-9 125206-15-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(asym. dihydroxylation of, chiral dihydroquinidine derivative for osmium catalyzed)

IT 98-83-9, reactions 100-42-5, reactions 103-30-0, trans-Stilbene  
766-90-5 771-98-2, 1-Phenylcyclohexene 827-54-3, 2-Vinylnaphthalene  
872-05-9, 1-Decene 873-66-5 1463-04-3 3901-07-3, trans-Methyl  
4-methoxycinnamate 6714-96-1 7433-56-9, trans-5-Decene 13269-52-8,  
trans-3-Hexene 13633-26-6 17343-88-3 61142-41-4, Vinylcyclooctane

RL: RCT (Reactant); RACT (Reactant or reagent)

(asym. dihydroxylation of, chiral dihydroquinidine ligand for osmium catalyzed)

IT 56-54-2, Quinidine

RL: RCT (Reactant); RACT (Reactant or reagent)  
(hydrogenation of)

IT 2325-10-2P 16355-00-3P 25779-13-9P 31612-63-2P 32345-64-5P  
34281-90-8P 35638-92-7P 40421-51-0P 40560-98-3P 49801-14-1P  
52340-78-0P 53448-10-5P 57495-92-8P 77977-74-3P 78805-31-9P  
79299-22-2P 83603-02-5P 84276-14-2P 84518-30-9P 87827-60-9P  
87858-06-8P 88196-06-9P 89063-88-7P 98464-24-5P 99881-77-3P  
108666-29-1P 108741-12-4P 110549-79-6P 113162-03-1P 113162-04-2P  
113162-11-1P 115889-27-5P 121564-12-3P 122517-80-0P  
124649-67-8P 125132-75-4P 130876-03-8P 130932-13-7P 130932-14-8P  
132486-47-6P 135042-86-3P 135042-87-4P 135096-77-4P 136031-93-1P  
138890-41-2P 139093-40-6P 139093-41-7P 139093-42-8P 139093-44-0P  
139093-45-1P 139093-46-2P 139093-47-3P 139165-53-0P 139165-54-1P  
139165-55-2P 139165-56-3P 139165-57-4P 139165-58-5P 139165-59-6P  
139165-60-9P 139165-61-0P 139165-62-1P 139165-63-2P 139165-64-3P  
139165-65-4P 139165-66-5P 139165-67-6P 139165-68-7P 139165-69-8P  
139165-70-1P 143536-11-2P 149519-66-4P 149519-67-5P 149519-68-6P  
149519-69-7P 149562-10-7P 149562-11-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

IT 72989-10-7P 120385-14-0P 139093-52-0P 146333-99-5P 146334-00-1P  
146334-01-2P 146334-02-3P 146334-03-4P 146334-04-5P 146334-05-6P  
146334-06-7P 146334-07-8P 146334-08-9P 146334-09-0P 146334-10-3P

149519-70-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as ligand for osmium catalyzed asym.  
dihydroxylation)

IT 113162-02-0P 113216-88-9P 130876-04-9P 130876-05-0P 130876-06-1P  
130876-07-2P 130876-08-3P 135042-88-5P 135042-89-6P 135096-78-5P  
138890-32-1P 138890-33-2P 138890-34-3P 138890-35-4P 138890-36-5P  
138890-37-6P 138890-38-7P 138890-39-8P 138890-40-1P 138923-13-4P  
139012-31-0P 140853-10-7P 140924-50-1P 146333-98-4P 148215-08-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as ligand for osmium tetroxide catalyzed  
dihydroxylation of olefins)

=> d 19 ibib abs 6-10

L9 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:169109 CAPLUS Full-text

DOCUMENT NUMBER: 118:169109

ORIGINAL REFERENCE NO.: 118:29012h,29013a

TITLE: Preparation of  
(tetrazolylbiphenylmethyl)benzazepinones and related  
compounds as growth hormone release promoters

INVENTOR(S): Fisher, Michael H.; Wyvratt, Matthew J.; Schoen,  
William R.; Devita, Robert J.

PATENT ASSIGNEE(S): Merck and Co., Inc., USA

SOURCE: PCT Int. Appl., 346 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9216524	A1	19921001	WO 1992-US2271	19920319 <--
W: BB, BG, BR, LK, MG, MN, MW, PL, RO, RU, SD				
US 5206235	A	19930427	US 1992-839742	19920228 <--
EP 513974	A1	19921119	EP 1992-302143	19920312 <--
EP 513974	B1	19960904		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE				
AT 142206	T	19960915	AT 1992-302143	19920312 <--
IL 101206	A	19970218	IL 1992-101206	19920312 <--
CA 2063185	A1	19920921	CA 1992-2063185	19920317 <--
AU 9213012	A	19920924	AU 1992-13012	19920319 <--
AU 653992	B2	19941020		
CN 1066070	A	19921111	CN 1992-102954	19920319 <--
CN 1033584	C	19961218		
ZA 9202009	A	19921125	ZA 1992-2009	19920319 <--
JP 06172316	A	19940621	JP 1992-112069	19920319 <--
JP 08000814	B	19960110		
HU 66796	A2	19941228	HU 1992-915	19920319 <--
RO 117326	B1	20020130	RO 1993-1245	19920319 <--
US 5310737	A	19940510	US 1993-12190	19930202 <--
PRIORITY APPLN. INFO.:			US 1991-673695	A 19910320 <--
			US 1992-839742	A 19920228 <--
			WO 1992-US2271	W 19920319 <--

OTHER SOURCE(S): MARPAT 118:169109

GI

/ Structure 109 in file .gra /

AB Title compds. [I; L = (substituted) phenylene; n, w = 0, 1; p = 0-3; q = 0-4; X = CO, O, S, SO, SO<sub>2</sub>, CH(OH), CH:CH, imino; R<sub>1</sub>, R<sub>2</sub>, R<sub>7</sub>, R<sub>8</sub> = H, halo, (perfluoro)alkyl, perfluoroalkoxy, cyano, NO<sub>2</sub>, (substituted) Ph, acyl(alkyl), etc.; R<sub>4</sub>, R<sub>5</sub> = H, (substituted) Ph, alkyl, alkenyl, alkynyl, alkanoyloxy, alkoxy carbonyl, carboxy, CHO, amino; R<sub>4</sub>R<sub>5</sub> = (CH<sub>2</sub>)<sub>r</sub>B(CH<sub>2</sub>)<sub>s</sub>; B = CH<sub>2</sub>, O, imino, S, SO, SO<sub>2</sub>; r, s = 1-3; R<sub>6</sub> = H, alkyl, Ph, phenylalkyl; R<sub>9</sub> = H, (substituted) tetrazolyl, acylalkyl, aminoalkyl, carbamoylalkyl, tetrazolylalkyl, tetrazolylphenyl, tetrazolylphenoxy, etc.; A = (CH<sub>2</sub>)<sub>x</sub>CR<sub>10</sub>R<sub>11</sub>(CH<sub>2</sub>)<sub>y</sub>; x, y = 0-3; R<sub>10</sub>, R<sub>11</sub> = H, CF<sub>3</sub>, (substituted) alkyl, Ph, etc.; R<sub>10</sub>R<sub>11</sub> = (CH<sub>2</sub>)<sub>t</sub>; t = 2-6; R<sub>10</sub>, R<sub>11</sub> may be joined to R<sub>4</sub> and/or R<sub>5</sub>], were prepared for promotion of release of growth hormone (no data). Thus, 3-benzyloxycarbonylamino-3-methyl-N-[2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3R-yl]butanamide (preparation from 3-azido-2,3,4,5-tetrahydro-1H-1-benzazepin-2-one given) was stirred 15 min with NaH in DMF; N-triphenylmethyl-5-[2-(4'-bromobiphen-4-yl)]tetrazole (preparation starting from 5-phenyl-2-trityltetrazole and 4-IC<sub>6</sub>H<sub>4</sub>Me given) in DMF was added and the mixture was stirred 90 min to give 95% coupling product, which was hydrogenated in MeOH over Pd(OH)<sub>2</sub>/C for 14 h to give 89% 3-amino-3-methyl-N-[2,3,4,5-tetrahydro-2-oxo-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-1-benzazepin-3R-yl]butanamide trifluoroacetate.

L9 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1990:75971 CAPLUS Full-text  
DOCUMENT NUMBER: 112:75971  
ORIGINAL REFERENCE NO.: 112:12975a,12978a  
TITLE: Ligand-accelerated catalytic asymmetric dihydroxylation  
INVENTOR(S): Marko, Istvan E.; Sharpless, K. Barry  
PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA  
SOURCE: PCT Int. Appl., 66 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 5  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 8906225	A1	19890713	WO 1989-US86	19890110 <--
W: JP				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
US 4871855	A	19891003	US 1988-159068	19880223 <--
US 4965364	A	19901023	US 1988-250378	19880928 <--
EP 395729	A1	19901107	EP 1989-901900	19890110 <--
EP 395729	B1	19950927		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 03503885	T	19910829	JP 1989-501814	19890110 <--
JP 3153540	B2	20010409		
EP 658532	A1	19950621	EP 1995-200458	19890110 <--
EP 658532	B1	19990407		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 128449	T	19951015	AT 1989-901900	19890110 <--
AT 178578	T	19990415	AT 1995-200458	19890110 <--
JP 2001192383	A	20010717	JP 2000-335775	19890110 <--
CA 1338314	C	19960507	CA 1989-587964	19890111 <--
PRIORITY APPLN. INFO.:			US 1988-142692	A 19880111 <--

US 1988-159068	A	19880223 <--
US 1988-250378	A	19880928 <--
EP 1989-901900	A3	19890110 <--
JP 1989-501814	A3	19890110 <--
WO 1989-US86	W	19890110 <--

AB Vicinal diols are prepared by asym. dihydroxylation of olefins in the presence of a chiral ligand, an Os-containing catalyst, an amine oxide, an organic solvent, and H<sub>2</sub>O. OsO<sub>4</sub> was injected into a solution of trans-stilbene, hydroquinidine p-chlorobenzoate, and N-methylmorpholine N-oxide in Me<sub>2</sub>CO and H<sub>2</sub>O at 0-4° with shaking, Na<sub>2</sub>S<sub>2</sub>O<sub>5</sub> added, and the mixture worked up to give 55% (R,R)-PhCH(OH)CH(OH)Ph of 99% enantiomeric excess. Preparation of dihydroquinidine derivs. and their recovery were also given. Asym. dihydroxylation of trans-3-hexene, 1-phenylcyclohexene, β-methylstyrene, and Me (E)-4-methoxycinnamate were also given.

L9 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1986:129936 CAPLUS Full-text

DOCUMENT NUMBER: 104:129936

ORIGINAL REFERENCE NO.: 104:20565a,20568a

TITLE: 1,5-Benzothiazepine derivatives

INVENTOR(S): Takeda, Mikio; Ohishi, Tokuro; Nakajima, Hiromichi; Nagao, Taku

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd. , Japan

SOURCE: Eur. Pat. Appl., 69 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 158339	A2	19851016	EP 1985-104341	19850410 <--
EP 158339	A3	19860611		
EP 158339	B1	19890118		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4585768	A	19860429	US 1985-715116	19850322 <--
AU 8540392	A	19851017	AU 1985-40392	19850326 <--
AU 572978	B2	19880519		
JP 60226866	A	19851112	JP 1985-73356	19850405 <--
JP 03074659	B	19911127		
DK 8501577	A	19851011	DK 1985-1577	19850409 <--
DK 172257	B1	19980209		
HU 37411	A2	19851228	HU 1985-1303	19850409 <--
HU 191785	B	19870428		
CA 1218991	A1	19870310	CA 1985-478613	19850409 <--
SU 1632372	A3	19910228	SU 1985-3880298	19850409 <--
AT 40126	T	19890215	AT 1985-104341	19850410 <--
CN 85103524	A	19861105	CN 1985-103524	19850502 <--
CN 1017706	B	19920805		
SU 1358784	A3	19871207	SU 1986-4027451	19860513 <--

PRIORITY APPLN. INFO.:	GB 1984-9258	A	19840410 <--
	EP 1985-104341	A	19850410 <--

OTHER SOURCE(S): CASREACT 104:129936; MARPAT 104:129936

GI

/ Structure 110 in file .gra /



AB (Aminoethyl)benzothiazepinones I (R1, R3 = alkyl; R2 = H, alkanoyl, PhCH2; 1 of R4, R5 = Cl, the other H; R6 = H) were prepared. Thus, 5,2-Cl(O2N)C6H3SH and Me trans-3-(4-methoxyphenyl)oxiranecarboxylate were stirred in PhMe containing Zn(OAc)2 to give (±)-threo-5,2-ClC6H3SCH(C6H4OMe-4)CH(OH)CO2Me. This was saponified and the acid resolved by crystallization of its L-lysine salt. The (-)-threo isomer was hydrogenated over Pd/C to give the amine which was cyclized by refluxing in xylene to give (-)-cis-I (R2 = R3 = Me, R2 = R5 = H, R4 = Cl, R6 = PhCH2) which was treated successively with PhCH2O2CCl and HBr/HOAc to give (-)-cis-I (R1 = R3 = Me, R2 = R5 = R6 = N, R4 = Cl), isolated as its hydrochloride (II). Blood plasma from rats given 10 mg II/kg orally showed ≥50% inhibition of collagen-induced platelet aggregation.

L9 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1976:58822 CAPLUS Full-text

DOCUMENT NUMBER: 84:58822

ORIGINAL REFERENCE NO.: 84:9659a,9662a

TITLE: Synthesis of guaiacylglycerol-β-guaiacyl ether

AUTHOR(S): Nakatsubo, Fumiaki; Sato, Kimihiko; Higuchi, Takayoshi

CORPORATE SOURCE: Wood Res. Inst., Kyoto Univ., Uji, Japan

SOURCE: Holzforschung (1975), 29(5), 165-8

CODEN: HOLZAZ; ISSN: 0018-3830

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB Guaiacylglycerol-β-guaiacyl ether (I), the model compound of arylglycerol-β-aryl ether structure in lignin was synthesized in high yield through five reaction steps from vanillin. The key step of this synthetic method was the condensation reaction between o-MeOC6H4OCH2CO2Et and 3,4-(MeO)(BzO)C6H3CHO (II). At this step, lithium diisopropyl amide was used as the base, and 3,4-(MeO)(BzO)C6H3CH(OH)CH(CO2Et)OC6H4OMe-o (III) was obtained in 95% yield as an oily substance consisted of two isomers, from which only erythro isomer was obtained as crystal in 51% yield. The residual oily substance was converted to its carbamate (IV) and crystallized in 70% yield. The crystalline III and IV were then converted to I by the LiAlH4 reduction and subsequent hydrogenation with Pd-C. The overall yield of I from II was about 72%.

L9 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1975:443121 CAPLUS Full-text

DOCUMENT NUMBER: 83:43121

ORIGINAL REFERENCE NO.: 83:6811a,6814a

TITLE: Polyphenolic acids of *Lithospermum ruderale* (Boraginaceae). I. Isolation and structure determination of lithospermic acid

AUTHOR(S): Kelley, Charles J.; Mahajan, J. R.; Brooks, Lucille C.; Neubert, Leonard A.; Breneman, W. R.; Carmack, Marvin

CORPORATE SOURCE: Dep. Chem., Indiana Univ., Bloomington, IN, USA

SOURCE: Journal of Organic Chemistry (1975), 40(12), 1804-15

CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB A structure is proposed for lithospermic acid (I), C27H22O12, the major polyphenolic acid of *Lithospermum ruderale* and several other plant species of the families, Boraginaceae and Labiatae. Chromatog. on Sephadex of aqueous

exts. of the plant yields the di-K salt of I, together with salts of lesser constituents which include (R)-3-(3,4-dihydroxyphenyl)lactic acid, 2-(3,4-dihydroxyphenyl)-3-carboxy-4-(2-carboxy-trans-vinyl)-7-hydroxycoumaran, and rosmarinic acid. Structures were deduced from spectral studies of the salts, the free acids, and also the methylated derivs., produced by the action of CH<sub>2</sub>N<sub>2</sub> on the free acids or Me<sub>2</sub>SO<sub>4</sub> on the salts.

=> d 19 11-15 ibib abs ti hit

L9 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1966:51892 CAPLUS Full-text

DOCUMENT NUMBER: 64:51892

ORIGINAL REFERENCE NO.: 64:9672d-h,9673a-c

TITLE: New synthesis of 2-hydroxy-2-benzyl-3-coumaranones

AUTHOR(S): Chopin, Jean; Durual, Pierre; Chadenson, Michele

CORPORATE SOURCE: Fac. Sci., Lyon

SOURCE: Bulletin de la Societe Chimique de France (1965), (12), 3572-7

CODEN: BSCFAS; ISSN: 0037-8968

DOCUMENT TYPE: Journal

LANGUAGE: French

OTHER SOURCE(S): CASREACT 64:51892

AB A series of 2-hydroxy-2-benzyl-3-coumaranones was prepared by the debenzylation of the appropriate  $\alpha$ -diketones obtained by the isomerization of 2'-benzyloxychalcones or of the corresponding 2'-benzyloxy- $\alpha$ -methoxychalcones. The existence of an equilibrium between the cyclic and open forms was demonstrated by their N. M.R. spectra and was in good agreement with the results of the alkaline rearrangement of the 3-hydroxyflavanones. 2,4-(HO)C<sub>6</sub>H<sub>3</sub>COCH<sub>2</sub>OMe (I) (5.5 g.) with Me<sub>2</sub>SO<sub>4</sub> yielded 4.1 g. 2,4-HO(MeO)C<sub>6</sub>H<sub>3</sub>COCH<sub>2</sub>OMe (II), m. 65-6° (EtOH). II (1.9 g.) with PhCH<sub>2</sub>Cl in HCONMe<sub>2</sub> in the presence of NaI and K<sub>2</sub>CO<sub>3</sub> gave 1.8 g. 2,4-phCH<sub>2</sub>O(MeO)C<sub>6</sub>H<sub>3</sub>COCH<sub>2</sub>OMe (III), m. 66° (EtOH). I (2 g.) with PhCH<sub>2</sub>Cl gave similarly 2.6 g. 2,4-(PhCH<sub>2</sub>O)C<sub>6</sub>H<sub>3</sub>COCH<sub>2</sub>OMe (IV), m. 104° (EtOH). II (1 g.) and 1 g. BzH in 20 cc. EtOH treated overnight with 2 g. 50% aq. NaOH and acidified yielded 785 mg. 2,4-PhCH<sub>2</sub>O(MeO)C<sub>6</sub>H<sub>3</sub>COC(OMe):CHPh (V), m. 95° (EtOH). V (1 g.) in 100 cc. MeOH and 20 cc. H<sub>2</sub>O refluxed 6 hrs. with 10 cc. concentrated HCl gave 550 mg. yellow 2,4-PhCH<sub>2</sub>O(MeO)C<sub>6</sub>H<sub>3</sub>COCOCH<sub>2</sub>Ph, m. 86° (EtOH). IV (1 g.) with 1 g. BzH gave 1.1 g. yellowish white 2,4-(PhCH<sub>2</sub>O)C<sub>6</sub>H<sub>3</sub>COC(OMe):CHPh (VI); m. 120°. III (1 g.) and 1 g. p-MeOC<sub>6</sub>H<sub>4</sub>CHO yielded 815 mg. yellowish white 4-MeO analog of VI, m. 92-3°. o-PhCH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>COCOCH<sub>2</sub>Ph (1 g.) in 20 cc. AcOH heated 1.5 hrs. on a water bath with 10 cc. concentrated HCl yielded 585 mg. beige 2-hydroxy-2-benzyl-3-coumaranone (VII), m. 104° (C<sub>6</sub>H<sub>6</sub>-hexane). o-PhCH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>COCH(OH)CHClPh gave similarly 78% VII. o-PhCH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>COCOCH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>OMe-p (1 g.) gave similarly 490 mg. beige 4'-MeO derivative (VIII) of VII, m. 120° (C<sub>6</sub>H<sub>6</sub>-hexane). 3-Hydroxy-4'-methoxyflavanone (IX) (1 g.) heated 5 min. on the water bath with 100 cc. 2N alc. KOH and poured into 200 cc. 2N HCl gave 403 mg. 4'-methoxyflavonol (X), m. 228° (EtOH); the filtrate from the X yielded 385 mg. oily o-HOC<sub>6</sub>H<sub>4</sub>C(OH)(CO<sub>2</sub>H)CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>OMe-p (XI) which gave an intense blue color with alc. FeCl<sub>3</sub>. The XI methylated with Me<sub>2</sub>SO<sub>4</sub> and K<sub>2</sub>CO<sub>3</sub> in MeOH gave o-MeOC<sub>6</sub>H<sub>4</sub>C(OH)(CO<sub>2</sub>Me)CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>OMe-p, m. 133° (EtOH), which saponified with alc. KOH yielded o-MeOC<sub>6</sub>H<sub>4</sub>C(OH)(CO<sub>2</sub>H)CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>OMe-p, m. 159° (EtOH), and 190 mg. VIII, m. 120°. VIII dehydrated with concentrated H<sub>2</sub>SO<sub>4</sub> gave 4'-methoxyaurone, m. 138-9°. IX heated 15 min. on the water bath with alc. KOH gave 646 mg. XI and 296 mg. X. 4,2-MeO(PhCH<sub>2</sub>O)C<sub>6</sub>H<sub>3</sub>COCOCH<sub>2</sub>Ph (XII) (1 g.) with HCl-AcOH gave 435 mg. 6-MeO derivative (XIII) of VII, m. 120° (C<sub>6</sub>H<sub>6</sub>-hexane). XII (1 g.) in 20 cc. EtOH hydrogenated over 100 mg. 10% Pd-C, and the product

chromatographed on Al<sub>2</sub>O<sub>3</sub> yielded 450 mg. XIII. 4,2-MeO(PhCH<sub>2</sub>O)C<sub>6</sub>H<sub>3</sub>COCH(OH)CH-ClPh with HCl-AcOH gave 55% XIII. V gave similarly 57% XIII. XIII (100 mg.) and 2 cc. concentrated H<sub>2</sub>SO<sub>4</sub> heated 10 min. on the water bath gave 76 mg. 6-methoxyaurone, m. 145° (EtOH). XIII (100 mg.) in 5 cc. EtOH and 3 cc. 2N KOH heated 3 min. on the water bath and acidified with 2N HCl yielded oily 2,4-HO(MeO)C<sub>6</sub>H<sub>3</sub>C(OH)(CO<sub>2</sub>H)CH<sub>2</sub>Ph (it gave an intense blue color with alc. FeCl<sub>3</sub>) which heated 3 min. on the water bath gave 79 mg. 6-methoxy-3-benzal-2-coumaranone, m. 129° (MeOH). 4,-2-MeO(PhCH<sub>2</sub>O)C<sub>6</sub>H<sub>3</sub>COCOCH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>OMe-p (1 g.) with HClAcOH yielded 470 mg. beige 4',6-dimethoxy derivative (XIV) of VII, m. 111° (C<sub>6</sub>H<sub>6</sub>-hexane). 4,2-MeO(PhCH<sub>2</sub>O)C<sub>6</sub>H<sub>3</sub>COC(OMe):CHC<sub>6</sub>H<sub>4</sub>OMe-p (500 mg.) gave similarly 225 mg. XIV. XIV treated with concentrated H<sub>2</sub>SO<sub>4</sub> gave 6,4'-dimethoxyaurone, m. 134°. 2,4-(PhCH<sub>2</sub>O)2C<sub>6</sub>H<sub>3</sub>COC(OMe):CHPh (500 mg.) with HClAcOH gave 179 mg. 6-PhCH<sub>2</sub> derivative of VII, m. 186-7° (C<sub>6</sub>H<sub>6</sub>), which dehydrated with concentrated H<sub>2</sub>SO<sub>4</sub> yielded 6-hydroxyaurone, m. 262-5°. 2'-Hydroxy-3,4-dimethoxychalcone (8 g.) with Ac<sub>2</sub>O and AcONa gave 8 g. acetate, m. 90°, which treated in 100 cc. CS<sub>2</sub> and 10 cc. CH<sub>2</sub>Cl<sub>2</sub> with 1.25 cc. Br in 10 cc. CS<sub>2</sub> and kept 1 hr. yielded 11 g. dibromide (XV), m. 162-3° (CHCl<sub>3</sub>-hexane). XV (11 g.) refluxed 15 min. with 80 cc. Me<sub>2</sub>CO and 20 cc. H<sub>2</sub>O and heated 5 min. with 10 g. Na<sub>2</sub>CO<sub>3</sub> in 70 cc. H<sub>2</sub>O gave 1.8 g. 3',4'-dimethoxyflavanol (XVI), m. 156-8° (MeOH). 3-Hydroxy-3',4'-dimethoxyflavanone (XVII) heated 5 min. on the water bath with 2N alc. KOH gave 235 mg. 3-hydroxy-3',4'-dimethoxyflavone, m. 196-7°, 275 mg. o-HOC<sub>6</sub>H<sub>4</sub>C(OH)(CO<sub>2</sub>H)CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>(OMe)2-3,4 (XVIII) (it gave an intense blue color with alc. FeCl<sub>3</sub>), and 365 mg. 3',4'-dimethoxy derivative of VII. XVIII with Me<sub>2</sub>SO<sub>4</sub> yielded o-MeOC<sub>6</sub>H<sub>4</sub>C(OH)(CO<sub>2</sub>Me)CH<sub>2</sub>C<sub>6</sub>H<sub>3</sub>(OMe)2-3,4, m. 129° (EtOH), which saponified with alc. KOH gave o-MeOC<sub>6</sub>H<sub>4</sub>C(OH)(CO<sub>2</sub>H)CH<sub>2</sub>C<sub>6</sub>H<sub>3</sub>(OMe)2-3,4, m. 179° (EtOH). XVII gave similarly during 15 min. 45% XVIII and 45% XVI.

TI New synthesis of 2-hydroxy-2-benzyl-3-coumaranones

SO Bulletin de la Societe Chimique de France (1965), (12), 3572-7

L9 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1965:438715 CAPLUS Full-text

DOCUMENT NUMBER: 63:38715

ORIGINAL REFERENCE NO.: 63:6873c-g

TITLE: Synthesis of prephenic acid diethyl acetal and its hydrolysis to phenylpyruvic acid and prephenic acid  
AUTHOR(S): Plieninger, Hans; Arnold, Lothar; Fischer, Rolf; Hoffmann, Werner

CORPORATE SOURCE: Univ. Heidelberg, Germany

SOURCE: Chemische Berichte (1965), 98(6), 1774-81

CODEN: CHBEAM; ISSN: 0009-2940

DOCUMENT TYPE: Journal

LANGUAGE: German

GI For diagram(s), see printed CA Issue.

AB I and the di-Et acetal (II) of III were prepared The time at which the maximum yield of III can be obtained by the acid hydrolysis of II was calculated from kinetic data and the calcn. confirmed by the experiment; III was formed together with larger amts. of PhCH<sub>2</sub>COCO<sub>2</sub>H (IV). Di-Et 2-cyclohexen-4-one-1-carboxylate-1-pyruvate di-Et acetal (35.6 g.), b<sub>0.1</sub> 155°, n<sub>25D</sub> 1.4087, in 350 cc. tert-BuOH refluxed 5 hrs. with stirring with 5 cc. AcOH and 11 g. SeO<sub>2</sub>, treated with an addnl. 11 g. SeO<sub>2</sub>, and again refluxed 5 hrs., and the product shaken in Et<sub>2</sub>O 6 hrs. with 10 g. deactivated Raney Ni yielded 25 g. I, b<sub>0.1</sub> 150°, n<sub>20D</sub> 1.4840. I (35.6 mg.), 5.0 cc. EtOH, and 4.0 cc. 0.1N NaOH heated 0.5 hr. at 50°, treated with 5 cc. N HCl, and heated 15 min. at 50°, and the mixture cooled and diluted with H<sub>2</sub>O to 100 cc. gave a solution containing 18 mg. p-HOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>COCO<sub>2</sub>H. I (1.0 g.), 100 mg. Na, and 5 cc. EtOH heated 3 hrs. at 50° gave 0.70 g. p-HOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>24C(OEt)2CO<sub>2</sub>Et (IV). I (7.1 g.) in 10 cc. EtOH added dropwise with stirring during 15 min. at 5° to 0.40 g. NaBH<sub>4</sub> in 40 cc. EtOH and kept 15 min. at 20° yielded 5.3 g. oily di-Et

ester (V) of II, n<sub>25</sub>D 1.4665, and 1.1 g. IV. V (3.6 g.) in 30 cc. EtOH treated 2 days at room temperature with 1.6 g. NaOH in 20 cc. H<sub>2</sub>O and evaporated to 15 cc., buffered to pH 8 with N HCl, and diluted with H<sub>2</sub>O to 25 cc. gave a 0.4M solution; a 0.1-cc. portion and 4 cc. N HCl heated 15 min. at 50° and the mixture adjusted to pH 14 with N NaOH gave a 0.3M II solution; a 6.25-cc. portion stirred with 4.25 g. Ba(OAc)<sub>2</sub>, centrifuged to remove some solid, diluted with about 200 cc. EtOH, and kept several hrs. yielded 1.3 g. Ba salt; a 0.5-g. portion in 10 cc. H<sub>2</sub>O hydrogenated over PdBaSO<sub>4</sub>, filtered, and treated 20 hrs. with 2,4-(O<sub>2</sub>N)<sub>2</sub>C<sub>6</sub>H<sub>3</sub>NHNH<sub>2</sub> in 2N HCl, and the precipitate chromatographed on paper showed the presence of the 2,4-dinitrophenylhydrazones of cis- and trans-tetrahydroprephenic acid (relative to OH and CO<sub>2</sub>H groups). II (0.3M aqueous solution) (10 cc.) adjusted with N HCl to pH 1.8, kept 10 min. at 20°, neutralized with N NaOH, and treated with 1.0 g. Ba(OAc)<sub>2</sub> in 5 cc, H<sub>2</sub>O gave 0.5 g. Ba salt of a 6:50 mole ratio mixture of III and IV.

TI Synthesis of prephenic acid diethyl acetal and its hydrolysis to phenylpyruvic acid and prephenic acid

SO Chemische Berichte (1965), 98(6), 1774-81

CODEN: CHBEAM; ISSN: 0009-2940

AB I and the di-Et acetal (II) of III were prepared The time at which the maximum yield of III can be obtained by the acid hydrolysis of II was calculated from kinetic data and the calcn. confirmed by the experiment; III was formed together with larger amts. of PhCH<sub>2</sub>COCO<sub>2</sub>H (IV). Di-Et 2-cyclohexen-4-one-1-carboxylate-1-pyruvate di-Et acetal (35.6 g.), b<sub>0.1</sub> 155°, n<sub>25</sub>D 1.4087, in 350 cc. tert-BuOH refluxed 5 hrs. with stirring with 5 cc. AcOH and 11 g. SeO<sub>2</sub>, treated with an addnl. 11 g. SeO<sub>2</sub>, and again refluxed 5 hrs., and the product shaken in Et<sub>2</sub>O 6 hrs. with 10 g. deactivated Raney Ni yielded 25 g. I, b<sub>0.1</sub> 150°, n<sub>20</sub>D 1.4840. I (35.6 mg.), 5.0 cc. EtOH, and 4.0 cc. 0.1N NaOH heated 0.5 hr. at 50°, treated with 5 cc. N HCl, and heated 15 min. at 50°, and the mixture cooled and diluted with H<sub>2</sub>O to 100 cc. gave a solution containing 18 mg. p-HOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>COCO<sub>2</sub>H. I (1.0 g.), 100 mg. Na, and 5 cc. EtOH heated 3 hrs. at 50° gave 0.70 g. p-HOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CO<sub>2</sub>Et (IV). I (7.1 g.) in 10 cc. EtOH added dropwise with stirring during 15 min. at 5° to 0.40 g. NaBH<sub>4</sub> in 40 cc. EtOH and kept 15 min. at 20° yielded 5.3 g. oily di-Et ester (V) of II, n<sub>25</sub>D 1.4665, and 1.1 g. IV. V (3.6 g.) in 30 cc. EtOH treated 2 days at room temperature with 1.6 g. NaOH in 20 cc. H<sub>2</sub>O and evaporated to 15 cc., buffered to pH 8 with N HCl, and diluted with H<sub>2</sub>O to 25 cc. gave a 0.4M solution; a 0.1-cc. portion and 4 cc. N HCl heated 15 min. at 50° and the mixture adjusted to pH 14 with N NaOH gave a 0.3M II solution; a 6.25-cc. portion stirred with 4.25 g. Ba(OAc)<sub>2</sub>, centrifuged to remove some solid, diluted with about 200 cc. EtOH, and kept several hrs. yielded 1.3 g. Ba salt; a 0.5-g. portion in 10 cc. H<sub>2</sub>O hydrogenated over PdBaSO<sub>4</sub>, filtered, and treated 20 hrs. with 2,4-(O<sub>2</sub>N)<sub>2</sub>C<sub>6</sub>H<sub>3</sub>NHNH<sub>2</sub> in 2N HCl, and the precipitate chromatographed on paper showed the presence of the 2,4-dinitrophenylhydrazones of cis- and trans-tetrahydroprephenic acid (relative to OH and CO<sub>2</sub>H groups). II (0.3M aqueous solution) (10 cc.) adjusted with N HCl to pH 1.8, kept 10 min. at 20°, neutralized with N NaOH, and treated with 1.0 g. Ba(OAc)<sub>2</sub> in 5 cc, H<sub>2</sub>O gave 0.5 g. Ba salt of a 6:50 mole ratio mixture of III and IV.

IT 126-49-8P, 2,5-Cyclohexadiene-1-pyruvic acid, 1-carboxy-4-hydroxy-156-06-9P, Pyruvic acid, phenyl- 156-39-8P, Pyruvic acid, (p-hydroxyphenyl)- 2931-07-9P, 2,5-Cyclohexadiene-1-propionic acid, 1-carboxy- $\alpha,\alpha$ -diethoxy-4-hydroxy-, diethyl ester 2931-07-9P, 2,5-Cyclohexadiene-1-pyruvic acid, 1-carboxy-4-hydroxy-, diethyl ester, di-Et acetal 2931-35-3P, 2,5-Cyclohexadiene-1-pyruvic acid, 1-carboxy-4-hydroxy-, diethyl acetal 2931-35-3P, 2,5-Cyclohexadiene-1-propionic acid, 1-carboxy- $\alpha,\alpha$ -diethoxy-4-hydroxy- 2931-38-6P, 2-Cyclohexene-1-propionic acid, 1-carboxy- $\alpha,\alpha$ -diethoxy-4-oxo-,

diethyl ester 2931-38-6P, 2-Cyclohexene-1-pyruvic acid,  
1-carboxy-4-oxo-, diethyl ester, di-Et acetal 2931-39-7P,  
2,5-Cyclohexadiene-1-propionic acid,  
1-carboxy- $\alpha,\alpha$ -diethoxy-4-oxo-, diethyl ester  
4375-92-2P, Pyruvic acid, (p-hydroxyphenyl)-, ethyl ester, di-Et  
acetal 4387-06-8P, 1,4-Methanonaphthalene-5,8,9-trione,  
1-bromo-1,4,4a,8a-tetrahydro-, 9-(dimethyl acetal) 4387-08-0P,  
1,4-Methanonaphthalene-5,8-dione, 9,9-diethoxy-1,4,4a,8a-tetrahydro-  
4423-91-0P, 5-Norbornene-2,3-dicarboxylic anhydride, 7-oxo-  
825632-90-4P, 2,5-Cyclohexadiene-1-pyruvic acid, 1-carboxy-4-oxo-, diethyl  
ester, di-Et acetal  
RL: PREP (Preparation)  
(preparation of)

L9 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1963:435348 CAPLUS Full-text

DOCUMENT NUMBER: 59:35348

ORIGINAL REFERENCE NO.: 59:6301g-h,6302a-d

TITLE: Preparation of the threo- and erythro-forms of  
DL-guaiacylglycerol and of DL-veratrylglycerol

AUTHOR(S): Adler, Erich; Gustafsson, Bo

CORPORATE SOURCE: Chalmers Tek. Hogskola, Goteborg, Swed.

SOURCE: Acta Chemica Scandinavica (1963), 17, 27-36

CODEN: ACHSE7; ISSN: 0904-213X

DOCUMENT TYPE: Journal

LANGUAGE: German

OTHER SOURCE(S): CASREACT 59:35348

AB cf. CA 48, 5147g. Hydrogenation of 3,4-dimethoxyphenylpropionic acid in EtOH with Lindlar catalyst 50 min. gave 70% cis-methylferulic acid (I), m. 104°, which with CH<sub>2</sub>N<sub>2</sub> yielded 90% Me ester, prisms, m. 92-3°. Reduction of 30 g. Me trans-methylferulate (II) in 200 cc. dioxane with 5.7 g. LiAlH<sub>4</sub> in 500 cc. absolute Et<sub>2</sub>O, addition of H<sub>2</sub>O and dilute H<sub>2</sub>SO<sub>4</sub>, extraction with CHCl<sub>3</sub>, and distillation of the residue of the CHCl<sub>3</sub> extract gave 70% methylconiferyl alc., b<sub>5</sub> 110-20°, needles, m. 79-80°; Ac derivative (III) b<sub>12</sub> 190-5°. Treating 80 mg. III in 3 cc. Et<sub>2</sub>O-C<sub>5</sub>H<sub>5</sub>N (25:1) 16 hrs. with 0.1 g. OsO<sub>4</sub> in 2 cc. Et<sub>2</sub>O and hydrolyzing the osmic ester in 2 cc. EtOH with 0.65 g. Na<sub>2</sub>SO<sub>3</sub> in 3 cc. H<sub>2</sub>O 1 hr. at 100°, evaporating the filtered solution in vacuo, and extracting the residue with CHCl<sub>3</sub> gave 85% DL-threoveratrylglycerol (IV), m. 109-10°. Treating II similarly with OsO<sub>4</sub> and acetylating the hydrolyzed Os ester gave 60%

DL-threo- $\alpha,\beta$ -diacetoxymethylhydroferulic acid (V), prisms, m. 148-9°.

Esterification of V with CH<sub>2</sub>N<sub>2</sub> followed by reduction yielded IV. Refluxing 15 g. Me  $\alpha$ -bromo- $\beta$ -acetoxymethyl-hydroferulate in 65 cc. AcOH and 65 cc. Ac<sub>2</sub>O 45 min. with 7 g. AgOAc, treating the filtered solution with H<sub>2</sub>O, evaporating the solution in vacuo, extracting the residue with CHCl<sub>3</sub>, evaporating the washed (NaHCO<sub>3</sub>) solution, and crystallizing the residue from Et<sub>2</sub>O-C<sub>6</sub>H<sub>14</sub> gave 41% Me threo- $\alpha,\beta$ -diacetoxymethylhydroferulate (VI), m. 102-3°. Concentration of the mother liquor gave 40% erythro isomer (VII), prisms, m. 71-3°. VI was also obtained in 10% yield when 4.44 g. II was oxidized with KMnO<sub>4</sub> at -50° according to Riiber (CA 9, 2244). Reduction of VII with LiAlH<sub>4</sub> gave DL-erythroveratrylglycerol (VIII), plates, m. 92-3°,  $\lambda_{\text{maximum}}$  278 m $\mu$  (log  $\epsilon$  3.52). The infrared spectra of IV and VIII differed distinctly. When Me erythro-diacetoxymethylhydroferulate was reduced with LiAlH<sub>4</sub> (cf. loc. cit.) and the acid step was avoided by neutralizing the reaction mixture with AcOH, 55% DL-erythro-guaiacylglycerol (IX), m. 83-4° was obtained; IX tetraacetate m. 86-8°. IX and CH<sub>2</sub>N<sub>2</sub> gave 90% VIII. Treating 0.31 g. IX with 0.1N H<sub>2</sub>SO<sub>4</sub> neutralizing the mixture with BaCO<sub>3</sub>, evaporating the filtered solution in vacuo, and treating the residue with moist EtOAc gave 0.18 g. unchanged IX and, from the mother liquor, 0.05 g. threo-DL-guaiacylglycerol (X);

tetraacetate m. 113-14°. Benzyl-coniferyl alc. benzoate (0.515 g.) (Freudenberg and Achtzehn, CA 50, 1661h) was treated in 12 cc. Et<sub>2</sub>O-C<sub>5</sub>H<sub>5</sub>N with 0.35 g. OsO<sub>4</sub> and the precipitate formed was boiled 1 hr. with 2.3 g. Na<sub>2</sub>SO<sub>3</sub> in 10 cc. H<sub>2</sub>O, giving threo-(O-benzylguaiacyl)glycerol, m. 101°, which when treated in EtOH with prehydrogenated PdCl<sub>2</sub>-BaSO<sub>4</sub>, yielded X as a sirup; tetraacetate, 70%, m. 113-14°. X and CH<sub>2</sub>N<sub>2</sub> gave 70% IV. Careful fractionation of the mother liquor of the Me erythro- $\alpha,\beta$ -diacetoxymethylhydroferulate gave 10% threo isomer, prisms, m. 81-2°, which with LiAlH<sub>4</sub> gave 55% X. Treating 0.074 g. trans-methylisoeugenol (XI) with OsO<sub>4</sub> gave 75% DL-threo-methylisoeugenol glycol, m. 90°, which was also obtained in 15% yield when 1.93 g. XI was treated at -50° with 1.96 g. KMnO<sub>4</sub>. Acetylation of 3.3 g. XI in 3 cc. AcOH with 6.6 g. Pb(OAc)<sub>4</sub> and reduction of the  $\alpha,\beta$ -diacetoxymethylveratrylpropane formed with LiAlH<sub>4</sub> gave 2 g. of a product, m. 80-100°, which on fractional crystallization yielded erythro-methylisoeugenol glycol, m. 123°, and the threo isomer, m. 88°.

II Preparation of the threo- and erythro-forms of DL-guaiacylglycerol and of DL-veratrylglycerol

SO Acta Chemica Scandinavica (1963), 17, 27-36  
CODEN: ACHSE7; ISSN: 0904-213X

AB cf. CA 48, 5147g. Hydrogenation of 3,4-dimethoxyphenylpropionic acid in EtOH with Lindlar catalyst 50 min. gave 70% cis-methylferulic acid (I), m. 104°, which with CH<sub>2</sub>N<sub>2</sub> yielded 90% Me ester, prisms, m. 92-3°. Reduction of 30 g. Me trans-methylferulate (II) in 200 cc. dioxane with 5.7 g. LiAlH<sub>4</sub> in 500 cc. absolute Et<sub>2</sub>O, addition of H<sub>2</sub>O and dilute H<sub>2</sub>SO<sub>4</sub>, extraction with CHCl<sub>3</sub>, and distillation of the residue of the CHCl<sub>3</sub> extract gave 70% methylconiferyl alc., b<sub>5</sub> 110-20°, needles, m. 79-80°; Ac derivative (III) b<sub>12</sub> 190-5°. Treating 80 mg. III in 3 cc. Et<sub>2</sub>O-C<sub>5</sub>H<sub>5</sub>N (25:1) 16 hrs. with 0.1 g. OsO<sub>4</sub> in 2 cc. Et<sub>2</sub>O and hydrolyzing the osmic ester in 2 cc. EtOH with 0.65 g. Na<sub>2</sub>SO<sub>3</sub> in 3 cc. H<sub>2</sub>O 1 hr. at 100°, evaporating the filtered solution in vacuo, and extracting the residue with CHCl<sub>3</sub> gave 85% DL-threoveratrylglycerol (IV), m. 109-10°. Treating II similarly with OsO<sub>4</sub> and acetylating the hydrolyzed Os ester gave 60%

DL-threo- $\alpha,\beta$ -diacetoxymethylhydroferulic acid (V), prisms, m. 148-9°. Esterification of V with CH<sub>2</sub>N<sub>2</sub> followed by reduction yielded IV. Refluxing 15 g. Me  $\alpha$ -bromo- $\beta$ -acetoxymethyl-hydroferulate in 65 cc. AcOH and 65 cc. Ac<sub>2</sub>O 45 min. with 7 g. AgOAc, treating the filtered solution with H<sub>2</sub>O, evaporating the solution in vacuo, extracting the residue with CHCl<sub>3</sub>, evaporating the washed (NaHCO<sub>3</sub>) solution, and crystallizing the residue from Et<sub>2</sub>O-C<sub>6</sub>H<sub>14</sub> gave 41% Me threo- $\alpha,\beta$ -diacetoxymethylhydroferulate (VI), m. 102-3°. Concentration of the mother liquor gave 40% erythro isomer (VII), prisms, m. 71-3°. VI was also obtained in 10% yield when 4.44 g. II was oxidized with KMnO<sub>4</sub> at -50° according to Riiber (CA 9, 2244). Reduction of VII with LiAlH<sub>4</sub> gave DL-erythroveratrylglycerol (VIII), plates, m. 92-3°,  $\lambda_{\text{maximum}}$  278 m $\mu$  (log  $\epsilon$  3.52). The infrared spectra of IV and VIII differed distinctly. When Me erythro-diacetoxymethylhydroferulate was reduced with LiAlH<sub>4</sub> (cf. loc. cit.) and the acid step was avoided by neutralizing the reaction mixture with AcOH, 55% DL-erythro-guaiacylglycerol (IX), m. 83-4° was obtained; IX tetraacetate m. 86-8°. IX and CH<sub>2</sub>N<sub>2</sub> gave 90% VIII. Treating 0.31 g. IX with 0.1N H<sub>2</sub>SO<sub>4</sub> neutralizing the mixture with BaCO<sub>3</sub>, evaporating the filtered solution in vacuo, and treating the residue with moist EtOAc gave 0.18 g. unchanged IX and, from the mother liquor, 0.05 g. threo-DL-guaiacylglycerol (X); tetraacetate m. 113-14°. Benzyl-coniferyl alc. benzoate (0.515 g.) (Freudenberg and Achtzehn, CA 50, 1661h) was treated in 12 cc. Et<sub>2</sub>O-C<sub>5</sub>H<sub>5</sub>N with 0.35 g. OsO<sub>4</sub> and the precipitate formed was boiled 1 hr. with 2.3 g. Na<sub>2</sub>SO<sub>3</sub> in 10 cc. H<sub>2</sub>O, giving threo-(O-benzylguaiacyl)glycerol, m. 101°, which when treated in EtOH with prehydrogenated PdCl<sub>2</sub>-BaSO<sub>4</sub>, yielded X as a sirup; tetraacetate, 70%, m. 113-14°. X and CH<sub>2</sub>N<sub>2</sub> gave 70% IV. Careful fractionation of the mother liquor of the Me erythro- $\alpha,\beta$ -diacetoxymethylhydroferulate gave 10% threo isomer, prisms, m. 81-2°, which with LiAlH<sub>4</sub> gave 55% X. Treating

0.074 g. trans-methylisoeugenol (XI) with OsO<sub>4</sub> gave 75% DL-threo-methylisoeugenol glycol, m. 90°, which was also obtained in 15% yield when 1.93 g. XI was treated at -50° with 1.96 g. KMnO<sub>4</sub>. Acetylation of 3.3 g. XI in 3 cc. AcOH with 6.6 g. Pb(OAc)<sub>4</sub> and reduction of the  $\alpha,\beta$ -diacetoxyveratrylpropane formed with LiAlH<sub>4</sub> gave 2 g. of a product, m. 80-100°, which on fractional crystallization yielded erythro-methylisoeugenol glycol, m. 123°, and the threo isomer, m. 88°.

IT 4756-11-0P, 1,2,3-Propanetriol, 1-(3,4-dimethoxyphenyl)-, DL-erythro-14737-88-3P, Cinnamic acid, 3,4-dimethoxy-, cis- 18523-76-7P, 2-Propen-1-ol, 3-(3,4-dimethoxyphenyl)- 20133-19-1P, 1,2-Propanediol, 1-(3,4-dimethoxyphenyl)-, DL-erythro- 20133-19-1P, 1,2-Propanediol, 1-(3,4-dimethoxyphenyl)-, DL-threo- 27391-16-8P, 1,2,3-Propanetriol, 1-(4-hydroxy-3-methoxyphenyl)-, DL-threo- 30461-78-0P, Cinnamic acid, 3,4-dimethoxy-, methyl ester, cis- 38916-91-5P, 1,2,3-Propanetriol, 1-(4-hydroxy-3-methoxyphenyl)-, DL-erythro- 65401-84-5P, 2-Propen-1-ol, 3-(3,4-dimethoxyphenyl)-, acetate 69731-37-9P, 1,2,3-Propanetriol, 1-(4-hydroxy-3-methoxyphenyl)-, tetraacetate, DL-erythro- 69731-38-0P, 1,2,3-Propanetriol, 1-(4-hydroxy-3-methoxyphenyl)-, tetraacetate, DL-threo- 69731-40-4P, 1,2,3-Propanetriol, 1-(3,4-dimethoxyphenyl)-, DL-threo- 92582-54-2P, Hydrocinnamic acid,  $\alpha,\beta$ -dihydroxy-3,4-dimethoxy-, methyl ester, diacetate, DL-erythro- 92582-54-2P, Hydrocinnamic acid,  $\alpha,\beta$ -dihydroxy-3,4-dimethoxy-, diacetate, DL-threo- 93160-12-4P, Hydrocinnamic acid,  $\alpha,\beta$ -dihydroxy-3,4-dimethoxy-, methyl ester, diacetate, DL-threo- 95560-55-7P, 2-Propen-1-ol, 3-[4-(benzyloxy)-3-methoxyphenyl]-, benzoate 876369-20-9P, 1,2,3-Propanetriol, 1-[4-(benzyloxy)-3-methoxyphenyl]-, threo- 882025-72-1P, Hydrocinnamic acid,  $\alpha,\beta$ ,4-trihydroxy-3-methoxy-, methyl ester, triacetate, erythro- 882025-73-2P, Hydrocinnamic acid,  $\alpha,\beta$ ,4-trihydroxy-3-methoxy-, methyl ester, threo-  
 RL: PREP (Preparation)  
 (preparation of)

L9 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1958:35300 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 52:35300  
 ORIGINAL REFERENCE NO.: 52:6362c-i,6363a-h  
 TITLE: Clarifying the constitution of xanthocillin-a new antibiotic  
 AUTHOR(S): Hagedorn, I.; Tonjes, H.  
 CORPORATE SOURCE: Tech. Hochschule, Dresden, Germany  
 SOURCE: Pharmazie (1957), 12, 567-80  
 CODEN: PHARAT; ISSN: 0031-7144  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Unavailable

AB cf. C.A. 50, 17161e. Xanthocillin-X (I), C<sub>18</sub>H<sub>12</sub>O<sub>2</sub>N<sub>2</sub>, occurs in yellow crystals, decompose 220°. Di-Me ether of I, m. 181° (decomposition), is prepared by treating with CH<sub>2</sub>N<sub>2</sub> in Et<sub>2</sub>O. Di-Ac derivative, decompose above 200°, is formed by heating I with Ac<sub>2</sub>O and anhydrous AcONa to 80° and precipitating with H<sub>2</sub>O. Di-Bz derivative of I, decompose 200°, is formed by acetylation with BzCl in NaOH without heating. 1,4-Bis(p-hydroxyphenyl)-2,3-butanedione (II), m. 181-2°, may be prepared either by heating I with 1:1 AcOH-HCl at 100° 15 min. (yield 8%) or by storing I in 5:3 EtOH-H<sub>2</sub>SO<sub>4</sub> 15 hrs. at room temperature, treating with H<sub>2</sub>O, and extracting with Et<sub>2</sub>O (yield 20%); the osazone of II, m. 228-9°. 2,3-Bis(p-hydroxybenzyl)quinoxaline, m. 234-5° (decomposition), is prepared by boiling II and o-C<sub>6</sub>H<sub>4</sub>(NH<sub>2</sub>)<sub>2</sub> in alc. for a

short time and precipitating with H<sub>2</sub>O. 2,3-Bis(p-methoxybenzyl)quinoxaline is prepared from the last compound by treatment with Me<sub>2</sub>SO<sub>4</sub> in NaOH solution (mono-Me ether forms 1st., m. 144-6°; more heat and stronger solution of NaOH gives the di-Me ether, m. 89-90°). 1,4-Bis(p-methoxyphenyl)-2,3-butanedione (III), m. 135-6°, is prepared analogously, as in the case of II, but using I di-Me ether in place of I; osazone of III, m. 185-6°; dioxime, m. 201-3°. 2,3-Bis(p-methoxybenzyl)quinoxaline, m. 90-1, is prepared by treating III with o-C<sub>6</sub>H<sub>4</sub>(NH<sub>2</sub>)<sub>2</sub>. Oxidation of III with CrO<sub>3</sub> gave p-MeOC<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>H, m. 182-3°. Oxidation with H<sub>2</sub>O<sub>2</sub> furnished p-MeOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CO<sub>2</sub>H, m. 85°. When III was heated in AcOH with Zn dust and H<sub>2</sub>O, the α-hydroxyketone (IV), m. 77-7.5°, was formed. 1,4-Bis(p-methoxyphenyl)-2,3-butanediol (V), m. 160.5-161.50, was formed when LiBH<sub>4</sub> in absolute alc. and III in absolute Et<sub>2</sub>O were mixed and heated 60 min. at 100° (protected from H<sub>2</sub>O) and the resulting complex destroyed with 2N NaOH (redistn. with NaBH<sub>4</sub> led to same product). (AcO)<sub>4</sub>Pb was added to V at 40-5°, after 30 min. the mixture filtered, the filtrate concentrated, and semicarbazide, HCl, and AcONa added to give p-methoxyphenylacetaldehyde semicarbazone, m. 180-1.5°. 1,4-Bis(p-methoxyphenyl)butane (VI), m. 77-8°, was prepared by refluxing 25 hrs. III with Zn-Hg, HCl, PhMe, and H<sub>2</sub>O, with occasional addition of HCl. Treatment of I with Na-Hg furnished 2 end products, one Et<sub>2</sub>O-insol. 1,4-bis(p-methoxyphenyl)-2-butanone (VII), m. 87-7.5, and the other Et<sub>2</sub>O-soluble 1,4-bis(p-methoxyphenyl)-1,3-butadiene (VIII), m. 229-31°. VII is also prepared by methylation of 1,4-bis(p-hydroxyphenyl)-2-butanone (IX), m. 185.5-6.5°, with Me<sub>2</sub>SO<sub>4</sub>. Di-Ac derivative of IX, m. 86.5-8°, was prepared by heating IX with Ac<sub>2</sub>O and AcONa. Di-Bz derivative of IX, m. 153-4°, was prepared by treatment with BzCl; 2,4-dinitrophenylhydrazine was prepared by heating VII with dinitrophenylhydrazine and H<sub>3</sub>PO<sub>4</sub>, yellow needles, m. 144-5°. A synthesis of VII in 4 steps is given: p-MeOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CN is condensed with PhCH<sub>2</sub>COCH<sub>2</sub>CN to form p-methoxyphenylacetoacetonitrile, this converted to p-methoxyphenylacetone, and the latter condensed with anisaldehyde, forming 1,4-bis(p-methoxyphenyl)-3-buten-2-one, which is then hydrogenated in Me<sub>2</sub>CO in the presence of Pd black giving VIII, m. 86-7°. Bis(p-methoxybenzyl)glycolic acid (X), m. 166.5-67, was prepared from III by suspending it in KOH solution, warming to 60-70° with agitation, and acidifying; the Me ester of X m. 114-15°. 1,3-Bis(p-methoxyphenyl)-2-propanone (XI), m. 85-5.5°, was made by treating AcOH solution of X with (AcO)<sub>4</sub>Pb, warming to sep. CO<sub>2</sub>, and adding H<sub>2</sub>O to sep. the product; the oxime m. 102.5-103°. Reduction of XI by the Clemmensen procedure furnished the reduced product, m. 44-5°. The osazone of III was prepared by condensation of p-MeOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CO<sub>2</sub>Et in the presence of a fine suspension of Na in PhMe and Et<sub>2</sub>O and treatment with phenylhydrazine. Catalytic hydrogenation of VIII was carried out in semimicro apparatus using Pt from PtO, furnishing 1,4-bis(p-methoxyphenyl)butane, m. 77-8°. The presence of two isonitrile groups in I was proven quantitatively by warming an alc. solution with HgCl<sub>2</sub> and titrating the reduced HgCl gravimetrically; in another type of determination, (CO<sub>2</sub>H)<sub>2</sub> was treated with I and the evolved CO measured. I dimethyl ether imino ether (XII) was prepared in yellow rhombs, m. 121-2°; the di-imino ether was formed at the same time in colorless needles, m. 193-4°. 1,4-Bis(p-methoxyphenyl)-2,3-bis(formamido)-1,3-butadiene (XIII), m. 235-6°, was prepared from I di-Me ether by boiling with glacial AcOH and adding H<sub>2</sub>O. 1,4-Bis(p-hydroxyphenyl)-2,3-bis(formamido)-1,3-butadiene (XIV), pale yellow needles, decomposing above 200°, was prepared by warming XIII in glacial AcOH. 1,4-Bis(p-methoxyphenyl)-2,3-bis(methylformamido)-1,3-butadiene (XV), m. 165-6, was prepared by treating XIV with Me<sub>2</sub>SO<sub>4</sub> and NaOH. 1,4-Bis(p-hydroxyphenyl)-2,3-bis(dimethylhydroxyacetamido)-1,3-butadiene (XVI), m. 271-2° (decomposition), was prepared by treating I in Me<sub>2</sub>CO solution with 2N H<sub>2</sub>SO<sub>4</sub>. 1,4-Bis(p-methoxyphenyl)-2,3-bis[(dimethylhydroxyacetyl)methylamino]-1,3-butadiene, m. 240° (decomposition), was prepared by dissolving XVI in NaOH and treating with Me<sub>2</sub>SO<sub>4</sub> at 100° 15 min. Imidazole-4,5-dicarboxylic acid (XVII), decompose above 300° was prepared by refluxing I, I dimethyl ether, XIII, or



XIV with H<sub>2</sub>O<sub>2</sub>. The following salts of XVII were prepared (m.p. given): diethylamine (m. 180°), imidazole (m. 244°), acid K salt (m. 280°), acid Na salt, nitrate (118°), and picrate (211°). From the mother liquor remaining from the preparation of XVII, 12-15% (of theory) anisic acid was isolated, m. 184°. By hydrogenation of I with Raney Ni, 2,3-bis(p-hydroxybenzyl)pyrazine (XVIII), m. 203-4°, was obtained (diacetate, m. 91-2°, dibenzoate, m. 122-3°). 2,3-Bis(p-methoxybenzyl)pyrazine (XIX), m. 57-8°, was prepared by treating XVIII in MeOH and Et<sub>2</sub>O with CH<sub>2</sub>N<sub>2</sub>. Pyrazine-2,3-dicarboxylate was formed when XVIII was heated 2 hrs. on an H<sub>2</sub>O bath with 3% KMnO<sub>4</sub>, acidified with AcOH, vacuum-dried, heated 2 hrs. with glacial AcOH in a "bombtube," and distilled after alkalization; picrate, m. 156-7°, R<sub>f</sub> 0.58. 2,3-Bis(p-methoxybenzoyl)pyrazine (XX), m. 164-5° was prepared from XIX by treatment with Beckmann's mixture, m. 164-5°; the bis-(2,4-dinitrophenylhydrazone), dark red crystals, m. 299-300° (decomposition); dioxime, m. 224-9°. 3,6-Bis(p-methoxyphenyl)-1,2-diazino[4,5;2,3]pyrazine, yellow plates, m. 293.5-4.5, was prepared from XX by treatment with hydrazine sulfate and NaOH. XV in CHCl<sub>3</sub> solution was treated with BzO<sub>2</sub>H and the rate of consumption determined XV (1 mole) consumed 2.5 moles of the acid; however, the reaction velocity after the consumption of 2 moles acid was considerably greater, indicating the presence of double bond in I. 4,5-Bis(p-methoxybenzoyl)imidazole (XXI), m. 173-4°, was prepared by oxidizing I di-Me ether with CrO<sub>3</sub>; at the same time, 2 strongly acidic substances were obtained, one being anisic acid; the bis(2,4-dinitrophenylhydrazone) of XXI, dark red crystals, m. 278-9°. 3,6 - Bis(p - methoxyphenyl)1,2 - diazino[4,5;4,5]imidazole (XXII), m. 146-7°, was obtained from XXI by refluxing 30 min. with hydrazine hydrate. I was not synthesized, but it was felt that the structure of I was fully established, by the results of these various studies, as [HOC<sub>6</sub>H<sub>4</sub>CH:C(NC)]<sub>2</sub>. 23 references.

TI Clarifying the constitution of xanthocillin-a new antibiotic

SO Pharmazie (1957), 12, 567-80

CODEN: PHARAT; ISSN: 0031-7144

AB cf. C.A. 50, 17161e. Xanthocillin-X (I), C<sub>18</sub>H<sub>12</sub>O<sub>2</sub>N<sub>2</sub>, occurs in yellow crystals, decompose 220°. Di-Me ether of I, m. 181° (decomposition), is prepared by treating with CH<sub>2</sub>N<sub>2</sub> in Et<sub>2</sub>O. Di-Ac derivative, decompose above 200°, is formed by heating I with Ac<sub>2</sub>O and anhydrous AcONa to 80° and precipitating with H<sub>2</sub>O. Di-Bz derivative of I, decompose 200°, is formed by acetylation with BzCl in NaOH without heating. 1,4-Bis(p-hydroxyphenyl)-2,3-butanedione (II), m. 181-2°, may be prepared either by heating I with 1:1 AcOH-HCl at 100° 15 min. (yield 8%) or by storing I in 5:3 EtOH-H<sub>2</sub>SO<sub>4</sub> 15 hrs. at room temperature, treating with H<sub>2</sub>O, and extracting with Et<sub>2</sub>O (yield 20%); the osazone of II, m. 228-9°. 2,3-Bis(p-hydroxybenzyl)quinoxaline, m. 234-5° (decomposition), is prepared by boiling II and o-C<sub>6</sub>H<sub>4</sub>(NH<sub>2</sub>)<sub>2</sub> in alc. for a short time and precipitating with H<sub>2</sub>O. 2,3-Bis(p-methoxybenzyl)quinoxaline is prepared from the last compound by treatment with Me<sub>2</sub>SO<sub>4</sub> in NaOH solution (mono-Me ether forms 1st., m. 144-6°; more heat and stronger solution of NaOH gives the di-Me ether, m. 89-90°). 1,4-Bis(p-methoxyphenyl)-2,3-butanedione (III), m. 135-6°, is prepared analogously, as in the case of II, but using I di-Me ether in place of I; osazone of III, m. 185-6°; dioxime, m. 201-3°. 2,3-Bis(p-methoxybenzyl)quinoxaline, m. 90-1, is prepared by treating III with o-C<sub>6</sub>H<sub>4</sub>(NH<sub>2</sub>)<sub>2</sub>. Oxidation of III with CrO<sub>3</sub> gave p-MeOC<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>H, m. 182-3°. Oxidation with H<sub>2</sub>O<sub>2</sub> furnished p-MeOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CO<sub>2</sub>H, m. 85°. When III was heated in AcOH with Zn dust and H<sub>2</sub>O, the α-hydroxyketone (IV), m. 77-7.5°, was formed. 1,4-Bis(p-methoxyphenyl)-2,3-butanediol (V), m. 160.5-161.50, was formed when LiBH<sub>4</sub> in absolute alc. and III in absolute Et<sub>2</sub>O were mixed and heated 60 min. at 100° (protected from H<sub>2</sub>O) and the resulting complex destroyed with 2N NaOH (redistn. with NaBH<sub>4</sub> led to same product). (AcO)<sub>4</sub>Pb was added to V at 40-5°, after 30 min. the mixture filtered, the filtrate concentrated, and semicarbazide, HCl, and AcONa added to give p-methoxyphenylacetaldehyde semicarbazone, m. 180-1.5°. 1,4-Bis(p-methoxyphenyl)butane (VI), m. 77-8°, was prepared by refluxing 25 hrs. III

with Zn-Hg, HCl, PhMe, and H<sub>2</sub>O, with occasional addition of HCl. Treatment of I with Na-Hg furnished 2 end products, one Et<sub>2</sub>O-insol. 1,4-bis(p-methoxyphenyl)-2-butanone (VII), m. 87-7.5, and the other Et<sub>2</sub>O-soluble 1,4-bis(p-methoxyphenyl)-1,3-butadiene (VIII), m. 229-31°. VII is also prepared by methylation of 1,4-bis(p-hydroxyphenyl)-2-butanone (IX), m. 185.5-6.5°, with Me<sub>2</sub>SO<sub>4</sub>. Di-Ac derivative of IX, m. 86.5-8°, was prepared by heating IX with Ac<sub>2</sub>O and AcONa. Di-Bz derivative of IX, m. 153-4°, was prepared by treatment with BzCl; 2,4-dinitrophenylhydrazine was prepared by heating VII with dinitrophenylhydrazine and H<sub>3</sub>PO<sub>4</sub>, yellow needles, m. 144-5°. A synthesis of VII in 4 steps is given: p-MeOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CN is condensed with PhCH<sub>2</sub>COCH<sub>2</sub>CN to form p-methoxyphenylacetoacetonitrile, this converted to p-methoxyphenylacetone, and the latter condensed with anisaldehyde, forming 1,4-bis(p-methoxyphenyl)-3-buten-2-one, which is then hydrogenated in Me<sub>2</sub>CO in the presence of Pd black giving VIII, m. 86-7°. Bis(p-methoxybenzyl)glycolic acid (X), m. 166.5-67, was prepared from III by suspending it in KOH solution, warming to 60-70° with agitation, and acidifying; the Me ester of X m. 114-15°. 1,3-Bis(p-methoxyphenyl)-2-propanone (XI), m. 85-5.5°, was made by treating AcOH solution of X with (AcO)<sub>4</sub>Pb, warming to sep. CO<sub>2</sub>, and adding H<sub>2</sub>O to sep. the product; the oxime m. 102.5-103°. Reduction of XI by the Clemmensen procedure furnished the reduced product, m. 44-5°. The osazone of III was prepared by condensation of p-MeOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CO<sub>2</sub>Et in the presence of a fine suspension of Na in PhMe and Et<sub>2</sub>O and treatment with phenylhydrazine. Catalytic hydrogenation of VIII was carried out in semimicro apparatus using Pt from PtO, furnishing 1,4-bis(p-methoxyphenyl)butane, m. 77-8°. The presence of two isonitrile groups in I was proven quantitatively by warming an alc. solution with HgCl<sub>2</sub> and titrating the reduced HgCl gravimetrically; in another type of determination, (CO<sub>2</sub>H)<sub>2</sub> was treated with I and the evolved CO measured. I dimethyl ether imino ether (XII) was prepared in yellow rhombs, m. 121-2°; the di-imino ether was formed at the same time in colorless needles, m. 193-4°. 1,4-Bis(p-methoxyphenyl)-2,3-bis(formamido)-1,3-butadiene (XIII), m. 235-6°, was prepared from I di-Me ether by boiling with glacial AcOH and adding H<sub>2</sub>O. 1,4-Bis(p-hydroxyphenyl)-2,3-bis(formamido)-1,3-butadiene (XIV), pale yellow needles, decomposing above 200°, was prepared by warming VIII in glacial AcOH. 1,4-Bis(p-methoxyphenyl)-2,3-bis(methylformamido)-1,3-butadiene (XV), m. 165-6, was prepared by treating XIV with Me<sub>2</sub>SO<sub>4</sub> and NaOH. 1,4-Bis(p-hydroxyphenyl)-2,3-bis(dimethylhydroxyacetamido)-1,3-butadiene (XVI), m. 271-2° (decomposition), was prepared by treating I in Me<sub>2</sub>CO solution with 2N H<sub>2</sub>SO<sub>4</sub>. 1,4-Bis(p-methoxyphenyl)-2,3-bis[(dimethylhydroxyacetyl)methylamino]-1,3-butadiene, m. 240° (decomposition), was prepared by dissolving XVI in NaOH and treating with Me<sub>2</sub>SO<sub>4</sub> at 100° 15 min. Imidazole-4,5-dicarboxylic acid (XVII), decompose above 300° was prepared by refluxing I, I dimethyl ether, XIII, or XIV with H<sub>2</sub>O<sub>2</sub>. The following salts of XVII were prepared (m.p. given): diethylamine (m. 180°), imidazole (m. 244°), acid K salt (m. 280°), acid Na salt, nitrate (118°), and picrate (211°). From the mother liquor remaining from the preparation of XVII, 12-15% (of theory) anisic acid was isolated, m. 184°. By hydrogenation of I with Raney Ni, 2,3-bis(p-hydroxybenzyl)pyrazine (XVIII), m. 203-4°, was obtained (diacetate, m. 91-2°, dibenzoate, m. 122-3°). 2,3-Bis(p-methoxybenzyl)pyrazine (XIX), m. 57-8°, was prepared by treating XVIII in MeOH and Et<sub>2</sub>O with CH<sub>2</sub>N<sub>2</sub>. Pyrazine-2,3-dicarboxylate was formed when XVIII was heated 2 hrs. on an H<sub>2</sub>O bath with 3% KMnO<sub>4</sub>, acidified with AcOH, vacuum-dried, heated 2 hrs. with glacial AcOH in a "bombtube," and distilled after alkanization; picrate, m. 156-7°, Rf 0.58. 2,3-Bis(p-methoxybenzoyl)pyrazine (XX), m. 164-5° was prepared from XIX by treatment with Beckmann's mixture, m. 164-5°; the bis-(2,4-dinitrophenylhydrazine), dark red crystals, m. 299-300° (decomposition); dioxime, m. 224-9°. 3,6-Bis(p-methoxyphenyl)-1,2-diazino[4,5;2,3]pyrazine, yellow plates, m. 293.5-4.5, was prepared from XX by treatment with hydrazine sulfate and NaOH. XV in CHCl<sub>3</sub> solution was treated with BzO<sub>2</sub>H and the rate of consumption determined XV (1 mole) consumed 2.5 moles of the acid; however, the reaction velocity after the

consumption of 2 moles acid was considerably greater, indicating the presence of double bond in I. 4,5-Bis(p-methoxybenzoyl)imidazole (XXI), m. 173-4°, was prepared by oxidizing I di-Me ether with CrO<sub>3</sub>; at the same time, 2 strongly acidic substances were obtained, one being anisic acid; the bis(2,4-dinitrophenylhydrazone) of XXI, dark red crystals, m. 278-9°. 3,6 - Bis(p-methoxyphenyl)1,2 - diazino[4,5;4,5]imidazole (XXII), m. 146-7°, was obtained from XXI by refluxing 30 min. with hydrazine hydrate. I was not synthesized, but it was felt that the structure of I was fully established, by the results of these various studies, as [HOC<sub>6</sub>H<sub>4</sub>CH:C(NC)]<sub>2</sub>. 23 references.

IT 89-01-0P, 2,3-Pyrazinedicarboxylic acid 100-09-4P, p-Anisic acid  
 104-01-8P, Acetic acid, (p-methoxyphenyl)- 122-84-9P, 2-Propanone,  
 (p-methoxyphenyl)- 4741-73-5P, Propane, 1,3-bis(p-methoxyphenyl)-  
 5701-83-7P, Butane, 1,4-bis(p-methoxyphenyl)- 29903-09-1P, 2-Propanone,  
 1,3-bis(p-methoxyphenyl)- 38565-14-9P, Formamide,  
 N,N'-[bis(p-hydroxybenzylidene)ethylene]bis- 43212-67-5P, 1,3-Butadiene,  
 1,4-bis(p-methoxyphenyl)- 51622-85-6P, Acetaldehyde, (p-methoxyphenyl)-,  
 semicarbazone 65816-19-5P, Pyrazine, picrate 74026-69-0P, 2-Butanone,  
 3-hydroxy-1,4-bis(p-methoxyphenyl)- 101110-57-0P, 2,3-Butanedione,  
 1,4-bis(p-hydroxyphenyl)- 101585-09-5P, 2-Propanone,  
 1,3-bis(p-methoxyphenyl)-, oxime 101744-01-8P, Lactic acid,  
 2-p-methoxybenzyl-3-(p-methoxyphenyl)- 101869-37-8P, Imidazole,  
 4,5-di-p-anisoyl- 102162-84-5P, Lactic acid,  
 2-p-methoxybenzyl-3-(p-methoxyphenyl)-, methyl ester 102316-70-1P,  
 Pyrazine, 2,3-bis(p-methoxybenzyl)- 102590-83-0P, p-Cresol,  
 $\alpha$ -(2-p-methoxybenzyl-3-quinoxaliny)- 102704-38-1P, p-Cresol,  
 $\alpha,\alpha'$ -2,3-quinoxalinediyl-di- 102748-31-2P, 2-Butanone,  
 1,4-bis(p-methoxyphenyl)-, (2,4-dinitrophenyl)hydrazone 102749-91-7P,  
 Quinoxaline, 2,3-bis(p-methoxybenzyl)- 103271-07-4P, Imidazole,  
 4,5-di-p-anisoyl-, bis[(2,4-dinitrophenyl)hydrazone] 103986-01-2P,  
 Acetoacetonitrile, 4-(p-methoxyphenyl)- 107627-09-8P, 2-Butanone,  
 1,4-bis(p-methoxyphenyl)- 108370-05-4P, 1H-Imidazo[4,5-d]pyridazine,  
 4,7-bis(p-methoxyphenyl)- 109398-70-1P, 2,3-Butanediol,  
 1,4-bis(p-methoxyphenyl)- 110435-88-6P, 3-Buten-2-one,  
 1,4-bis(p-methoxyphenyl)- 111240-82-5P, Pyrazino[2,3-d]pyridazine,  
 5,8-bis(p-methoxyphenyl)- 112271-44-0P, Formamide,  
 N,N'-[bis(p-methoxybenzylidene)ethylene]bis- 113090-73-6P, Formimidic  
 acid, N-( $\beta$ -isocyano-p-methoxy- $\alpha$ -p-methoxybenzylidenecinnamyl)-,  
 methyl ester 114696-86-5P, 2,3-Butanedione, 1,4-bis(p-hydroxyphenyl)-,  
 bis(phenylhydrazone) 118871-24-2P, Formimidic acid,  
 N,N'-[bis(p-methoxybenzylidene)ethylene]di-, dimethyl ester  
 118871-26-4P, Formamide, N,N'-[bis(p-methoxybenzylidene)ethylene]bis[N-  
 methyl- 122360-58-1P, Lactamide,  
 N,N'-[bis(p-methoxybenzylidene)-ethylene]bis[N,2-dimethyl- 124131-77-7P,  
 Lactamide, N,N'-[bis(p-hydroxybenzylidene)-ethylene]bis[2-methyl-  
 131252-64-7P, 2-Butanone, 1,4-bis(p-hydroxyphenyl)- 856638-96-5P,  
 Imidazole, compound with 4,5-imidazoledicarboxylic acid  
 RL: PREP (Preparation)  
 (preparation of)

L9 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1957:5337 CAPLUS Full-text  
 DOCUMENT NUMBER: 51:5337  
 ORIGINAL REFERENCE NO.: 51:1084e-i,1085a-d  
 TITLE: Synthesis and reactions of guaiacylglycerol  
 AUTHOR(S): Stumpf, Walter; Rumpf, Gunther  
 CORPORATE SOURCE: Univ. Heidelberg, Germany  
 SOURCE: Annalen der Chemie, Justus Liebigs (1956),  
 599, 51-60  
 CODEN: 9X224Y

DOCUMENT TYPE: Journal  
LANGUAGE: Unavailable  
OTHER SOURCE(S): CASREACT 51:5337

AB 3,4-MeO(PhCH<sub>2</sub>O)C<sub>6</sub>H<sub>3</sub>CHO (138 g.) in 230 cc. AcOMe, after standing overnight with 17.1 g. Na wire and 2 cc. MeOH was triturated carefully with 230 cc. AcOMe, kept another 48 hrs. at room temperature, refluxed 1 hr. with 230 cc. absolute Et<sub>2</sub>O, and shaken with 740 cc. H<sub>2</sub>SO<sub>4</sub>. The organic phase washed with aqueous NaHCO<sub>3</sub> and H<sub>2</sub>O, dried and evaporated gave 95.5% crude and 83% pure 3,4-MeO(PhCH<sub>2</sub>O)C<sub>6</sub>H<sub>3</sub>CH:CHCO<sub>2</sub>Me (I), m. 98-9° (from MeOH or PrOH). To 7.16 g. I in 24 cc. CHCl<sub>2</sub> at 0°-5° were added dropwise (over a 1.5-hr. period) 3.84 g. Br; the mixture after 1 hr. at 0° was evaporated giving the crude di-Br derivative (II) of I (not weighed or analyzed), 22.9 g. of which were added to 15 g. dry AcOK in 150 cc. AcOH and 50 cc. Ac<sub>2</sub>O, heated 9 hrs. on a steam bath, then boiled 8 hrs., filtered, and concentrated in vacuo to incipient crystallization, treated with H<sub>2</sub>O and extracted with Et<sub>2</sub>O; the washed and dried extract evaporated in vacuo gave 19 g. sirup, a small sample of which, triturated with MeOH, gave seed crystals of (III), C<sub>22</sub>H<sub>24</sub>O<sub>8</sub>, m. sharply 112.5-13.5° (after 2 crystns. from MeOH). The main portion of the sirup, inoculated with III, crystallized gradually giving 8.25 g. of what was probably a mixture of isomeric forms of 3,4-MeO(PhCH<sub>2</sub>O)C<sub>6</sub>H<sub>3</sub>CH(OAc)CH(OAc)CO<sub>2</sub>Me (IV), m. poorly 90-100° (even after repeated crystallization from MeOH). In another experiment in which 169 g. crude II was heated 15 hrs. at 100° with 110 g. AcOK, 800 cc. AcOH, and 400 cc. Ac<sub>2</sub>O, a red sirup was formed, which, with III, gave 52.45 g. IV, leaflets, m. poorly 89-98°, the mother liquors from which gave I. A series of fully described attempts were made to fractionate IV into its component (racemic) isomers, but although 3 fractions were obtained, m., resp., 85.5-87°, 86-91°, and 88-91°, none of these was homogeneous. IV (m. 89-98°) (12.5 g.) in 50 cc. dry AcOMe was hydrogenated with 0.75 g. 2% pd-BaSO<sub>4</sub>. After 1.5 hrs. 745 cc. H had been taken up. The filtered, evaporated solution gave 3,4-MeO(HO)C<sub>6</sub>H<sub>3</sub>CH(OAc)CH(OAc)CO<sub>2</sub>Me (V), viscous, uncrystallizable pale yellow sirup. V (8.34 g.) in 100 cc. absolute Et<sub>2</sub>O was added dropwise to 5.6 g. LiAlH<sub>4</sub> in 200 cc. Et<sub>2</sub>O, and after 5 hrs. at room temperature was refluxed 2 hrs., cooled to 0° in a stream of CO<sub>2</sub> and treated dropwise with H<sub>2</sub>O, shaken with H<sub>2</sub>O saturated with CO<sub>2</sub>, the Et<sub>2</sub>O layer separated and the aqueous phase extracted continuously for 7 days with peroxide-free Et<sub>2</sub>O in a Perforator, using fresh Et<sub>2</sub>O after 28 hrs. (when a sirup separated from the Et<sub>2</sub>O-phase). The various combined Et<sub>2</sub>O exts. evaporated in vacuo gave 2.7 g. crude resinous guaiacylglycerol (VI), which was boiled briefly with 200 cc. H<sub>2</sub>O, filtered and reextd. twice with Et<sub>2</sub>O. The aqueous phase (in which VI is very soluble) was evaporated to dryness in vacuo under N, giving 1.98 g. (36.3%) purified VI, C<sub>10</sub>H<sub>14</sub>O<sub>5</sub>, yellow sirup (after drying 14 hrs. at 34° in vacuo and 2 days at 20° over P<sub>2</sub>O<sub>5</sub>). VI is difficultly soluble in Et<sub>2</sub>O and C<sub>6</sub>H<sub>6</sub> and could not be crystallized. IV (m. 87-93°) (21.2 g.) in 750 cc. absolute Et<sub>2</sub>O was stirred into a mixture of 10 g. LiAlH<sub>4</sub> and 200 cc. Et<sub>2</sub>O, and treated as in the case of V. The resultant aqueous solution was filtered and extracted 40 hrs. with Et<sub>2</sub>O; the Et<sub>2</sub>O layer yielded 2.15 g. PhCH<sub>2</sub> derivative (VII) of VI, m. 68-74° (from C<sub>6</sub>H<sub>6</sub>), m. 99-100.5° (from MeOH by addition of Et<sub>2</sub>O and petr. ether to incipient cloudiness, or from AcOEt). Even this purified VII may be a mixture of racemic isomers. VI (1.81 g.) and Na<sub>2</sub>S<sub>2</sub>O<sub>5</sub> in 85 cc. H<sub>2</sub>O was heated and shaken 19 hrs. at 135° in a sealed tube, then freed from SO<sub>2</sub> and extracted 40 hrs. with Et<sub>2</sub>O giving 0.15 g. impure 4,3-HO(MeO)C<sub>6</sub>H<sub>3</sub>CH(SO<sub>3</sub>H)CH(OH)CH<sub>2</sub>OH, 81% of which was soluble in cold H<sub>2</sub>O forming a pale pink Ba salt (VIII) (containing 32.68% C and 21.3% Ba; calculated 34.71 and 19.85%, resp.). Oxidations with NaIO<sub>4</sub> were carried out with various phenolic compds. or their derivs., and results are given in terms of moles NaIO<sub>4</sub> consumed per mole of compound within a specific time period. No NaIO<sub>4</sub> was consumed by veratrole within 17.5 hrs. The consumption of NaIO<sub>4</sub> by PhOH, vanillin, and p-cresol was very slight (0.14-0.33 mole within 21.5-24 hrs.). V, VI, guaiacol, cresol, guaiacylethylcarbinol, VIII, 1,4-C<sub>6</sub>H<sub>4</sub>(OH)<sub>2</sub>, catechol, and pyrogallol all consumed appreciable amts. of NaIO<sub>4</sub> within

relatively short periods. On oxidation all guaiacyl compds. gave red solns., the color being ascribed to quinoid oxidation products. Oxidation data are discussed at length.

TI Synthesis and reactions of guaiacylglycerol

SO Annalen der Chemie, Justus Liebig's (1956), 599, 51-60

CODEN: 9X224Y

AB 3,4-MeO(PhCH<sub>2</sub>O)C<sub>6</sub>H<sub>3</sub>CHO (138 g.) in 230 cc. AcOMe, after standing overnight with 17.1 g. Na wire and 2 cc. MeOH was triturated carefully with 230 cc. AcOMe, kept another 48 hrs. at room temperature, refluxed 1 hr. with 230 cc. absolute Et<sub>2</sub>O, and shaken with 740 cc. H<sub>2</sub>SO<sub>4</sub>. The organic phase washed with aqueous NaHCO<sub>3</sub> and H<sub>2</sub>O, dried and evaporated gave 95.5% crude and 83% pure 3,4-MeO(PhCH<sub>2</sub>O)C<sub>6</sub>H<sub>3</sub>CH:CHCO<sub>2</sub>Me (I), m. 98-9° (from MeOH or PrOH). To 7.16 g. I in 24 cc. CHCl<sub>3</sub> at 0°-5° were added dropwise (over a 1.5-hr. period) 3.84 g. Br; the mixture after 1 hr. at 0° was evaporated giving the crude di-Br derivative (II) of I (not weighed or analyzed), 22.9 g. of which were added to 15 g. dry AcOK in 150 cc. AcOH and 50 cc. Ac<sub>2</sub>O, heated 9 hrs. on a steam bath, then boiled 8 hrs., filtered, and concentrated in vacuo to incipient crystallization, treated with H<sub>2</sub>O and extracted with Et<sub>2</sub>O; the washed and dried extract evaporated in vacuo gave 19 g. sirup, a small sample of which, triturated with MeOH, gave seed crystals of (III), C<sub>22</sub>H<sub>24</sub>O<sub>8</sub>, m. sharply 112.5-13.5° (after 2 crystns. from MeOH). The main portion of the sirup, inoculated with III, crystallized gradually giving 8.25 g. of what was probably a mixture of isomeric forms of 3,4-MeO(PhCH<sub>2</sub>O)C<sub>6</sub>H<sub>3</sub>CH(OAc)CH(OAc)CO<sub>2</sub>Me (IV), m. poorly 90-100° (even after repeated crystallization from MeOH). In another experiment in which 169 g. crude II was heated 15 hrs. at 100° with 110 g. AcOK, 800 cc. AcOH, and 400 cc. Ac<sub>2</sub>O, a red sirup was formed, which, with III, gave 52.45 g. IV, leaflets, m. poorly 89-98°, the mother liquors from which gave I. A series of fully described attempts were made to fractionate IV into its component (racemic) isomers, but although 3 fractions were obtained, m., resp., 85.5-87°, 86-91°, and 88-91°, none of these was homogeneous. IV (m. 89-98°) (12.5 g.) in 50 cc. dry AcOMe was hydrogenated with 0.75 g. 2% Pd-BaSO<sub>4</sub>. After 1.5 hrs. 745 cc. H<sub>2</sub> had been taken up. The filtered, evaporated solution gave 3,4-MeO(HO)C<sub>6</sub>H<sub>3</sub>CH(OAc)CH(OAc)CO<sub>2</sub>Me (V), viscous, uncrystallizable pale yellow sirup. V (8.34 g.) in 100 cc. absolute Et<sub>2</sub>O was added dropwise to 5.6 g. LiAlH<sub>4</sub> in 200 cc. Et<sub>2</sub>O, and after 5 hrs. at room temperature was refluxed 2 hrs., cooled to 0° in a stream of CO<sub>2</sub> and treated dropwise with H<sub>2</sub>O, shaken with H<sub>2</sub>O saturated with CO<sub>2</sub>, the Et<sub>2</sub>O layer separated and the aqueous phase extracted continuously for 7 days with peroxide-free Et<sub>2</sub>O in a Perforator, using fresh Et<sub>2</sub>O after 28 hrs. (when a sirup separated from the Et<sub>2</sub>O-phase). The various combined Et<sub>2</sub>O exts. evaporated in vacuo gave 2.7 g. crude resinous guaiacylglycerol (VI), which was boiled briefly with 200 cc. H<sub>2</sub>O, filtered and reextd. twice with Et<sub>2</sub>O. The aqueous phase (in which VI is very soluble) was evaporated to dryness in vacuo under N, giving 1.98 g. (36.3%) purified VI, C<sub>10</sub>H<sub>14</sub>O<sub>5</sub>, yellow sirup (after drying 14 hrs. at 34° in vacuo and 2 days at 20° over P<sub>2</sub>O<sub>5</sub>). VI is difficultly soluble in Et<sub>2</sub>O and C<sub>6</sub>H<sub>6</sub> and could not be crystallized. IV (m. 87-93°) (21.2 g.) in 750 cc. absolute Et<sub>2</sub>O was stirred into a mixture of 10 g. LiAlH<sub>4</sub> and 200 cc. Et<sub>2</sub>O, and treated as in the case of V. The resultant aqueous solution was filtered and extracted 40 hrs. with Et<sub>2</sub>O; the Et<sub>2</sub>O layer yielded 2.15 g. PhCH<sub>2</sub> derivative (VII) of VI, m. 68-74° (from C<sub>6</sub>H<sub>6</sub>), m. 99-100.5° (from MeOH by addition of Et<sub>2</sub>O and petr. ether to incipient cloudiness, or from AcOEt). Even this purified VII may be a mixture of racemic isomers. VI (1.81 g.) and Na<sub>2</sub>S<sub>2</sub>O<sub>5</sub> in 85 cc. H<sub>2</sub>O was heated and shaken 19 hrs. at 135° in a sealed tube, then freed from SO<sub>2</sub> and extracted 40 hrs. with Et<sub>2</sub>O giving 0.15 g. impure 4,3-HO(MeO)C<sub>6</sub>H<sub>3</sub>CH(SO<sub>3</sub>H)CH(OH)CH<sub>2</sub>OH, 81% of which was soluble in cold H<sub>2</sub>O forming a pale pink Ba salt (VIII) (containing 32.68% C and 21.3% Ba; calculated 34.71 and 19.85%, resp.). Oxidations with NaIO<sub>4</sub> were carried out with various phenolic compds. or their derivs., and results are given in terms of moles NaIO<sub>4</sub> consumed per mole of compound within a specific time period. No NaIO<sub>4</sub> was consumed by veratrole within 17.5 hrs. The consumption of NaIO<sub>4</sub> by

PhOH, vanillin, and p-cresol was very slight (0.14-0.33 mole within 21.5-24 hrs.). V, VI, guaiacol, cresol, guaiacylethylcarbinol, VIII, 1,4-C<sub>6</sub>H<sub>4</sub>(OH)<sub>2</sub>, catechol, and pyrogallol all consumed appreciable amts. of NaIO<sub>4</sub> within relatively short periods. On oxidation all guaiacyl compds. gave red solns., the color being ascribed to quinoid oxidation products. Oxidation data are discussed at length.

IT 10548-93-3P,  $\alpha$ -Toluenesulfonic acid,  
 $\alpha$ -1,2-dihydroxyethyl-4-hydroxy-3-methoxy- 66266-31-7P,  
 $\alpha$ -Toluenesulfonic acid,  $\alpha$ -1,2-dihydroxyethyl-4-hydroxy-3-  
methoxy-, barium salt 93878-20-7P, Cinnamic acid,  
4-(benzyloxy)-3-methoxy-, methyl ester 101721-98-6P, Hydrocinnamic acid,  
4-(benzyloxy)- $\alpha,\beta$ -dibromo-3-methoxy-, methyl ester  
109476-22-4P, Glyceric acid, 3-(4-hydroxy-3-methoxyphenyl)-,  
methyl ester, 2,3-diacetate 856945-37-4P, Glyceric acid,  
3-[4-(benzyloxy)-3-methoxyphenyl]-, diacetates 856945-42-1P, Glyceric  
acid, 3-[4-(benzyloxy)-3-methoxyphenyl]-, Me esters  
RL: PREP (Preparation)  
(preparation of)

=> d 19 16-18 ibib abs ti hit

L9 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1955:84086 CAPLUS Full-text

DOCUMENT NUMBER: 49:84086

ORIGINAL REFERENCE NO.: 49:15798a-i,15799a-c

TITLE: Constituents of Cortex piscidiaae erythrinae. II.  
Synthesis of O-methylpiscidic acid

AUTHOR(S): Buckle, A. L. J.; McGookin, Alexander; Robertson,  
Alexander

CORPORATE SOURCE: Univ. Liverpool, UK

SOURCE: Journal of the Chemical Society (1954)  
3981-6

CODEN: JCSOA9; ISSN: 0368-1769

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB cf. C.A. 42, 4981f. Piscidic acid was shown previously to be (+)-p-HOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>C(OH)(CO<sub>2</sub>H)CH(OH)CO<sub>2</sub>H (loc. cit.) and now has been confirmed by the synthesis of p-methoxybenzyltartaric acid, identical with natural O-Me piscidic acid. Several routes for the synthesis of tartaric acids of this type were examined Et  $\alpha$ -phenylacetoacetate, b0.8 110° (2,4-dinitrophenylhydrazone, m. 94-5°), prepared by the method of Attwood, et al. (C.A. 17, 3183), with Pb(OAc)<sub>4</sub> in HOAc, gave Et  $\alpha$ -acetoxy- $\alpha$ -phenylacetoacetate, b0.2 128-30°. Similarly, from Et  $\gamma$ -phenylacetoacetate there resulted Et  $\alpha$ -acetoxy- $\gamma$ -phenylacetoacetate (I), b0.5 143-5°. I was obtained also from phenylacetyl bromide, Et diazoacetate, and HOAc. A mixture of I, HCN, and NaOH after 12 h. was diluted with EtOH, saturated with HCl, refluxed 4 h. and filtered to remove NH<sub>4</sub>Cl. The residue after evaporation of the filtrate gave Et benzyltartrate as a mixture which was separated manually into equal amts. of racemate A, m. 174-5° (diamide, 204-6°), and racemate B, m. 194-5° (diamide, m. 185-6°). Reduction of Et phenyloxaloacetate with moist Al amalgam gave Et  $\beta$ -phenylmalate, b0.04 131°, which after hydrolysis with KOH and purification from EtOAc gave  $\beta$ -phenylmalic acid, m. 150-60°. Fractional crystallization from EtOAc gave the racemic isomeride A, m. 172°, and from EtOAc-light petroleum (b.p. 60-80°) the racemic isomeride B, m. 162°. Dehydration with Ac<sub>2</sub>O of a mixture of the isomerides gave phenylmaleic anhydride, m. 120°, which on treatment with alkali gave phenylmaleic acid (II), m. 90-2°. II with pyridine and OsO<sub>4</sub> in Et<sub>2</sub>O gave phenyltartaric acid, m. 173-4°. Oxidation of citraconic acid with NaClO<sub>3</sub> and OsO<sub>4</sub> gave C-

methyltartaric acid, m. 144-5° (m. 146°, given by Schmidt and Perkow, C.A. 45, 2412h); Me ester, m. 99-100°; diamide, m. 152-3°. The condensation of NaOEt and Et oxalate with Et  $\beta$ -p-methoxyphenylpropionate, gave Et  $\alpha$ -ethoxalyl- $\beta$ -p-methoxyphenylpropionate. After reduction with moist amalgam, there was isolated Et  $\beta$ -hydroxy- $\alpha$ -p-methoxybenzylsuccinate, b0.1. 75-7°. Hydrolysis with KOH gave a mixture of acids, m. about 130°. Fractional crystallization from EtOAc-light petroleum (b.p. 60-80°) gave racemate A, m. 136-7°, and racemate B, m. 125-6°. A mixture of these racemates with Ac2O gave p-methoxybenzylidenesuccinic anhydride (III), m. 160°, which on boiling with H2O gave p-methoxybenzylidenesuccinic acid (IV), m. and mixed m.p. 194-5° (decomposition). IV was obtained also from the condensation of anisaldehyde, Et succinate, and NaOEt. IV with Ac2O gave III, which by the boiling MeOH-H2SO4 method gave Me p-methoxybenzylidenesuccinate (V), b0.5 165°. Hydrogenation with PdCl2 catalyst of IV gave p-methoxybenzylsuccinic acid (VI) m. 98-101°, and of V gave Me p-methoxybenzylsuccinate, b1 156°, m. 35-7°. Distillation of VI at 180°/0.5 mm. gave the anhydride, m. 91-2°. From p-methoxybenzyl alc. with PCl3 in Et2O there was obtained p-methoxybenzyl chloride as an unstable oil, b25 125-7°, which on condensation with Et sodiomalonate gave Et p-methoxybenzylmalonate (VII), b0.5 145°. There was isolated from BrCH2CO2Et and VII Et  $\alpha$ -ethoxycarbonyl- $\alpha$ -p-methoxybenzylsuccinate, b0.2 166-9° which on heating with EtOH-KOH gave  $\alpha$ -carboxy- $\alpha$ -p-methoxybenzylsuccinic acid, m. 157-9° (decomposition). When this was heated at 160°/25 mm. for 15 min., there was obtained VI. A stirred mixture of N-bromosuccinimide, p-methoxybenzylsuccinic anhydride, benzoyl peroxide, and CCl4 or CS2 as solvent, after refluxing for 12 h., evaporating the filtered mixture and extracting with EtOAc gave III. III was heated until molten, then rapidly poured on to a cold surface, the solid pulverized and refluxed with CS2, collected and washed with more solvent and the process repeated 22 times. Evaporation of the combined CS2 exts. left an orange semisolid which was extracted with Et2O. The residue left on evaporation of Et2O was extracted with light petroleum (b.p. 40-60°) and on cooling, deposited p-methoxybenzylmaleic anhydride (VIII), m. 64-5°, which on recrystn. from CHCl3-light petroleum (b.p. 60-80°), m. 65-6°. VIII reverted to III on melting. Hydrolysis of VIII with H2O gave p-methoxybenzylmaleic acid (IX), m. 120° (sintered at 117°). Addition of pyridine and OsO4 to IX in Et2O and the mixture kept in a closed vessel for 3 days resulted in a brown precipitate, which after collection was treated with aqueous KOH, the solution extracted with Et2O, acidified, evaporated, the residue extracted with Et2O in a Soxhlet apparatus 9 h. and the extract evaporated to obtain p-methoxybenzyltartaric acid (X), m. 205-7° (decomposition); brucine salt,  $[\alpha]_{23.5D} -14.39^\circ \pm 0.6^\circ$  (c 2.96, 50% EtOH). Resolution of X with brucine gave p-O-methylpiscidic acid,  $[\alpha]_{23D} 44.01^\circ \pm 5.0^\circ$  (c 1.262, H2O), m. 169-70° (mixed m.p. with X, 173-6°); cinchonine salt,  $[\alpha]_{17D} 139.6^\circ$  (c 6.1, EtOH); brucine salt,  $[\alpha]_{24D} -13.03^\circ$  (c 2.131, 50% EtOH); Me ester,  $[\alpha]_{18D} 78.16^\circ$  (c 1.54, EtOH). The following derivs. of piscidic acid were cited: Me ester,  $[\alpha]_{23D} 41.52^\circ$  (c 1.325, H2O); Et ester,  $[\alpha]_{17.5D} 59.70^\circ$  (c 1.551, EtOH); di-Me ester,  $[\alpha]_{19D} 23.71^\circ$  (c 6.367, EtOH); Me p-O-benzylpiscidate,  $[\alpha]_{19D} 48.73^\circ$  (c 1.786, EtOH); cinchonine salt,  $[\alpha]_{21D} 146.2^\circ$  (c 0.424, EtOH); (+)-N-methylphenylisopropylamine salt, m. 179°,  $[\alpha]_{24D} 12.73^\circ$  (c 2.09, H2O). Reduction of p-methoxyphenylpyruvic acid in aqueous NaOH with 2% Na-Hg gave p-methoxyphenyllactic acid, m. 88°; Me ester (XI), b0.1 135°. Methylation of XI with Ag2O in MeI gave the Me ether of Me p-methoxyphenyllactate, b0.5 120°.

II Constituents of Cortex piscidia erythrinae. II. Synthesis of O-methylpiscidic acid

SO Journal of the Chemical Society (1954) 3981-6  
 CODEN: JCSOA9; ISSN: 0368-1769

AB cf. C.A. 42, 4981f. Piscidic acid was shown previously to be (+)-p-HOC6H4CH2C(OH)(CO2H)CH(OH)CO2H (loc. cit.) and now has been confirmed by the

synthesis of p-methoxybenzyltartaric acid, identical with natural O-Me piscidic acid. Several routes for the synthesis of tartaric acids of this type were examined Et  $\alpha$ -phenylacetoacetate, b0.8 110° (2,4-dinitrophenylhydrazone, m. 94-5°), prepared by the method of Attwood, et al. (C.A. 17, 3183), with Pb(OAc)<sub>4</sub> in HOAc, gave Et  $\alpha$ -acetoxy- $\alpha$ -phenylacetoacetate, b0.2 128-30°. Similarly, from Et  $\gamma$ -phenylacetoacetate there resulted Et  $\alpha$ -acetoxy- $\gamma$ -phenylacetoacetate (I), b0.5 143-5°. I was obtained also from phenylacetyl bromide, Et diazoacetate, and HOAc. A mixture of I, HCN, and NaOH after 12 h. was diluted with EtOH, saturated with HCl, refluxed 4 h. and filtered to remove NH<sub>4</sub>Cl. The residue after evaporation of the filtrate gave Et benzyltartrate as a mixture which was separated manually into equal amts. of racemate A, m. 174-5° (diamide, 204-6°), and racemate B, m. 194-5° (diamide, m. 185-6°). Reduction of Et phenyloxaloacetate with moist Al amalgam gave Et  $\beta$ -phenylmalate, b0.04 131°, which after hydrolysis with KOH and purification from EtOAc gave  $\beta$ -phenylmalic acid, m. 150-60°. Fractional crystallization from EtOAc gave the racemic isomeride A, m. 172°, and from EtOAc-light petroleum (b.p. 60-80°) the racemic isomeride B, m. 162°. Dehydration with Ac<sub>2</sub>O of a mixture of the isomerides gave phenylmaleic anhydride, m. 120°, which on treatment with alkali gave phenylmaleic acid (II), m. 90-2°. II with pyridine and OsO<sub>4</sub> in Et<sub>2</sub>O gave phenyltartaric acid, m. 173-4°. Oxidation of citraconic acid with NaClO<sub>3</sub> and OsO<sub>4</sub> gave C-methyltartaric acid, m. 144-5° (m. 146°, given by Schmidt and Perkow, C.A. 45, 2412h); Me ester, m. 99-100°; diamide, m. 152-3°. The condensation of NaOEt and Et oxalate with Et  $\beta$ -p-methoxyphenylpropionate, gave Et  $\alpha$ -ethoxalyl- $\beta$ -p-methoxyphenylpropionate. After reduction with moist amalgam, there was isolated Et  $\beta$ -hydroxy- $\alpha$ -p-methoxybenzylsuccinate, b0.1. 75-7°. Hydrolysis with KOH gave a mixture of acids, m. about 130°. Fractional crystallization from EtOAc-light petroleum (b.p. 60-80°) gave racemate A, m. 136-7°, and racemate B, m. 125-6°. A mixture of these racemates with Ac<sub>2</sub>O gave p-methoxybenzylidenesuccinic anhydride (III), m. 160°, which on boiling with H<sub>2</sub>O gave p-methoxybenzylidenesuccinic acid (IV), m. and mixed m.p. 194-5° (decomposition). IV was obtained also from the condensation of anisaldehyde, Et succinate, and NaOEt. IV with Ac<sub>2</sub>O gave III, which by the boiling MeOH-H<sub>2</sub>SO<sub>4</sub> method gave Me p-methoxybenzylidenesuccinate (V), b0.5 165°. Hydrogenation with PdCl<sub>2</sub> catalyst of IV gave p-methoxybenzylsuccinic acid (VI) m. 98-101°, and of V gave Me p-methoxybenzylsuccinate, b1 156°, m. 35-7°. Distillation of VI at 180°/0.5 mm. gave the anhydride, m. 91-2°. From p-methoxybenzyl alc. with PCl<sub>3</sub> in Et<sub>2</sub>O there was obtained p-methoxybenzyl chloride as an unstable oil, b25 125-7°, which on condensation with Et sodiomalonate gave Et p-methoxybenzylmalonate (VII), b0.5 145°. There was isolated from BrCH<sub>2</sub>CO<sub>2</sub>Et and VII Et  $\alpha$ -ethoxycarbonyl- $\alpha$ -p-methoxybenzylsuccinate, b0.2 166-9° which on heating with EtOH-KOH gave  $\alpha$ -carboxy- $\alpha$ -p-methoxybenzylsuccinic acid, m. 157-9° (decomposition). When this was heated at 160°/25 mm. for 15 min., there was obtained VI. A stirred mixture of N-bromosuccinimide, p-methoxybenzylsuccinic anhydride, benzoyl peroxide, and CCl<sub>4</sub> or CS<sub>2</sub> as solvent, after refluxing for 12 h., evaporating the filtered mixture and extracting with EtOAc gave III. III was heated until molten, then rapidly poured on to a cold surface, the solid pulverized and refluxed with CS<sub>2</sub>, collected and washed with more solvent and the process repeated 22 times. Evaporation of the combined CS<sub>2</sub> exts. left an orange semisolid which was extracted with Et<sub>2</sub>O. The residue left on evaporation of Et<sub>2</sub>O was extracted with light petroleum (b.p. 40-60°) and on cooling, deposited p-methoxybenzylmaleic anhydride (VIII), m. 64-5°, which on recrystn. from CHCl<sub>3</sub>-light petroleum (b.p. 60-80°), m. 65-6°. VIII reverted to III on melting. Hydrolysis of VIII with H<sub>2</sub>O gave p-methoxybenzylmaleic acid (IX), m. 120° (sintered at 117°). Addition of pyridine and OsO<sub>4</sub> to IX in Et<sub>2</sub>O and the mixture kept in a closed vessel for 3 days resulted in a brown precipitate, which after collection was treated with aqueous KOH, the solution extracted



with Et<sub>2</sub>O, acidified, evaporated, the residue extracted with Et<sub>2</sub>O in a Soxhlet apparatus 9 h. and the extract evaporated to obtain p-methoxybenzyltartaric acid (X), m. 205-7° (decomposition); brucine salt, [α]<sub>D</sub><sup>23.5</sup> -14.39° ± 0.6° (c 2.96, 50% EtOH). Resolution of X with brucine gave p-O-methylpiscidic acid, [α]<sub>D</sub><sup>23</sup> 44.01° ± 5.0° (c 1.262, H<sub>2</sub>O), m. 169-70° (mixed m.p. with X, 173-6°); cinchonine salt, [α]<sub>D</sub><sup>17</sup> 139.6° (c 6.1, EtOH); brucine salt, [α]<sub>D</sub><sup>24</sup> -13.03° (c 2.131, 50% EtOH); Me ester, [α]<sub>D</sub><sup>18</sup> 78.16° (c 1.54, EtOH). The following derivs. of piscidic acid were cited: Me ester, [α]<sub>D</sub><sup>23</sup> 41.52° (c 1.325, H<sub>2</sub>O); Et ester, [α]<sub>D</sub><sup>17.5</sup> 59.70° (c 1.551, EtOH); di-Me ester, [α]<sub>D</sub><sup>19</sup> 23.71° (c 6.367, EtOH); Me p-O-benzylpiscidate, [α]<sub>D</sub><sup>19</sup> 48.73° (c 1.786, EtOH); cinchonine salt, [α]<sub>D</sub><sup>21</sup> 146.2° (c 0.424, EtOH); (+)-N-

methylphenylisopropylamine salt, m. 179°, [α]<sub>D</sub><sup>24</sup> 12.73° (c 2.09, H<sub>2</sub>O). Reduction of p-methoxyphenylpyruvic acid in aqueous NaOH with 2% Na-Hg gave p-methoxyphenyllactic acid, m. 88°; Me ester (XI), b<sub>0.1</sub> 135°. Methylation of XI with Ag<sub>2</sub>O in MeI gave the Me ether of Me p-methoxyphenyllactate, b<sub>0.5</sub> 120°.

IT 824-94-2P, Anisole, p-(chloromethyl)- 886-30-6P, Succinic anhydride, p-methoxybenzyl- 889-10-1P, Succinic acid, p-methoxybenzylidene- 956-41-2P, Succinic acid, p-methoxybenzyl- 5413-05-8P, Acetoacetic acid, 2-phenyl-, ethyl ester 6335-37-1P, Malonic acid, p-methoxybenzyl-, diethyl ester 10436-75-6P, p-Toluidine, N-isopropyl-, piscidate 15542-71-9P, 1,2,2-Propanetricarboxylic acid, 3-(p-methoxyphenyl)-, triethyl ester 15853-34-6P, Tartaric acid, methyl- 28030-15-1P, Lactic acid, 3-(p-methoxyphenyl)- 42151-36-0P, Succinic acid, p-methoxybenzylidene-, dimethyl ester 46727-01-9P, Succinic anhydride, p-methoxybenzylidene- 55301-58-1P, Lactic acid, 3-(p-methoxyphenyl)-, methyl ester 76595-36-3P, Acetoacetic acid, 2-hydroxy-4-phenyl-, ethyl ester, acetate 184242-36-2P, Oxalacetic acid, p-methoxybenzyl-, diethyl ester 474317-22-1P, Malic acid, 3-phenyl-, di-Et ester 792942-87-1P, Succinic acid, p-methoxybenzyl-, dimethyl ester 845886-49-9P, Tartaric acid, methyl-, dimethyl ester 855644-88-1P, Maleic anhydride, p-methoxybenzyl- 857232-37-2P, 1,2,2-Propanetricarboxylic acid, 3-(p-methoxyphenyl)- 857559-71-8P, Acetoacetic acid, 2-hydroxy-2-phenyl-, ethyl ester, acetate 858215-84-6P, Hydrocinnamic acid, p,α-dimethoxy-, methyl ester 860373-79-1P, Malic acid, 3-p-methoxybenzyl-, di-Et ester 861067-75-6P, Acetoacetic acid, 2-phenyl-, ethyl ester, 2,4-dinitrophenylhydrazone 874506-60-2P, Tartramide, 2-methyl- 874506-62-4P, Tartaric acid, [p-(benzyloxy)benzyl]-, dimethyl ester 883310-90-5P, Maleic acid, p-methoxybenzyl- 907575-67-1P, Cinchonine, compound with piscidic acid 907575-84-2P, Cinchonine, compound with p-O-methylpiscidic acid

RL: PREP (Preparation)

(preparation of)

L9 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1955:19917 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 49:19917

ORIGINAL REFERENCE NO.: 49:3885i,3886a-i,3887a-e

TITLE: Synthetic experiments connected with lignin

AUTHOR(S): Freudenberg, Karl; Muller, Heinz G.

CORPORATE SOURCE: Univ. Heidelberg, Germany

SOURCE: Annalen der Chemie, Justus Liebig's (1953), 584, 40-53

CODEN: 9X224Y

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

OTHER SOURCE(S): CASREACT 49:19917

AB The following model substances are in part related to the dimers obtained by F. in expts. with coniferyl alc. (C.A. 47, 12296g), which are considered "secondary building stones" in lignin formation. Veratraldehyde condensed with  $\text{CH}_2(\text{CO}_2\text{H})_2$  gave quant. yields of 3,4-(MeO) $_2$ C $_6$ H $_3$ CH:CHCO $_2$ H, whose Et ester (obtained in 94% yield) with Br in  $\text{CHCl}_3$  in artificial light yielded the dibromide, m. 110°; this was refluxed 7-8 hrs. with 3 moles KOH in alc., cooled, filtered, neutralized gradually (at about 0°) with concentrated HCl, refiltered, and concentrated in vacuo. Any salts that had been filtered, combined with those separating on concentration, were dissolved in H $_2$ O and acidified with 20% H $_2$ SO $_4$ , giving 20-30% 3,4-(MeO) $_2$ C $_6$ H $_3$ C.tplbond.CCO 2H (I), m. 156° (Fulton and Robinson, J. Chemical Society 1903, 1463). Carefully purified 4,3-Me(MeO)C $_6$ H $_3$ OH (13.8 g.) and 50 cc. MeOH containing 2.3 g. Na, evaporated in vacuo, heated 5 hrs. at 100° with 22 g. I Me ester, 50 cc. PhMe, and 13.8 g. creosol, allowed to stand 12 hrs. at room temperature, extracted with Et $_2$ O, shaken repeatedly with aqueous H $_2$ SO $_4$ , and the excess creosol extracted from the Et $_2$ O with aqueous NaOH, followed by washing, drying, evaporation, and fractionation, gave 17 g. Me  $\beta$ -(3-methoxy-4-methylphenoxy)-3,4-dimethoxycinnamate (II), prisms, m. 107-8°. At -70 to -80°, 5 g. crude II in 100 cc. dry Et $_2$ O with 0.3 g. LiAlH $_4$  in 26 cc. Et $_2$ O gave a precipitate which, when decomposed with H $_2$ SO $_4$ , yielded a mixture of creosol, dimethoxycinnamyl alc. (III), and  $\alpha$ -(2-methoxy-4-methylphenoxy)-3,4-dimethoxycinnamyl alcohol (IV). III and IV could not be separated by distillation, or by adsorption in C $_6$ H $_6$  on Al $_2$ O $_3$  but the separation was effected on a paper chromatogram with C $_6$ H $_6$  (R $_f$  of III and IV being 0 and 0.9, resp.). IV was noncryst., but gave a red, crystalline p-PhN $_2$ C $_6$ H $_4$ CO derivative, m. 118-19°; and a crystalline phenyl-urethan, m. 134-5°. The phenylurethan of III m. 107-8°. PhOCH $_2$ CO $_2$ Me (22 g.) and 14 g. BzH reacted vigorously with 3 g. Na wire and 40 cc. dry Et $_2$ O. After 12 hrs. 8.2 g. glacial AcOH, 60 cc. H $_2$ O, and 20 cc. Et $_2$ O were added successively, giving 38% PhCH(OH)CH(OPh)CO $_2$ Na (V), the Et $_2$ O and alc. washings from which, when concentrated and esterified, yielded 48% PhCH:C(OPh)CO $_2$ Me (VI), bll 210°, m. 60-1°. The free acid from V, oil (not characterized) gave the Me ester (VII), m. 61° (from petr. ether); Ac derivative of VII, m. 69-70°; S-benzylthiuronium salt (corresponding to V), m. 188°. VI in Et $_2$ O, under N at -70° with LiAlH $_4$ , gradually warmed to -20° with aqueous H $_2$ SO $_4$  gave PhCH:C(OPh)CH $_2$ OH, viscous oil; phenyl urethan, m. 104°. VII, similarly reduced (at -20°) gave PhCH(OH)CH(OPh)CH $_2$ OH, b1 197°, m. 74-5°. Using Giacosa's technique [J. prakt. Chemical 19, 396(1879)] but with longer initial heating, creosol, ClCH $_2$ CO $_2$ H, and NaOH gave 67% 4,2-Me(MeO)C $_6$ H $_3$ OCH $_2$ CO $_2$ H, m. 115°; Me ester (VIII), bll 167°; amide, m. 134-5°. Veratraldehyde (15.8 g.), 20 g. VIII, and 2.2 g. powdered Na under Et $_2$ O, first cooled, then heated several hrs. on a steam bath and acidified with AcOH, gave 3,4-(MeO) $_2$ C $_6$ H $_3$ CH:CHCO $_2$ Me (IX) [R in this and other compds. = 4,2-Me(MeO)C $_6$ H $_3$ O], which, reduced with LiAlH $_4$  at -70° yielded the alc., C $_{19}$ H $_{22}$ O $_5$  (isolated by treating the intermediate salt, under Et $_2$ O, with Dry Ice), oil, setting to a resin; 3,5-dinitrobenzoate, yellow needles, m. 158-9° (from BuOH). When 15.8 g. veratraldehyde, 20 g. VIII, 2.2 g. Na, and 50 cc. Et $_2$ O were kept at about 0° and then acidified with aqueous AcOH, the product was a mixture, b0.01 225°, of IX and 3,4-(MeO) $_2$ C $_6$ H $_3$ (OH)CHRCO $_2$ Me, m. 137° (from aqueous MeOH). To 8 g. Na (powdered under 100 cc. absolute PhMe) were added successively 25 g. abs EtOH and 50 g. vanillin, and the resulting Na derivative was filtered, triturated with and suspended in PhMe, well-cooled, and treated with freshly distilled ClCH $_2$ OMe; this kept at least 6 hrs. at room temperature, washed with 2% NaOH, and fractionated gave 41 g. methoxymethylvanillin (X), b1.5 145-7°, m. 39-40°. Freshly prepared X (9.8 g.) fused with 10.5 g. VIII, the product cooled, treated with 1.15 g. Na wire and 40 cc. Et $_2$ O, allowed to stand overnight, 3.1 g. AcOH in 40 cc. H $_2$ O added, and the mixture extracted with Et $_2$ O gave 9 g. 4,3-(MeOCH $_2$ )(MeO)C $_6$ H $_3$ CH(OH)CHRCO $_2$ Me, b0.05 175-7°. With 30 g. 14-day-old X (or with fresh X containing small amts. of vanillin), the reaction was sluggish and required heating for completion, giving as the principal product 3,4-

MeO(MeOCH<sub>2</sub>O)C<sub>6</sub>H<sub>3</sub>CH:CRCO<sub>2</sub>Me (XI), m. 112-13° (from aqueous MeOH). With a drop of H<sub>2</sub>SO<sub>4</sub>, AcOH, and Ac<sub>2</sub>O, 2 g. XI at 0° gave, after 1.5 hrs., 1.3 g. 3,4-MeO(AcO)C<sub>6</sub>H<sub>3</sub>CH:CRCO<sub>2</sub>Me (XII), m. 80° (from aqueous EtOH); when cooling was omitted, but the reaction continued for 8 hrs., the yield of XII was 87%. XII reduced with LiAlH<sub>4</sub> under N at -20°, followed by a fully described extensive purification, including chromatographic fractionation on powdered cellulose, gave 3,4-MeO(HO)C<sub>6</sub>H<sub>3</sub>CH:CRCH<sub>2</sub>OH (XIII), b0.0001 140° (bath temperature), prisms, m. 90-1° (from CH<sub>2</sub>Cl<sub>2</sub>-petr. ether). Hydrogenated in MeOH with 5% Pd - BaSO<sub>4</sub>, XII gave the dihydro derivative, C<sub>21</sub>H<sub>24</sub>C<sub>7</sub>, b0.01 197°, which, reduced with LiAlH<sub>4</sub>, yielded the dihydro derivative of XIII, C<sub>18</sub>H<sub>22</sub>O<sub>5</sub>, b0.01 150°. Vanillin (10 g.), 6.25 g. CH<sub>2</sub>ClCO<sub>2</sub>H, 8.5 g. KOH, and 30 cc. H<sub>2</sub>O heated 4 hrs. at 100° and acidified with aqueous HCl gave quantitatively 2,4-MeO(OHC)C<sub>6</sub>H<sub>3</sub>OCH<sub>2</sub>CO<sub>2</sub>H, m. 188-9° [Elkan, Ber. 19, 3045(1886)], 8 g. of which with 10 g. CH<sub>2</sub>(CO<sub>2</sub>H)<sub>2</sub> in 50 cc. pyridine containing small amts. of piperidine heated 2 hrs. at 100° yielded quantitatively 3,4-MeO(HO<sub>2</sub>CCH<sub>2</sub>O)C<sub>6</sub>H<sub>3</sub>CH:CHCO<sub>2</sub>H, m. 234° (also formed in 73% yield from ferulic acid, CH<sub>2</sub>ClCO<sub>2</sub>H and NaOH); di-Me ester (XIV), m. 104-5°. Veratraldehyde, (3 g.), 5 g. XIV, 0.41 g. Na powder, 20 cc. Et<sub>2</sub>O, and several drops absolute MeOH, heated several hrs. and acidified with aqueous AcOH, gave 2 g. Me α-[2-methoxy-4-(β-carbomethoxyvinyl)phenoxy]-3,4-dimethoxycinnamate, b0.01 260°, m. 129°. XIV and X refluxed with Na in Et<sub>2</sub>O gave, after acidification and fractionation of the Et<sub>2</sub>O extract, 31% Me O-methoxymethyl-α-[2-methoxy-4-(β-carbomethoxyvinyl)phenoxy]ferulate (XV), b0.01 275°, m. 100-1° (from MeOH). By replacing the MeOCH<sub>2</sub> group in XV by Ac, the O-Ac analog (XVI), C<sub>24</sub>H<sub>24</sub>O<sub>9</sub>, b0.0001 180° (bath temperature), m. 117-18°, was formed. XVI (18 g.) in Et<sub>2</sub>O reduced by stepwise addition of LiAlH<sub>4</sub> at room temperature, followed by adding moist Et<sub>2</sub>O, Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub>, and Dry Ice to the aqueous phase, and fractionation in high vacuum of the Et<sub>2</sub>O extract, gave about 100 mg. resinous. 3,4-MeO[3,4-MeO(HO)C<sub>6</sub>H<sub>3</sub>CH:C(CH<sub>2</sub>OH)O]C<sub>6</sub>H<sub>3</sub>CH:CHCH<sub>2</sub>OH (XVII). The tetrahydro derivative of XVI, sirup, b0.001 160° (bath temperature); the tetrahydro derivative of XVII, colorless sirup, b0.001 150° (bath temperature). Inasmuch as both acetone-lignin and the dehydrogenation polymers of coniferyl alc. yielded 1.5-2% HCHO when distilled with H<sub>2</sub>SO<sub>4</sub>, a similar treatment was applied to a number of the synthetic compds. listed above. None of these gave more than faint traces of HCHO, with the single exception of PhCH(OH)CH(OPh)CH<sub>2</sub>OH, which yielded 1.3% HCHO. From this and previous studies (C.A. 42, 882a). F. and M. have indicated what types of structure, in O-containing derivs. of PhPr, are capable of giving rise to HCHO. 19 references.

TI Synthetic experiments connected with lignin

SO Annalen der Chemie, Justus Liebig's (1953), 584, 40-53

CODEN: 9X224Y

AB The following model substances are in part related to the dimers obtained by F. in expts. with coniferyl alc. (C.A. 47, 12296g), which are considered "secondary building stones" in lignin formation. Veratraldehyde condensed with CH<sub>2</sub>(CO<sub>2</sub>H)<sub>2</sub> gave quant. yields of 3,4-(MeO)<sub>2</sub>C<sub>6</sub>H<sub>3</sub>CH:CHCO<sub>2</sub>H, whose Et ester (obtained in 94% yield) with Br in CHCl<sub>3</sub> in artificial light yielded the dibromide, m. 110°; this was refluxed 7-8 hrs. with 3 moles KOH in alc., cooled, filtered, neutralized gradually (at about 0°) with concentrated HCl, refiltered, and concentrated in vacuo. Any salts that had been filtered, combined with those separating on concentration, were dissolved in H<sub>2</sub>O and acidified with 20% H<sub>2</sub>SO<sub>4</sub>, giving 20-30% 3,4-(MeO)<sub>2</sub>C<sub>6</sub>H<sub>3</sub>C.tplbond.CCO<sub>2</sub>H (I), m. 156° (Fulton and Robinson, J. Chemical Society 1903, 1463). Carefully purified 4,3-Me(MeO)C<sub>6</sub>H<sub>3</sub>OH (13.8 g.) and 50 cc. MeOH containing 2.3 g. Na, evaporated in vacuo, heated 5 hrs. at 100° with 22 g. I Me ester, 50 cc. PhMe, and 13.8 g. creosol, allowed to stand 12 hrs. at room temperature, extracted with Et<sub>2</sub>O, shaken repeatedly with aqueous H<sub>2</sub>SO<sub>4</sub>, and the excess creosol extracted from the Et<sub>2</sub>O with aqueous NaOH, followed by washing, drying, evaporation, and fractionation, gave 17 g. Me β-(3-methoxy-4-methylphenoxy)-3,4-dimethoxycinnamate (II), prisms, m. 107-8°. At -70 to -80°, 5 g. crude II

in 100 cc. dry Et<sub>2</sub>O with 0.3 g. LiAlH<sub>4</sub> in 26 cc. Et<sub>2</sub>O gave a precipitate which, when decomposed with H<sub>2</sub>SO<sub>4</sub>, yielded a mixture of creosol, dimethoxycinnamyl alc. (III), and α-(2-methoxy-4-methylphenoxy)-3,4-dimethoxycinnamyl alcohol (IV). III and IV could not be separated by distillation, or by adsorption in C<sub>6</sub>H<sub>6</sub> on Al<sub>2</sub>O<sub>3</sub> but the separation was effected on a paper chromatogram with C<sub>6</sub>H<sub>6</sub> (R<sub>f</sub> of III and IV being 0 and 0.9, resp.). IV was noncryst., but gave a red, crystalline p-PhN<sub>2</sub>C<sub>6</sub>H<sub>4</sub>CO derivative, m. 118-19°; and a crystalline phenyl-urethan, m. 134-5°. The phenylurethan of III m. 107-8°. PhOCH<sub>2</sub>CO<sub>2</sub>Me (22 g.) and 14 g. BzH reacted vigorously with 3 g. Na wire and 40 cc. dry Et<sub>2</sub>O. After 12 hrs. 8.2 g. glacial AcOH, 60 cc. H<sub>2</sub>O, and 20 cc. Et<sub>2</sub>O were added successively, giving 38% PhCH(OH)CH(OPh)CO<sub>2</sub>Na (V), the Et<sub>2</sub>O and alc. washings from which, when concentrated and esterified, yielded 48% PhCH:C(OPh)CO<sub>2</sub>Me (VI), b<sub>11</sub> 210°, m. 60-1°. The free acid from V, oil (not characterized) gave the Me ester (VII), m. 61° (from petr. ether); Ac derivative of VII, m. 69-70°; S-benzylthiuronium salt (corresponding to V), m. 188°. VI in Et<sub>2</sub>O, under N at -70° with LiAlH<sub>4</sub>, gradually warmed to -20° with aqueous H<sub>2</sub>SO<sub>4</sub> gave PhCH:C(OPh)CH<sub>2</sub>OH, viscous oil; phenyl urethan, m. 104°. VII, similarly reduced (at -20°) gave PhCH(OH)CH(OPh)CH<sub>2</sub>OH, b<sub>1</sub> 197°, m. 74-5°. Using Giacosa's technique [J. prakt. Chemical 19, 396(1879)] but with longer initial heating, creosol, ClCH<sub>2</sub>CO<sub>2</sub>H, and NaOH gave 67% 4,2-Me(MeO)C<sub>6</sub>H<sub>3</sub>OCH<sub>2</sub>CO<sub>2</sub>H, m. 115°; Me ester (VIII), b<sub>11</sub> 167°; amide, m. 134-5°. Veratraldehyde (15.8 g.), 20 g. VIII, and 2.2 g. powdered Na under Et<sub>2</sub>O, first cooled, then heated several hrs. on a steam bath and acidified with AcOH, gave 3,4-(MeO)<sub>2</sub>C<sub>6</sub>H<sub>3</sub>CH:CRCO<sub>2</sub>Me (IX) [R in this and other compds. = 4,2-Me(MeO)C<sub>6</sub>H<sub>3</sub>O], which, reduced with LiAlH<sub>4</sub> at -70° yielded the alc., C<sub>19</sub>H<sub>22</sub>O<sub>5</sub> (isolated by treating the intermediate salt, under Et<sub>2</sub>O, with Dry Ice), oil, setting to a resin; 3,5-dinitrobenzoate, yellow needles, m. 158-9° (from BuOH). When 15.8 g. veratraldehyde, 20 g. VIII, 2.2 g. Na, and 50 cc. Et<sub>2</sub>O were kept at about 0° and then acidified with aqueous AcOH, the product was a mixture, b<sub>0.01</sub> 225°, of IX and 3,4-(MeO)<sub>2</sub>C<sub>6</sub>H<sub>3</sub>(OH)CHRCO<sub>2</sub>Me, m. 137° (from aqueous MeOH). To 8 g. Na (powdered under 100 cc. absolute PhMe) were added successively 25 g. abs EtOH and 50 g. vanillin, and the resulting Na derivative was filtered, triturated with and suspended in PhMe, well-cooled, and treated with freshly distilled ClCH<sub>2</sub>OMe; this kept at least 6 hrs. at room temperature, washed with 2% NaOH, and fractionated gave 41 g. methoxymethylvanillin (X), b<sub>1.5</sub> 145-7°, m. 39-40°. Freshly prepared X (9.8 g.) fused with 10.5 g. VIII, the product cooled, treated with 1.15 g. Na wire and 40 cc. Et<sub>2</sub>O, allowed to stand overnight, 3.1 g. AcOH in 40 cc. H<sub>2</sub>O added, and the mixture extracted with Et<sub>2</sub>O gave 9 g. 4,3-(MeOCH<sub>2</sub>)(MeO)C<sub>6</sub>H<sub>3</sub>CH(OH)CHRCO<sub>2</sub>Me, b<sub>0.05</sub> 175-7°. With 30 g. 14-day-old X (or with fresh X containing small amts. of vanillin), the reaction was sluggish and required heating for completion, giving as the principal product 3,4-MeO(MeOCH<sub>2</sub>)C<sub>6</sub>H<sub>3</sub>CH:CRCO<sub>2</sub>Me (XI), m. 112-13° (from aqueous MeOH). With a drop of H<sub>2</sub>SO<sub>4</sub>, AcOH, and Ac<sub>2</sub>O, 2 g. XI at 0° gave, after 1.5 hrs., 1.3 g. 3,4-MeO(AcO)C<sub>6</sub>H<sub>3</sub>CH:CRCO<sub>2</sub>Me (XII), m. 80° (from aqueous EtOH); when cooling was omitted, but the reaction continued for 8 hrs., the yield of XII was 87%. XII reduced with LiAlH<sub>4</sub> under N at -20°, followed by a fully described extensive purification, including chromatographic fractionation on powdered cellulose, gave 3,4-MeO(HO)C<sub>6</sub>H<sub>3</sub>CH:CRCH<sub>2</sub>OH (XIII), b<sub>0.0001</sub> 140° (bath temperature), prisms, m. 90-1° (from CH<sub>2</sub>Cl<sub>2</sub>-petr. ether). Hydrogenated in MeOH with 5% Pd - BaSO<sub>4</sub>, XII gave the dihydro derivative, C<sub>21</sub>H<sub>24</sub>C<sub>7</sub>, b<sub>0.01</sub> 197°, which, reduced with LiAlH<sub>4</sub>, yielded the dihydro derivative of XIII, C<sub>18</sub>H<sub>22</sub>O<sub>5</sub>, b<sub>0.01</sub> 150°. Vanillin (10 g.), 6.25 g. CH<sub>2</sub>ClCO<sub>2</sub>H, 8.5 g. KOH, and 30 cc. H<sub>2</sub>O heated 4 hrs. at 100° and acidified with aqueous HCl gave quantitatively 2,4-MeO(OHC)C<sub>6</sub>H<sub>3</sub>OCH<sub>2</sub>CO<sub>2</sub>H, m. 188-9° [Elkan, Ber. 19, 3045(1886)], 8 g. of which with 10 g. CH<sub>2</sub>(CO<sub>2</sub>H)<sub>2</sub> in 50 cc. pyridine containing small amts. of piperidine heated 2 hrs. at 100° yielded quantitatively 3,4-MeO(HO<sub>2</sub>CCH<sub>2</sub>O)C<sub>6</sub>H<sub>3</sub>CH:CHCO<sub>2</sub>H, m. 234° (also formed in 73% yield from ferulic acid, CH<sub>2</sub>ClCO<sub>2</sub>H and NaOH); di-Me ester (XIV), m. 104-5°. Veratraldehyde, (3 g.), 5 g. XIV, 0.41 g. Na powder, 20 cc. Et<sub>2</sub>O, and several drops absolute MeOH, heated several hrs. and

acidified with aqueous AcOH, gave 2 g. Me  $\alpha$ -[2-methoxy-4-( $\beta$ -carbomethoxyvinyl)phenoxy]-3,4-dimethoxycinnamate, b0.01 260°, m. 129°. XIV and X refluxed with Na in Et2O gave, after acidification and fractionation of the Et2O extract, 31% Me O-methoxymethyl- $\alpha$ -[2-methoxy-4-( $\beta$ -carbomethoxyvinyl)phenoxy]ferulate (XV), b0.01 275°, m. 100-1° (from MeOH). By replacing the MeOCH2 group in XV by Ac, the O-Ac analog (XVI), C24H24O9, b0.0001 180° (bath temperature), m. 117-18°, was formed. XVI (18 g.) in Et2O reduced by stepwise addition of LiAlH4 at room temperature, followed by adding moist Et2O, Na2S2O4, and Dry Ice to the aqueous phase, and fractionation in high vacuum of the Et2O extract, gave about 100 mg. resinous. 3,4-MeO[3,4-MeO(HO)C6H3CH:C(CH2OH)O] C6H3CH:CHCH2OH (XVII). The tetrahydro derivative of XVI, sirup, b0.001 160° (bath temperature); the tetrahydro derivative of XVII, colorless sirup, b0.001 150° (bath temperature). Inasmuch as both acetone-lignin and the dehydrogenation polymers of coniferyl alc. yielded 1.5-2% HCHO when distilled with H2SO4, a similar treatment was applied to a number of the synthetic compds. listed above. None of these gave more than faint traces of HCHO, with the single exception of PhCH(OH)CH(OPh)CH2OH, which yielded 1.3% HCHO. From this and previous studies (C.A. 42, 882a). F. and M. have indicated what types of structure, in O-containing derivs. of PhPr, are capable of giving rise to HCHO. 19 references.

IT 1660-19-1P, Acetic acid, (4-formyl-2-methoxyphenoxy)- 2316-26-9P, Cinnamic acid, 3,4-dimethoxy- 5533-00-6P, Veratraldehyde,  $\alpha$ 4-methoxy- 6270-23-1P, Acetic acid, (2-methoxy-p-tolyloxy)- 18523-76-7P, 2-Propen-1-ol, 3-(3,4-dimethoxyphenyl)- 20583-78-2P, Cinnamic acid, 3,4-dimethoxy-, ethyl ester 22511-06-4P, Propiolic acid, (3,4-dimethoxyphenyl)- 41247-45-4P, 2-Propen-1-ol, 3-(4-hydroxy-3-methoxyphenyl)-2-(2-methoxy-p-tolyloxy)- 53505-68-3P, 1-Propanol, 3-(4-hydroxy-3-methoxyphenyl)-2-[4-(3-hydroxypropyl)-2-methoxyphenoxy]- 62497-24-9P, Propiolic acid, (3,4-dimethoxyphenyl)-, methyl ester 70110-65-5P, 1,3-Propanediol, 2-phenoxy-1-phenyl- 84159-61-5P, Acetic acid, (2-methoxy-p-tolyloxy)-, methyl ester 99873-50-4P, Hydrocinnamic acid,  $\alpha,\beta$ -dibromo-3,4-dimethoxy-, ethyl ester 100519-48-0P, Cinnamic acid, 4-(carboxymethoxy)-3-methoxy- 102448-71-5P, Ferulic acid,  $\alpha$ -(2-methoxy-p-tolyloxy)-, methyl ester, acetate 102448-71-5P, Hydroferulic acid,  $\alpha$ -(2-methoxy-p-tolyloxy)-, methyl ester, acetate 102596-16-7P, Cinnamic acid, 3-methoxy-4-(methoxymethoxy)- $\alpha$ -(2-methoxy-p-tolyloxy)-, methyl ester 102749-35-9P, Cinnamic acid, 4-hydroxy- $\alpha,4'$ -oxybis[3-methoxy-, dimethyl ester, acetate 102749-35-9P, Ferulic acid,  $\alpha$ -[4-(2-carboxyvinyl)-2-methoxyphenoxy]-, dimethyl ester, acetate 198897-12-0P, Cinnamic acid, 4-(carboxymethoxy)-3-methoxy-, dimethyl ester 854884-24-5P, Cinnamic acid,  $\alpha$ -phenoxy-, methyl ester 854888-06-5P, Cinnamic acid, 3,3',4'-trimethoxy- $\alpha,4'$ -oxydi-, dimethyl ester 856179-22-1P, Cinnamic acid, 4-(methoxymethoxy)- $\alpha,4'$ -oxybis[3-methoxy-, dimethyl ester 856818-05-8P, 1-Propanol, 3-(4-hydroxy-3-methoxyphenyl)-2-(2-methoxy-p-tolyloxy)- 857231-66-4P, 2-Propen-1-ol, 2-phenoxy-3-phenyl-, carbanilate 857234-56-1P, 2-Propen-1-ol, 3-(4-hydroxy-3-methoxyphenyl)-2-[4-(3-hydroxypropenyl)-2-methoxyphenoxy]- 857946-32-8P, Acetamide, 2-(2-methoxy-p-tolyloxy)- 858207-72-4P, Hydracrylic acid, 3-(3,4-dimethoxyphenyl)-2-(2-methoxy-p-tolyloxy)-, methyl ester 858207-82-6P, Hydracrylic acid, 3-[3-methoxy-4-(methoxymethoxy)phenyl]-2-(2-methoxy-p-tolyloxy)-, methyl ester 858217-33-1P, Hydrocinnamic acid, 4-hydroxy- $\alpha,4'$ -oxybis[3-methoxy-, dimethyl ester, acetate 859056-37-4P, 2-Propen-1-ol, 2-phenoxy-3-phenyl- 859056-69-2P, 2-Propen-1-ol, 3-(3,4-dimethoxyphenyl)-2-(2-methoxy-p-tolyloxy)-, 3,5-dinitrobenzoate 859056-72-7P, 2-Propen-1-ol,

3-(3,4-dimethoxyphenyl)-, carbanilate 859060-89-2P, Pseudourea, 2-benzyl-2-thio-, compound with 2-phenoxy-3-phenylhydracrylic acid 860257-90-5P, Hydroferulic acid,  $\alpha$ -[4-(2-carboxyethyl)-3-methoxyphenoxy]-, dimethyl ester, acetate 873410-58-3P, Benzoic acid, p-phenylazo-, 3,4-dimethoxy- $\gamma$ -(2-methoxy-p-tolyloxy)cinnamyl ester 874009-71-9P, 2-Propen-1-ol, 3-(3,4-dimethoxyphenyl)-2-(2-methoxy-p-tolyloxy)-

RL: PREP (Preparation)

(preparation of)

L9 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1953:72704 CAPLUS Full-text

DOCUMENT NUMBER: 47:72704

ORIGINAL REFERENCE NO.: 47:12323b-i,12324a-h

TITLE: Aliphatic nitro compounds. IV. Various addition and condensation reactions of ethyl nitroacetate

AUTHOR(S): Dornow, Alfred; Frese, Albert

CORPORATE SOURCE: Tech. Hochschule, Hannover, Germany

SOURCE: Annalen der Chemie, Justus Liebig's (1952),

578, 122-36

CODEN: 9X224Y

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

OTHER SOURCE(S): CASREACT 47:72704

GI For diagram(s), see printed CA Issue.

AB O<sub>2</sub>NCH<sub>2</sub>CO<sub>2</sub>Et (I) (prepared by Steinkopf's method, C.A. 18, 377) added  $\alpha,\beta$ -unsatd. ketones at room temperature, with Et<sub>2</sub>NH (II) or PhCH<sub>2</sub>NH<sub>3</sub>OH (III) as catalysts. In ligroine, I and PhCH:CHAc with II gave 92% [AcCH<sub>2</sub>CHPhC(NO<sub>2</sub>)(CO<sub>2</sub>Et)]NH<sub>2</sub>Et<sub>2</sub> (IV), m. 114°. Similarly I, II, and PhCH<sub>2</sub>:CHNO<sub>2</sub> gave the NH<sub>2</sub>Et<sub>2</sub> salt of Et 2-aci-2,4-dinitro-3-phenylbutyrate (V), m. 98° (and traces of polynitrostyrene). V (96% was also formed from equivalent amts. of Ph(PhNH)CHCH<sub>2</sub>NO<sub>2</sub>, I, and II, in ligroine and Et<sub>2</sub>O; in the absence of Et<sub>2</sub>O, polynitrostyrene is a by-product. I (3.7 g.), 2-cc. of 40% III, 4 cc. dioxane, and 4 g. PhCH:CHCO<sub>2</sub>Et, kept 3 days at 60°, then at 0°, and the mixture acidified with N HCl and extracted with Et<sub>2</sub>O gave 66% EtO<sub>2</sub>CCCH(NO<sub>2</sub>)CHPhCH<sub>2</sub>CO<sub>2</sub>Et, b<sub>1</sub> 176-8°. PhCH:CHAc and I with III gave, after 14 days, a brown smear from which only 30 mg. of the PhCh<sub>2</sub>NMe<sub>2</sub> analog of V, m. 175°, could be isolated by Et<sub>2</sub>O extraction. The residual Et<sub>2</sub>O extract treated with II gave 54% V. I, II, and (PhN:)<sub>2</sub> yielded 82% of the adduct C<sub>20</sub>H<sub>28</sub>O<sub>4</sub>N<sub>4</sub>, m. 88°. In ligroine or petr. ether, I with a variety of Schiff bases in the presence of II yielded unstable adducts [R<sub>1</sub>HNC<sub>2</sub>HRC(NO<sub>2</sub>)CO<sub>2</sub>Et]NH<sub>2</sub>Et<sub>2</sub> (VI), in which R and R<sub>1</sub> are usually aryl groups, given in the following table. Schiff base used, Yield of, VI %, Decomposition, °C., Formula of VI; PhN:CHPh, 99, 106, (VIa) C<sub>21</sub>H<sub>29</sub>O<sub>4</sub>N<sub>3</sub>; p-MeC<sub>6</sub>H<sub>4</sub>N:CHPh, 94, 86, (VIb) C<sub>22</sub>H<sub>31</sub>O<sub>4</sub>N<sub>3</sub>; p-EtOC<sub>6</sub>H<sub>4</sub>N:CHPh, 96, 106, (VIc) C<sub>23</sub>H<sub>33</sub>O<sub>5</sub>N<sub>3</sub>; m-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>N:CHPh, 93, 109, (VId) C<sub>21</sub>H<sub>28</sub>O<sub>6</sub>N<sub>4</sub>; p-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>N:CHPh, 95, 120, (VIe) C<sub>21</sub>H<sub>28</sub>O<sub>6</sub>N<sub>4</sub>; MeN:CHPh, 97, 78, (VIf) C<sub>16</sub>H<sub>27</sub>O<sub>4</sub>N<sub>3</sub>; o-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CH:NPh, 95, 105, (VIg) C<sub>21</sub>H<sub>27</sub>O<sub>6</sub>N<sub>4</sub>; m-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CH:NPh, 96, 113, (VIh) C<sub>21</sub>H<sub>28</sub>O<sub>6</sub>N<sub>4</sub>; p-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CH:NPh, 86, 105, (VIi) C<sub>21</sub>H<sub>28</sub>O<sub>6</sub>N<sub>4</sub>; m-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CH:NC<sub>6</sub>H<sub>4</sub>Me-p, Too unstable for isolation; o-HOC<sub>6</sub>H<sub>4</sub>CH:NPh, " " " "; 2,1-HOC<sub>10</sub>H<sub>6</sub>CH:NPh, " " " "; p-HOC<sub>6</sub>H<sub>4</sub>CH:NPh, " " " "; p-MeOC<sub>6</sub>H<sub>4</sub>CH:NPh, " " " "; o-ClC<sub>6</sub>H<sub>4</sub>CH:NPh, 98, 108, (VIj) C<sub>21</sub>H<sub>28</sub>O<sub>4</sub>N<sub>3</sub>Cl; p-ClC<sub>6</sub>H<sub>4</sub>CH:NPh, 99, 84, (VIk) C<sub>21</sub>H<sub>28</sub>O<sub>4</sub>N<sub>3</sub>Cl; N-(2-Pyridylmethylene)-p-phenetidine, 95, 86, (VIl) C<sub>22</sub>H<sub>32</sub>O<sub>5</sub>N<sub>4</sub>; N-(3-Pyridylmethylene)-p-phenetidine, 82, 103, (VIIm) C<sub>22</sub>H<sub>32</sub>O<sub>5</sub>N<sub>4</sub>; N-furfurylidene-p-phenetidine, 85, 112, (VIIn) C<sub>21</sub>H<sub>31</sub>O<sub>6</sub>N<sub>3</sub>; Attempts to precipitate the VI in CHCl<sub>3</sub> with petr. ether, or solution in alc. (or Et<sub>2</sub>O) caused decomposition to the corresponding Et<sub>2</sub>NH salts (VII) of RCH[CH(NO<sub>2</sub>)CO<sub>2</sub>Et]<sub>2</sub> (R = aryl). Thus VIa, VIb, VIc, VId, and VIe yielded resp. 94-98, 95, 92, 89, and 84% VIIa, C<sub>19</sub>H<sub>29</sub>O<sub>8</sub>N<sub>3</sub>, m. 129° (decomposition). VIg gave 82% (VIIb) C<sub>19</sub>H<sub>28</sub>O<sub>10</sub>N<sub>4</sub>, m. 126°. VIh gave 90% VIIc C<sub>19</sub>H<sub>28</sub>O<sub>10</sub>N<sub>4</sub>, m. 121°.

VII gave 82% VIId, C<sub>19</sub>H<sub>28</sub>O<sub>10</sub>N<sub>4</sub>, m. 125°. From m-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CH:NC<sub>6</sub>H<sub>4</sub>Me-p was formed 95% VIId, m. 121°; from o-HOC<sub>6</sub>H<sub>4</sub>CH:NPh, 90% VIId, C<sub>19</sub>H<sub>29</sub>O<sub>9</sub>N<sub>3</sub>, m. 128°; from p-HOC<sub>6</sub>H<sub>4</sub>CH:NPh, 64%, VIId, C<sub>19</sub>H<sub>29</sub>O<sub>9</sub>N<sub>3</sub>, m. 119°; from p-MeOC<sub>6</sub>H<sub>4</sub>CH:NPh, 72% VIId, C<sub>20</sub>H<sub>31</sub>O<sub>9</sub>N<sub>3</sub>, m. 95-7°. The product from 2-HOC<sub>10</sub>H<sub>6</sub>CH:NPh could not be isolated. VIj gave 97% VIId, C<sub>19</sub>H<sub>28</sub>O<sub>8</sub>N<sub>3</sub>Cl, m. 118°; VIk, 67% VIId, C<sub>19</sub>H<sub>28</sub>O<sub>8</sub>N<sub>3</sub>Cl, m. 125°; VIl, 84% VIId, C<sub>18</sub>H<sub>28</sub>O<sub>8</sub>N<sub>4</sub>, m. 139°; VIm, 55% VIId, C<sub>18</sub>H<sub>28</sub>O<sub>8</sub>N<sub>4</sub>, m. 148°; and VIn, 88% VIId, C<sub>17</sub>H<sub>27</sub>O<sub>9</sub>N<sub>3</sub>, m. 125°. When compds. of type VI in alc. were heated, preferably with an excess II, the following corresponding isoxazoline oxides (VIII) [all m. (decomposition)] were formed (cf. preceding abstract): from VIa, 76-80% C<sub>17</sub>H<sub>22</sub>O<sub>5</sub>N<sub>2</sub>, m. 181°; from VIb, 78% C<sub>14</sub>H<sub>16</sub>O<sub>5</sub>N<sub>2</sub>, m. 181°; from VIc, 38% C<sub>17</sub>H<sub>21</sub>O<sub>7</sub>N<sub>3</sub>, (VIIIa), m. 189°; from VIh, 46% of the m-isomer of VIIIa, m. 181°; from VIIi, 32% of the p-isomer of VIIIa, m. 187°; from VIj, 68% C<sub>17</sub>H<sub>21</sub>O<sub>5</sub>N<sub>2</sub>Cl, m. 196°; from VIk, 70% of the p-isomer, m. 168°. Although the corresponding VI and VII from 2-HOC<sub>10</sub>H<sub>6</sub>CH:NPh could not be isolated, D. and F. claim the formation of 73% VIII from this Schiff base but give the isoxazoline oxide formula as "C<sub>23</sub>H<sub>29</sub>O<sub>5</sub>N<sub>3</sub>" m. 162° (decomposition). o-HOC<sub>6</sub>H<sub>4</sub>CH:NPh gave the isoxazoline oxide, C<sub>17</sub>H<sub>22</sub>O<sub>6</sub>N<sub>2</sub> (incorrectly given as "C<sub>17</sub>H<sub>22</sub>O<sub>5</sub>N<sub>2</sub>"), m. 198° (decomposition). p-MeOC<sub>6</sub>H<sub>4</sub>CH:NPh gave C<sub>18</sub>H<sub>24</sub>O<sub>6</sub>N<sub>2</sub>, m. 195° (decomposition). VIId refluxed 15 min. in absolute alc. with a large excess of II gave 42% O←N:C(CONEt<sub>2</sub>).CH(C<sub>6</sub>H<sub>4</sub>NO<sub>2</sub>).CH(CONEt<sub>2</sub>).O, m. 203° (from EtOH). Aldehydes or Schiff bases react with Et<sub>2</sub>NH<sub>2</sub><sup>+</sup> salts of I, giving, in the case of BzH, o-HOC<sub>6</sub>H<sub>4</sub>CH:NPh, or N-(2-pyridylmethylene)-p-phenetidine, compds. of type VII. However PhCH:NPh or its m-NO<sub>2</sub> derivative (IX), gave directly the corresponding VIII. With the MeNH<sub>3</sub><sup>+</sup> salt (X) of I, a compound of type VII, C<sub>16</sub>H<sub>22</sub>O<sub>10</sub>N<sub>4</sub>, m. 130°, was obtained from IX. In all other cases X gave the following compds. of type VIII: from BzH or PhCH:NPh, 78-86% C<sub>14</sub>H<sub>16</sub>O<sub>5</sub>N<sub>2</sub>, m. 181-2° (decomposition); from p-HOC<sub>6</sub>H<sub>4</sub>CH:NPh, 62% C<sub>14</sub>H<sub>16</sub>O<sub>6</sub>N<sub>2</sub>, m. 197° (decomposition); from p-MeOC<sub>6</sub>H<sub>4</sub>CH:NPh, 57% C<sub>15</sub>H<sub>18</sub>O<sub>6</sub>N<sub>2</sub>, m. 180° (decomposition). Hydrobenzamide (3 g.) treated in ligroine at 0° with 2.6 g. I and the crystalline deposit promptly separated and washed with Et<sub>2</sub>O gave 0.7 g. NH<sub>4</sub> salt of I, m. 124°. If the salt is not separated, it forms an oil, resolidifying in 24 hrs. and giving 2.5 g. of the di-NH<sub>4</sub> salt of di-Et 2,4-dinitro-3-phenylglutarate, C<sub>15</sub>H<sub>24</sub>O<sub>8</sub>N<sub>4</sub>, m. 95-6°. I (2 moles), 1.5 moles II, and 1,1'-benzylidenedipiperidine (XI) in Et<sub>2</sub>O-alc. (1:1) at room temperature gave 93% VIIa, m. 129°. Similarly the o-HO analog of XI gave VIId. p-Cl<sub>3</sub>CCH:NC<sub>6</sub>H<sub>4</sub>Me in alc.-Et<sub>2</sub>O with I and II gave 93% [CCl<sub>3</sub>CH(OH)C(NO<sub>2</sub>)(CO<sub>2</sub>Et)](NH<sub>2</sub>Et<sub>2</sub>), m. 126° (decomposition). Cyclohexanone (5 g.), 6 g. I, and 3 cc. of 25% PhCH<sub>2</sub>NMe<sub>3</sub>OBu (XII) in BuOH gave 3.9 g. CH<sub>2</sub>.(CH<sub>2</sub>)<sub>4</sub>.C[CH(NO<sub>2</sub>)CO<sub>2</sub>Et]<sub>2</sub>, b<sub>0.8</sub> 120°. BzMe and I with XII gave 70% EtO<sub>2</sub>C.CH(NO<sub>2</sub>)CMePhCH(NO<sub>2</sub>)CO<sub>2</sub>Et, b<sub>1</sub> 150° O←N:C(CONEt<sub>2</sub>).CH(C<sub>6</sub>H<sub>4</sub>OH-p).CH(CO<sub>2</sub>Et).O in Et<sub>2</sub>O at 0° with HCl gas gave 83% O.N: C(CO<sub>2</sub>H).C(C<sub>6</sub>H<sub>4</sub>OH-p):CCO<sub>2</sub>Et(XIII), m. 155° (from C<sub>6</sub>H<sub>6</sub>). Hydrogenated in the presence Pd-BaSO<sub>4</sub> or PtO<sub>2</sub> and MeOH, XIII gave 83% HON:C(CONEt<sub>2</sub>) CH(C<sub>6</sub>H<sub>4</sub>OH) CH(OH) CO<sub>2</sub>Et, yellow, m. 157° (decomposition); the Ph analog, m. 140° (decomposition).

TI Aliphatic nitro compounds. IV. Various addition and condensation reactions of ethyl nitroacetate

SO Annalen der Chemie, Justus Liebig's (1952), 578, 122-36  
CODEN: 9X224Y

AB O<sub>2</sub>NCH<sub>2</sub>CO<sub>2</sub>Et (I) (prepared by Steinkopf's method, C.A. 18, 377) added α,β-unsatd. ketones at room temperature, with Et<sub>2</sub>NH (II) or PhCH<sub>2</sub>NH<sub>3</sub>OH (III) as catalysts. In ligroine, I and PhCH:CHAc with II gave 92% [AcCH<sub>2</sub>CHPhC(NO<sub>2</sub>)(CO<sub>2</sub>Et)]NH<sub>2</sub>Et<sub>2</sub> (IV), m. 114°. Similarly I, II, and PhCH<sub>2</sub>:CHNO<sub>2</sub> gave the NH<sub>2</sub>Et<sub>2</sub> salt of Et 2-aci-2,4-dinitro-3-phenylbutyrate (V), m. 98° (and traces of polynitrostyrene). V (96% was also formed from equivalent amts. of Ph(PhNH)CHCH<sub>2</sub>NO<sub>2</sub>, I, and II, in ligroine and Et<sub>2</sub>O; in the absence of Et<sub>2</sub>O, polynitrostyrene is a by-product. I (3.7 g.), 2-cc. of 40% III, 4 cc. dioxane, and 4 g. PhCH:CHCO<sub>2</sub>Et, kept 3 days at 60°, then at 0°, and the mixture acidified with N HCl and extracted with Et<sub>2</sub>O gave 66% EtO<sub>2</sub>CCCH(NO<sub>2</sub>)CHPhCH<sub>2</sub>CO<sub>2</sub>Et, b<sub>1</sub> 176-8°. PhCH:CHAc and I with III gave, after 14

days, a brown smear from which only 30 mg. of the PhCh<sub>2</sub>NMe<sub>2</sub> analog of V, m. 175°, could be isolated by Et<sub>2</sub>O extraction. The residual Et<sub>2</sub>O extract treated with II gave 54% V. I, II, and (PhN:)<sub>2</sub> yielded 82% of the adduct C<sub>20</sub>H<sub>28</sub>O<sub>4</sub>N<sub>4</sub>, m. 88°. In ligroine or petr. ether, I with a variety of Schiff bases in the presence of II yielded unstable adducts [R<sub>1</sub>HNC<sub>2</sub>HRC(NO<sub>2</sub>)CO<sub>2</sub>Et]NH<sub>2</sub>Et<sub>2</sub> (VI), in which R and R<sub>1</sub> are usually aryl groups, given in the following table. Schiff base used, Yield of, VI %, Decomposition, °C., Formula of VI; PhN:CHPh, 99, 106, (VIa) C<sub>21</sub>H<sub>29</sub>O<sub>4</sub>N<sub>3</sub>; p-MeC<sub>6</sub>H<sub>4</sub>N:CHPh, 94, 86, (VIb) C<sub>22</sub>H<sub>31</sub>O<sub>4</sub>N<sub>3</sub>; p-EtOC<sub>6</sub>H<sub>4</sub>N:CHPh, 96, 106, (VIc) C<sub>23</sub>H<sub>33</sub>O<sub>5</sub>N<sub>3</sub>; m-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>N:CHPh, 93, 109, (VId) C<sub>21</sub>H<sub>28</sub>O<sub>6</sub>N<sub>4</sub>; p-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>N:CHPh, 95, 120, (VIE) C<sub>21</sub>H<sub>28</sub>O<sub>6</sub>N<sub>4</sub>; MeN:CHPh, 97, 78, (VIf) C<sub>16</sub>H<sub>27</sub>O<sub>4</sub>N<sub>3</sub>; o-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CH:NPh, 95, 105, (VIg) C<sub>21</sub>H<sub>27</sub>O<sub>6</sub>N<sub>4</sub>; m-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CH:NPh, 96, 113, (VIh) C<sub>21</sub>H<sub>28</sub>O<sub>6</sub>N<sub>4</sub>; p-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CH:NPh, 86, 105, (VIi) C<sub>21</sub>H<sub>28</sub>O<sub>6</sub>N<sub>4</sub>; m-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CH:NC<sub>6</sub>H<sub>4</sub>Me-p, Too unstable for isolation; o-HOC<sub>6</sub>H<sub>4</sub>CH:NPh, " " " "; 2,1-HOC<sub>10</sub>H<sub>6</sub>CH:NPh, " " " "; p-HOC<sub>6</sub>H<sub>4</sub>CH:NPh, " " " "; p-MeOC<sub>6</sub>H<sub>4</sub>CH:NPh, " " " "; o-ClC<sub>6</sub>H<sub>4</sub>CH:NPh, 98, 108, (VIj) C<sub>21</sub>H<sub>28</sub>O<sub>4</sub>N<sub>3</sub>Cl; p-ClC<sub>6</sub>H<sub>4</sub>CH:NPh, 99, 84, (VIk) C<sub>21</sub>H<sub>28</sub>O<sub>4</sub>N<sub>3</sub>Cl; N-(2-Pyridylmethylene)-p-phenetidine, 95, 86, (VII) C<sub>22</sub>H<sub>32</sub>O<sub>5</sub>N<sub>4</sub>; N-(3-Pyridylmethylene)-p-phenetidine, 82, 103, (VIIm) C<sub>22</sub>H<sub>32</sub>O<sub>5</sub>N<sub>4</sub>; N-furfurylidene-p-phenetidine, 85, 112, (VIIn) C<sub>21</sub>H<sub>31</sub>O<sub>6</sub>N<sub>3</sub>; Attempts to precipitate the VI in CHCl<sub>3</sub> with petr. ether, or solution in alc. (or Et<sub>2</sub>O) caused decomposition to the corresponding Et<sub>2</sub>NH salts (VII) of RCH[CH(NO<sub>2</sub>)CO<sub>2</sub>Et]<sub>2</sub> (R = aryl). Thus VIa, VIb, VIc, VId, and VIE yielded resp. 94-98, 95, 92, 89, and 84% VIIa, C<sub>19</sub>H<sub>29</sub>O<sub>8</sub>N<sub>3</sub>, m. 129° (decomposition). VIg gave 82% (VIIf) C<sub>19</sub>H<sub>28</sub>O<sub>10</sub>N<sub>4</sub>, m. 126°. VIh gave 90% VIIc C<sub>19</sub>H<sub>28</sub>O<sub>10</sub>N<sub>4</sub>, m. 121°. VIIi gave 82% VIId, C<sub>19</sub>H<sub>28</sub>O<sub>10</sub>N<sub>4</sub>, m. 125°. From m-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CH:NC<sub>6</sub>H<sub>4</sub>Me-p was formed 95% VIIc, m. 121°; from o-HOC<sub>6</sub>H<sub>4</sub>CH:NPh, 90% VIIe, C<sub>19</sub>H<sub>29</sub>O<sub>9</sub>N<sub>3</sub>, m. 128°; from p-HOC<sub>6</sub>H<sub>4</sub>CH:NPh, 64%, VIIIf, C<sub>19</sub>H<sub>29</sub>O<sub>9</sub>N<sub>3</sub>, m. 119°; from p-MeOC<sub>6</sub>H<sub>4</sub>CH:NPh, 72% VIIg, C<sub>20</sub>H<sub>31</sub>O<sub>9</sub>N<sub>3</sub>, m. 95-7°. The product from 2-HOC<sub>10</sub>H<sub>6</sub>CH:NPh could not be isolated. VIj gave 97% VIIh, C<sub>19</sub>H<sub>28</sub>O<sub>8</sub>N<sub>3</sub>Cl, m. 118°; VIk, 67% VIIi; C<sub>19</sub>H<sub>28</sub>O<sub>8</sub>N<sub>3</sub>Cl, m. 125°; VIIl, 84% VIIk, C<sub>18</sub>H<sub>28</sub>O<sub>8</sub>N<sub>4</sub>, m. 139°; VIIm, 55% VIIl, C<sub>18</sub>H<sub>28</sub>O<sub>8</sub>N<sub>4</sub>, m. 148°; and VIIn, 88% VIIm, C<sub>17</sub>H<sub>27</sub>O<sub>9</sub>N<sub>3</sub>, m. 125°. When compds. of type VI in alc. were heated, preferably with an excess II, the following corresponding isoxazoline oxides (VIII) [all m. (decomposition)] were formed (cf. preceding abstract): from VIa, 76-80% C<sub>17</sub>H<sub>22</sub>O<sub>5</sub>N<sub>2</sub>, m. 181°; from VIf, 78% C<sub>14</sub>H<sub>16</sub>O<sub>5</sub>N<sub>2</sub>, m. 181°; from VIg, 38% C<sub>17</sub>H<sub>21</sub>O<sub>7</sub>N<sub>3</sub>, (VIIIa), m. 189°; from VIh, 46% of the m-isomer of VIIIa, m. 181°; from VIIi, 32% of the p-isomer of VIIIa, m. 187°; from VIj, 68% C<sub>17</sub>H<sub>21</sub>O<sub>5</sub>N<sub>2</sub>Cl, m. 196°; from VIk, 70% of the p-isomer, m. 168°. Although the corresponding VI and VII from 2-HOC<sub>10</sub>H<sub>6</sub>CH:NPh could not be isolated, D. and F. claim the formation of 73% VIII from this Schiff base but give the isoxazoline oxide formula as "C<sub>23</sub>H<sub>29</sub>O<sub>5</sub>N<sub>3</sub>" m. 162° (decomposition). o-HOC<sub>6</sub>H<sub>4</sub>CH:NPh gave the isoxazoline oxide, C<sub>17</sub>H<sub>22</sub>O<sub>6</sub>N<sub>2</sub> (incorrectly given as "C<sub>17</sub>H<sub>22</sub>O<sub>5</sub>N<sub>2</sub>"), m. 198° (decomposition). p-MeOC<sub>6</sub>H<sub>4</sub>CH:NPh gave C<sub>18</sub>H<sub>24</sub>O<sub>6</sub>N<sub>2</sub>, m. 195° (decomposition). VIIc refluxed 15 min. in absolute alc. with a large excess of II gave 42% O=C(N:CONEt<sub>2</sub>).CH(C<sub>6</sub>H<sub>4</sub>NO<sub>2</sub>).CH(CONEt<sub>2</sub>).O, m. 203° (from EtOH). Aldehydes or Schiff bases react with Et<sub>2</sub>NH<sub>2</sub><sup>+</sup> salts of I, giving, in the case of BzH, o-HOC<sub>6</sub>H<sub>4</sub>CH:NPh, or N-(2-pyridylmethylene)-p-phenetidine, compds. of type VII. However PhCH:NPh or its m-NO<sub>2</sub> derivative (IX), gave directly the corresponding VIII. With the MeNH<sub>3</sub><sup>+</sup> salt (X) of I, a compound of type VII, C<sub>16</sub>H<sub>22</sub>O<sub>10</sub>N<sub>4</sub>, m. 130°, was obtained from IX. In all other cases X gave the following compds. of type VIII: from BzH or PhCH:NPh, 78-86% C<sub>14</sub>H<sub>16</sub>O<sub>5</sub>N<sub>2</sub>, m. 181-2° (decomposition); from p-HOC<sub>6</sub>H<sub>4</sub>CH:NPh, 62% C<sub>14</sub>H<sub>16</sub>O<sub>6</sub>N<sub>2</sub>, m. 197° (decomposition); from p-MeOC<sub>6</sub>H<sub>4</sub>CH:NPh, 57% C<sub>15</sub>H<sub>18</sub>O<sub>6</sub>N<sub>2</sub>, m. 180° (decomposition). Hydrobenzamide (3 g.) treated in ligroine at 0° with 2.6 g. I and the crystalline deposit promptly separated and washed with Et<sub>2</sub>O gave 0.7 g. NH<sub>4</sub> salt of I, m. 124°. If the salt is not separated, it forms an oil, resolidifying in 24 hrs. and giving 2.5 g. of the di-NH<sub>4</sub> salt of di-Et 2,4-dinitro-3-phenylglutarate, C<sub>15</sub>H<sub>24</sub>O<sub>8</sub>N<sub>4</sub>, m. 95-6°. I (2 moles), 1.5 moles II, and 1,1'-benzylidenedipiperidine (XI) in Et<sub>2</sub>O-alc. (1:1) at room temperature gave 93% VIIa, m. 129°. Similarly the o-HO analog of XI gave VIIe. p-Cl<sub>3</sub>CCH:NC<sub>6</sub>H<sub>4</sub>Me in alc.-Et<sub>2</sub>O with I and II gave 93% [CCl<sub>3</sub>CH(OH)C(NO<sub>2</sub>)(CO<sub>2</sub>Et)](NH<sub>2</sub>Et<sub>2</sub>), m. 126° (decomposition). Cyclohexanone (5



g.), 6 g. I, and 3 cc. of 25% PhCH<sub>2</sub>NMe<sub>3</sub>OBu (XII) in BuOH gave 3.9 g. CH<sub>2</sub>.(CH<sub>2</sub>)<sub>4</sub>.C[CH(NO<sub>2</sub>)CO<sub>2</sub>Et]<sub>2</sub>, b0.8 120°. BzMe and I with XII gave 70% EtO<sub>2</sub>C.CH(NO<sub>2</sub>)CMePhCH(NO<sub>2</sub>)CO<sub>2</sub>Et, b1 150° O←N:C(CONEt<sub>2</sub>).CH(C<sub>6</sub>H<sub>4</sub>OH-p).CH(CO<sub>2</sub>Et).O in Et<sub>2</sub>O at 0° with HCl gas gave 83% O.N: C(CO<sub>2</sub>H).C(C<sub>6</sub>H<sub>4</sub>OH-p):CCO<sub>2</sub>Et(XIII), m. 155° (from C<sub>6</sub>H<sub>6</sub>). Hydrogenated in the presence Pd-BaSO<sub>4</sub> or PtO<sub>2</sub> and MeOH, XIII gave 83% HON:C(CONEt<sub>2</sub>) CH(C<sub>6</sub>H<sub>4</sub>OH) CH(OH) CO<sub>2</sub>Et, yellow, m. 157° (decomposition); the Ph analog, m. 140° (decomposition).

IT 521942-14-3P, 1,1-Cyclohexanediadicetic acid,  $\alpha,\alpha'$ -dinitro-, diethyl ester 354704-42-0P, Glutaramic acid, N,N-diethyl-2-hydroxy-3-(p-hydroxyphenyl)-4-oxo-, ethyl ester, oxime 854705-67-2P, Glutaric acid, 2-nitro-3-phenyl-, diethyl ester 855601-37-5P, 2-Isoxazoline-3,5-dicarboxamide, N,N,N',N'-tetraethyl-4-(m-nitro-phenyl)-, 2-oxide 855601-50-2P, 2-Isoxazoline-5-carboxylic acid, 4-(p-hydroxyphenyl)-3-methyl-carbamoyl-, ethyl ester, 2-oxide 855747-58-9P, 2-Isoxazoline-5-carboxylic acid, 3-diethylcarbamoyl-4-[p-nitrophenyl]-, ethyl ester, 2-oxide 855747-59-0P, 2-Isoxazoline-5-carboxylic acid, 3-diethylcarbamoyl-4-[o-nitrophenyl]-, ethyl ester, 2-oxide 855747-60-3P, 2-Isoxazoline-5-carboxylic acid, 3-diethylcarbamoyl-4-[m-nitrophenyl]-, ethyl ester, 2-oxide 855747-62-5P, 2-Isoxazoline-5-carboxylic acid, 3-diethylcarbamoyl-4-(o-hydroxyphenyl)-, ethyl ester, 2-oxide 857557-42-7P, Acetic acid, aci-nitro-, ethyl ester, NH<sub>4</sub> derivative 858250-71-2P, Glutaric acid, 3-methyl-2,4-dinitro-3-phenyl-, diethyl ester 859305-07-0P, Glutaramic acid, N,N-diethyl-2-hydroxy-4-oxo-3-phenyl-, ethyl ester, oxime 860372-21-0P, 2-Isoxazoline-5-carboxylic acid, 3-diethylcarbamoyl-4-(2-hydroxy-1-naphthyl)-, ethyl ester, 2-oxide 872788-69-7P, 2-Isoxazoline-5-carboxylic acid, 3-methylcarbamoyl-4-phenyl-, ethyl ester, 2-oxide 872788-69-7P, 2-Isoxazoline-5-carboxylic acid, 3-methylcarbamoyl-4-phenyl-, ethyl ester, 2-oxide 872788-71-1P, 2-Isoxazoline-5-carboxylic acid, 4-(p-methoxyphenyl)-3-methyl-carbamoyl-, ethyl ester, 2-oxide 872788-73-3P, 2-Isoxazoline-5-carboxylic acid, 3-diethylcarbamoyl-4-phenyl-, ethyl ester, 2-oxide 872788-75-5P, 2-Isoxazoline-5-carboxylic acid, 3-diethylcarbamoyl-4-(p-methoxyphenyl)-, ethyl ester, 2-oxide 872788-77-7P, 2-Isoxazoline-5-carboxylic acid, 4-[p-chlorophenyl]-3-diethylcarbamoyl-, ethyl ester, 2-oxide 874533-61-6P, 2-Isoxazoline-5-carboxylic acid, 4-[o-chlorophenyl]-3-diethylcarbamoyl-, ethyl ester, 2-oxide  
 RL: PREP (Preparation)  
 (preparation of)

L12 STRUCTURE UPLOADED

=> s 112 sss sam

SAMPLE SEARCH INITIATED 13:15:50 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2561 TO ITERATE

78.1% PROCESSED 2000 ITERATIONS

21 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 48185 TO 54255

PROJECTED ANSWERS: 226 TO 848

L13 21 SEA SSS SAM L12

=> d 113

L13 ANSWER 1 OF 21 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 1089316-65-3 REGISTRY  
ED Entered STN: 24 Dec 2008  
CN Benzenepropanoic acid, 4-hydroxy-3-methoxy- $\alpha$ -(2-methoxy-4-propylphenoxy)- $\beta$ -oxo- $\alpha$ -(phenylmethyl)-, ethyl ester (CA INDEX NAME)  
MF C29 H32 O7  
SR CA

/ Structure 112 in file .gra /

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

=> s 112 sss full  
FULL SEARCH INITIATED 13:16:55 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 50873 TO ITERATE

100.0% PROCESSED 50873 ITERATIONS 499 ANSWERS  
SEARCH TIME: 00.00.01

L14 499 SEA SSS FUL L12

=> d scan

L14 499 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Butanedioic acid, 2-[3-(3,4-dihydroxyphenyl)-2-hydroxy-1-oxopropoxy]-3-[[3-(3,4-dihydroxyphenyl)-1-oxo-2-propen-1-yl]oxy]-  
MF C22 H20 O13

=> s 114/prep  
450 L14  
4706241 PREP/RL  
L15 224 L14/PREP  
(L14 (L) PREP/RL)

=> s 115 and (py<2003 or ay<2003 or pry<2003)  
22983071 PY<2003  
4502933 AY<2003  
3971676 PRY<2003  
L16 142 L15 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> s 116 and (asymmetri? hydrogenati?)  
93416 ASYMMETRI?  
147845 ASYM  
6 ASYMS  
147848 ASYM  
(ASYM OR ASYMS)  
184557 ASYMMETRI?  
(ASYMMETRI? OR ASYM)  
187623 HYDROGENATI?  
4068 ASYMMETRI? HYDROGENATI?  
(ASYMMETRI?(W)HYDROGENATI?)  
L17 0 L16 AND (ASYMMETRI? HYDROGENATI?)

```
=> s l16 and asymmetric? hydrogenation?
      82387 ASYMMETRIC?
      147845 ASYM
        6 ASYMS
      147848 ASYM
        (ASYM OR ASYMS)
      174519 ASYMMETRIC?
        (ASYMMETRIC? OR ASYM)
      184506 HYDROGENATION?
        4063 ASYMMETRIC? HYDROGENATION?
          (ASYMMETRIC?(W)HYDROGENATION?)
L18      0 L16 AND ASYMMETRIC? HYDROGENATION?
```

```
=> s l16 and 'chiral? cataly?'
      129207 'CHIRAL'
        19 'CHIRALS'
      129212 'CHIRAL'
        ('CHIRAL' OR 'CHIRALS')
        2 'CATALY'
        0 'CHIRAL? CATALY?'
          ('CHIRAL'(W)'CATALY')
L19      0 L16 AND 'CHIRAL? CATALY?'
```

```
=> s l16 and (Ru? or Rh? or Pd? or Ir?)
UNMATCHED LEFT PARENTHESIS 'AND (RU?'
The number of right parentheses in a query must be equal to the
number of left parentheses.
```

```
=> s l16 and (Ru? or Rh? or Pd? or Ir?)
      1446878 RU?
      783851 RH?
      329541 PD?
      2695423 IR?
L20      26 L16 AND (RU? OR RH? OR PD? OR IR?)
```

```
=> d l20 ibib abs 1-5
```

```
L20  ANSWER 1 OF 26  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:      2003:855905  CAPLUS  Full-text
DOCUMENT NUMBER:       139:350938
TITLE:                 Preparation of N-cinnamoyl-DOPA esters and related
                        compounds as T lymphocyte inhibitors
INVENTOR(S):           Won, Jongwha; Lee, Keunhyeung; Park, Seehyoung; Kim,
                        Sung-Joo; Yun, Su-Young; Kang, Mi-Ae; Hur, Yun-Gyoung;
                        Youn, Jeehee; Yun, Yungdae; Park, Doohong; Oh, Jaetaek
PATENT ASSIGNEE(S):    Mogam Biotechnology Research Institute, S. Korea
SOURCE:                PCT Int. Appl., 109 pp.
                        CODEN: PIXXD2
DOCUMENT TYPE:         Patent
LANGUAGE:              English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2003089405	A1	20031030	WO 2003-KR751	20030414 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,			

PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,  
 UG, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 US 20040082664 A1 20040429 US 2003-411772 20030411 <--  
 AU 2003221144 A1 20031103 AU 2003-221144 20030414 <--  
 EP 1499585 A1 20050126 EP 2003-715837 20030414 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 CN 1646480 A 20050727 CN 2003-808343 20030414 <--  
 JP 2005522523 T 20050728 JP 2003-586126 20030414 <--  
 PRIORITY APPLN. INFO.: KR 2002-20481 A 20020415 <--  
 WO 2003-KR751 W 20030414  
 OTHER SOURCE(S): MARPAT 139:350938  
 GI

/ Structure 118 in file .gra /

AB Title compds. I [R1-R10 = H, OH, halogen, alkoxy, CHO, CO2H, NH2, CF3, NO2, ≥  
 1 of R1-R5 and R6-R10 = OH; X1 = O, S, NH, NMe, NEt, NHNH; X2 = CH2, CO, CS,  
 CONH; X3 = bond, (un)substituted CH:CH, CH:CHCH:CH, CH2, CH2CH2; Y1 = H, CH2,  
 CO, CS, alkyl, amino, 3-methyl-1,2,4-oxadiazol-5-yl, 3-benzyl-1,2,4-oxadiazol-  
 5-yl; Y = absent, (un)substituted NH2, OH, SH; B = H, alkyl] were prepared as  
 inhibitors of the activation of T lymphocytes by the src homol. region 2(SH2)  
 domain of T lymphocyte (lck), useful for the treatment, prevention and/or  
 diagnosis of graft rejection, autoimmune diseases, inflammatory diseases, etc.  
 Thus, D-DOPA was converted to its Me ester and treated with caffeic acid to  
 give the amide II which inhibited the binding of the lck SH2 domain with its  
 cognate peptide < 10µM.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2003:570940 CAPLUS Full-text  
 DOCUMENT NUMBER: 139:133345  
 TITLE: Preparation of Phenyl(alkyl)carboxylic acid  
 derivatives and analogs and their serum glucose and/or  
 serum lipid lowering activity  
 INVENTOR(S): Giannessi, Fabio; Tassoni, Emanuela; Dell'Uomo,  
 Natalina; Brunetti, Tiziana; Tinti, Maria Ornella;  
 Arduini, Arduino; Pessotto, Pompeo  
 PATENT ASSIGNEE(S): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,  
 Italy  
 SOURCE: PCT Int. Appl., 97 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2003059864	A2	20030724	WO 2003-IT7	20030113 <--
WO 2003059864	A3	20040129		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,			
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,			

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,  
 UG, US, UZ, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 IT 2002RM0016 A1 20030715 IT 2002-RM16 20020115 <--  
 CA 2472209 A1 20030724 CA 2003-2472209 20030113 <--  
 AU 2003209676 A1 20030730 AU 2003-209676 20030113 <--  
 EP 1465858 A2 20041013 EP 2003-729544 20030113 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 BR 2003006880 A 20041221 BR 2003-6880 20030113 <--  
 CN 1617854 A 20050518 CN 2003-802295 20030113 <--  
 JP 2005514452 T 20050519 JP 2003-559969 20030113 <--  
 MX 2004PA06802 A 20041011 MX 2004-PA6802 20040713 <--  
 US 20050032787 A1 20050210 US 2004-501135 20040713 <--  
 PRIORITY APPLN. INFO.: IT 2002-RM16 A 20020115 <--  
 WO 2003-IT7 W 20030113  
 OTHER SOURCE(S): MARPAT 139:133345  
 GI

/ Structure 119 in file .gra /

AB Title compds. I [A = CH; alkanylidene with 2-4 C atoms, etc.; Ar =  
 mono/bicyclic (hetero)aryl; f, h = 0-1; m = 0-3; n = 0-1 and if n = 0, R1 =  
 absent and COY is directly bound to benzene; Q, Z = NH, O, S, NHCO, etc.; Y =  
 OH, alkoxy, amino] are prepared For instance, 3-hydroxybenzaldehyde is  
 condensed with dimethylmalonate (HOAc, piperidine, 5 h) and the product  
 reduced (MeOH, H<sub>2</sub>-10% Pd/C @ 50 psi, 18 h) to give II. II is capable of  
 increasing glucose consumption in 3T3 - L1 cells to a similar extent to that  
 achieved by rosiglitazone. I are serum glucose and serum lipid lowering  
 agents and are useful for the prophylaxis and treatment of diabetes,  
 particularly type 2, and its complications, Syndrome X, the various forms of  
 insulin resistance, and hyperlipidemias, and present reduced side effects,  
 and, particularly, reduced or no liver toxicity.

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2003:511336 CAPLUS Full-text  
 DOCUMENT NUMBER: 139:85372  
 TITLE: Preparation of pyrazolopyrimidines and related  
 compounds as hPPAR $\alpha$  and hPPAR $\gamma$  ligands  
 INVENTOR(S): Das, Saibal Kumar; Bhuniya, Debnath; Madhavan, Gurram  
 Ranga; Iqbal, Javed; Chakrabarti, Ranjan  
 PATENT ASSIGNEE(S): Reddy's Laboratories Ltd., India  
 SOURCE: PCT Int. Appl., 139 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003033453	A1	20030424	WO 2002-DK692	20021015 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2462514	A1	20030424	CA 2002-2462514	20021015 <--
AU 2002336916	A1	20030428	AU 2002-336916	20021015 <--
EP 1438283	A1	20040721	EP 2002-772084	20021015 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002013253	A	20041026	BR 2002-13253	20021015 <--
HU 2004001837	A2	20041228	HU 2004-1837	20021015 <--
CN 1571766	A	20050126	CN 2002-820547	20021015 <--
JP 2005505616	T	20050224	JP 2003-536195	20021015 <--
US 20030109579	A1	20030612	US 2002-272613	20021016 <--
US 7220877	B2	20070522		
IN 2004CN00771	A	20060113	IN 2004-CN771	20040415 <--
PRIORITY APPLN. INFO.:			DK 2001-1524	A 20011017 <--
			US 2001-330346P	P 20011018 <--
			WO 2002-DK692	W 20021015 <--
OTHER SOURCE(S):	MARPAT 138:337836			
GI				

/ Structure 121 in file .gra /

AB A novel class of dicarboxylic acid derivs., I, is disclosed [wherein: A = (un)substituted C1-3 alkylene, or A'O or A'S where A' is (un)substituted C1-3 alkylene; B = (un)substituted C1-3 alkylene, or OB' or SB' where B' is (un)substituted C1-3 alkylene; D, E = H, C1-6 alkyl, C3-6 cycloalkyl; L, M = O or S; T, U = C3-9 divalent, (un)substituted, unsatd. carbon chain; X, Y = (un)substituted arylene or heteroarylene; Z = (un)substituted arylene, heteroarylene, or divalent polycyclic ring system]. Also disclosed is the use of I in pharmaceutical compns., pharmaceutical compns. comprising I, and methods of treatment employing I and the compns. The present compds. may be useful (no data) in the treatment and/or prevention of conditions mediated by peroxisome proliferator-activated receptors (PPAR). For example, 1,4-diiodobenzene was coupled with excess 2-penten-4-yn-1-ol in (iso-Pr)<sub>2</sub>NH in the presence of CuI and Pd(PPh<sub>3</sub>)<sub>4</sub> at 60°, to give 55% (E,E)-5-[4-(5-hydroxypent-3-en-1-ynyl)phenyl]pent-2-en-4-yn-1-ol. Mitsunobu reaction of this diol with (S)-2-ethoxy-3-(4-hydroxyphenyl)propionic acid Et ester using azodicarboxylic acid dipiperidide and PBu<sub>3</sub> in THF gave 27% invention compound II. A total of 29 synthetic examples illustrate a variety of I, mostly sym. diacids and diesters, and mostly stereoisomeric, with all stereoisomers having (E) and (S) stereochem. at double bonds and chiral centers. Claims list a wide variety of sym. and asym. I, all named without stereochem. Claimed applications include treatment of type I and II diabetes, dyslipidemia, syndrome X and its conditions, cardiovascular diseases including atherosclerosis, and hypercholesterolemia.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 5 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2003:242286 CAPLUS Full-text  
DOCUMENT NUMBER: 138:271396  
TITLE: Preparation of 3-aryl-2-alkoxypropanoates from  
3-aryl-2-oxopropanoates via ketalization and reduction  
INVENTOR(S): Siripragada, Mahender Rao; Vanadanapu, Loka Appala  
Purushotham; Mamillapalli, Ramabhadra Sarma; Gaddam,  
Om Reddy  
PATENT ASSIGNEE(S): Reddy's Laboratories Ltd., India  
SOURCE: PCT Int. Appl., 12 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2003024915	A1	20030327	WO 2002-IB3874	20020919 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,				
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 193612	A1	20040724	IN 2001-MA779	20010920 <--
AU 2002339216	A1	20030401	AU 2002-339216	20020919 <--
PRIORITY APPLN. INFO.:			IN 2001-MA779	A 20010920 <--
			WO 2002-IB3874	W 20020919 <--

OTHER SOURCE(S): CASREACT 138:271396; MARPAT 138:271396  
AB 4-HOC6H4CH2CH(OR1)CO2R2 (R1 = H, alkyl; R2 = alkyl), were prepared by  
converting 4-HOC6H4CH2COCO2H to 4-HOC6H4CH2C(OR1)2CO2R2 (variables as above)  
in the presence of acid followed by reduction in HOAc at 40-80 psi for 6-12 h.  
Thus, 4-hydroxyphenylpyruvic acid was stirred in EtOH at 10-15° for 3 h, at  
room temperature for 6 h, and at 50-60° for 4 h to give 4-  
HOC6H4CH2C(OEt)2CO2Et. The latter was hydrogenated in EtOH/HOAc over Rh/Al2O3  
at 60 psi for 12 h to give 4-HOC6H4CH2CH(OEt)CO2Et.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 120 ibib abs ti hit 6-10

L20 ANSWER 6 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2002:964313 CAPLUS Full-text  
DOCUMENT NUMBER: 138:55745  
TITLE: Preparation of substituted 3-phenyl-2-alkoxypropanoic  
acids and analogs as modulators of peroxisome  
proliferator activated receptors for treatment of  
diabetes and related conditions  
INVENTOR(S): Brooks, Dawn Alisa; Warshawsky, Alan M.;  
Montrose-Rafezadeh, Chahrzad; Reifel-Miller, Anne;  
Prieto, Lourdes; Rojo, Isabel; Martin, Jose Alfredo;



Gonzales Garcia, Maria Rosario; Torrado, Alicia;  
 Ferritto Crespo, Rafael; Lamas-Peteira, Carlos;  
 Martin-Ortega Finger, Maria; Ardecky, Robert J.  
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Ligand Pharmaceuticals  
 Incorporated  
 SOURCE: PCT Int. Appl., 458 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100813	A2	20021219	WO 2002-US16950	20020530 <--
WO 2002100813	A3	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2449256	A1	20021219	CA 2002-2449256	20020530 <--
AU 2002312147	A1	20021223	AU 2002-312147	20020530 <--
EE 200400001	A	20040216	EE 2004-1	20020530 <--
EP 1392637	A2	20040303	EP 2002-739503	20020530 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002010190	A	20040406	BR 2002-10190	20020530 <--
CN 1543451	A	20041103	CN 2002-811530	20020530 <--
HU 2004000280	A2	20050128	HU 2004-280	20020530 <--
HU 2004000280	A3	20060130		
JP 2005509590	T	20050414	JP 2003-503584	20020530 <--
NZ 529351	A	20060127	NZ 2002-529351	20020530 <--
IN 2003KN01456	A	20060414	IN 2003-KN1456	20031110 <--
ZA 2003008863	A	20050214	ZA 2003-8863	20031113 <--
US 20050020684	A1	20050127	US 2003-479262	20031201 <--
US 7192982	B2	20070320		
MX 2003PA11201	A	20040226	MX 2003-PA11201	20031204 <--
US 20070276138	A1	20071129	US 2006-637223	20061211 <--
PRIORITY APPLN. INFO.:			US 2001-297144P	P 20010607 <--
			WO 2002-US16950	W 20020530 <--
			US 2003-479262	A1 20031201
OTHER SOURCE(S):			MARPAT 138:55745	
GI				

/ Structure 122 in file .gra /

AB Title compds. I [wherein Ar = (un)substituted aryl; Q = covalent bond, CH<sub>2</sub>,  
 CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>, or CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>; W = (un)substituted (hetero)alkylene from  
 2-10 atoms in length in which 1 or more methylene groups have been replaced  
 with CH=CH, C.tplbond.C, O, CO, NR<sub>7</sub>, NR<sub>7</sub>CO, C(=NOH), S, SO, SO<sub>2</sub>, or CHNR<sub>7</sub>R<sub>8</sub>;  
 ring A is optionally substituted with up to 4 substituents in addition to R<sub>1</sub>;  
 R<sub>1</sub> = (CH<sub>2</sub>)<sub>n</sub>CH(OR<sub>2</sub>)(CH<sub>2</sub>)<sub>m</sub>E, CH=C(OR<sub>2</sub>)(CH<sub>2</sub>)<sub>m</sub>E, (CH<sub>2</sub>)<sub>n</sub>CHY(CH<sub>2</sub>)<sub>m</sub>E, or

CH=CY(CH<sub>2</sub>)<sub>m</sub>E; E = CO<sub>2</sub>R<sub>3</sub>, alkyl nitrile, carboxamide, or (un)substituted sulfonamide, acylsulfonamide, or tetrazole; R<sub>2</sub> = H, haloalkyl, COR<sub>4</sub>, CO<sub>2</sub>R<sub>4</sub>, CONR<sub>5</sub>R<sub>6</sub>, CSR<sub>4</sub>, CSOR<sub>4</sub>, CSNR<sub>5</sub>R<sub>6</sub>, or (un)substituted aliphatic group, aralkyl, or aryl; Y = O, CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>, or CH=CH bonded ortho to R<sub>1</sub> on ring A; R<sub>3</sub>-R<sub>8</sub> = independently H or (un)substituted aliphatic group or aryl; m and n = independently 0-2; or pharmaceutically acceptable salts, hydrates, stereoisomers, or solvates thereof] were prepared by solution phase and solid phase synthetic methods as peroxisome proliferator activated receptor (PPAR) modulators (no data). For example, (S)-2-methoxy-3-hydroxyphenylpropanoic acid Et ester was treated with Ph triflimide to give the 4-trifluoromethanesulfonyloxyphenyl derivative (97%). Substitution with propargyl alc. in the presence of P<sub>2</sub>O<sub>5</sub>(PPh<sub>3</sub>)<sub>2</sub> and TEA in DMF afforded the 4-(3-hydroxyprop-1-ynyl)phenyl intermediate (32%), which was coupled with 4-phenylphenol using the Mitsunobu procedure to give II. Binding and cotransfection studies showed that many of the compds. of the invention are selective PPAR<sub>γ</sub> agonists or PPAR<sub>α</sub>/PPAR<sub>γ</sub> co-agonists (no data). Thus, I are useful for the treatment of hyperglycemia, dyslipidemia, Type I or II diabetes, hypertriglyceridemia, syndrome X, insulin resistance, heart failure, diabetic dyslipidemia, hyperlipidemia, hypercholesteremia, hypertension, obesity, anorexia bulimia, polycystic ovarian syndrome, anorexia nervosa, cardiovascular disease or other diseases where insulin resistance is a component (no data).

II Preparation of substituted 3-phenyl-2-alkoxypropanoic acids and analogs as modulators of peroxisome proliferator activated receptors for treatment of diabetes and related conditions

PI WO 2002100813 A2 20021219

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002100813	A2	20021219	WO 2002-US16950	20020530 <--
	WO 2002100813	A3	20031127		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2449256	A1	20021219	CA 2002-2449256	20020530 <--
	AU 2002312147	A1	20021223	AU 2002-312147	20020530 <--
	EE 200400001	A	20040216	EE 2004-1	20020530 <--
	EP 1392637	A2	20040303	EP 2002-739503	20020530 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002010190	A	20040406	BR 2002-10190	20020530 <--
	CN 1543451	A	20041103	CN 2002-811530	20020530 <--
	HU 2004000280	A2	20050128	HU 2004-280	20020530 <--
	HU 2004000280	A3	20060130		
	JP 2005509590	T	20050414	JP 2003-503584	20020530 <--
	NZ 529351	A	20060127	NZ 2002-529351	20020530 <--
	IN 2003KN01456	A	20060414	IN 2003-KN1456	20031110 <--
	ZA 2003008863	A	20050214	ZA 2003-8863	20031113 <--
	US 20050020684	A1	20050127	US 2003-479262	20031201 <--
	US 7192982	B2	20070320		
	MX 2003PA11201	A	20040226	MX 2003-PA11201	20031204 <--
	US 20070276138	A1	20071129	US 2006-637223	20061211 <--
PRAI	US 2001-297144P	P	20010607	<--	
	WO 2002-US16950	W	20020530	<--	

- AB Title compds. I [wherein Ar = (un)substituted aryl; Q = covalent bond, CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>, or CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>; W = (un)substituted (hetero)alkylene from 2-10 atoms in length in which 1 or more methylene groups have been replaced with CH=CH, C.tplbond.C, O, CO, NR<sub>7</sub>, NR<sub>7</sub>CO, C(=NOH), S, SO, SO<sub>2</sub>, or CHNR<sub>7</sub>R<sub>8</sub>; ring A is optionally substituted with up to 4 substituents in addition to R<sub>1</sub>; R<sub>1</sub> = (CH<sub>2</sub>)<sub>n</sub>CH(OR<sub>2</sub>)(CH<sub>2</sub>)<sub>m</sub>E, CH=C(OR<sub>2</sub>)(CH<sub>2</sub>)<sub>m</sub>E, (CH<sub>2</sub>)<sub>n</sub>CHY(CH<sub>2</sub>)<sub>m</sub>E, or CH=CY(CH<sub>2</sub>)<sub>m</sub>E; E = CO<sub>2</sub>R<sub>3</sub>, alkyl nitrile, carboxamide, or (un)substituted sulfonamide, acylsulfonamide, or tetrazole; R<sub>2</sub> = H, haloalkyl, COR<sub>4</sub>, CO<sub>2</sub>R<sub>4</sub>, CONR<sub>5</sub>R<sub>6</sub>, CSR<sub>4</sub>, CSOR<sub>4</sub>, CSNR<sub>5</sub>R<sub>6</sub>, or (un)substituted aliphatic group, aralkyl, or aryl; Y = O, CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>, or CH=CH bonded ortho to R<sub>1</sub> on ring A; R<sub>3</sub>-R<sub>8</sub> = independently H or (un)substituted aliphatic group or aryl; m and n = independently 0-2; or pharmaceutically acceptable salts, hydrates, stereoisomers, or solvates thereof] were prepared by solution phase and solid phase synthetic methods as peroxisome proliferator activated receptor (PPAR) modulators (no data). For example, (S)-2-methoxy-3-hydroxyphenylpropanoic acid Et ester was treated with Ph triflimide to give the 4-trifluoromethanesulfonyloxyphenyl derivative (97%). Substitution with propargyl alc. in the presence of PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> and TEA in DMF afforded the 4-(3-hydroxyprop-1-ynyl)phenyl intermediate (32%), which was coupled with 4-phenylphenol using the Mitsunobu procedure to give II. Binding and cotransfection studies showed that many of the compds. of the invention are selective PPAR $\gamma$  agonists or PPAR $\alpha$ /PPAR $\gamma$  co-agonists (no data). Thus, I are useful for the treatment of hyperglycemia, dyslipidemia, Type I or II diabetes, hypertriglyceridemia, syndrome X, insulin resistance, heart failure, diabetic dyslipidemia, hyperlipidemia, hypercholesteremia, hypertension, obesity, anorexia bulimia, polycystic ovarian syndrome, anorexia nervosa, cardiovascular disease or other diseases where insulin resistance is a component (no data).
- IT 348-27-6P, 2-Fluoro-4-hydroxybenzaldehyde 405-05-0P,  
 3-Fluoro-4-hydroxybenzaldehyde 627-18-9P, 3-Bromopropan-1-ol  
 1073-05-8P, [1,3,2]Dioxathiane 2,2-dioxide 2973-78-6P,  
 3-Bromo-4-hydroxybenzaldehyde 3351-60-8P, 4-(2-Bromoethoxy)biphenyl  
 16251-33-5P, 1-Bromo-3-(4-phenoxyphenyl)propane 19070-95-2P,  
 2-(Biphenyl-4-yloxy)ethanol 23418-85-1P, Toluene-4-sulfonic acid  
 but-3-ynyl ester 29169-19-5P 54334-74-6P, (Biphenyl-4-yloxy)acetic  
 acid ethyl ester 63457-51-2P, 1-(3-Bromopropoxy)-4-phenoxybenzene  
 69455-12-5P, 4-Benzyloxy-3-bromobenzaldehyde 87545-48-0P,  
 4-(2-Bromoethoxy)phenoxybenzene 96363-80-3P, Methanesulfonic acid  
 3-dimethylaminopropyl ester 102229-10-7P,  
 2-(tert-Butyldimethylsilanyloxy)ethanol 111915-33-4P,  
 4-(2,2,3,3-Tetrafluoropropoxy)phenol 113795-28-1P,  
 4-(3-Bromopropoxy)biphenyl 119437-35-3P,  
 1-Chloro-3-(4-phenoxyphenyl)propane 128316-64-3P,  
 3-(4-Benzyloxyphenyl)-2-hydroxypropanoic acid methyl ester  
 156335-14-7P, Methyl 3-(4-hydroxyphenyl)-2-methoxypropanoate  
 156335-15-8P, 2-Ethoxy-3-(4-hydroxyphenyl)propionic acid methyl  
 ester 156659-87-9P, (2S,4S)-4-(tert-Butyldimethylsilanyloxy)pentan-2-ol  
 162919-37-1P 173025-78-0P, 3-(Biphenyl-4-yloxy)propan-1-ol  
 183612-97-7P, (1R\*,3S\*)-3-(tert-Butyldimethylsilanyloxy)cyclopentanol  
 183795-20-2P, trans-3-(tert-Butyldimethylsilanyloxy)cyclopentanol  
 211617-68-4P 222835-03-2P, 3-(4-Benzyloxyphenyl)-2-ethoxyacrylic acid  
 ethyl ester 223126-28-1P, 3-(4-Benzyloxyphenyl)-2-ethoxypropionic acid  
 ethyl ester 251978-39-9P, 3-(4-Hydroxyphenyl)-2-phenoxypropanoic  
 acid methyl ester 267228-40-0P, (S)-3-(4-Benzyloxyphenyl)-2-  
 hydroxypropionic acid ethyl ester 267228-41-1P,  
 (2S)-2-Hydroxy-3-(4-hydroxyphenyl)propionic acid ethyl ester  
 325827-53-0P, (S)-3-(4-Hydroxyphenyl)-2-isopropoxypropionic acid  
 ethyl ester 361576-28-5P, 3-(4-Benzyloxyphenyl)-2-ethoxy-3-  
 hydroxypropionic acid ethyl ester 477979-19-4P,

(2S)-2-Methoxy-3-(4-trifluoromethanesulfonyloxyphenyl)propionic acid ethyl ester 477979-21-8P, (2S)-3-[4-(3-Hydroxyprop-1-ynyl)phenyl]-2-methoxypropionic acid ethyl ester 477979-26-3P, (2S)-3-[4-(3-Chloroprop-1-ynyl)phenyl]-2-methoxypropionic acid ethyl ester 477979-44-5P, (2S)-3-[4-(5-Hydroxypent-1-ynyl)phenyl]-2-methoxypropionic acid ethyl ester 477979-49-0P, 3-[4-(5-Bromopent-1-ynyl)phenyl]-2-methoxypropionic acid ethyl ester 477979-66-1P, 4-But-3-ynyloxybiphenyl 477979-67-2P, (2S)-3-[4-[4-(Biphenyl-4-yloxy)but-1-ynyl]phenyl]-2-methoxypropionic acid ethyl ester 477979-69-4P, 1-(But-3-ynyloxy)-4-phenoxybenzene 477979-71-8P, [4-(But-3-ynyloxy)phenyl]phenylmethanone 477979-72-9P, (2S)-3-[4-[4-(4-Benzoylphenoxy)but-1-ynyl]phenyl]-2-methoxypropionic acid ethyl ester 477979-80-9P, (2S)-3-[4-(6-Hydroxyhex-1-ynyl)phenyl]-2-methoxypropionic acid ethyl ester 477979-88-7P, (2S)-3-[4-[4-(4-Benzoylphenoxy)butyryl]phenyl]-2-methoxypropionic acid ethyl ester 477979-96-7P, cis-2-(tert-Butyldimethylsilanyloxy)cyclopentanol 477979-97-8P 477979-99-0P 477980-00-0P 477980-11-3P, (2R,3S)-3-(4-Phenoxyphenoxy)butan-2-ol 477980-12-4P 477980-13-5P 477980-20-4P, (2S)-3-(3'-Hydroxymethylbiphenyl-4-yl)-2-methoxypropionic acid ethyl ester 477980-23-7P 477980-24-8P 477980-35-1P 477980-36-2P, 3-(Biphenyl-4-yloxy)cyclohexanol 477980-37-3P, (trans)-3-(Biphenyl-4-yloxy)cyclohexanol 477980-38-4P, (cis)-3-(Biphenyl-4-yloxy)cyclohexanol 477980-44-2P, (2S)-3-[4-(tert-Butyldimethylsilanyloxy)phenyl]-2-methoxypropionic acid 477980-45-3P, (2S)-3-[4-(3-Hydroxypropoxy)phenyl]-2-methoxypropionic acid 477980-56-6P, (2S)-3-[4-(2-Hydroxyethoxy)phenyl]-2-methoxypropanoic acid 477980-59-9P, (2S)-3-(4-Ethynylphenyl)-2-methoxypropionic acid ethyl ester 477980-60-2P, (2S)-3-(4-Acetylphenyl)-2-methoxypropionic acid ethyl ester 477980-61-3P, (2S)-3-[4-(2-Bromoacetyl)phenyl]-2-methoxypropionic acid ethyl ester 477980-66-8P, (2S)-3-[4-(4-Hydroxybutyl)phenyl]-2-methoxypropionic acid ethyl ester 477980-69-1P, 3-(4-Benzoyloxy-3-methoxyphenyl)-3-hydroxy-2-methoxypropionic acid methyl ester 477980-70-4P, 3-(4-Hydroxy-3-methoxyphenyl)-2-methoxypropionic acid methyl ester 477980-71-5P, 3-(4-Hydroxy-3-methoxyphenyl)-2-methoxypropionic acid 477980-72-6P, 3-[4-(tert-Butyldimethylsilanyloxy)-3-methoxyphenyl]-2-methoxypropionic acid 477980-76-0P, 3-(4-Hydroxy-3-methoxyphenyl)-2-methoxypropionic acid ethyl ester 477980-77-1P, 3-[4-[3-(Biphenyl-4-yloxy)propoxy]-3-methoxyphenyl]-2-methoxypropionic acid ethyl ester 477980-80-6P, (2S)-3-(3-Chloro-4-hydroxyphenyl)-2-methoxypropionic acid ethyl ester 477980-82-8P, (2S)-3-[4-[3-(Biphenyl-4-yloxy)propoxy]-3-chlorophenyl]-2-methoxypropionic acid ethyl ester 477980-84-0P, 2-(3-Fluoro-4-methoxyphenyl)-[1,3]dioxolane 477980-85-1P, 4-[1,3]Dioxolan-2-yl-2-fluorophenol 477980-86-2P, 4-[3-(Biphenyl-4-yloxy)propoxy]-3-fluorobenzaldehyde 477980-87-3P, 3-[4-[3-(Biphenyl-4-yloxy)propoxy]-3-fluorophenyl]-3-hydroxy-2-methoxypropionic acid methyl ester 477980-88-4P, 3-[4-[3-(Biphenyl-4-yloxy)propoxy]-3-fluorophenyl]-2-methoxypropionic acid methyl ester 477980-90-8P, 4-Benzoyloxy-3-trifluoromethylbenzaldehyde 477980-91-9P, 3-(4-Hydroxy-3-trifluoromethylphenyl)-2-methoxyacrylic acid methyl ester 477980-92-0P, 3-[4-[3-(Biphenyl-4-yloxy)propoxy]-3-trifluoromethylphenyl]-2-methoxyacrylic acid methyl ester 477980-93-1P, 3-[4-[3-(Biphenyl-4-yloxy)propoxy]-3-trifluoromethylphenyl]-2-methoxyacrylic acid 477980-95-3P 477980-96-4P, (2S)-3-(6-Hydroxy-4'-methoxybiphenyl-3-yl)-2-methoxypropionic acid ethyl ester 477980-97-5P, (2S)-3-[6-[3-(Biphenyl-4-yloxy)propoxy]-4'-methoxybiphenyl-3-yl]-2-methoxypropionic acid ethyl ester 477981-00-3P, 2-Methyl-4-(triisopropylsilanyloxy)benzaldehyde 477981-01-4P,

3-[4-[3-(Biphenyl-4-yloxy)propoxy]-2-methylphenyl]-2-methoxyacrylic acid  
 methyl ester 477981-02-5P, 3-(4-Hydroxy-2-methylphenyl)-2-methoxyacrylic  
 acid 477981-04-7P, 3-[4-[3-(Biphenyl-4-yloxy)propoxy]-2-methylphenyl]-2-  
 methoxypropionic acid methyl ester 477981-07-0P,  
 3-(3-Hydroxyphenyl)-2-methoxypropionic acid methyl ester 477981-20-7P,  
 (2S)-3-[4-(3-Bromopropoxy)phenyl]-2-methoxypropionic acid ethyl ester  
 477981-27-4P, (S)-5-(4-Benzoyloxybenzyl)-2,2-dimethyl-[1,3]dioxolan-4-one  
 477981-33-2P, (S)-5-(4-Hydroxybenzyl)-2,2-dimethyl-[1,3]dioxolan-4-one  
 477982-20-0P, 4-[3-(Biphenyl-4-yloxy)propoxy]-2-fluorobenzaldehyde  
 477982-21-1P, 3-[4-[3-(Biphenyl-4-yloxy)propoxy]-2-fluorophenyl]-3-hydroxy-  
 2-methoxypropionic acid methyl ester 477982-22-2P,  
 3-[4-[3-(Biphenyl-4-yloxy)propoxy]-2-fluorophenyl]-2-methoxypropionic acid  
 methyl ester 477982-24-4P, 3-(4-Benzoyloxyphenyl)-2-(4-  
 chlorophenoxy)propanoic acid methyl ester 477982-25-5P,  
 2-Phenoxy-3-[4-[3-(4-phenoxyphenoxy)propoxy]phenyl]propanoic acid methyl  
 ester 477982-27-7P, Methyl 3-hydroxy-2-methoxy-3-[4-  
 (phenylmethoxy)phenyl]propanoate 477982-28-8P,  
 3-(4-Hydroxyphenyl)-2-methoxypropanoic acid 477982-29-9P 477982-30-2P,  
 Ethyl (2S)-2-methoxy-3-[4-[3-(4-phenoxyphenoxy)propoxy]phenyl]propanoate  
 477982-37-9P, (2S)-2-Hydroxy-3-[4-[3-(4-  
 phenoxyphenoxy)propoxy]phenyl]propionic acid ethyl ester 477982-38-0P,  
 (2S)-2-Ethoxy-3-[4-[3-(4-phenoxyphenoxy)propoxy]phenyl]propionic acid  
 ethyl ester 477982-41-5P, (2S)-3-[4-[3-[4-(4-  
 Hydroxybenzoyl)phenoxy]propoxy]phenyl]-2-methoxypropionic acid ethyl ester  
 477982-42-6P, (2S)-3-[4-[3-[4-[4-[2-(tert-  
 Butyldimethylsilyloxy)ethoxy]benzoyl]phenoxy]propoxy]phenyl]-2-  
 methoxypropionic acid ethyl ester 477982-45-9P,  
 (2S)-2-Allyloxy-3-(4-benzyloxyphenyl)propionic acid ethyl ester  
 477982-46-0P, (2S)-3-(4-Hydroxyphenyl)-2-propoxypropionic acid  
 ethyl ester 477982-47-1P, (2S)-3-[4-[3-(4-Phenoxyphenoxy)propoxy]phenyl]-  
 2-propoxypropionic acid ethyl ester 477982-49-3P,  
 (2S)-3-[4-[3-(4-Benzoylphenoxy)propoxy]phenyl]-2-ethoxypropionic acid  
 methyl ester 477982-51-7P, (2S)-3-[4-[3-(4-Benzylphenoxy)propoxy]phenyl]-  
 2-ethoxypropionic acid ethyl ester 477982-53-9P,  
 (2S)-3-(3-Chloro-4-hydroxyphenyl)-2-ethoxypropionic acid ethyl ester  
 477982-54-0P, (2S)-3-[4-[3-(4-Benzoylphenoxy)propoxy]-3-chlorophenyl]-2-  
 ethoxypropionic acid ethyl ester 477982-56-2P,  
 3-[4-(3-Hydroxypropoxy)-3-methoxyphenyl]-2-methoxypropionic acid methyl  
 ester 477982-57-3P, (2S)-4'-[3-[2-Methoxy-4-(2-methoxy-2-  
 methoxycarbonyl)ethoxy]phenoxy]propoxy]biphenyl-4-carboxylic acid methyl  
 ester 477982-59-5P, 3-[4-(3-Bromopropoxy)-2-methoxy-phenyl]-2-  
 methoxypropionic acid methyl ester 477982-61-9P,  
 (2S)-3-[4-[3-(4'-tert-Butylbiphenyl-4-yloxy)propoxy]-2-methoxyphenyl]-2-  
 methoxypropionic acid methyl ester 477982-64-2P,  
 4-(2,2,3,3-Tetrafluoropropoxy)-1-benzyloxybenzene 477982-65-3P,  
 (2S)-2-Methoxy-3-[4-[3-[4-(2,2,3,3-  
 tetrafluoropropoxy)phenoxy]propoxy]phenyl]propionic acid ethyl ester  
 477982-68-6P, (2S)-3-[4-[3-(4-Benzoyloxyphenoxy)propoxy]phenyl]-2-  
 methoxypropionic acid ethyl ester 477982-69-7P,  
 (2S)-3-[4-[3-(4-Hydroxyphenoxy)propoxy]phenyl]-2-methoxypropionic acid  
 ethyl ester 477982-70-0P, (2S)-2-Methoxy-3-[4-[3-[4-(3-  
 methylbutoxy)phenoxy]propoxy]phenyl]propionic acid ethyl ester  
 477982-78-8P, (2S)-3-[4-[3-(4-Iodophenoxy)propoxy]phenyl]-2-  
 methoxypropionic acid ethyl ester 477982-79-9P,  
 (2S)-3-[4-[3-[4-(1H-Indol-5-yl)phenoxy]propoxy]phenyl]-2-methoxypropionic  
 acid ethyl ester 477982-84-6P, (2S)-3-[4-[3-(4'-Cyanobiphenyl-4-  
 yloxy)propoxy]phenyl]-2-methoxypropionic acid ethyl ester 477982-86-8P,  
 (2S)-2-Methoxy-3-[4-[3-[4'-(1H-tetrazol-5-yl)biphenyl-4-  
 yloxy]propoxy]phenyl]propionic acid ethyl ester 477982-91-5P,  
 (2S)-2-Methoxy-3-[4-[3-[4-(piperazin-1-yl)phenoxy]propoxy]phenyl]propionic

acid ethyl ester 477982-93-7P, (2S)-2-Methoxy-3-[4-[3-[4-(morpholin-4-yl)phenoxy]propoxy]phenyl]propionic acid ethyl ester 477982-95-9P, 3-[4-[3-(Biphenyl-4-yloxy)propoxy]-2-chlorophenyl]-2-hydroxypropionic acid 477982-97-1P, (2S)-3-[4-(2-Bromoethoxy)phenyl]-2-methoxypropionic acid ethyl ester 477983-02-1P, 3-(3-Benzyloxyphenyl)-3-hydroxy-2-methoxypropionic acid methyl ester 477983-03-2P, 3-(3-Benzyloxyphenyl)-2-methoxyacrylic acid methyl ester 477983-04-3P 477983-05-4P, 3-(3-Benzyloxyphenyl)-2-methoxypropionic acid methyl ester 477983-44-1P, 3-[3-(3-Bromopropoxy)phenyl]-2-methoxypropionic acid methyl ester 477983-82-7P, 3-[3-(2-Bromoethoxy)phenyl]-2-methoxypropionic acid methyl ester 477984-10-4P, (2S)-3-(4-Benzyloxyphenyl)-2-propoxypropionic acid ethyl ester 477984-12-6P, 2-Ethoxy-3-(3-hydroxyphenyl)propionic acid methyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of substituted (phenyl)(alkoxy)propanoic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

IT 186895-45-4P, 3-(4-Benzyloxyphenyl)propionic acid ethyl ester 477980-81-7P, (2S)-3-(3,5-Dichloro-4-hydroxyphenyl)-2-methoxypropionic acid ethyl ester

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of substituted (phenyl)(alkoxy)propanoic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

L20 ANSWER 7 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:793403 CAPLUS Full-text

DOCUMENT NUMBER: 137:310931

TITLE: Preparation of phenylalkanoic acid derivatives as preventive or remedial agents for digestive tract diseases

INVENTOR(S): Horizoe, Tatsuo; Shinoda, Masanobu; Emori, Eita; Matsuura, Fumiyoshi; Kaneko, Toshihiko; Ohi, Norihito; Kasai, Shunji; Yoshitomi, Hideki; Yamazaki, Kazuto; Miyashita, Sadakazu; Hihara, Taro; Seiki, Takashi; Clark, Richard; Harada, Hitoshi

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: PCT Int. Appl., 344 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2002080899	A1	20021017	WO 2002-JP3006	20020327 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002242989	A1	20021021	AU 2002-242989	20020327 <--
PRIORITY APPLN. INFO.:			JP 2001-101465	A 20010330 <--
			JP 2001-105131	A 20010403 <--
			WO 2002-JP3006	W 20020327 <--

OTHER SOURCE(S):           MARPAT 137:310931  
GI

/ Structure 123 in file .gra /

AB     Disclosed is a preventive/remedy for digestive tract or inflammatory diseases, which contains as the active ingredient a novel carboxylic acid derivative represented by the following formula [I; R<sub>1</sub> = H, OH, each (un)substituted C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 hydroxyalkyl, C1-6 hydroxyalkoxy, C1-6 hydroxyalkylthio, C1-6 aminoalkyl, C1-6 aminoalkoxy, C1-6 aminoalkylthio, C2-12 alkoxyalkyl, C3-7 cycloalkyl, C3-7 cycloalkyloxy, C3-7 cycloalkylthio, C2-6 alkenyl, C2-6 alkenyloxy, or C2-6 alkenylthio, etc.; L = a single or double bond, each (un)substituted C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene; M = a single bond, each (un)substituted C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene; T = a single bond, each (un)substituted C1-3 alkylene, C2-3 alkenylene, or C2-3 alkynylene; W = 2,4-dioxothiazolidin-5-yl, 2,4-dioxothiazolidin-5-ylidene, carboxy, (un)substituted CONH<sub>2</sub>; X = O, (un)substituted C2-6 alkenylene, hydroxymethylene, CO, CS, N-(un)substituted CQN<sub>H</sub>, NHCQ, SO<sub>2</sub>NH, NHSO<sub>2</sub>, or NHCQN<sub>H</sub> (Q = O, S); Y = (un)substituted C5-12 aromatic hydrocarb<sub>yl</sub> or C3-7 aliphatic hydrocarb<sub>yl</sub> optionally containing ≥1 heteroatoms; ring Z = C5-6 aromatic hydrocarb<sub>yl</sub>; Y = (un)substituted aromatic hydrocarbon group optionally containing ≥1 heteroatoms; some provisos given], a salt of the derivative, or a hydrate of either. The above digestive tract diseases include (1) inflammatory digestive tract diseases such as ulcerous colitis, Crohn's disease, pancreatitis, and gastritis, (2) digestive tract proliferative diseases such as digestive tract benign tumors, digestive tract polyp, hereditary (genetic) polyposis syndromes, colon cancer, rectum cancer, and stomach cancer, and (3) digestive tract ulcerous diseases such as duodenal ulcer, stomach ulcer, esophagus ulcer, regurgitant esophagitis, stress ulcer or erosion, erosion caused by drugs, and Zollinger-Ellison syndromes. The above inflammatory diseases include arthritic rheumatism, multiple sclerosis, immunodeficiency, cachexia, osteoarthritis, osteoporosis, asthma, and allergy. The compds. I are triple agonists for PPAR (peroxisome proliferator-activated receptor) α, β, and γ subtype. Thus, 2-isopropoxy-3-[4-methoxy-3-[[[4-(trifluoromethyl)benzyl]amino]carbonyl]phenyl]propanoic acid in vitro showed the transcription activity for PPARα, β, and γ with EC<sub>50</sub> of 0.08, 2.513, and 0.382 μM, resp., in CV-1 cell. (2S)-3-[3-[[[(2,4-dichlorobenzoyl)amino]methyl]-4-methoxyphenyl]-2-isopropoxypropanoic acid at 1 mg/kg/day p.o. for 3 days showed a disease activity index based on diarrhea, bloody excrement, and weight loss (DAI) of 2.0±0.3 in mice suffering from colitis induced by dextran sulfate sodium salt vs. 2.8±0.2 for the control group and 2.1±0.3 for the mice treated with rosiglitazone at 30 mg/kg/day. Many compds. prepared do not possess the thiazolidine skeleton and thereby may completely avoid toxicity such as liver disorder which was noted in the past as a problem for compds. having PPARγ agonist activity.

L20 ANSWER 8 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:       2002:286703 CAPLUS Full-text

DOCUMENT NUMBER:       136:309930

TITLE:                   Preparation of benzimidazole derivatives for treatment and prevention of diabetes

INVENTOR(S):           Fujita, Takashi; Wada, Kunio; Koguchi, Minoru; Honma, Eiji; Fujiwara, Toshihiko

PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 135 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002114781	A	20020416	JP 2000-307157	20001006 <--
PRIORITY APPLN. INFO.:			JP 2000-307157	20001006 <--
OTHER SOURCE(S):	MARPAT	136:309930		

GI

/ Structure 124 in file .gra /

AB The title compds. I [R1 - R6 = H, alkyl, etc.; n, q = 1 - 5; Q, Y = O, S; X = CH2, etc.; Z = CH, N; A = (CH2)mCH(CO2H)BR7, etc.; B = O, etc.; R7 = H, alkyl, etc.; m = 0 - 8] are prepared Compds. of this invention at 0.01% in feed (given for 3 days) gave 34.9% to 66.7% decrease of blood sugar in diabetic KK mice.

TI Preparation of benzimidazole derivatives for treatment and prevention of diabetes

PI JP 2002114781 A 20020416

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002114781	A	20020416	JP 2000-307157	20001006 <--
JP 2000-307157		20001006	<--	

IT Arteriosclerosis  
 Arthritis  
 Autoimmune disease  
 Cachexia  
 Cardiovascular system, disease  
 Glaucoma (disease)  
 Gout  
 Hypertension  
 Osteoporosis  
 Rheumatoid arthritis

(preparation and effect of benzimidazole derivs.)

IT 62517-34-4P	300666-00-6P	300666-01-7P	300666-02-8P	
300666-03-9P	300666-04-0P	300666-05-1P	300666-06-2P	300666-07-3P
300666-08-4P	300666-09-5P	300666-10-8P	300666-11-9P	300666-12-0P
300666-13-1P	300666-14-2P	300666-15-3P	300666-16-4P	300666-17-5P
300666-18-6P	300666-19-7P	300666-20-0P	300666-21-1P	300666-22-2P
300666-23-3P	300666-24-4P	300666-25-5P	300666-26-6P	300666-27-7P
300666-28-8P	300666-29-9P	300666-30-2P	300666-31-3P	300666-32-4P
300666-33-5P	300666-34-6P	300666-35-7P	300666-36-8P	300666-37-9P
300666-38-0P	300666-39-1P			

RL: RCT (Reactant); SPN (Synthetic preparation); PREP  
 (Preparation); RACT (Reactant or reagent)  
 (preparation of benzimidazole derivs. for treatment and prevention of diabetes)



DOCUMENT NUMBER: 136:200176  
 TITLE: Preparation of  
 3-[(oxazolylalkoxy)phenyl]-2-phenoxypropionic acid  
 derivatives as PPAR agonists for treatment of diabetes  
 mellitus and related conditions  
 INVENTOR(S): Ardecky, Robert J.; Brooks, Dawn Alisa; Godfrey,  
 Alexander Glenn; Jones, Sarah Beth; Mantlo, Nathan  
 Bryan; McCarthy, James Ray; Michellys, Pierre-Yves;  
 Rito, Christopher John; Tyhonas, John S.; Winneroski,  
 Leonard Larry; Xu, Yanping  
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Ligand Pharmaceuticals  
 SOURCE: PCT Int. Appl., 217 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002016332	A1	20020228	WO 2001-US22617	20010823 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2418134	A1	20020228	CA 2001-2418134	20010823 <--
AU 2001084660	A	20020304	AU 2001-84660	20010823 <--
EP 1313717	A1	20030528	EP 2001-963734	20010823 <--
EP 1313717	B1	20071017		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004506722	T	20040304	JP 2002-521433	20010823 <--
AT 375985	T	20071115	AT 2001-963734	20010823 <--
ES 2295200	T3	20080416	ES 2001-963734	20010823 <--
MX 2003PA01610	A	20030910	MX 2003-PA1610	20030221 <--
US 20040138277	A1	20040715	US 2003-343187	20030729 <--
US 7176224	B2	20070213		
PRIORITY APPLN. INFO.:			US 2000-227456P	P 20000823 <--
			WO 2001-US22617	W 20010823 <--
OTHER SOURCE(S):			MARPAT 136:200176	
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [wherein n = 2-4; R1 = H, (halo)alkyl, or Ph; R2 and R3 = independently H, alkyl, cycloalkyl(alkyl), alkoxy, or aryl(alkyl); or R2 forms (tetrahydro)naphthyl together with the Ph to which they are bound; R4 = alkyl; R5 = independently H or (un)substituted (hetero)aryl, with provisos; R6 = H or (amino)alkyl; R7 and R8 = independently H, (cyclo)alkyl, (halo)alkoxy, or halo(alkyl); or R8 form benzodioxolyl together with the Ph to which they are bound; and pharmaceutically acceptable salts, solvates, and hydrates thereof] were prepared as agonists of peroxisome proliferator activated receptors

(PPARs). For example, 2-[2-(3-bromophenyl)-5-methyloxazol-4-yl]ethanol was coupled with p-fluorophenyl boronic acid in the presence of PPh<sub>3</sub>, Pd(OAc)<sub>2</sub>, and Na<sub>2</sub>CO<sub>3</sub> to give the biphenyl derivative (36%). Esterification with tosyl anhydride in the presence of pyridine and DMAP, followed by reaction with 3-(4-hydroxyphenyl)-2-methyl-2-phenoxypionic acid Et ester in the presence of polystyrene bound 1,5,7-triazabicyclo[4.4.0]dec-5-ene and hydrolysis with NaOH, afforded II (24%). The latter bound to PPAR $\alpha$  and PPAR $\gamma$  with IC<sub>50</sub> values of 147 nM and 41 nM, resp., and activated the nuclear transcription factors huPPAR $\alpha$  and huPPAR $\gamma$  with cotransfection efficacies of 38% and 93%, resp. In addition, HDLc serum levels increased by 40.4% in male transgenic mice dosed with 30 mg/kg of II, and glucose levels were normalized to 91% in male diabetic (db/db) mice dosed with 30 mg/kg of II. Thus, I are useful in the treatment and prevention of diabetes mellitus and related conditions.

L20 ANSWER 10 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:115318 CAPLUS Full-text

DOCUMENT NUMBER: 134:177470

TITLE: Process for the preparation of substituted  
3-phenyl-propanoic acid esters and substituted  
3-phenyl-propanoic acids

INVENTOR(S): Ebdrup, Soren; Deussen, Heinz-Josef W.; Zundel,  
Magali; Bury, Paul Stanley

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.

SOURCE: PCT Int. Appl., 118 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001011073	A1	20010215	WO 2000-DK440	20000807 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1206565	A1	20020522	EP 2000-952953	20000807 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2003506065	T	20030218	JP 2001-515321	20000807 <--
WO 2002012472	A1	20020214	WO 2001-DK508	20010719 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001081739	A	20020218	AU 2001-81739	20010719 <--
EP 1309674	A1	20030514	EP 2001-960183	20010719 <--
EP 1309674	B1	20070613		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

AT 364691	T	20070715	AT 2001-960183	20010719 <--
ES 2288976	T3	20080201	ES 2001-960183	20010719 <--
US 20030008361	A1	20030109	US 2002-132428	20020424 <--
US 20030199048	A1	20031023	US 2003-343879	20030205 <--
US 7091023	B2	20060815		

PRIORITY APPLN. INFO.:

DK 1999-1101	A	19990805 <--
US 1999-148643P	P	19990812 <--
US 2000-633613	B1	20000807 <--
WO 2000-DK439	A	20000807 <--
WO 2000-DK440	W	20000807 <--
DK 2001-88	A	20010117 <--
US 2001-263364P	P	20010123 <--
WO 2001-DK508	W	20010719 <--

OTHER SOURCE(S): CASREACT 134:177470; MARPAT 134:177470

AB A process is provided for the preparation of optically enriched substituted esters of 3-phenyl-propanoic acids and substituted 3-phenyl-propanoic acids by the hydrolysis or transesterification of one of the two enantiomeric forms of a racemic or enantiomerically enriched 3-phenyl-propanoic acid ester by an enzyme. This enzymic resolution may be catalyzed by a large number of com. available lipases, proteases, peptidases, esterases or other hydrolytic enzymes. Thus, Et (2RS)-2-ethoxy-3-(4-hydroxyphenyl)propanoic acid ester was converted to (2S)-2-ethoxy-3-(4-hydroxyphenyl)propanoic acid and Et (2R)-2-ethoxy-3-(4-hydroxyphenyl)propanoic acid ester by immobilized Mucor mihei lipase in 9 h with an enantiomeric selectivity of 81% for the ester.

=> d 120 ibib abs ti hit 11-15

L20 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:742095 CAPLUS Full-text

DOCUMENT NUMBER: 133:296438

TITLE: Preparation of substituted fused imidazole derivatives as hypoglycemics

INVENTOR(S): Fujita, Takashi; Wada, Kunio; Oguchi, Minoru; Honma, Hidehito; Fujiwara, Toshihiko

PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan

SOURCE: PCT Int. Appl., 274 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2000061582	A1	20001019	WO 2000-JP2217	20000406 <--
W: AU, BR, CA, CN, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, TR, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 2000351777	A	20001219	JP 2000-105985	20000407 <--

PRIORITY APPLN. INFO.:

JP 1999-101369	A	19990408 <--
----------------	---	--------------

OTHER SOURCE(S): MARPAT 133:296438

GI

/ Structure 125 in file .gra /

AB Compds. represented by general formula (I) and salts and esters thereof [wherein R1 is hydrogen, C1-6 alkyl, (un)substituted C6-10 aryl or C7-16 aralkyl, HO, (un)substituted acyloxy, C1-6 alkoxy, (un)substituted NH2, etc.; R2 is hydrogen, C1-6 alkyl, or (un)substituted C7-16 aralkyl; R4, R4, or R5 is each hydrogen, C1-6 alkyl, or C1-6 alkoxy; R6 is hydrogen, C1-6 alkyl, (un)substituted C6-10 aryl or C7-16 aralkyl; Q and Y are each oxygen or sulfur; X is CH2, CO, CH(OR9), or C(:NOR10); wherein R9 or R10 is hydrogen, (un)substituted C1-6 alkyl, C7-16 aralkyl, or acyl; Z is CH or nitrogen; n and q are each 1 to 5; and A is a group represented by general formula Q1, Q2, Q3, or (CH2)m CH(CO2H)-BR7; wherein m is 0 to 8; X1 is oxygen or sulfur; B is oxygen, sulfur, or (un)substituted NH; and R7 is hydrogen, C1-6 alkyl, (un)substituted C6-10 aryl or C7-16 aralkyl, or haloalkyl] are prepared These compds. are useful as insulin resistance improvers, hypoglycemics, antiinflammatory agents, immunomodulators, aldose reductase inhibitors, 5-lipoxygenase inhibitors, lipid peroxide-formation inhibitors, peroxisome proliferator-activated receptor (PPAR) activators, anti-osteoporosis agents, leukotriene antagonists, promoters of fat cell formation, cancer cell-proliferation inhibitors, or calcium antagonists. They are useful for the prevention or treatment of diabetes, hyperlipidemia, obesity, glucose tolerance insufficiency, hypertension, fatty liver, diabetes complication, arteriosclerosis, gestational diabetes, polycystic ovarian syndrome, cardiovascular diseases, cell damages caused by atherosclerosis or ischemic heart diseases, gout, osteoarthritis, rheumatic arthritis, allergic diseases, asthma, gastrointestinal ulcer, cachexia, autoimmune diseases, cancer, osteoporosis, or cataract. Thus, N-[2-amino-5-(6-methoxymethoxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)phenyl]-N-methylcarbamic acid tert-Bu ester was condensed with 4-(2,4-dioxothiazolin-5-ylmethyl)phenoxyacetic acid using di-Et cyanophosphate and Et3N in THF at room temperature for 30 min, followed by treatment of the product with 4 N HCl/dioxane at room temperature for 5 h gave 5-[4-[6-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione hydrochloride (II.HCl). When a feed containing 0.01% II.HCl was fed to mice for 3 days, the blood sugar level was lowered by 66.7% compared to control animal.

L20 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1999:383506 CAPLUS Full-text  
DOCUMENT NUMBER: 131:179289  
TITLE: Non-thiazolidinedione antihyperglycemic agents. Part  
3: The effects of stereochemistry on the potency of  
 $\alpha$ -methoxy- $\beta$ -phenylpropanoic acids  
AUTHOR(S): Haigh, David; Allen, Graham; Birrell, Helen C.;  
Buckle, Derek R.; Cantello, Barrie C. C.; Eggleston,  
Drake S.; Haltiwanger, R. Curtis; Holder, Julie C.;  
Lister, Carolyn A.; Pinto, Ivan L.; Rami, Harshad K.;  
Sime, John T.; Smith, Stephen A.; Sweeney, John D.  
CORPORATE SOURCE: SmithKline Beecham Pharmaceuticals, Essex, CM19 5AW,  
UK  
SOURCE: Bioorganic & Medicinal Chemistry (1999),  
7(5), 821-830  
CODEN: BMECEP; ISSN: 0968-0896  
PUBLISHER: Elsevier Science Ltd.  
DOCUMENT TYPE: Journal

LANGUAGE: English  
GI

/ Structure 126 in file .gra /

AB Rhizopus delemar lipase catalyzed ester hydrolysis of the  $\alpha$ -methoxy- $\beta$ -phenylpropanoate (I) affords the (R)-(+ and (S)-(-) isomers in > 84% enantiomeric excess. Absolute stereochem. was determined by a single crystal X-ray anal. of a related synthetic analog. The activity of these two enantiomers on glucose transport in vitro and as anti-diabetic agents in vivo is reported and their unexpected equivalence attributed to an enzyme-mediated stereospecific isomerization of the (R)-(+ isomer. Binding studies using recombinant human PPAR $\gamma$  (peroxisomal proliferator activated receptor  $\gamma$ ), now established as a mol. target for this compound class, indicate a 20-fold higher binding affinity for the (S) antipode relative to the (R) antipode.

L20 ANSWER 13 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:244628 CAPLUS Full-text

DOCUMENT NUMBER: 130:296612

TITLE: Preparation of amidocarboxylic acid derivatives as inhibitors of aldose reductase, 5-lipoxygenase, and lipid peroxide formation and as peroxisome proliferator-activated receptor (PPAR) activators

INVENTOR(S): Yanagisawa, Hiroaki; Sakurai, Mitsuya; Takamura, Makoto; Fujiwara, Toshihiko

PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan

SOURCE: PCT Int. Appl., 720 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9918066	A1	19990415	WO 1998-JP4396	19980930 <--
W: AU, BR, CA, CN, CZ, HU, ID, IL, JP, KR, MX, NO, NZ, PL, RU, TR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2305808	A1	19990415	CA 1998-2305808	19980930 <--
AU 9892798	A	19990427	AU 1998-92798	19980930 <--
AU 738134	B2	20010906		
EP 1026149	A1	20000809	EP 1998-945527	19980930 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9813019	A	20000905	BR 1998-13019	19980930 <--
TR 200000896	T2	20000921	TR 2000-896	19980930 <--
HU 2000003881	A2	20010129	HU 2000-3881	19980930 <--
HU 2000003881	A3	20010428		
RU 2176999	C2	20011220	RU 2000-108440	19980930 <--
US 6528525	B1	20030304	US 2000-540765	20000330 <--
NO 2000001689	A	20000531	NO 2000-1689	20000331 <--
MX 200003309	A	20010629	MX 2000-3309	20000404 <--
US 20040006141	A1	20040108	US 2002-254154	20020925 <--
PRIORITY APPLN. INFO.:			JP 1997-269923	A 19971002 <--
			WO 1998-JP4396	W 19980930 <--
			US 2000-540765	A3 20000330 <--

OTHER SOURCE(S) : MARPAT 130:296612  
GI

```

/ Structure 127 in file .gra /

```

AB Claimed and prepared are amidocarboxylic acid derivs. (phenylalkanoic acids containing arylcarboxamide derivs.) represented by general formula (I), pharmacol. acceptable salts thereof, or pharmacol. acceptable esters thereof, [wherein R1 = H, linear or branched C1-6 alkyl, C7-12 aralkyl; R2 = linear or branched C1-6 alkylene; R3 = H, linear or branched alkyl C1-6 alkyl, C1-4 alkoxy, or C1-4 alkylthio, halo, NO2, di(linear or branched C1-4 alkyl)amino, (un)substituted C6-10 aryl, C7-12 aralkyl optionally having 1-5 substituents on the aryl, OH, linear or branched C1-5 aliphatic acyl; R4 = H, linear or branched C1-6 alkyl; Z = linear or branched C1-6 alkylene; W = HO, linear or branched C1-6 alkyl, C1-4 alkoxy, or C1-4 alkylthio, (un)substituted C6-10 aryl, C6-10 aryloxy, C6-10 arylthio, C7-12 aralkyloxy, C7-12 aralkylthio, or C6-10 aryloxy-linear or branched C1-4 alkyl each optionally having 1-5 substituents on the aryl, 5- to 10-membered mono- or bicyclic heteroaryloxy containing 1-4 heteroatoms selected from O, N, and S, etc.; X = C6-10 aryl optionally having 1-3 substituents, 5- to 10-membered mono- or bicyclic heteroaryl containing 1-4 heteroatoms selected from O, N, and S; Y = single bond, O, S, (un)substituted NH]. Also claimed are blood sugar- and blood lipid-lowering agents, insulin resistance improver, antiinflammatory agents, immunomodulators, aldose reductase inhibitors, 5-lipoxygenase inhibitors, lipid peroxide formation inhibitors, PPAR activators, and anti-osteoporosis agents and therapeutic or prophylactic agents for diabetes, hyperlipemia, obesity, impaired glucose tolerance, insulin resistant non-impaired glucose tolerance, fatty liver, diabetes complications, gestational diabetes mellitus, polycystic ovary syndrome, osteoarthritis, rheumatoid arthritis, allergies, asthma, cancers, autoimmune diseases, pancreatitis, and cataract. Thus, N-deprotection of Et 2-ethoxy-3-[4-(2-phthalimidoethoxy)phenyl]propionate with hydrazine hydrate in MeOH at room temperature for 1.5 h followed by amidation with 4-pyridin-2-ylbenzoic acid using carbonyl diimidazole in CH2Cl2 at room temperature for 1.5 h followed by saponification with a mixture of 1 N aqueous NaOH and MeOH and acidification gave 3-[4-[2-(4-pyridin-2-ylbenzoylamino)ethoxy]phenyl]propionic acid derivative (II.Na; R = H, R1 = Et) (III). III and (S)-II (R = H, R1 = 4-isopropoxyphenyl) in feed containing 0.01% at .apprx.10 mg drug/kg/day for 3 days lowered blood sugar level by 43 and 73%, resp. A capsule, a tablet, and a granule formulation containing III were prepared

L20 ANSWER 14 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:45114 CAPLUS Full-text

DOCUMENT NUMBER: 126:148282

ORIGINAL REFERENCE NO.: 126:28607a, 28610a

TITLE: Flavonol glycosides and phenolics from leaves of  
Cordia dichotoma

AUTHOR(S): Wang, Yan; Ohtani, Kazuhiro; Kasai, Ryoji; Yamasaki, Kazuo

CORPORATE SOURCE: Institute Pharmaceutical Sciences, Hiroshima  
University School Medicine, Hiroshima, 734, Japan

SOURCE: Natural Medicines (1996), 50(5), 367  
CODEN: NMEDEO; ISSN: 1340-3443

PUBLISHER: Japanese Society of Pharmacognosy  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Fresh leaves of *Cordia dichotoma* were extracted with MeOH. The concentrated extract was dissolved in water and successively extracted with hexane, EtOAc, and 1-BuOH. Six flavonol glycosides and two phenolic compds. were isolated from the butanol extract by a series of chromatog. Rosmarinic acid was the major constituent of the leaves of the plant, which may be responsible for the anti-inflammatory action of this plant.

TI Flavonol glycosides and phenolics from leaves of *Cordia dichotoma*

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

SO Natural Medicines (1996), 50(5), 367

CODEN: NMEDEO; ISSN: 1340-3443

IT 153-18-4P, Quercetin-3-O-rutinoside 604-80-8P,  
Isorhamnetin-3-O-rutinoside 17297-56-2P 17650-84-9P,  
Kaempferol-3-O-rutinoside 20283-92-5P, Rosmarinic acid  
55696-57-6P 55804-74-5P 99353-00-1P, Methyl rosmarinate  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation)  
(flavonol glycosides and phenolics from leaves of *Cordia dichotoma*)

L20 ANSWER 15 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:515023 CAPLUS Full-text

DOCUMENT NUMBER: 125:212112

ORIGINAL REFERENCE NO.: 125:39394h,39395a

TITLE: 3 $\alpha$ -Hydroxysteroid dehydrogenase inhibitory  
actions of flavonoids and phenylpropanoids from  
*Schizonepeta spikes*

AUTHOR(S): Matsuta, Muneto; Kanita, Rie; Saito, Yuji; Yamashita,  
Akira

CORPORATE SOURCE: Kampo Res. Lab., Kanebo Ltd., Osaka, 534, Japan

SOURCE: Natural Medicines (1996), 50(3), 204-211

CODEN: NMEDEO; ISSN: 1340-3443

PUBLISHER: Japanese Society of Pharmacognosy

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

AB Dry spikes of *Schizonepeta tenuifolia* Briquet (Labiatae) exhibited an inhibitory activity on 3 $\alpha$ -hydroxysteroid dehydrogenase. From *S. spikes*, five flavonoids (hesperidin, hesperetin, apigenin, luteolin and ladanein), five phenylpropanoids (caffeic acid, rosmarinic acid, cinnamic acid, p-coumaric acid and 2,3-di-O-cinnamoyltartaric acid) and eight new caffeic acid derivs. (schizotenuins A-F) were isolated and their structures were elucidated on the basis of NMR, IR, UV, MS and other physicochem. evidences. The inhibitory activities of all of these compds. on 3 $\alpha$ -hydroxysteroid dehydrogenase were stronger than that of aspirin. The pharmacol. effect of *S. spikes* was considered to be mainly due to luteolin, rosmarinic acid, schizotenuins A and C1, because they have strong inhibitory activities on 3 $\alpha$ -hydroxysteroid dehydrogenase, and their contents were high.

=> d 120 ibib abs ti hit 16-20

L20 ANSWER 16 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:482641 CAPLUS Full-text

DOCUMENT NUMBER: 121:82641

ORIGINAL REFERENCE NO.: 121:14837a,14840a  
TITLE: Competing O-H insertion and  $\beta$ -elimination in  
rhodium carbenoid reactions; synthesis of  
2-alkoxy-3-arylpropanoates  
AUTHOR(S): Cox, Geoffrey G.; Haigh, David; Hindley, Richard M.;  
Miller, David J.; Moody, Christopher J.  
CORPORATE SOURCE: Dep. Chem., Loughborough Univ. Tech., Leicestershire,  
KT18 5XQ, UK  
SOURCE: Tetrahedron Letters (1994), 35(19), 3139-42  
CODEN: TELEAY; ISSN: 0040-4039  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 121:82641  
GI

/ Structure 128 in file .gra /

AB Rhodium(II) carboxylate catalyzed decomposition of diazo esters 3 (shown as I)  
and PhCH<sub>2</sub>C(CO<sub>2</sub>Et)N<sub>2</sub> 4 in the presence of alcs. or water results in formation  
of 2-alkoxy- or 2-hydroxy-3-arylpropanoates, resp., by O-H insertion in  
competition with cinnamates by elimination; the ratio of insertion to  
elimination is dramatically affected by the carboxylate ligand on rhodium.  
Use of methanol-d as the alc. confirms that the alkene does not arise by  
elimination from the initial alkoxyester product.  
TI Competing O-H insertion and  $\beta$ -elimination in rhodium  
carbenoid reactions; synthesis of 2-alkoxy-3-arylpropanoates  
TI Competing O-H insertion and  $\beta$ -elimination in rhodium  
carbenoid reactions; synthesis of 2-alkoxy-3-arylpropanoates  
SO Tetrahedron Letters (1994), 35(19), 3139-42  
CODEN: TELEAY; ISSN: 0040-4039  
AB Rhodium(II) carboxylate catalyzed decomposition of diazo esters 3 (shown as I)  
and PhCH<sub>2</sub>C(CO<sub>2</sub>Et)N<sub>2</sub> 4 in the presence of alcs. or water results in formation  
of 2-alkoxy- or 2-hydroxy-3-arylpropanoates, resp., by O-H insertion in  
competition with cinnamates by elimination; the ratio of insertion to  
elimination is dramatically affected by the carboxylate ligand on rhodium.  
Use of methanol-d as the alc. confirms that the alkene does not arise by  
elimination from the initial alkoxyester product.

L20 ANSWER 17 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:169109 CAPLUS Full-text  
DOCUMENT NUMBER: 118:169109  
ORIGINAL REFERENCE NO.: 118:29012h,29013a  
TITLE: Preparation of  
(tetrazolylbiphenylmethyl)benzazepinones and related  
compounds as growth hormone release promoters  
INVENTOR(S): Fisher, Michael H.; Wyvratt, Matthew J.; Schoen,  
William R.; Devita, Robert J.  
PATENT ASSIGNEE(S): Merck and Co., Inc., USA  
SOURCE: PCT Int. Appl., 346 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9216524	A1	19921001	WO 1992-US2271	19920319 <--
W: BB, BG, BR, LK, MG, MN, MW, PL, RO, RU, SD				
US 5206235	A	19930427	US 1992-839742	19920228 <--
EP 513974	A1	19921119	EP 1992-302143	19920312 <--
EP 513974	B1	19960904		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE				
AT 142206	T	19960915	AT 1992-302143	19920312 <--
IL 101206	A	19970218	IL 1992-101206	19920312 <--
CA 2063185	A1	19920921	CA 1992-2063185	19920317 <--
AU 9213012	A	19920924	AU 1992-13012	19920319 <--
AU 653992	B2	19941020		
CN 1066070	A	19921111	CN 1992-102954	19920319 <--
CN 1033584	C	19961218		
ZA 9202009	A	19921125	ZA 1992-2009	19920319 <--
JP 06172316	A	19940621	JP 1992-112069	19920319 <--
JP 08000814	B	19960110		
HU 66796	A2	19941228	HU 1992-915	19920319 <--
RO 117326	B1	20020130	RO 1993-1245	19920319 <--
US 5310737	A	19940510	US 1993-12190	19930202 <--
PRIORITY APPLN. INFO.:			US 1991-673695	A 19910320 <--
			US 1992-839742	A 19920228 <--
			WO 1992-US2271	W 19920319 <--
OTHER SOURCE(S):	MARPAT 118:169109			
GI				

/ Structure 129 in file .gra /

AB Title compds. [I; L = (substituted) phenylene; n, w = 0, 1; p = 0-3; q = 0-4; X = CO, O, S, SO, SO<sub>2</sub>, CH(OH), CH:CH, imino; R<sub>1</sub>, R<sub>2</sub>, R<sub>7</sub>, R<sub>8</sub> = H, halo, (perfluoro)alkyl, perfluoroalkoxy, cyano, NO<sub>2</sub>, (substituted) Ph, acyl(alkyl), etc.; R<sub>4</sub>, R<sub>5</sub> = H, (substituted) Ph, alkyl, alkenyl, alkynyl, alkanoyloxy, alkoxycarbonyl, carboxy, CHO, amino; R<sub>4</sub>R<sub>5</sub> = (CH<sub>2</sub>)<sub>r</sub>B(CH<sub>2</sub>)<sub>s</sub>; B = CH<sub>2</sub>, O, imino, S, SO, SO<sub>2</sub>; r, s = 1-3; R<sub>6</sub> = H, alkyl, Ph, phenylalkyl; R<sub>9</sub> = H, (substituted) tetrazolyl, acylalkyl, aminoalkyl, carbamoylalkyl, tetrazolylalkyl, tetrazolylphenyl, tetrazolylphenoxy, etc.; A = (CH<sub>2</sub>)<sub>x</sub>CR<sub>10</sub>R<sub>11</sub>(CH<sub>2</sub>)<sub>y</sub>; x, y = 0-3; R<sub>10</sub>, R<sub>11</sub> = H, CF<sub>3</sub>, (substituted) alkyl, Ph, etc.; R<sub>10</sub>R<sub>11</sub> = (CH<sub>2</sub>)<sub>t</sub>; t = 2-6; R<sub>10</sub>, R<sub>11</sub> may be joined to R<sub>4</sub> and/or R<sub>5</sub>], were prepared for promotion of release of growth hormone (no data). Thus, 3-benzyloxycarbonylamino-3-methyl-N-[2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3R-yl]butanamide (preparation from 3-azido-2,3,4,5-tetrahydro-1H-1-benzazepin-2-one given) was stirred 15 min with NaH in DMF; N-triphenylmethyl-5-[2-(4'-bromobiphen-4-yl)]tetrazole (preparation starting from 5-phenyl-2-trityltetrazole and 4-IC<sub>6</sub>H<sub>4</sub>Me given) in DMF was added and the mixture was stirred 90 min to give 95% coupling product, which was hydrogenated in MeOH over Pd(OH)<sub>2</sub>/C for 14 h to give 89% 3-amino-3-methyl-N-[2,3,4,5-tetrahydro-2-oxo-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-1-benzazepin-3R-yl]butanamide trifluoroacetate.

ACCESSION NUMBER: 1990:459705 CAPLUS Full-text  
DOCUMENT NUMBER: 113:59705  
ORIGINAL REFERENCE NO.: 113:10119a,10122a  
TITLE: Total syntheses of potassium lespedezate and potassium  
isolespedezate, bioactive substances concerned with  
circadian rhythm in nyctinastic plants  
AUTHOR(S): Shigemori, Hideyuki; Miyoshi, Eiichi; Shizuri,  
Yoshikazu; Yamamura, Shosuke  
CORPORATE SOURCE: Fac. Sci. Technol., Keio Univ., Yokohama, 223, Japan  
SOURCE: Tetrahedron Letters (1989), 30(46), 6389-92  
CODEN: TELEAY; ISSN: 0040-4039  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 113:59705  
GI

/ Structure 130 in file .gra /

AB Potassium lespedezate (I) and potassium isolesspedezate (II) have been  
synthesized. The synthetic compds. have exhibited activities  
indistinguishable from the natural ones on leaf-opening of nyctinastic plants.

L20 ANSWER 19 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1975:443121 CAPLUS Full-text  
DOCUMENT NUMBER: 83:43121  
ORIGINAL REFERENCE NO.: 83:6811a,6814a  
TITLE: Polyphenolic acids of Lithospermum ruderale  
(Boraginaceae). I. Isolation and structure  
determination of lithospermic acid  
AUTHOR(S): Kelley, Charles J.; Mahajan, J. R.; Brooks, Lucille  
C.; Neubert, Leonard A.; Breneman, W. R.; Carmack,  
Marvin  
CORPORATE SOURCE: Dep. Chem., Indiana Univ., Bloomington, IN, USA  
SOURCE: Journal of Organic Chemistry (1975), 40(12),  
1804-15  
CODEN: JOCEAH; ISSN: 0022-3263  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI For diagram(s), see printed CA Issue.

AB A structure is proposed for lithospermic acid (I), C<sub>27</sub>H<sub>22</sub>O<sub>12</sub>, the major  
polyphenolic acid of Lithospermum ruderale and several other plant species of  
the families, Boraginaceae and Labiatae. Chromatog. on Sephadex of aqueous  
exts. of the plant yields the di-K salt of I, together with salts of lesser  
constituents which include (R)-3-(3,4-dihydroxyphenyl)lactic acid, 2-(3,4-  
dihydroxyphenyl)-3-carboxy-4-(2-carboxy-trans-vinyl)-7-hydroxycoumaran, and  
rosmarinic acid. Structures were deduced from spectral studies of the salts,  
the free acids, and also the methylated derivs., produced by the action of  
CH<sub>2</sub>N<sub>2</sub> on the free acids or Me<sub>2</sub>SO<sub>4</sub> on the salts.

L20 ANSWER 20 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1970:121115 CAPLUS Full-text  
DOCUMENT NUMBER: 72:121115

ORIGINAL REFERENCE NO.: 72:21759a,21762a  
TITLE: Fukiic acid isolated from the hydrolysate of a polyphenol in *Petasites japonicus*  
AUTHOR(S): Sakamura, Sadao; Yoshihara, Teruhiko; Toyoda, Katsuhiko  
CORPORATE SOURCE: Dep. Agr. Chem., Hokkaido Univ., Sapporo, Japan  
SOURCE: Agricultural and Biological Chemistry (1969), 33(12), 1795-7  
CODEN: ABCHA6; ISSN: 0002-1369  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB A new polyphenol was isolated from leaves, leave stems, and flower stalks of *P. japonicus*, and named as fukinic acid (I). Alkaline hydrolysis of I yielded equal moles of caffeic acid and a polyphenol, fukiic acid (II). II was crystallized as its monomethyl ester, 3,4-(HO)2C6H3CH2C(OH)(CO2H)C(OH)CO2Me, m. 188-90°.  $[\alpha]_D^{25}$  40.5° (c 1, water), C12H14O8. II was also crystallized as its dimethyl ester, m. 140°, and the dimethyl ester of the dimethyl ether derivative m., 117-18°. The structure of II was suggested to be 3,4-(HO)2C6H3CH2C(OH)(CO2H)CH(OH)CO2H based on ir and mass spectra.

=> d 120 ibib abs ti hit 21-25

L20 ANSWER 21 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1966:473090 CAPLUS Full-text  
DOCUMENT NUMBER: 65:73090  
ORIGINAL REFERENCE NO.: 65:13587d-h,13588a  
TITLE: Two diastereomeric forms of guaiacylglycerol  $\beta$ -(2-methoxyphenyl) ether and of guaiacylglycerol  
AUTHOR(S): Miksche, Gerhard E.; Gratzl, Josef; Fried-Matzka, Maria  
CORPORATE SOURCE: Chalmers Tekn. Hoegskol., Goteborg, Swed.  
SOURCE: Acta Chemica Scandinavica (1966), 20(4), 1038-43  
CODEN: ACHSE7; ISSN: 0904-213X  
DOCUMENT TYPE: Journal  
LANGUAGE: German  
GI For diagram(s), see printed CA Issue.  
AB The title compds. have been prepared as model substances to study lignin degradation products. Bromination of 109 g. Et benzylvanilloylacetate in 500 ml. CHCl3 with 17.4 ml. Br in 100 ml. CHCl3 in the presence of .apprx.75 g. (precipitated) CaCO3 gives 80% Et  $\alpha$ -bromobenzylvanilloylacetate (I), 75-90° (decomposition), which is converted to 70% Et  $\alpha$ -(2-methoxy-phenoxy) benzylvanilloylacetate (II), m. 87-9°, by treating with 60 g. K guaiacolate in 250 ml. HCONMe2 (DMF). Analogously, I with Na dihydroeugenol in DMF gives the 2-methoxy-4-propylphenoxy derivative which crystallizes in 2 modifications, a: m. 779°, b: m. 103-6°. I (5 g.) with 4.2 g. Na vanillate gives 4 g. 2-methoxy-4-formylphenoxy derivative, m. 118-20°. Reduction of 10 g. II in 150 ml. EtOH with H (1 g. Pd/C, 1 atmospheric) yields 75% Et erythro-2-(2-methoxyphenoxy)-3-hydroxy-3-(3-methoxy-4-hydroxyphenyl)propionate (III), m. 137-9° (EtOH-H2O); diacetyl derivative (from Ac2O-C5H5N) m. 106° (EtOH), b0.005 185-90°. Evaporation of the mother liquor gives 10% threo-form of III; diacetyl derivative, m. 98-100° c. (EtOH). Reduction of 6 g. erythro-III in 100 ml. anhydrous tetrahydrofuran (THF) with 3 g. LiAlH4 in 200 ml. THF, 50° c., 6 hrs., gives, on addition of H2O, precipitation with dry-ice, and extraction with AcOEt, 3.8 g. erythro-guaiacylglycerol- $\beta$ -(2methoxyphenyl) ether (IV), m. 90-2°. This ether can also be obtained by reduction of II with LiAlH4. Analogously, reduction of 2.6 g. threo-III with LiAlH4 yields 93% 1.7 g.

threo-IV, m. 119-20°. Methylation of 2 g. III in 30 ml. 1:1 MeOH-dioxane with CH<sub>2</sub>N<sub>2</sub> in Et<sub>2</sub>O yields Et erythro-2-(2-methoxyphenoxy)-3-hydroxy-3-(3,4-dimethoxyphenyl)propionate, m. 101-2°. The methylated threo derivative, m. 99-101°, is obtained analogously from threo-III. Methylation of IV gives 75% erythro-3,4-dimethoxyphenylglycerol-β-(2-methoxyphenyl) ether, m. 98-9°. The analogous methylated threo derivative obtained from threo-IV failed to crystallize; diacetate (from Ac<sub>2</sub>O-C<sub>5</sub>H<sub>5</sub>N) m. 96°. Treatment of 1 g. I in 10 ml. DMF with 2 g. anhydrous K acetate 1 hr. at 55° gives on dilution with H<sub>2</sub>O and extraction with Et<sub>2</sub>O 0.61 g. Et α-acetoxybenzylvanilloacetate, b<sub>0.201</sub> 185-8°. Further treatment (402 mg.) in 50 ml. EtOH with H over 0.1 g. Pd/C gives 307 mg. oily mixture of Et threo- and erythro-2-acetoxy-3-hydroxy-3-(3-methoxy-4-hydroxyphenyl)propionate. A crystalline triacetate (from Ac<sub>2</sub>O-C<sub>5</sub>H<sub>5</sub>N) of the erythro form is obtained, m. 110.5-11.5°, b<sub>0.007</sub> 145-50°, which can be reduced with LiAlH<sub>4</sub> to yield the known erythro-guaiacylglycerol (V), m. 83-4° (Adler and Gustafsson, CA 59, 6301g).

L20 ANSWER 22 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1965:438715 CAPLUS Full-text

DOCUMENT NUMBER: 63:38715

ORIGINAL REFERENCE NO.: 63:6873c-g

TITLE: Synthesis of prephenic acid diethyl acetal and its hydrolysis to phenylpyruvic acid and prephenic acid  
AUTHOR(S): Plieninger, Hans; Arnold, Lothar; Fischer, Rolf; Hoffmann, Werner

CORPORATE SOURCE: Univ. Heidelberg, Germany

SOURCE: Chemische Berichte (1965), 98(6), 1774-81

CODEN: CHBEAM; ISSN: 0009-2940

DOCUMENT TYPE: Journal

LANGUAGE: German

GI For diagram(s), see printed CA Issue.

AB I and the di-Et acetal (II) of III were prepared. The time at which the maximum yield of III can be obtained by the acid hydrolysis of II was calculated from kinetic data and the calcn. confirmed by the experiment; III was formed together with larger amts. of PhCH<sub>2</sub>COCO<sub>2</sub>H (IV). Di-Et 2-cyclohexen-4-one-1-carboxylate-1-pyruvate di-Et acetal (35.6 g.), b<sub>0.1</sub> 155°, n<sub>25D</sub> 1.4087, in 350 cc. tert-BuOH refluxed 5 hrs. with stirring with 5 cc. AcOH and 11 g. SeO<sub>2</sub>, treated with an addnl. 11 g. SeO<sub>2</sub>, and again refluxed 5 hrs., and the product shaken in Et<sub>2</sub>O 6 hrs. with 10 g. deactivated Raney Ni yielded 25 g. I, b<sub>0.1</sub> 150°, n<sub>20D</sub> 1.4840. I (35.6 mg.), 5.0 cc. EtOH, and 4.0 cc. 0.1N NaOH heated 0.5 hr. at 50°, treated with 5 cc. N HCl, and heated 15 min. at 50°, and the mixture cooled and diluted with H<sub>2</sub>O to 100 cc. gave a solution containing 18 mg. p-HOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>COCO<sub>2</sub>H. I (1.0 g.), 100 mg. Na, and 5 cc. EtOH heated 3 hrs. at 50° gave 0.70 g. p-HOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>4C(OEt)<sub>2</sub>CO<sub>2</sub>Et (IV). I (7.1 g.) in 10 cc. EtOH added dropwise with stirring during 15 min. at 5° to 0.40 g. NaBH<sub>4</sub> in 40 cc. EtOH and kept 15 min. at 20° yielded 5.3 g. oily di-Et ester (V) of II, n<sub>25D</sub> 1.4665, and 1.1 g. IV. V (3.6 g.) in 30 cc. EtOH treated 2 days at room temperature with 1.6 g. NaOH in 20 cc. H<sub>2</sub>O and evaporated to 15 cc., buffered to pH 8 with N HCl, and diluted with H<sub>2</sub>O to 25 cc. gave a 0.4M solution; a 0.1-cc. portion and 4 cc. N HCl heated 15 min. at 50° and the mixture adjusted to pH 14 with N NaOH gave a 0.3M II solution; a 6.25-cc. portion stirred with 4.25 g. Ba(OAc)<sub>2</sub>, centrifuged to remove some solid, diluted with about 200 cc. EtOH, and kept several hrs. yielded 1.3 g. Ba salt; a 0.5-g. portion in 10 cc. H<sub>2</sub>O hydrogenated over PdBaSO<sub>4</sub>, filtered, and treated 20 hrs. with 2,4-(O<sub>2</sub>N)<sub>2</sub>C<sub>6</sub>H<sub>3</sub>NHNH<sub>2</sub> in 2N HCl, and the precipitate chromatographed on paper showed the presence of the 2,4-dinitrophenylhydrazones of cis- and trans-tetrahydroprephenic acid (relative to OH and CO<sub>2</sub>H groups). II (0.3M aqueous solution) (10 cc.) adjusted with N HCl to pH 1.8, kept 10 min. at 20°, neutralized with N NaOH, and treated with

1.0 g. Ba(OAc)<sub>2</sub> in 5 cc, H<sub>2</sub>O gave 0.5 g. Ba salt of a 6:50 mole ratio mixture of III and IV.

L20 ANSWER 23 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1965:30781 CAPLUS Full-text

DOCUMENT NUMBER: 62:30781

ORIGINAL REFERENCE NO.: 62:5491f-g

TITLE: The nonvolatile acids of succulent plants exhibiting a marked diurnal oscillation in their acid content. I. The detection of piscidic acid in *Agave americana*

AUTHOR(S): Nordal, Arnold; Ogner, Gunnar

CORPORATE SOURCE: Univ. Oslo, Norway

SOURCE: Acta Chemica Scandinavica (1964), 18(8), 1979-83

CODEN: ACHSE7; ISSN: 0904-213X

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Piscidic acid (I) was detected in the leaves of *A. americana* by the following procedure: the acid mixture, isolated over the Pb salts from fresh leaves of the plant, was converted to the corresponding Me and Et esters, and the ester mixts. were fractionated in vacuo. From the individual fractions the hydrazides and benzylidene hydrazides were prepared and examined A crystalline hydrazide (C<sub>11</sub>H<sub>16</sub>O<sub>5</sub>N<sub>4</sub>; m. 185-187°), corresponding to the hydrazide of I, was isolated from the highest boiling fractions, and from this hydrazide the corresponding benzylidene hydrazide (C<sub>25</sub>H<sub>25</sub>O<sub>5</sub>N<sub>4</sub>; m. 136-138°) was prepared From the highest boiling fractions of the Me ester mixture, a crystalline ester (C<sub>13</sub>H<sub>16</sub>O<sub>7</sub>; m. 126-127°), corresponding to the Me ester of I, was isolated and from this an acetyl derivative (m. 84°) was prepared The properties of these 4 derivs. and the ir spectra of the ester identified the acid in question as I.

TI The nonvolatile acids of succulent plants exhibiting a marked diurnal oscillation in their acid content. I. The detection of piscidic acid in *Agave americana*

SO Acta Chemica Scandinavica (1964), 18(8), 1979-83

CODEN: ACHSE7; ISSN: 0904-213X

AB Piscidic acid (I) was detected in the leaves of *A. americana* by the following procedure: the acid mixture, isolated over the Pb salts from fresh leaves of the plant, was converted to the corresponding Me and Et esters, and the ester mixts. were fractionated in vacuo. From the individual fractions the hydrazides and benzylidene hydrazides were prepared and examined A crystalline hydrazide (C<sub>11</sub>H<sub>16</sub>O<sub>5</sub>N<sub>4</sub>; m. 185-187°), corresponding to the hydrazide of I, was isolated from the highest boiling fractions, and from this hydrazide the corresponding benzylidene hydrazide (C<sub>25</sub>H<sub>25</sub>O<sub>5</sub>N<sub>4</sub>; m. 136-138°) was prepared From the highest boiling fractions of the Me ester mixture, a crystalline ester (C<sub>13</sub>H<sub>16</sub>O<sub>7</sub>; m. 126-127°), corresponding to the Me ester of I, was isolated and from this an acetyl derivative (m. 84°) was prepared The properties of these 4 derivs. and the ir spectra of the ester identified the acid in question as I.

L20 ANSWER 24 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1963:435348 CAPLUS Full-text

DOCUMENT NUMBER: 59:35348

ORIGINAL REFERENCE NO.: 59:6301g-h,6302a-d

TITLE: Preparation of the threo- and erythro-forms of DL-guaiacylglycerol and of DL-veratrylglycerol

AUTHOR(S): Adler, Erich; Gustafsson, Bo

CORPORATE SOURCE: Chalmers Tek. Hogskola, Goteborg, Swed.

SOURCE: Acta Chemica Scandinavica (1963), 17, 27-36

DOCUMENT TYPE: Journal  
LANGUAGE: German  
OTHER SOURCE(S): CASREACT 59:35348

AB cf. CA 48, 5147g. Hydrogenation of 3,4-dimethoxyphenylpropionic acid in EtOH with Lindlar catalyst 50 min. gave 70% cis-methylferulic acid (I), m. 104°, which with CH<sub>2</sub>N<sub>2</sub> yielded 90% Me ester, prisms, m. 92-3°. Reduction of 30 g. Me trans-methylferulate (II) in 200 cc. dioxane with 5.7 g. LiAlH<sub>4</sub> in 500 cc. absolute Et<sub>2</sub>O, addition of H<sub>2</sub>O and dilute H<sub>2</sub>SO<sub>4</sub>, extraction with CHCl<sub>3</sub>, and distillation of the residue of the CHCl<sub>3</sub> extract gave 70% methylconiferyl alc., b<sub>5</sub> 110-20°, needles, m. 79-80°; Ac derivative (III) b<sub>12</sub> 190-5°. Treating 80 mg. III in 3 cc. Et<sub>2</sub>O-C<sub>5</sub>H<sub>5</sub>N (25:1) 16 hrs. with 0.1 g. OsO<sub>4</sub> in 2 cc. Et<sub>2</sub>O and hydrolyzing the osmic ester in 2 cc. EtOH with 0.65 g. Na<sub>2</sub>SO<sub>3</sub> in 3 cc. H<sub>2</sub>O 1 hr. at 100°, evaporating the filtered solution in vacuo, and extracting the residue with CHCl<sub>3</sub> gave 85% DL-threoveratrylglycerol (IV), m. 109-10°. Treating II similarly with OsO<sub>4</sub> and acetylating the hydrolyzed Os ester gave 60% DL-threo- $\alpha,\beta$ -diacetoxymethylhydroferulic acid (V), prisms, m. 148-9°. Esterification of V with CH<sub>2</sub>N<sub>2</sub> followed by reduction yielded IV. Refluxing 15 g. Me  $\alpha$ -bromo- $\beta$ -acetoxymethyl-hydroferulate in 65 cc. AcOH and 65 cc. Ac<sub>2</sub>O 45 min. with 7 g. AgOAc, treating the filtered solution with H<sub>2</sub>O, evaporating the solution in vacuo, extracting the residue with CHCl<sub>3</sub>, evaporating the washed (NaHCO<sub>3</sub>) solution, and crystallizing the residue from Et<sub>2</sub>O-C<sub>6</sub>H<sub>14</sub> gave 41% Me threo- $\alpha,\beta$ -diacetoxymethylhydroferulate (VI), m. 102-3°. Concentration of the mother liquor gave 40% erythro isomer (VII), prisms, m. 71-3°. VI was also obtained in 10% yield when 4.44 g. II was oxidized with KMnO<sub>4</sub> at -50° according to Riiber (CA 9, 2244). Reduction of VII with LiAlH<sub>4</sub> gave DL-erythroveratrylglycerol (VIII), plates, m. 92-3°,  $\lambda_{\text{maximum}}$  278 m $\mu$  (log  $\epsilon$  3.52). The infrared spectra of IV and VIII differed distinctly. When Me erythro-diacetoxymethylhydroferulate was reduced with LiAlH<sub>4</sub> (cf. loc. cit.) and the acid step was avoided by neutralizing the reaction mixture with AcOH, 55% DL-erythro-guaiacylglycerol (IX), m. 83-4° was obtained; IX tetraacetate m. 86-8°. IX and CH<sub>2</sub>N<sub>2</sub> gave 90% VIII. Treating 0.31 g. IX with 0.1N H<sub>2</sub>SO<sub>4</sub> neutralizing the mixture with BaCO<sub>3</sub>, evaporating the filtered solution in vacuo, and treating the residue with moist EtOAc gave 0.18 g. unchanged IX and, from the mother liquor, 0.05 g. threo-DL-guaiacylglycerol (X); tetraacetate m. 113-14°. Benzyl-coniferyl alc. benzoate (0.515 g.) (Freudenberg and Achtzehn, CA 50, 1661h) was treated in 12 cc. Et<sub>2</sub>O-C<sub>5</sub>H<sub>5</sub>N with 0.35 g. OsO<sub>4</sub> and the precipitate formed was boiled 1 hr. with 2.3 g. Na<sub>2</sub>SO<sub>3</sub> in 10 cc. H<sub>2</sub>O, giving threo-(O-benzylguaiacyl)glycerol, m. 101°, which when treated in EtOH with prehydrogenated PdCl<sub>2</sub>-BaSO<sub>4</sub>, yielded X as a sirup; tetraacetate, 70%, m. 113-14°. X and CH<sub>2</sub>N<sub>2</sub> gave 70% IV. Careful fractionation of the mother liquor of the Me erythro- $\alpha,\beta$ -diacetoxymethylhydroferulate gave 10% threo isomer, prisms, m. 81-2°, which with LiAlH<sub>4</sub> gave 55% X. Treating 0.074 g. trans-methylisoeugenol (XI) with OsO<sub>4</sub> gave 75% DL-threo-methylisoeugenol glycol, m. 90°, which was also obtained in 15% yield when 1.93 g. XI was treated at -50° with 1.96 g. KMnO<sub>4</sub>. Acetylation of 3.3 g. XI in 3 cc. AcOH with 6.6 g. Pb(OAc)<sub>4</sub> and reduction of the  $\alpha,\beta$ -diacetoxymethylpropane formed with LiAlH<sub>4</sub> gave 2 g. of a product, m. 80-100°, which on fractional crystallization yielded erythro-methylisoeugenol glycol, m. 123°, and the threo isomer, m. 88°.

L20 ANSWER 25 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1957:5337 CAPLUS Full-text  
DOCUMENT NUMBER: 51:5337  
ORIGINAL REFERENCE NO.: 51:1084e-i,1085a-d  
TITLE: Synthesis and reactions of guaiacylglycerol  
AUTHOR(S): Stumpf, Walter; Rumpf, Gunther  
CORPORATE SOURCE: Univ. Heidelberg, Germany

SOURCE: Annalen der Chemie, Justus Liebig's (1956),  
599, 51-60  
CODEN: 9X224Y

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

OTHER SOURCE(S): CASREACT 51:5337

AB 3,4-MeO(PhCH<sub>2</sub>O)C<sub>6</sub>H<sub>3</sub>CHO (138 g.) in 230 cc. AcOMe, after standing overnight with 17.1 g. Na wire and 2 cc. MeOH was triturated carefully with 230 cc. AcOMe, kept another 48 hrs. at room temperature, refluxed 1 hr. with 230 cc. absolute Et<sub>2</sub>O, and shaken with 740 cc. H<sub>2</sub>SO<sub>4</sub>. The organic phase washed with aqueous NaHCO<sub>3</sub> and H<sub>2</sub>O, dried and evaporated gave 95.5% crude and 83% pure 3,4-MeO(PhCH<sub>2</sub>O)C<sub>6</sub>H<sub>3</sub>CH:CHCO<sub>2</sub>Me (I), m. 98-9° (from MeOH or PrOH). To 7.16 g. I in 24 cc. CHCl<sub>3</sub> at 0°-5° were added dropwise (over a 1.5-hr. period) 3.84 g. Br; the mixture after 1 hr. at 0° was evaporated giving the crude di-Br derivative (II) of I (not weighed or analyzed), 22.9 g. of which were added to 15 g. dry AcOK in 150 cc. AcOH and 50 cc. Ac<sub>2</sub>O, heated 9 hrs. on a steam bath, then boiled 8 hrs., filtered, and concentrated in vacuo to incipient crystallization, treated with H<sub>2</sub>O and extracted with Et<sub>2</sub>O; the washed and dried extract evaporated in vacuo gave 19 g. sirup, a small sample of which, triturated with MeOH, gave seed crystals of (III), C<sub>22</sub>H<sub>24</sub>O<sub>8</sub>, m. sharply 112.5-13.5° (after 2 crystns. from MeOH). The main portion of the sirup, inoculated with III, crystallized gradually giving 8.25 g. of what was probably a mixture of isomeric forms of 3,4-MeO(PhCH<sub>2</sub>O)C<sub>6</sub>H<sub>3</sub>CH(OAc)CH(OAc)CO<sub>2</sub>Me (IV), m. poorly 90-100° (even after repeated crystallization from MeOH). In another experiment in which 169 g. crude II was heated 15 hrs. at 100° with 110 g. AcOK, 800 cc. AcOH, and 400 cc. Ac<sub>2</sub>O, a red sirup was formed, which, with III, gave 52.45 g. IV, leaflets, m. poorly 89-98°, the mother liquors from which gave I. A series of fully described attempts were made to fractionate IV into its component (racemic) isomers, but although 3 fractions were obtained, m., resp., 85.5-87°, 86-91°, and 88-91°, none of these was homogeneous. IV (m. 89-98°) (12.5 g.) in 50 cc. dry AcOMe was hydrogenated with 0.75 g. 2% Pd-BaSO<sub>4</sub>. After 1.5 hrs. 745 cc. H had been taken up. The filtered, evaporated solution gave 3,4-MeO(HO)C<sub>6</sub>H<sub>3</sub>CH(OAc)CH(OAc)CO<sub>2</sub>Me (V), viscous, uncrystallizable pale yellow sirup. V (8.34 g.) in 100 cc. absolute Et<sub>2</sub>O was added dropwise to 5.6 g. LiAlH<sub>4</sub> in 200 cc. Et<sub>2</sub>O, and after 5 hrs. at room temperature was refluxed 2 hrs., cooled to 0° in a stream of CO<sub>2</sub> and treated dropwise with H<sub>2</sub>O, shaken with H<sub>2</sub>O saturated with CO<sub>2</sub>, the Et<sub>2</sub>O layer separated and the aqueous phase extracted continuously for 7 days with peroxide-free Et<sub>2</sub>O in a Perforator, using fresh Et<sub>2</sub>O after 28 hrs. (when a sirup separated from the Et<sub>2</sub>O-phase). The various combined Et<sub>2</sub>O exts. evaporated in vacuo gave 2.7 g. crude resinous guaiacylglycerol (VI), which was boiled briefly with 200 cc. H<sub>2</sub>O, filtered and reextd. twice with Et<sub>2</sub>O. The aqueous phase (in which VI is very soluble) was evaporated to dryness in vacuo under N, giving 1.98 g. (36.3%) purified VI, C<sub>10</sub>H<sub>14</sub>O<sub>5</sub>, yellow sirup (after drying 14 hrs. at 34° in vacuo and 2 days at 20° over P<sub>2</sub>O<sub>5</sub>). VI is difficultly soluble in Et<sub>2</sub>O and C<sub>6</sub>H<sub>6</sub> and could not be crystallized. IV (m. 87-93°) (21.2 g.) in 750 cc. absolute Et<sub>2</sub>O was stirred into a mixture of 10 g. LiAlH<sub>4</sub> and 200 cc. Et<sub>2</sub>O, and treated as in the case of V. The resultant aqueous solution was filtered and extracted 40 hrs. with Et<sub>2</sub>O; the Et<sub>2</sub>O layer yielded 2.15 g. PhCH<sub>2</sub> derivative (VII) of VI, m. 68-74° (from C<sub>6</sub>H<sub>6</sub>), m. 99-100.5° (from MeOH by addition of Et<sub>2</sub>O and petr. ether to incipient cloudiness, or from AcOEt). Even this purified VII may be a mixture of racemic isomers. VI (1.81 g.) and Na<sub>2</sub>S<sub>2</sub>O<sub>5</sub> in 85 cc. H<sub>2</sub>O was heated and shaken 19 hrs. at 135° in a sealed tube, then freed from SO<sub>2</sub> and extracted 40 hrs. with Et<sub>2</sub>O giving 0.15 g. impure 4,3-HO(MeO)C<sub>6</sub>H<sub>3</sub>CH(SO<sub>3</sub>H)CH(OH)CH<sub>2</sub>OH, 81% of which was soluble in cold H<sub>2</sub>O forming a pale pink Ba salt (VIII) (containing 32.68% C and 21.3% Ba; calculated 34.71 and 19.85%, resp.). Oxidations with NaIO<sub>4</sub> were carried out with various phenolic compds. or their derivs., and results are given in terms of moles NaIO<sub>4</sub> consumed per mole of compound within a specific time period. No NaIO<sub>4</sub> was consumed by veratrole within 17.5 hrs. The consumption of NaIO<sub>4</sub> by

PhOH, vanillin, and p-cresol was very slight (0.14-0.33 mole within 21.5-24 hrs.). V, VI, guaiacol, cresol, guaiacylethylcarbinol, VIII, 1,4-C<sub>6</sub>H<sub>4</sub>(OH)<sub>2</sub>, catechol, and pyrogallol all consumed appreciable amts. of NaIO<sub>4</sub> within relatively short periods. On oxidation all guaiacyl compds. gave red solns., the color being ascribed to quinoid oxidation products. Oxidation data are discussed at length.

L16 17 SEA SSS SAM L15

=> s l15 sss full  
FULL SEARCH INITIATED 14:46:55 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 12084 TO ITERATE

100.0% PROCESSED 12084 ITERATIONS 232 ANSWERS  
SEARCH TIME: 00.00.01

L17 232 SEA SSS FUL L15

=> d scan

L17 232 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-hydroxy-3-(phenylmethyl)-  
MF C18 H20 O4

=> s l17/prep  
2028 L17  
4706241 PREP/RL  
L18 433 L17/PREP  
(L17 (L) PREP/RL)

=> s l18 and (PY<2003 or AY<2003 or PRY<2003)  
22983071 PY<2003  
4502933 AY<2003  
3971676 PRY<2003  
L19 151 L18 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> s l19 and 'asymmetric? hydrogenation?'  
76842 'ASYMMETRIC'  
31 'ASYMMETRICS'  
76873 'ASYMMETRIC'  
( 'ASYMMETRIC' OR 'ASYMMETRICS' )  
147845 'ASYM'  
6 'ASYMS'  
147848 'ASYM'  
( 'ASYM' OR 'ASYMS' )  
171543 'ASYMMETRIC'  
( 'ASYMMETRIC' OR 'ASYM' )  
184239 'HYDROGENATION'  
2478 'HYDROGENATIONS'  
184500 'HYDROGENATION'  
( 'HYDROGENATION' OR 'HYDROGENATIONS' )  
4062 'ASYMMETRIC? HYDROGENATION?'  
( 'ASYMMETRIC' (W) 'HYDROGENATION' )  
L20 0 L19 AND 'ASYMMETRIC? HYDROGENATION?'

=> s l19 and 'chiral cataly?'  
129207 'CHIRAL'



```

        19 'CHIRALS'
    129212 'CHIRAL'
            ('CHIRAL' OR 'CHIRALS')
        2 'CATALY'
        0 'CHIRAL CATALY?'
            ('CHIRAL'(W)'CATALY')
L21      0 L19 AND 'CHIRAL CATALY?'

=> s l19 and 'transition metal'
    1075521 'TRANSITION'
    279137 'TRANSITIONS'
    1194858 'TRANSITION'
            ('TRANSITION' OR 'TRANSITIONS')
    1895500 'METAL'
    944697 'METALS'
    2295558 'METAL'
            ('METAL' OR 'METALS')
    199466 'TRANSITION METAL'
            ('TRANSITION'(W)'METAL')
L22      0 L19 AND 'TRANSITION METAL'

=> s l19 and 'transition metal?'
    1075521 'TRANSITION'
    279137 'TRANSITIONS'
    1194858 'TRANSITION'
            ('TRANSITION' OR 'TRANSITIONS')
    1895500 'METAL'
    944697 'METALS'
    2295558 'METAL'
            ('METAL' OR 'METALS')
    199466 'TRANSITION METAL?'
            ('TRANSITION'(W)'METAL')
L23      0 L19 AND 'TRANSITION METAL?'

=> s l19 and 'chiral ligand?'
    129207 'CHIRAL'
        19 'CHIRALS'
    129212 'CHIRAL'
            ('CHIRAL' OR 'CHIRALS')
    357937 'LIGAND'
    243988 'LIGANDS'
    486792 'LIGAND'
            ('LIGAND' OR 'LIGANDS')
    4294 'CHIRAL LIGAND?'
            ('CHIRAL'(W)'LIGAND')
L24      0 L19 AND 'CHIRAL LIGAND?'

=> s l19 and 'chiral?'
    129207 'CHIRAL'
        19 'CHIRALS'
    129212 'CHIRAL?'
            ('CHIRAL' OR 'CHIRALS')
L25      4 L19 AND 'CHIRAL?'

=> s l19 and ('chiral?' or 'optical?')
    129207 'CHIRAL'
        19 'CHIRALS'
    129212 'CHIRAL?'
            ('CHIRAL' OR 'CHIRALS')
    1078969 'OPTICAL'

```

```

      24 'OPTICALS'
1078978 'OPTICAL?'
      ('OPTICAL' OR 'OPTICALS')
L26      5 L19 AND ('CHIRAL?' OR 'OPTICAL?')

=> s l19 and ('chiral?' or 'optical?' or 'hydrogenation?')
      129207 'CHIRAL'
      19 'CHIRALS'
      129212 'CHIRAL?'
      ('CHIRAL' OR 'CHIRALS')
1078969 'OPTICAL'
      24 'OPTICALS'
1078978 'OPTICAL?'
      ('OPTICAL' OR 'OPTICALS')
184239 'HYDROGENATION'
      2478 'HYDROGENATIONS'
184500 'HYDROGENATION?'
      ('HYDROGENATION' OR 'HYDROGENATIONS')
L27      8 L19 AND ('CHIRAL?' OR 'OPTICAL?' OR 'HYDROGENATION?')

```

```

=> d l27 ibib abs ti hit 1-8

```

```

L27  ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:      2008:994060  CAPLUS  Full-text
DOCUMENT NUMBER:      149:306485
TITLE:                  Di-m-Chlorobis[Bis-(cyclooctene)rhodium]
AUTHOR(S):              Judd, Andrew S.
CORPORATE SOURCE:      USA
SOURCE:                  e-EROS Encyclopedia of Reagents for Organic Synthesis
                        (2001), No pp. given.  John Wiley & Sons,
                        Ltd.: Chichester, UK.
                        CODEN: 69KUHI
                        URL: http://www3.interscience.wiley.com/cgi-
                        bin/mrwhome/104554785/HOME
DOCUMENT TYPE:          Conference; General Review; (online computer file)
LANGUAGE:               English
OTHER SOURCE(S):        CASREACT 149:306485
AB  A review of the article Di-m-Chlorobis[Bis-(cyclooctene)rhodium].
TI  Di-m-Chlorobis[Bis-(cyclooctene)rhodium]
SO  e-EROS Encyclopedia of Reagents for Organic Synthesis (2001), No
    pp. given Publisher: John Wiley & Sons, Ltd., Chichester, UK.
    CODEN: 69KUHI
    URL: http://www3.interscience.wiley.com/cgi-bin/mrwhome/104554785/HOME
ST  review Dim Chlorobis Biscyclooctene rhodium Cycloaddn
    Hydrogenation Bond Activation
IT  583-60-8P   716-79-0P   833-50-1P   932-56-9P   933-17-5P   937-05-3P
    942-92-7P   948-65-2P   1120-72-5P   4255-62-3P   4423-94-3P   4971-18-0P
    19312-06-2P  21862-63-5P  28831-65-4P   29981-98-4P
    65193-45-5P  134856-46-5P   159659-47-9P   159659-48-0P   194787-73-0P
    202808-66-0P  321337-92-2P   336106-30-0P   481697-69-2P   481697-91-0P
    615576-81-3P  851530-46-6P   1035814-95-9P
    RL: SPN (Synthetic preparation); PREP (Preparation)
        (Di-m-Chlorobis[Bis-(cyclooctene)rhodium])

```

```

L27  ANSWER 2 OF 8  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:      2004:2837  CAPLUS  Full-text
DOCUMENT NUMBER:      140:59411
TITLE:                  Preparation of phenoxyalkanamides as amide linker
                        peroxisome proliferator activated receptor agonists
                        for treating and/or preventing diabetes mellitus and

```

syndrome X  
 INVENTOR(S): Ferritto Crespo, Rafael; Martin, Jose Alfredo;  
 Martin-Ortega, Finger Maria Dolores; Rojo Garcia,  
 Isabel; Shen, Quanrong; Warshawsky, Alan M.; Xu,  
 Yanping  
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA  
 SOURCE: PCT Int. Appl., 168 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000789	A1	20031231	WO 2003-US16207	20030611 <--
WO 2004000789	A9	20040311		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2488972	A1	20031231	CA 2003-2488972	20030611 <--
AU 2003241579	A1	20040106	AU 2003-241579	20030611 <--
EP 1517882	A1	20050330	EP 2003-731326	20030611 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011834	A	20050412	BR 2003-11834	20030611 <--
CN 1662487	A	20050831	CN 2003-814173	20030611 <--
JP 2005529975	T	20051006	JP 2004-515700	20030611 <--
US 20060111406	A1	20060525	US 2004-517581	20041208 <--
US 7220880	B2	20070522		
MX 2004PA13000	A	20050912	MX 2004-PA13000	20041217 <--
IN 2004KN01957	A	20061215	IN 2004-KN1957	20041220 <--
PRIORITY APPLN. INFO.:			US 2002-390102P	P 20020619 <--
			WO 2003-US16207	W 20030611
OTHER SOURCE(S): MARPAT 140:59411				
GI				

/ Structure 180 in file .gra /

AB The present invention is directed to phenoxyalkanamides (shown as I; variables defined below; e.g. II), compns., and their use as peroxisome proliferator activated receptor agonists for treating and/or preventing diabetes mellitus and syndrome X. The binding and cotransfection efficacy values found for compds. of this invention that are useful for modulating a PPAR $\alpha$  receptor are about <100 nM and >50%, resp. Although the methods of preparation are not claimed, .apprx.140 example prepn. of I are included. For example, II was prepared in 3 steps starting from (2S)-2-ethoxy-3-(4-hydroxyphenyl)propionic acid Me ester, (2S)-2-hydroxypropionic acid benzyl ester and involving intermediates (2S)-3-[4-[[[(1R)-1-[(benzyloxy)carbonyl]ethyl]oxy]phenyl]-2-ethoxypropionic acid Et ester and (2S)-3-[4-[[[(1R)-1-carboxyethyl]oxy]phenyl]-2-ethoxypropionic acid. For I: R1 = H, C1-C8 alkyl,

C3-C6 cycloalkyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, aminoC1-C4alkyl, C3-C6 cycloalkylaryl-C0-2-alkyl, arylheteroC1-C8alkyl, -CHC(O)C1-C4 alkoxy, C0-4-alkyl-C(O)heteroC1-C8alkyl, and -CH2C(O)-R15R16. R2 = C1-C8 alkyl, C3-C6 cycloalkyl, aryl-C0-C4-alkyl, heteroaryl-C0-C4-alkyl, heteroC1-C6cycloalkylaryl, heteroC1-C6cycloalkylarylC1-C4alkyl, aminoC1-C4alkyl, C3-C6 cycloalkylaryl-C0-C2-alkyl, arylheteroC1-C8alkyl, C0-C4-alkyl-C(O)heteroC1-C8alkyl, -CH(C(O)OCH3)benzyl, and -CH2C(O)R15''R16''. R1 and R2 together may form a heterocyclic ring which heterocyclic ring is (un)substituted with 1-3 substituents R1' and which heterocyclic ring is optionally fused with an aryl; E = C(R3)(R4)A, (CH2)nCOOR13, aryl-C0-C4-alkyl, thio-C1-C4-alkyl, thioaryl, arylC1-C4alkoxy, C1-C4alkoxy C1-C4alkyl, aminoaryl, and aminoC1-C4alkyl. R5 and R6 = H, C1-C8 alkyl, aryl-C0-C4-alkyl, heteroaryl-C0-C4-alkyl, C3-C6 cycloalkyl, aryl-C0-C2-alkyl, C3-C6 cycloalkyl-C0-2-alkyl, and -CH2C(O)R17R18.

L27 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:416876 CAPLUS Full-text

DOCUMENT NUMBER: 135:33368

TITLE: Preparation of  
(S)-2-ethoxy-3-(4-hydroxyphenyl)propanoates by  
resolution using chiral amines.

INVENTOR(S): Andersson, Kjell; Fischer, Alan Eric; Ioannidis,  
Panagiotis; Larsson, Magnus; Larsson, Maria;  
Sivadasan, Sivaprasad

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001040159	A1	20010607	WO 2000-SE2382	20001129 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2392032	A1	20010607	CA 2000-2392032	20001129 <--
CA 2392032	C	20081028		
BR 2000016136	A	20020820	BR 2000-16136	20001129 <--
EP 1237838	A1	20020911	EP 2000-983617	20001129 <--
EP 1237838	B1	20040414		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003515578	T	20030507	JP 2001-541849	20001129 <--
AU 765938	B2	20031002	AU 2001-20349	20001129 <--
AT 264287	T	20040415	AT 2000-983617	20001129 <--
PT 1237838	T	20040831	PT 2000-983617	20001129 <--
ES 2218258	T3	20041116	ES 2000-983617	20001129 <--
CN 1213016	C	20050803	CN 2000-818703	20001129 <--
ZA 2002003705	A	20030811	ZA 2002-3705	20020509 <--

MX 2002PA05321	A	20021206	MX 2002-PA5321	20020529 <--
NO 2002002604	A	20020711	NO 2002-2604	20020531 <--
KR 794091	B1	20080110	KR 2002-707070	20020601 <--
US 20030139474	A1	20030724	US 2002-148818	20021113 <--
US 7002037	B2	20060221		
US 20060069283	A1	20060330	US 2005-282247	20051118 <--
PRIORITY APPLN. INFO.:			SE 1999-4415	A 19991203 <--
			WO 2000-SE2382	W 20001129 <--
			US 2002-148818	A1 20021113 <--
OTHER SOURCE(S):	CASREACT 135:33368; MARPAT 135:33368			
GI				

/ Structure 181 in file .gra /

AB Title compds. (I; R2 = H, protecting group; the aryl ring may be halogenated) (II; Q = H, protecting group) with chiral amines to form the diastereomeric salts, which were separated by crystallization followed by removal of the amine and optional deprotection and protection steps. Thus, 2-ethoxy-3-(4-methoxyphenyl)propionic acid (preparation given) in iPrOAc at 0-5° was treated with (S)-1-(1-naphthyl)ethylamine followed by heating to 75-80°, cooling, and seeding with (S)-2-ethoxy-3-(4-methoxyphenyl)propionic acid (S)-1-(1-naphthyl)ethylamine salt (III) to precipitate crude III, which was recrystd. from iPrOAc to give 74% III. III in PhMe was treated with aqueous NaOH and then with aqueous HCl followed by extraction of the aqueous layer with EtOAc to give an EtOAc solution of (S)-2-ethoxy-3-(4-methoxyphenyl)propionic acid. The EtOAc was replaced with N-methylpyrrolidone and the resulting solution was heated with NaOH and octanethiol at 115-125° to give 52% (S)-2-ethoxy-3-(4-hydroxyphenyl)propionic acid in 99.8% chemical purity and 97.8% enantiomeric excess.

L27 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:82175 CAPLUS Full-text

DOCUMENT NUMBER: 128:167302

ORIGINAL REFERENCE NO.: 128:32973a,32976a

TITLE: A non-enzymic synthesis of (S)-(-)-rosmarinic acid and a study of a biomimetic route to (+)-rabdosiin

AUTHOR(S): Bogucki, David E.; Charlton, James L.

CORPORATE SOURCE: Dep. Chem., Univ. Manitoba, Winnipeg, MB, R3T 2N2, Can.

SOURCE: Canadian Journal of Chemistry (1997), 75(12), 1783-1794  
CODEN: CJCHAG; ISSN: 0008-4042

PUBLISHER: National Research Council of Canada

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 128:167302

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The synthesis of (S)-(-)-rosmarinic acid (I; R = R1 = H) in 9% overall yield is described. The synthesis was achieved by a convergent route in which 3-(3',4'-dihydroxyphenyl)-(S)-lactic acid and caffeic acid, (E)-3,4-(HO)2C6H3CH:CHCO2H, both appropriately protected, were coupled to produce a pentaallyl precursor I (R = R1 = CH2CH:CH2), which was then deprotected to give (S)-(-)-rosmarinic acid (I; R = R1 = H). A triallyl derivative I (R = H, R1 = CH2CH:CH2) was similarly prepared and converted to (+)-rabdosiin (II) and its (1R,2S) isomer via a biomimetic oxidative free radical coupling-cyclization followed by deallylation. The coupling-cyclization gave a ratio of rabdosiin diastereomers unlike that found in nature. A preliminary study showed that Me (R)-mandelyl sinapate (III) could be dimerized diastereoselectively to give a 1,2-trans thomasidioate diester (IV).

L27 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:436105 CAPLUS Full-text

DOCUMENT NUMBER: 125:109268

ORIGINAL REFERENCE NO.: 125:20363a,20366a

TITLE: Separation of rosmarinic acid enantiomers by three different chromatographic methods (HPLC, CE, GC) and the determination of rosmarinic acid in *Hedera helix* L

AUTHOR(S): Trute, Andreas; Nahrstedt, Adolf

CORPORATE SOURCE: Inst. Pharm. Biol. Phytochem., Wilhelms-Univ., Muenster, D-48149, Germany

SOURCE: Phytochemical Analysis (1996), 7(4), 204-208

CODEN: PHANEL; ISSN: 0958-0344

PUBLISHER: Wiley

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Three methods with HPLC, capillary electrophoresis (CE), and gas chromatog. (GC) were developed for the separation of enantiomers of rosmarinic acid (RA). Chiral resolution of underivatized RA was achieved on a chiral AGP HPLC column and by micellar electrokinetic capillary chromatog. Alternatively, after derivatization, the resulting diastereomeric 3,4-dihydroxyphenyllactic acid(-)-menthyl esters were separated by non-chiral GC. These methods allow reliable and rapid determination of the enantiomeric ratio of RA samples. RA obtained from *Hedera helix* L. (Araliaceae) was determined to be (R)-(+)-RA. In contrast to published data, the optical rotation value of rosmarinic acid was + 106°.

TI Separation of rosmarinic acid enantiomers by three different chromatographic methods (HPLC, CE, GC) and the determination of rosmarinic acid in *Hedera helix* L

SO Phytochemical Analysis (1996), 7(4), 204-208

CODEN: PHANEL; ISSN: 0958-0344

AB Three methods with HPLC, capillary electrophoresis (CE), and gas chromatog. (GC) were developed for the separation of enantiomers of rosmarinic acid (RA). Chiral resolution of underivatized RA was achieved on a chiral AGP HPLC column and by micellar electrokinetic capillary chromatog. Alternatively, after derivatization, the resulting diastereomeric 3,4-dihydroxyphenyllactic acid(-)-menthyl esters were separated by non-chiral GC. These methods allow reliable and rapid determination of the enantiomeric ratio of RA samples. RA obtained from *Hedera helix* L. (Araliaceae) was determined to be (R)-(+)-RA. In contrast to published data, the optical rotation value of rosmarinic acid was + 106°.

L27 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1991:490598 CAPLUS Full-text

DOCUMENT NUMBER: 115:90598  
ORIGINAL REFERENCE NO.: 115:15571a,15574a  
TITLE: Chemo-enzymic synthesis of rosmarinic acid  
AUTHOR(S): Pabsch, K.; Petersen, M.; Rao, N. N.; Alfermann, A.  
W.; Wandrey, C.  
CORPORATE SOURCE: Inst. Biotechnol., Res. Cent. Juelich, Juelich,  
D-5170, Germany  
SOURCE: Recueil des Travaux Chimiques des Pays-Bas (  
1991), 110(05), 199-205  
CODEN: RTCPA3; ISSN: 0165-0513  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI

/ Structure 182 in file .gra /

AB (R)-(+)-3-(3,4-Dihydroxyphenyl)lactic acid (I) was produced in an enzyme membrane reactor with an optical purity >99%. Complete reactor modeling of the process was done and the theor. evaluated data was verified by a continuous experiment with volumetric yields of >1000 g/L-day. For the synthesis of CoA-activated caffeic acid, a new method was found to prepare the ester via the caffeic acid imidazolid. In a batch experiment, enzymically prepared I and chemical synthesized CoA caffeic ester were converted to rosmarinic acid (II) by an enzyme isolated from *Coleus blumei* cell cultures.

L27 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1988:492624 CAPLUS Full-text  
DOCUMENT NUMBER: 109:92624  
ORIGINAL REFERENCE NO.: 109:15441a,15444a  
TITLE: Stereostructure of salvianolic acid B and isolation of  
salvianolic acid C from *Salvia miltiorrhiza*  
AUTHOR(S): Ai, Chunbo; Li, Lianniang  
CORPORATE SOURCE: Inst. Mater. Med., Chin. Acad. Med. Sci., Beijing,  
Peop. Rep. China  
SOURCE: Journal of Natural Products (1988), 51(1),  
145-9  
CODEN: JNPRDF; ISSN: 0163-3864  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI

/ Structure 183 in file .gra /

AB The depside salvianolic acid B (I), isolated from roots of *S. miltiorrhiza* was assigned a 2R,3R configuration and a 2 $\beta$ -pseudoequatorial aryl, 3 $\alpha$ -pseudoaxial carboxyl conformation based on chemical degradation and spectral anal. Salvianolic acid C (II) was isolated from *S. miltiorrhiza* roots and the structure determined. The fact that salvianolic acid A was converted to II in a TLC plate impregnated with 2% formic acid suggests II to be the cyclization product of the former.

L27 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1975:443121 CAPLUS Full-text

DOCUMENT NUMBER: 83:43121

ORIGINAL REFERENCE NO.: 83:6811a,6814a

TITLE: Polyphenolic acids of Lithospermum ruderales  
(Boraginaceae). I. Isolation and structure  
determination of lithospermic acid

AUTHOR(S): Kelley, Charles J.; Mahajan, J. R.; Brooks, Lucille  
C.; Neubert, Leonard A.; Breneman, W. R.; Carmack,  
Marvin

CORPORATE SOURCE: Dep. Chem., Indiana Univ., Bloomington, IN, USA

SOURCE: Journal of Organic Chemistry (1975), 40(12),  
1804-15

CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB A structure is proposed for lithospermic acid (I), C<sub>27</sub>H<sub>22</sub>O<sub>12</sub>, the major  
polyphenolic acid of Lithospermum ruderales and several other plant species of  
the families, Boraginaceae and Labiatae. Chromatog. on Sephadex of aqueous  
exts. of the plant yields the di-K salt of I, together with salts of lesser  
constituents which include (R)-3-(3,4-dihydroxyphenyl)lactic acid, 2-(3,4-  
dihydroxyphenyl)-3-carboxy-4-(2-carboxy-trans-vinyl)-7-hydroxycoumaran, and  
rosmarinic acid. Structures were deduced from spectral studies of the salts,  
the free acids, and also the methylated derivs., produced by the action of  
CH<sub>2</sub>N<sub>2</sub> on the free acids or Me<sub>2</sub>SO<sub>4</sub> on the salts.

=> s l17 and 'asymmetric hydrogenation'

2028 L17  
76842 'ASYMMETRIC'  
31 'ASYMMETRICS'  
76873 'ASYMMETRIC'  
( 'ASYMMETRIC' OR 'ASYMMETRICS' )  
147845 'ASYM'  
6 'ASYMS'  
147848 'ASYM'  
( 'ASYM' OR 'ASYMS' )  
171543 'ASYMMETRIC'  
( 'ASYMMETRIC' OR 'ASYM' )  
184239 'HYDROGENATION'  
2478 'HYDROGENATIONS'  
184500 'HYDROGENATION'  
( 'HYDROGENATION' OR 'HYDROGENATIONS' )  
4062 'ASYMMETRIC HYDROGENATION'  
( 'ASYMMETRIC' (W) 'HYDROGENATION' )  
L28 2 L17 AND 'ASYMMETRIC HYDROGENATION'

=> d l28 ibib abs 1-2

L28 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:696717 CAPLUS Full-text

DOCUMENT NUMBER: 147:95305

TITLE: Process for the preparation of enantiomer-enriched  
2-alkoxy-3-arylpropionic acids by asymmetric  
hydrogenation of substituted 2-alkoxycinnamic  
acids



INVENTOR(S): Woltering, Michael; Bunlaksananusorn, Tanasri;  
Gerlach, Arne  
PATENT ASSIGNEE(S): Saltigo G.m.b.H., Germany  
SOURCE: Eur. Pat. Appl., 16pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1801093	A1	20070627	EP 2006-25546	20061211
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
DE 102005061472	A1	20070705	DE 2005-102005061472	20051222
US 20070149804	A1	20070628	US 2006-635302	20061207
US 7429676	B2	20080930		
CN 1986516	A	20070627	CN 2006-10168677	20061222
PRIORITY APPLN. INFO.:			DE 2005-102005061472A	20051222

OTHER SOURCE(S): CASREACT 147:95305; MARPAT 147:95305

AB Chiral 2-alkoxy-3-arylpropanoic acids  $R_2nC_6H_5-nCH_2CH(OR_1)CO_2H$  or their alkali metal salts [1;  $R_1$  = (un)substituted C1-18 alkyl, C4-24 aryl, C5-18 arylalkyl;  $R_2$  = OH, halo, (alkyl)amino, C1-18 alkyl(oxy), C4-24 aryl, C5-18 arylalkyl, C1-18 alkylsulfonyl(amino), acyl(amino), acyloxy, preferably  $R_2$  = OH;  $n$  = 1-5, preferably  $n$  = 1], useful as peroxisome proliferator activated receptors (PPAR) agonists, were prepared by an improved process comprising transition metal-catalyzed asym. hydrogenation of the corresponding cinnamic acids  $R_2nC_6H_5-nCH:C(OR_1)CO_2H$  (2; same  $R$ ,  $n$ ) in the presence of at least one protic solvent. Compds. 2 were preferably prepared by Perkin condensation of benzaldehydes  $R_2nC_6H_5-nCHO$  (3; same  $R_2$ ,  $n$ ) with 2-alkoxyacetates  $R_1OCH_2CO_2R_3$  (4; same  $R_1$ ;  $R_3$  = H, C1-18 alkyl, preferably C1-6 alkyl). In an example, sodium 4-hydroxy- $\alpha$ -methoxybenzenepropanoate ( $\alpha$ S)-4-HOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CH(OMe)CO<sub>2</sub>Na was prepared in 53% yield and 92% ee by asym. hydrogenation of 200.0 mmol of (2Z)-4-HOC<sub>6</sub>H<sub>4</sub>CH:C(OMe)CO<sub>2</sub>H catalyzed by 0.5 mmol of [Ir(COD)Cl]<sub>2</sub> and 1.0 mmol of (S,S)-2,4-bis(diphenylphosphino)pentane in 240 mL of iso-Pr acetate and 60 mL of MeOH for 24 h at 65° and 3 atm of H<sub>2</sub>.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:490344 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 143:43684

TITLE: Process for preparation of optically active 3-(4-hydroxyphenyl)propionic acids by reaction of protected 4-hydroxybenzaldehydes and glycolic acid derivatives to give cinnamates and asymmetric hydrogenation of the latter.

INVENTOR(S): Yokozawa, Tohru; Shimizu, Hideo; Fujiwara, Takahiro; Ino, Yasunori

PATENT ASSIGNEE(S): Takasago International Corporation, Japan

SOURCE: PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

```

-----
WO 2005051882      A1      20050609      WO 2004-JP17998      20041126
W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
    CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
    GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
    LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
    NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
    TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW:  BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
    AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
    EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
    SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
    NE, SN, TD, TG
EP 1687250      A1      20060809      EP 2004-819490      20041126
R:  CH, DE, ES, FR, GB, LI, IE
JP 2007512222      T      20070517      JP 2006-520429      20041126
US 20070142472      A1      20070621      US 2006-578744      20060510
PRIORITY APPLN. INFO.:      JP 2003-398201      A      20031127
                                WO 2004-JP17998      W      20041126
OTHER SOURCE(S):      CASREACT 143:43684; MARPAT 143:43684
GI

```

/ Structure 184 in file .gra /

AB Title compds. (I; R2 = alkyl; R5-R8 = H, substituent) and salts thereof were prepared by reaction of benzaldehydes (II; R1 = protective group; R5-R8 as defined above) with R2OCH2CO2R3 (R3 = hydrocarbyl; R2 as defined above), hydrolysis of the resulting cinnamate esters to give cinnamic acids, asym. hydrogenation, and O-deprotection. Thus, a mixture of 4-benzyloxybenzaldehyde, Me methoxyacetate, and NaOMe was refluxed 5 h in MeOH to give 80% Me 3-(4-benzyloxyphenyl)-2-methoxyacrylate. This was refluxed 2 h with 1N NaOH in MeOH to give 85% 3-(4-benzyloxyphenyl)-2-methoxyacrylic acid Na salt. The latter was hydrogenated in MeOH over [Ru(p-cymene)[(S)-dm-segphos]]Cl in MeOH at 5 MPa and 60° for 16 h to give Na 3-(4-hydroxyphenyl)-2-methoxypropionate in 20% yield and 92.9% enantiomeric excess.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```

=> s 117 and 'chiral catalyst'
    2028 L17
    129207 'CHIRAL'
    19 'CHIRALS'
    129212 'CHIRAL'
        ('CHIRAL' OR 'CHIRALS')
    827573 'CATALYST'
    823685 'CATALYSTS'
    1060345 'CATALYST'
        ('CATALYST' OR 'CATALYSTS')
    2138 'CHIRAL CATALYST'
        ('CHIRAL' (W) 'CATALYST')
L29      0 L17 AND 'CHIRAL CATALYST'

```

```

=> s 117 and 'asymmetric react?'
    2028 L17
    76842 'ASYMMETRIC'
    31 'ASYMMETRICS'
    76873 'ASYMMETRIC'

```

```

                ('ASYMMETRIC' OR 'ASYMMETRICS')
147845 'ASYM'
        6 'ASYMS'
147848 'ASYM'
                ('ASYM' OR 'ASYMS')
171543 'ASYMMETRIC'
                ('ASYMMETRIC' OR 'ASYM')
160456 'REACT'
102018 'REACTS'
249419 'REACT'
                ('REACT' OR 'REACTS')
        0 'ASYMMETRIC REACT?'
                ('ASYMMETRIC'(W)'REACT')
L30          0 L17 AND 'ASYMMETRIC REACT?'

=> s l17 and 'asymmetric?'
        2028 L17
        76842 'ASYMMETRIC'
        31 'ASYMMETRICS'
        76873 'ASYMMETRIC'
                ('ASYMMETRIC' OR 'ASYMMETRICS')
147845 'ASYM'
        6 'ASYMS'
147848 'ASYM'
                ('ASYM' OR 'ASYMS')
171543 'ASYMMETRIC?'
                ('ASYMMETRIC' OR 'ASYM')
L31          10 L17 AND 'ASYMMETRIC?'

L31 ANSWER 1 OF 10  CAPLUS  COPYRIGHT 2009 ACS on STN
AN  2007:1187668  CAPLUS  Full-text
DN  148:54698
TI  Asymmetric intramolecular alkylation of chiral aromatic imines
    via catalytic C-H bond activation
AU  Watzke, Anja; Wilson, Rebecca M.; O'Malley, Steven J.; Bergman, Robert G.;
    Ellman, Jonathan A.
CS  Department of Chemistry and Division of Chemical Sciences, Lawrence
    Berkeley National Laboratory, University of California, Berkeley, CA,
    94720, USA
SO  Synlett (2007), (15), 2383-2389
    CODEN: SYNLES; ISSN: 0936-5214
PB  Georg Thieme Verlag
DT  Journal
LA  English
OS  CASREACT 148:54698
RE.CNT  19      THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
                ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 2 OF 10  CAPLUS  COPYRIGHT 2009 ACS on STN
AN  2007:696717  CAPLUS  Full-text
DN  147:95305
TI  Process for the preparation of enantiomer-enriched
    2-alkoxy-3-arylpropionic acids by asymmetric hydrogenation of
    substituted 2-alkoxycinnamic acids
IN  Woltering, Michael; Bunlaksananusorn, Tanasri; Gerlach, Arne
PA  Saltigo G.m.b.H., Germany
SO  Eur. Pat. Appl., 16pp.
    CODEN: EPXXDW
DT  Patent
LA  German

```

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1801093	A1	20070627	EP 2006-25546	20061211
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	DE 102005061472	A1	20070705	DE 2005-102005061472	20051222
	US 20070149804	A1	20070628	US 2006-635302	20061207
	US 7429676	B2	20080930		
	CN 1986516	A	20070627	CN 2006-10168677	20061222
PRAI	DE 2005-102005061472	A	20051222		
OS	CASREACT 147:95305; MARPAT 147:95305				
RE.CNT	5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD				
	ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L31 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:1173484 CAPLUS Full-text

DN 145:489283

TI N-Acylpiperidines and related compounds as CGRP-antagonists, methods for preparing them, pharmaceutical compositions and their use as pharmaceutical compositions

IN Mueller, Stephan Georg; Rudolf, Klaus; Lustenberger, Philipp; Stenkamp, Dirk; Santagostino, Marco; Paleari, Fabio; Schaenzle, Gerhard; Arndt, Kirsten; Doods, Henri

PA Boehringer Ingelheim International GmbH, Germany

SO U.S. Pat. Appl. Publ., 156pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060252931	A1	20061109	US 2006-277177	20060322
	WO 2005092880	A1	20051006	WO 2005-EP3094	20050323
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2005103037	A2	20051103	WO 2005-EP4104	20050418
	WO 2005103037	A3	20060112		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

EP 1770091 A1 20070404 EP 2005-21283 20050929  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,  
 BA, HR, MK, YU  
 PRAI AR 2005-101139 A 20050323  
 WO 2005-EP3094 A 20050323  
 WO 2005-EP4104 A 20050418  
 EP 2005-21283 A 20050929  
 DE 2004-102004015723 A 20040329  
 DE 2004-102004019492 A 20040422  
 OS MARPAT 145:489283

L31 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2005:973972 CAPLUS Full-text  
 DN 143:422193  
 TI Total Synthesis of (+)-Lithospermic Acid by Asymmetric  
 Intramolecular Alkylation via Catalytic C-H Bond Activation  
 AU O'Malley, Steven J.; Tan, Kian L.; Watzke, Anja; Bergman, Robert G.;  
 Ellman, Jonathan A.  
 CS Department of Chemistry, University of California, Berkeley, CA, 94720,  
 USA  
 SO Journal of the American Chemical Society (2005), 127(39), 13496-13497  
 CODEN: JACSAT; ISSN: 0002-7863  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 143:422193  
 RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2005:490344 CAPLUS Full-text  
 DN 143:43684  
 TI Process for preparation of optically active 3-(4-hydroxyphenyl)propionic  
 acids by reaction of protected 4-hydroxybenzaldehydes and glycolic acid  
 derivatives to give cinnamates and asymmetric hydrogenation of  
 the latter.  
 IN Yokozawa, Tohru; Shimizu, Hideo; Fujiwara, Takahiro; Ino, Yasunori  
 PA Takasago International Corporation, Japan  
 SO PCT Int. Appl., 95 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051882	A1	20050609	WO 2004-JP17998	20041126
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1687250	A1	20060809	EP 2004-819490	20041126
R: CH, DE, ES, FR, GB, LI, IE				

JP 2007512222 T 20070517 JP 2006-520429 20041126  
US 20070142472 A1 20070621 US 2006-578744 20060510  
PRAI JP 2003-398201 A 20031127  
WO 2004-JP17998 W 20041126  
OS CASREACT 143:43684; MARPAT 143:43684  
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2003:746329 CAPLUS Full-text  
DN 139:395734  
TI Design and synthesis of small chemical inhibitors containing different  
scaffolds for lck SH2 domain  
AU Park, See-Hyoung; Kang, Sun-Hee; Lim, Sang-Hyeong; Oh, Hyun-Sik; Lee,  
Keun-Hyeong  
CS Signal Transduction Laboratory, Mogam Biotechnology Research Institute,  
Koosung-Myun, Yongin-City, Kyunggi-Do, 449-910, S. Korea  
SO Bioorganic & Medicinal Chemistry Letters (2003), 13(20), 3455-3459  
CODEN: BMCLE8; ISSN: 0960-894X  
PB Elsevier Science B.V.  
DT Journal  
LA English  
OS CASREACT 139:395734  
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2003:262905 CAPLUS Full-text  
DN 139:149390  
TI Asymmetric rhodium carbene insertion into the Si-H bond:  
identification of new dirhodium(II) carboxylate catalysts using parallel  
synthesis techniques  
AU Buck, Richard T.; Coe, Diane M.; Drysdale, Martin J.; Ferris, Leigh;  
Haigh, David; Moody, Christopher J.; Pearson, Neil D.; Sanghera, J. Bobby  
CS Department of Chemistry, Loughborough University, Loughborough, LE11 3TU,  
UK  
SO Tetrahedron: Asymmetry (2003), 14(7), 791-816  
CODEN: TASYE3; ISSN: 0957-4166  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
OS CASREACT 139:149390  
RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN \_  
AN 2003:155400 CAPLUS Full-text  
DN 138:338116  
TI Synthesis and Biological and Structural Characterization of the  
Dual-Acting Peroxisome Proliferator-Activated Receptor  $\alpha/\gamma$   
Agonist Ragaglitazar  
AU Ebdrup, Soren; Pettersson, Ingrid; Rasmussen, Hanne B.; Deussen,  
Heinz-Josef; Jensen, Anette Frost; Mortensen, Steen B.; Fleckner, Jan;  
Pridal, Lone; Nygaard, Lars; Sauerberg, Per  
CS Novo Nordisk Park, Novo Nordisk A/S, Maalov, 2760, Den.  
SO Journal of Medicinal Chemistry (2003), 46(8), 1306-1317  
CODEN: JMCMAR; ISSN: 0022-2623  
PB American Chemical Society  
DT Journal  
LA English

OS CASREACT 138:338116  
RE.CNT 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 1998:82175 CAPLUS Full-text  
DN 128:167302  
OREF 128:32973a,32976a  
TI A non-enzymic synthesis of (S)-(-)-rosmarinic acid and a study of a  
biomimetic route to (+)-rabdosiin  
AU Bogucki, David E.; Charlton, James L.  
CS Dep. Chem., Univ. Manitoba, Winnipeg, MB, R3T 2N2, Can.  
SO Canadian Journal of Chemistry (1997), 75(12), 1783-1794  
CODEN: CJCHAG; ISSN: 0008-4042  
PB National Research Council of Canada  
DT Journal  
LA English  
OS CASREACT 128:167302  
RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 1989:92028 CAPLUS Full-text  
DN 110:92028  
OREF 110:15153a,15156a  
TI Rabdosiin, a new rosmarinic acid dimer with a lignan skeleton, from  
Rabdosia japonica  
AU Agata, Isao; Hatano, Tsutomu; Nishibe, Sansei; Okuda, Takuo  
CS Fac. Pharm. Sci., Higashi Nippon Gakuen Univ., Hokkaido, 061-02, Japan  
SO Chemical & Pharmaceutical Bulletin (1988), 36(8), 3223-5  
CODEN: CPBTAL; ISSN: 0009-2363  
DT Journal  
LA English  
OS CASREACT 110:92028

FILE 'REGISTRY' ENTERED AT 14:32:43 ON 16 JAN 2009

L1 STRUCTURE UPLOADED  
D L1  
L2 17 SEA FILE=REGISTRY SSS SAM L1  
L3 232 SEA FILE=REGISTRY SSS FUL L1

FILE 'CAPLUS' ENTERED AT 14:34:36 ON 16 JAN 2009

L4 433 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L3/PREP  
L5 151 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L4 AND (PY<2003 OR  
AY<2003 OR PRY<2003)  
L6 0 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L5 AND 'ASYMMETRIC?  
HYDROGENATION?'  
L7 0 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L5 AND 'ASYMMETRIC?  
CATALY?'  
L8 3 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L5 AND HYDROGENATION?  
D L8 1-3

FILE 'REGISTRY' ENTERED AT 14:36:53 ON 16 JAN 2009

L9 STRUCTURE UPLOADED  
D L9  
L10 232 SEA FILE=REGISTRY SSS FUL L9

FILE 'REGISTRY' ENTERED AT 14:38:28 ON 16 JAN 2009

L11 STRUCTURE UPLOADED

D L11  
 L12 4 SEA FILE=REGISTRY SSS SAM L11  
 L13 17 SEA FILE=REGISTRY SSS FUL L11  
  
 FILE 'CAPLUS' ENTERED AT 14:39:19 ON 16 JAN 2009  
 L14 9 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L13/PREP  
 D L14 IBIB ABS TI HIT 1-9  
  
 FILE 'REGISTRY' ENTERED AT 14:46:19 ON 16 JAN 2009  
 L15 STRUCTURE UPLOADED  
 D L15  
 L16 17 SEA FILE=REGISTRY SSS SAM L15  
 L17 232 SEA FILE=REGISTRY SSS FUL L15  
  
 FILE 'CAPLUS' ENTERED AT 14:47:17 ON 16 JAN 2009  
 L18 433 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L17/PREP  
 L19 151 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L18 AND (PY<2003 OR  
 AY<2003 OR PRY<2003)  
 L20 0 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L19 AND 'ASYMMETRIC?  
 HYDROGENATION?'  
 L21 0 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L19 AND 'CHIRAL  
 CATALY?'  
 L22 0 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L19 AND 'TRANSITION  
 METAL'  
 L23 0 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L19 AND 'TRANSITION  
 METAL?'  
 L24 0 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L19 AND 'CHIRAL  
 LIGAND?'  
 L25 4 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L19 AND 'CHIRAL?'  
 L26 5 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L19 AND ('CHIRAL?' OR  
 'OPTICAL?')  
 L27 8 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L19 AND ('CHIRAL?' OR  
 'OPTICAL?' OR 'HYDROGENATION?')  
 D L27 IBIB ABS TI HIT 1-8  
 L28 2 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L17 AND 'ASYMMETRIC  
 HYDROGENATION'  
 D L28 IBIB ABS 1-2  
 L29 0 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L17 AND 'CHIRAL  
 CATALYST'  
 L30 0 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L17 AND 'ASYMMETRIC  
 REACT?'  
 L31 10 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L17 AND 'ASYMMETRIC?'  
 D L 31 IBIB ABS 1-10